UCLA-Masterfile 03-08-13 Opt Direct Download At: HTTP://DB - tt/wl2hdhlk

~Yw!
~~--------:--He-nry-J'
H-eiml-ich, M-.D. Professor ofAdvanced Clinical Sciences
JuLy 14, 1986
Mr. Herbert C. EngLert Pres ident Fannie E. Rippel Foundation 333 Main Street Madison, NJ 07840 Dear Bert: This is the second quarterLy report on the RippeL Cancer Grant Project. In the interim since the first quarterLy report, I have sent you Letters regarding possibiLities for starting our project in Ecuador, Mexico, VenezueLa, and China, as weLL as my contact with Dr. James Mason, Director of the Center For Disease ControL (CDC) of the U.S. Department of HeaLth and Human Services (HHS) I have maintained contact with Dr. Gilbert in Ecuador through repeated teLephone caLLs. He says that everything is favorabLe but it wiLL take time. As Ambassador SoL Linowitz writes (encl osedr , "ObviousLy you are arousing interest in your proposaL, and this shouLd be gratifying. On the other hand, I know aLL too we LL how ha rd it is to move .some of these peopL e in the deveLopi ng wor Ld toward impLementation of ideas. You wiLL need aLL the patience you can muster, but I hope you wi LL not sLacken in your efforts." Through the good offices of Dr. Harry Gibbons, Director of HeaLth, SaLt Lake City and County, a reLationship was estabLished through his pubLic heaLth coLLeague in Mexico City, Dr. Luis A. Amezcua. Dr. Amezcua heLd two discussions with Dr. Arturo BeLtran Ortega, Director of the NationaL Cancer Institute of Mexico, who expressed interest in working with us on maLariatherapy for cancer. On JuLy 6, I traveLLed to Mexico City. A meeting was heLd at the NationaL Cancer Institute on JuLy 7 at 10:00 am and I returned home that night, after an exhausting but fruitfuL visit. Dr. Gibbons and Dr. Amezcua joined me at the Institute. I presented our paper on maLariatherapy for cancer to Dr. Be Ltran.
3800 Victory Parkway Cincinnati, Ohio 45207-1096 513/531-1053
Mr. Herbert C. EngLert JuLy 15, 1986 Page 2 Dr. BeLtran, who had trained at MemoriaL HospitaL in New York City and RosweLL Park in Rochester, NY, then described his work with BCG vaccine for meLanoma, demonstrating some exceLLent resuLts. His interest in BCG, an oLd antitubercuLosis vaccine was fortuitous since it is based on bioLogical immunity which is akin in concept to maLariatherapy. I had recentLy read a book on the use of BCG in cancer and was abLe to point out that the fever and uLceration from the BCG may aLso be providing beneficiaL resuLts. It was onLy after Dr. BeLtran became aware that I was the discoverer of the HeimLich Maneuver that his enthusiasm for our project became apparent. A tour of the Institute and hospitaL showed them to be modern and weLL equipped. They care for thousands of cancer patients. We aLL agreed that our treatment can do no ha rm. We Left with the understanding that Dr. BeLtran wouLd have an associate review aLL medicaL Literature on ~aLaria and immunity. After ~bout one month, we wiLL arrange for another session in Mexico to estabLish a protocoL for carrying out the treatment of patients with maLaria. He presented me with the protocoL form for research used in his hospitaL (encLosed) and said there shouLd be no difficuLty in starting the treatment program after going through the formaLities. I am pLanning to go to VenezueLa in the near future to discuss estabLishing our program there. In addition, I am scheduLing a meeting at the CDC in AtLanta with Dr. Mason and his staff. In the meantime our research continues at Xavier University and has provided new confirmation supporting the concept of treating cancer by induction of maLaria. We have Located a book in German by Prof. Dr. Med. Werner ZabeL who treated nineteen cancer patients with maLariatherapy in Bavaria in the 19501s. His work was under the direct supervision of British personneL on Loan from the MaLaria Reference Laboratory of Horton Hospital at Epsom, near London. Comparing malariatherapy to aLL other ancilLary modaLities for the treatment of metastatic cancer, Dr. Zabel writes "there is probabLy no other procedure that is as successfuL." We have devised a detaiLed protocoL (encLosed) that wiLL be avaiLabLe wherever treatment is carried out. It is being modified to conform with the format of the NationaL Cancer Institute of Mexico. Our goaL is to cure cancer and we have good reason to believe maLariatherapy wiLL be effective, but can onLy be certain after we have the opportunity to treat otherwise incurabLe patients. With persistence and patience we wilL succeed. A copy of the January 1 - June 30, 1986 Xavier University financial re~ort of the RippeL Cancer Grant is encLosed as per the agreement with the university.
HJH/jh
Apr il 12, 1988

CINCINNAn. OH45208 513531-1053
Mr. Eric R. Rippel President Fannie E. Rippel Foundation 333 Main Street Madison, NJ 07940-2394 Dear Eric: Thank you very much for the third installment of the grant.
Enclosed are letters given to me by Harry Gibbons about which we have spoken. Mr. McIntire had given a transfusion to his father some years ago. His father, at the time, had far advanced cancer and was also considered terminal. The father recovered completely and lived twelve years and died of other causes at a ripe old age. The father did not develop malaria but did have fever. Mr. McIntire believes the cure was related to the fact that he had malaria as per the report from the San Bernardino Station Hospital. He is writing on behalf ;f a relative, Barbara Metcalf, who has cancer and is seeking treatment through us. Best wishes,
Benefiting Humanity Through
Health and Peace
r
I
I
I
FANNIE
E. RIPPEL
FOUNDATION
333 MAIN STREET MADISON, NEW JERSEY 07940-2394

Mailing Address: Post Office Box 758 Madison, New Jersey 07940
April
18,1988
Henry J. Heimlich, M.D., President The Heimlich Institute Foundation, Post Office Box 8858 Cincinnati, Ohio 45208 Dear Dr. Heimlich:
Inc.
In connection with the annual examination of our accounts as of April 30, 1988, which is being made by Ernst & Whinney, 550 Broad Street, Newark, New Jersey 07102., we will appreciate it if you will confirm the correctness of the information set forth below pertaining to the grant made to Teh Heimlich Institute Foundation, Inc. as authorized by our Board of Trustees on June 17, 1987. Please send your reply directly stamped, addressed envelope. to our accountants in the
enclosed
Very truly yours, FANNIE E. RIPPEL FOUNDATION

/ ~?, /'
~q.~~'
Eric R. Rippel President Information 1. 2. 3. Pertaining to Grant Made Qy Fannie ~ Rippel
Foundation
Amount of grant made to you during the year ended April 30, 1988 Amount of funds received by you during the year ended April 30, 1988 Amount of unpaid grant as of April 1988, subject to the terms and conditions of the grant resolution 30,
$200,000.00 125,000.00
$ 75,000.00 of this grant
4.
You have notified us of your acceptance prior to April 30, 1988.
May 3, 1989 Mr. Eric R. Rippel, President Fannie E. Rippel Foundation Post Office Box 758 Madison, NJ 07940
XAVIER UNIVERSITY 3800 VICTORY PARt<!NAY CINCINNATI OHIO 45207 5137451099
Re: Dear Eric:
Report for six months ending December 31, 1988
As you know, a major landmark in our research project, "Malariatherapy for Cancer," was reached when we went to China, October, 1988. As a result of Dr. Hua Hong Shen's efforts, we were met in Beijing by Dr. Guang-Wei Xu, Director of the Beijing Institute for Cancer Research and his staff. Dr. Hua did not do as well in travel arrangements and booking accommodations, leaving us with some uncomfortable and trying times. It is remarkable to consider that we entered a huge oriental country half way around the world, and, in less than two weeks, developed a working relationship with their leading cancer institute to treat cancer patients with malariatherapy. In that period of time we visited the Beijing Institute for Cancer Research and you participated in my presentation. The physicians, who had received preliminary information on our cancer-malaria therapy program, enthusiastically endorsed the method and agreed to participate. Before we left China, Dr. Xu had received approval from the Minister of Health of the People's Republic of China (PRC) to proceed with the research, including patient treatment. He also presented you with a collaborative agreement that is to be finalized when arrangements to transport malaria to Beijing are established. Since that time, Dr. Xu has travelled to Ha Lnan Island, which has endemic malaria. He is also seeking other sites as sources for the proper parasite. Dr. Hua is in touch with me by phone every week to report his progress. His friend and classmate, Dr. Yong, in Shanghai, is a leading malariologist. Dr. Yong has contacted Dr. Xu and is working with him to get the malaria parasites to Beijing. Dr. Yong will be spending the entire summer in Hunan, a malarial province. He believes malaria transmission by mosquito transfer may be more expeditious than by blood transfusion. If so, we will have gained new experience that can help our research elsewhere. Before we leave the subject of China, I must mention Xiao Dong, the granddaughter of the late General Fu Tso Yi, my friend during my u.S. Navy days in China during World War II. Xiao Dong proved to us that she and her family's standing with the Chinese government, enables us to expedite any plans we have in China.
Benefiting
Humani~
Through Health and Peace
XAVIER UNIVERSITY 3800 VICTORY PARKWAY CINCINNATI OHIO 45207 513745-1099
It was very gratifying to appear before the Board of the Rippel Foundation with Dr. Arturo Beltran, Director of the National Cancer Institute of Mexico. I was proud to be privileged to be present when Dr. Beltran spoke and am certain the Board fully understood the high medical caliber and dignity of this outstanding gentleman. Dr. Beltran has attempted to induce malaria into two additional cancer patients. The disease did not take and one, with far advanced melanoma, left the hospital. She died of the cancer after two weeks, so it was just as well she is not part of our series. The second patient, with kidney carcinoma spread to the lungs, also did not develop malaria from the first transfusion and a second is planned. There is a difficulty in obtaining and transporting malarial blood. The malaria is seasonal and, in addition, the people take medication with the first signs of fever. We can try to improve the chances of success by visiting the malarial area with Dr. Beltran and considering compensation for the physicians who acquire the malarial blood. As you know, a trip for this purpose is being planned. Our goal now is to expand our patient treatment series, and we are surely on our way. Day-to-day research progress sometimes seems slow, but reviewing the accomplishments of the last six months, as in the past, makes us realize that it is quite remarkable. The interest of Intersearch researchers in the immunology related to our findings is additional evidence of the acceptance of the concept. The malariatherapy research has led to another offshoot. Lyme disease, caused by a tick bite, is one of the most rapidly spreading diseases in this country and the rest of the world. It causes severe rheumatism and nervous system disorders. Lyme disease is caused by a spirochete, similar to that of syphilis. As you know, malariatherapy was first used extensively for the treatment of neurosyphilis. I will be presenting an article recommending that malariatherapy be used to treat Lyme disease. Since this is a direct outgrowth of our research, the Rippel Foundation will be appropriately referred to and credited. I look forward to continuing the treatment of cancer with malaria with your vital cooperation. Your willingness to support a new $200,000 grant is greatly appreciated.
Benefiting Humanity Through Health and Peace
Clinical Sciences
FANNIE
E. RIPPEL
FOUNDATION
333 MAIN STREET POST OFFICE BOX 758 MADISON, NEW JERSEY 07940-0758 201-377-5333
May 15, 1989
Henry J. Heimlich, M.D. President The Heimlich Institute Foundation, Xavier University 3800 Victory Parkway Cincinnati, Ohio 45207 Dear Hank:
Inc.
We have your letter of 11 May and thanks. After some perusal we have determined the need to meet with you at our offices to discuss any potential further grants to the "malariatherapy" protocol. We suggest a date during the first week in July for this and will await your reply. To review, we started our last grant on August 6, 1987, with a payment of $75,000 and followed with periodical payments of $25,000 each until March 2, 1989, when we completed the funding of this grant for $200,000. Out of this grant $30,000 was sent to the National Cancer Institute of Mexico to cover the actual research protocol costs so only 15% of our grant went to fund this clinical protocol. Over the intervening 19 months from August, 1987 to March, 1989, The Heimlich Institute, Inc. expended on its own overhead costs $8,950 per month on average. We recognize that the wording of the grant motion may not have been specific enough; however, it was never our intent to in effect support The Heimlich Institute with $17a,000 over 19 months while providing only $30,000 for the actual clinical research in Mexico. As you can see, we have much to discuss together before we can think of another grant. Yours truly,
..~ ..~,,,,-.--'--'-
Eric R. Rippel President ERR:nlc
May 19, 1989 Mr. Eric Rippel, President Fannie E. Rippel Foundation 333 Main Street P.O. Box 758 Madison, New Jersey 07940 Dear Eric: Thank you for your letter of May 15. The amount expended, as detailed in the records, was $150,000, which includes the $30,000 to the National Cancer Institute of Mexico. There is $50,000 on hand to provide for patients in Mexico as well as to keep the project going here. The grant was scheduled for 18 months. We have passed that point and still have 25% of the funds. My desire to know about the new grant is because Dr. Carr's work is essential to the project. He constantly researches the literature and assimilates information and data. His knowledge will be indispensable when we analyze patient data. We cannot expect him to remain without the security that he deserves--knowing that the work will continue after the present grant ends. I am now not nearly as important to the project, and, as you know, I receive no compensation from the grant or the Heimlich Institute. Nothing will make you and me happier than increasing the number of patient treatments in Mexico. We could not predict that for the second series, the patients would not develop malaria after transfusion. Our next visit to Mexico may enable us to advise them on obtaining and transporting the malarial blood. You have evaluated more cancer research programs than I have. I am certain that there is none that has progressed to patient treatment as rapidly, with as much success, and with less " expense. Nor is any more prom1s1ng. I have been in weekly contact with Dr. Hua and am pleased with the letter he FAXed to us from Dr. Xu. I look forward to seeing you in June, as soon as we can arrange the trip to Mexico, and also welcome the opportunity to attend the meeting at the Rippel Foundation in July. Sincerely,
XAVIER UNIVERSITY 3800 VICTORY PARKWAY CINCINNATI

OHIO 45207 513745-1099
Henry J. Heimlich, MD, ScD President, Heimlich Institute P.S.: Do you think our visit influenced students seeking democracy in Beijing? Wouldn't be surprised!
if~rrr~~~
~ ,4.1]>.-1
~ -t" <p-J?,;.."... ~ Min
t.4- ~~
lL
1- ~,;...~.
S~7 ~
J w-
<1.-
dAA.~
1;
r-ln
:J.;1JM<-1~ ~(~ w ~~ ~~ '/ ~l
1- t...ue .;. J7) 1.0 ~ :.pr .NO' ~ -.J.,..., ~ w .....

R.uL 1':"'~~' J't- ~
/.J>-Jt
r}u..
~ ~.
~W-~~~~'.
I .
J.&th.Jt
~ ~k~7~
t~f{'~/ -b;
ik
~ a,..;.~ M.- 'Ad? ~
-Jkd . ~~~
~. Jt~~t ~ ~ ~ ~ ~d;-It)
i..,;vt
~
t;,
%- ~
.' .
Jr/liRwT~ (;; (,UL-Ifi V~~~,
~it~
MA.J2.- "t;
-k~~~~a-..J.,~
Af Jw.".;k ~
?tit
~.
3.
".
~ ;t~~~r 1-~~
~~, ~M ~ ~t;, t;.L.r ~~ ~,'h.w..-
. M<-1 ~ ~ D-Jt-.
~~~.
S~ we Jw.J k
f.-~
])bv 'Jr. ~-R-e-
"-' ~ ~ ~ ~ ~'-~
Juill.
~ HAN ~1 Mitt. J ~ 1& ~

fp
U1-Li;
tI'+t ~ r O
.
~ 'r-
~N e:~. J . ~ ~ ~~~~,;.
c,Rw.- k, /f q,r ..~
it ~
ft,
-t--Jv
y.1.. .
~.;.~: J~~ t;, ~~~. /fR
1-
Htov
~ ~ 11~a.v. cJ 1-., ~
7~
r...L ttfA.<l ~' .
8 '"" ~ .~
1$ . ~ "- ~fJ-
. /M..~ rhk.;r ..
. fjv.t ~w.v -If, Dr. JIw..~ ~4J ~ ; ~ ~ fur.., .
~M~
~h~
_..
T ~~;o~~.~~ '~"'~~?~:;~T
-I'l::llLADELPiHA; P...... 151146-
0' ~7
~
I"
0
.
~.
" Jf
~~~~$~~~
.
ff ~ ~
~ ~~ J ~~
~~
w-e- ~r ~
~u&_
~. f~~r~~
fr
/~
5'
~7~
~{rr-~--:7d~7
A fi2~ c7\/~' ,
4-~ ' ~
/#f
~r~~
//~
d
~,~~~
~~
k4 Lq7~'
_E:::e-=.e=
.::.- ,
E_CI
co
3"1
~-
.0
M.D . ~-S ' I Av e nu e, 12 a dwi 9 1 731 CA t e,
:::>ear Hon g-Shun: b a nk y ou for your New Year's greeting, and I wish you and you r family the same. I am sorry to hear of Dr. Cionci's illn ess and will write to him. I have just received from Dr. Cionci, the enclosed letter, dated September 3, 1990. It is from Guangzhou and speaks enthusiastically about doing our ma1ariatherapy for cancer and AIDS there. Why have we delayed in arranging to work with them? Their reasons for our working there are very imp r essive. Please contact Guangzhou regarding your progress. as soon as possible, and phone me
;r7
/ HJH/jd cc:
Y '
M. D., Sc. D
fl~~,~L~~~e imli ch,

presidd/ Heimlich Institute Fax 1513-221-0003
Enclosure Eric Rippel
Benefiting HumanITy Through Health and Peace
9+1
T..le Municipal Health & Anti-epidemic
Station of Guangzhou
Address: No. 23, 3rd Zongshnn Rd. Guangzhou. People's Republlc of Chine. Post No. 5 1 0 0 a0 Tel: 77. 103 (ext.) 765 %5 5 (office)
". '
SHS (t1il<: :;O
Yb,ff
vr.
/'. VI p"n
,
(/1 :
1l!C>-7-ti~s
-t~~
r"
~
pal'
/dk- ~~,
J -. k -;..tJJ ~ 74- !1~~'f ~
rv.y"U
7),-,
w'~ ~er tvu/ AIDS, J
t'" ~
tm ~ tL-
)/~kJz U ~
~ . ~.
M l
J
SfJd
/....-r..
;,., ~~7'
~:vv,
evmcf'
~"'77:
1;
1M! tIu- ~G;" )JtM0~''d 1h-- ~ {-#u- ~ ~ . , f--~( aWi<tLu ,;,., ,en e:i:J ;." ~4.. tuzd n..~ //7-
Ju
tv
flwr. -k,7
J,t.if5 GUft~~ ~~~ttY,

~
tUt
~'{r -~ ~
H1-dY-<-
(/d'ft17~n!
fr
-,:"
5r'
J
.-.
,/99fJ.
*lrPJ!~IW~1li
The Murucipal Health -& Anti-epidemic Station of Guangzhou
Address: No. 23, Srd Zongshan Rd. Ouan,zhou. People's Republlc of China. Post No. 6 1 0 0 8 0 . . Tel: 7 7 4 1 0 3 (ext.) 7 II 6 2 6 5 (office)
~ . ~
'
,.,
:.- ' :aII"~
.-. ...........
~.~,_ ~. ....... t .... ~'.
...
~ .......... ~t . . .
. . . . ..-..
~?<~Jk :tLt ~ N~'7 ,S'~ 7~ ~

0-
tPU'1 ~ -tii-trr ~t;U.
~,... <=1'(/
fnt8Uj
~ r ~;U ;,.. C~, -i7~ . _~. -t. Tunurr l,t~ ()A1i1 Tu.-r Hlfff:';w'
1- f~/l jdIt-tt
WI . lin:VMf']
fff
H~ ~~, .uU ;..

"",W':-J
"7 fi-{""p-- fftik-.
7/z.~/, a~k( n- ?v.ftnJrL,n p~.:. ~ ~
~, :;"td4 c.. L....,.,.
~ a..-~
m~&~, ~~ l-- ~" ~1 r~rt "",;);4. ~~ M ~ 1;; 7 /J~ ~ w..tZr )1l~'- ~A1 WYtt"~ ~~, ~r7 -tbI
trf ~~ r ~~~A-I-. CM~;:' r /r {<:<r( muJl m.~ Cff111/~f-r'- CUA41"J<?1f( ~ .

hfA'''/
----~YV"
CAn
;.,
/ :'1
N C<.ft i:""J
M1
-m~(I
f'Ut ds,
The Municipal Health & Anti-epidemic Station of Guangzhou

Address: No. 23, 3rd Zongshan Rd. Ouangzhou.
People's Republic of China.

Post No. 5 1 0 0 8 0 Tel: 77 4 103 (ext.) 785255 (office)
J r
n<
C/L-"r t'r ~ . al,J ~, (JH<

r>1<2-,
~ f J u.-" / 0 .)."~ 7J,~ 1/ U~ ~,tL:-e.dn-i ~b !LUMY /It~~ 6.",( t7Ir...- ~ i71u.. 7u-nw>'
;" -t~ w;J;4
-tLa'-
t' ut ,_-tr
C-dh1
JI;.V
,
tfut rfJ~~1ikm.#r ey~rt ;" c~ ~d 17 C'-r~ ~, 7 1~ ;, v/:.th ,0t- rr '

I'f "'VI , jd4,P- ;n&w ~,
a..--<.
~'7 {;/~tvnJ:?1uv.
tV""'" ""(/ -tu.-t/fu.s
~ ~ ~~
tl--
uJ~ Iv-4 w..'J/-J

,/
I
/ !
.
~I.A'"
looreign Affa i rs Office Jiangsu Provincial People's GOirernmcnt People's Republic of China
( 9I
) ~5'~ ~ A!f- ~ 2 l -
0 0057 6~
0~. J oh ~... ~. C! O~l_~!_.. ... tv) ~._H~tL>J J. Heih! I ;J,

b,7
J)y~sltertown
p.ci
_J~Su.prOtJilt.u...
Dr~51t~~ P/~~.~~!.f._.-'-_ U_~tl . _

YOU ARE KINDLY EXPECTED BY .. __ __ ._
rlfT5fita.i
Iq_t;_'_
_ .. __ .. __. .. ____ ._._... _. _ . TO COME TO _ ____ . ___ .. _. _ _ _ __
_ _ _ N~';"'J_,
FOR _ ___ Vis~L___
CHINA ON
15t/z, f'/I~
0
THE DURATIO N IN
CHINA WILL DE
S Q.V.QIL.
DAYS. PLS APPLY FORTHWITH lo O R
_ ._.ENTRY VISA(S)AT THE CHINESE EMD ASSY (OR CO NSULATE-GE NERAL,

S I NGAPOR~
COMMERCIAL REPRESENTATIVE'S
O FF ICE
TN
OR VISA OFFICE OF THE MINISTRY OF FORE IGN IN
AFFAIRS IN lIONG KONG) ( tELEGRAM)
Nee Ior~ c;~. WITH
THIS LETTER
Datil- - - -
As
'tit. 34027 FAOJS Cr-; 313 North Zhongshan Rd., Nanjing, <;hi.ra Tei. 85921 TLX , 34027 FAOJS CN
WfL
'I'm
m:t.rf.'f.4~l:.1&-313 ~
~i&-. 85921
~ :fia}
W.t.
8m
~c(n.lt r~Ci~
JtgMt.
-mvHcd~
As;!-
Oc1ob.er. SO
s-Utf tAR. . ~
. .,
FAX:
(513)
221-0003
FACSIMILE
TRANSMISSION
COVER:
2368 VICTORY
PARKW6.Y
TO:
SUITE 410 CINCINNATI OHIO 45206 51322HXXl2
LOCATION:
FROM:
-:
NUMBER
OF PAGES
TO
FOLLOW:
RE:
NAME
OF PERSON
TRANSMITTING:
Benefiting Humanity Through Health
and
Peace
(~
Chen Xiao-Ping, M.D. c/o Hua Hong-Shun, M.D. 3708 Baldwin Avenue, '2 EI Monte, CA 91731 FOUNDATION, INC.
2368 VICTORY PAR'{;;NAY SUITE 410 CINCINNATI OHIO 45206 513-22HXXJ2 fax 513-22HXlO3
Ap r i I 30,
1991
Dear
Dr.
Chen: of April 11, 1991. agree with the value I am pleased that of malariatherapy
Thank you for your letter you and your other experts for treating cancer.
Your suggestion that we travel to China for further discussion presents a difficulty. It would mean returning to China a second time, a short time later, to examine the patients being treated. The trip, as you know, is a very long one and is very expensive. It will drain funds that can be used for the project. Dr. Hong-Shun Hua has provided you with the protocol. As you know, patients can have squamous cell, adenocarcinoma, or melanoma. Visible tumors such as nasopharyngeal cancer or melanoma, palpable tumors, or tho~e seen on X-ray (such as in the lungs) enable us to measure the results. The cancer should be incurable with standard treatments such as surgery, radiotherapy, or chemotherapy; therefore, there is no risk to the patients and there is the possibility of benefit with malariatherapy. The care of a malaria patient is well known to you. Dr. Hua can discuss research beneficial arrangement can be we can exchange sufficient treatment. funding with you, and I am sure a reached. By mail, phone, and FAX, you to start information for
As you know, there is interest in other locations to cooperate in this project. We are obligated to participate first with those scientists who can start treatment on four to five patients a few weeks before we travel to China, for reasons stated above. I hope patient treatment can begin immediately. Please let me know if you can do this. When, together, we are ready to present research results at a medical meeting in the united States, it will be our pleasure to invite you and your colleagues to participate here in the presentation.
Benefi . g Humanity Through Health and Peace
M.D., Heimlich cc: Institute
Sc.D.
Eric Rippel, President, Dr. John Cionci
The
Rippel
Foundation
2368 VICTORY PARKWAY SUITE 410 CINCINNATI OHIO 45200
513-221-0012 April
fax 513-221-<XXl3
30,1991
Hua Hong-Shun, M.D. 3708 Baldwin Avenue, 12 El Monte, CA 91731 Dear Hong-Shun: of on
Please send the enclosed letter to Guangzhou if you approve it. Call me ~o discuss funding before you speak to Guangzhou. We must convince them that it is necessary to start the first patients before we travel to China. Please call when you have a chance. treatment
M.D., Heimlich HJH/jd Enclosures Institute
SC.D.
Dear Dr. Hua:
March
27, 1991
Enclosed is a semi-official letter written by the vice Director of the Municipal Health & Anti-epidemic Station of Guangzhou and the director of Guangzhou Tumor Hospital. This is the result after we had several meetings. Please keep in contact. In addition to letter and phone, you may send FAX 862482 c/o Dr. Wang Bao-chang. Also please give us your FAX number. Sincerely,
Chen Xiao-ping,M.D.
Liu Shu-kuo,M.D. Vice Director The Municipal Health & Anti-epidemic Station of Guangzhou 23, 3rd Zongshan Rd. Guangzhou 510080 People's Republic of China Yu Chang-tao,M.D. Director Guangzhou Tumor Hospital Henry J. Heimlich,M.D. President The Heimlich INstitute c/o Hua Hong-shun,M.D. 3708 Baldwin Ave. #2 EI Monte, CA 91731 Dear Dr. Heimlich: March 26,1991
The letters and a packet of papers on 'Malaria-therapy of Cancer' sent by Dr.Hua Hong-shun to Dr. Chen Xiao-pinghave been received and studied by us. We have invited experts of related fields to discuss with this matter in detail. As to the problems mentioned in these letters, we would like to reply as follows: 1 2 We do intend to participate Cancer" joint project. in this 'Malaria-therapy of
The Municipal Health & Anti-epidemic Station of Guangzhou is responsible for the prevention and treatment of malaria in this district. According to epidemic investigation of malaria in recent years, there are sUfficient number of malaria vivax patients available to serve for blood donation. Also, we have experience in treating malaria patients. The epidemic season of malaria here covers most part of the year, and will basicly fascilitate the carrying out of this research project. We would like to have further information as to: what kind of tumor and patients of what stage shall be selected, how to set treatment group and control group, number of patients needed,the research fund etc.
We might say, on one aspect, that we can readily select donor patients for artificially inducing malaria. But we are not quite clear about the protocol and requirement for tumor treatment. So we wish that you and other related experts of your party could visit China to discuss the feasibility of our joint research and the detailed protocol. To our belief, the official organizations, the Guangzhou Municipal Government and Guangzhou Ministry of Health will approve our project,once we, the participating organization and expertsconvince the project and apply for local government's approval.
Because by asking local government to send you official invitation, we should go through many procedures and that is ttme consuming, so we would suggest that you would visit China as tourists for giving lecture and academic exchange. We would supply your expenditure and make arrangement for your stay in Guangzhou for two days, not including the flight tickets. Please keep in contact with Dr. Chen Xiao-ping. We are looking for your visit and for a pleasant and successful co-operation. Sincerely,
Liu Shu-kuo,M.D. Vice Director
Yu Chang-tao,M.D. Director
Ap r i I 30,
1991
Dear
Dr.
Sc.D.
The
Rippel
Foundation
FAX:
(513)
221-0003
FACSIMILE
TRANSMISSION
COVER:
2368 VICTORY
PARKW6.Y
TO:
SUITE 410 CINCINNATI OHIO 45206 51322HXXl2
LOCATION:
FROM:
-:
NUMBER
OF PAGES
TO
FOLLOW:
RE:
NAME
OF PERSON
TRANSMITTING:
and
Peace
(~
Ap r i I 30,
1991
Dear
Dr.
Sc.D.
The
Rippel
Foundation
513-221-0012 April
fax 513-221-<XXl3
30,1991
SC.D.
Dear Dr. Hua:
March
27, 1991
Enclosed is a semi-official letter written by the vice Director of the Municipal Health & Anti-epidemic Station of Guangzhou and the director of Guangzhou Tumor Hospital. This is the result after we had several meetings. Please keep in contact. In addition to letter and phone, you may send FAX 862482 c/o Dr. Wang Bao-chang. Also please give us your FAX number. Sincerely,
Chen Xiao-ping,M.D.
Liu Shu-kuo,M.D. Vice Director The Municipal Health & Anti-epidemic Station of Guangzhou 23, 3rd Zongshan Rd. Guangzhou 510080 People's Republic of China Yu Chang-tao,M.D. Director Guangzhou Tumor Hospital Henry J. Heimlich,M.D. President The Heimlich INstitute c/o Hua Hong-shun,M.D. 3708 Baldwin Ave. #2 EI Monte, CA 91731 Dear Dr. Heimlich: March 26,1991
The letters and a packet of papers on 'Malaria-therapy of Cancer' sent by Dr.Hua Hong-shun to Dr. Chen Xiao-pinghave been received and studied by us. We have invited experts of related fields to discuss with this matter in detail. As to the problems mentioned in these letters, we would like to reply as follows: 1 2 We do intend to participate Cancer" joint project. in this 'Malaria-therapy of
The Municipal Health & Anti-epidemic Station of Guangzhou is responsible for the prevention and treatment of malaria in this district. According to epidemic investigation of malaria in recent years, there are sUfficient number of malaria vivax patients available to serve for blood donation. Also, we have experience in treating malaria patients. The epidemic season of malaria here covers most part of the year, and will basicly fascilitate the carrying out of this research project. We would like to have further information as to: what kind of tumor and patients of what stage shall be selected, how to set treatment group and control group, number of patients needed,the research fund etc.
We might say, on one aspect, that we can readily select donor patients for artificially inducing malaria. But we are not quite clear about the protocol and requirement for tumor treatment. So we wish that you and other related experts of your party could visit China to discuss the feasibility of our joint research and the detailed protocol. To our belief, the official organizations, the Guangzhou Municipal Government and Guangzhou Ministry of Health will approve our project,once we, the participating organization and expertsconvince the project and apply for local government's approval.
Because by asking local government to send you official invitation, we should go through many procedures and that is ttme consuming, so we would suggest that you would visit China as tourists for giving lecture and academic exchange. We would supply your expenditure and make arrangement for your stay in Guangzhou for two days, not including the flight tickets. Please keep in contact with Dr. Chen Xiao-ping. We are looking for your visit and for a pleasant and successful co-operation. Sincerely,
Liu Shu-kuo,M.D. Vice Director
Yu Chang-tao,M.D. Director
513-221-0012 April
fax 513-221-<XXl3
30,1991
SC.D.

AGREEMENT FOR JOINT PROJECT OF CANCER"
"MALARIATHERAPY BETWEEN JIANGSU
PROVINCE PEOPLE'S HOSPITAL AND 81 st. HOSPITAL AND
FANNIE E. RIPPEL FOUNDATION AND THE HEIMLICH INSTITUTE
Summary Both sides hold that it is beneficial to patients to explore malariatherapy for cancers and to assess the clinical effect in treating cancer as compared to other conventional methods. The primary objective of this project is to perform a clinical trial by means of blood transfer method so as to demonstrate that the therapy could be applied to cancer with no harm, or only with a limited amount of side effects, and to assess the effectiveness of this treatment. Collaborative Covenant enacted by Jiangsu Province People's Hospital in this action by Dr. Zhao Zhi-Quan, the 81 st. Hospital, and the Fannie E. Rippel Foundation represented in this action by the president, Mr. Eric R. Rippel, and the Heimlich Institute by Dr. Henry J. Heimlich, who hereafter for the purpose of this instrument are designated as "Jiangsu" for the first party and as "The Heimlich Institute" for the second party in accordance with the following: PROMISES On "Jiangsu" part:
To designate Dr. Wang Ming-Xiu and Dr. Ma Yong-Quan as principal scientists in charge of the project. To contribute the services of the human resources with which the hospitals now operate, for the duration and completion of the present covenant. To comply with all the medical, technical and ethical requirements that determine the standards applicable to this protocol. Ideally, malariatherapy should be carried out for a minimum of 30 days, preferably 45, if tolerated by the patient. Subsequent additional courses may be indicated. To send written reports, including temperature charts, to the Heimlich Institute at start of treatment, end of treatment, three months after completion of treatment, and three months thereafter. Since changes in tumor size and quality are essential to the study, whenever possible, visible lesions will be documented by photographs, palpable tumors and x-ray findings by sketches on the diagrams provided in the protocol, and measurements will be cited. The six month follow-up after treatment will insure that patient selection has been based on patients in favorable condition for treatment. Shorter follow-up will be of lesser value. It is understood that an occasional patient may survive only five months but will still warrant inclusion in the series. To submit reports to the Heimlich Institute on all patients to be included in the series, who have already received malariatherapy
prior to signing.
On "The Heimlich
Institute"
part:
To designate Dr. Henry J. Heimlich as principal investigator responsible for the investigation. To designate Dr. Hong-Shun Hua as coordinator. To contribute the necessary medical, technical and related information for the implementation of the therapy procedures. To support a fund of USD 2,000.00 for each malariatherapy-treated patient after treatment and follow-up course of six months and submission of patient records and reports. In view of initial expenses, USD 4,000.00 will be paid within one month of the signing of this Agreement. This amount will be applied in advance against the first two patients provided with a full course of malariatherapy, who will subsequently be followed for the agreed upon six months follow-up. When the two six-month reports have been delivered, an additional USD 4,000.00 will be sent as an advance on the next two patients, who have completed a full course of malariatherapy. Thereafter, payment will be made for each subsequent patient after the submission of the six month follow-up report. On the part of both parties: Up to December 31, 1992, ten (10) cancer patients will be treated under close investigation with comprehensive records. An assessment might be processed to warrant further research procedures. About the results: The parties agree that the progress and results this investigation cannot be utilized unilaterally parties.
obtained from by any of the
These promises of collaboration implement a medical research protocol entitled "Malariatherapy of cancer" in Nanjing,Jiangsu, People's Republic of China on the twelfth day of the month of November in the year 1991.
Zhao Zhi-Quan Vice President, Jiangsu Province People's Hospital
Eric R. Rippel, President The Fannie E. Rippel Foundation
Ma Yonq-Quan 81 st Hospital
Henry J. Heimlich President The Heimlich Institute
Honorary witnesses: Mr. Liu Hong-Qi, Director General, Health Department, Jiangsu, P.R.C. Date of Signing Dr. John L. cionci
------------------------------------
SUMMARY Both sides hold that it is beneficial to patients to explore malariatherapy for cancers and to assess the clinical effect in treating cancer as compared to other conventional methods. The primary objective of this project is to perfor. a clinical trial by means of blood transfer method so as to demonstrate that the therapy could be applied to cancer with no harm, or only with a limited amount of side effects, and to assess the effectiveness of this treatment. Collaborative covenant enacted by the Municipal Institute for Preventive Medicine of Guangzhou in this action by President Xiao BinQuan and Dr. Chen Xiao-Ping, Guangzhou Yishou Hospital by Vice President Li Nai-Du and The Heimlich Institute by President Henry J. Heimlich, who hereafter for the purpose of this instrument are designated as uGuangzhouu for the first party and as uThe Heimlich Institute" for the second party in accordance with the following:
PROMISES ON "GUANGZHOO" PART: To designate Dr. Chen Xiao-Ping as principal investigator in charge the project. To designate Dr. Liu Shu-Guo, Dr. Li Nai-Du, Dr. Xiao Bin-Quan as co-investigators. Lu Yue-Hen of
and Dr.
To contribute the services of the human resources and equiments with which the institute and the hostipal now operate, for the duration and completion of the present covenant. To comply with all the medical. technical and ethical requirement that determine the standards applicable to this protocol. Ideally. malariatherapy should be carried out for a minimum of ten(lO) paroxysms of hyperthermia,!, Subsepuent additional courses may be indicated. To send written reports, including temperature charts, to the Heimlich Institute at start of treatment, end of treatment, three .onths after completion of treatment, and three months thereafter. Since change in tumor size and quality are essential to the study, whenever possible, visible lesions will be documented by photographs, palpable tumors and X-ray findings by sketches on the diagrams provided in the protocol, and measurements will be cited. The six month follow-up after treatment will insure that patient selection has been based on patients in favorable condition for treatment. Shorter follow-up will be of lesser value, It is understood that an occasional patient!'i may survive only "four o't~ five months but will still warrant incIusion in the series.
To submit reports to the Heimlich Institute on all patients to be included in the series, who have already received malariatherapy prior to signing. ON "THE HEIMLICH INSTITUTE" PART: To designate Dr. Henry J. Heimlich responsible for the investigation. as principal investigator
To designate Dr. Hua Hong-Shun as coordinator. To contribute the necessary medical, technical and related for the implementation of the therapy procedures. information
At the first 10 cases, to support a fund of usn 3000 for each malariatherapy-treated patient after treatment and follow-up course of six months and submission of patient records and reports. After that, to support USD 1500 for each case. In.view of initial expenses, DSD 6000 will be paid within one month of the signing of this agreement. This amount will be applied in advance against the first two patients provided with a full course of malariatherapy, who will subsequently be followed for the agreed upon six months follow-up. Thereafter, Payment will be made for each subsequent patient after the submission of the six month follow-up reports. If necessary, one patient receive the second cours~ of malariatherapy according to above requirement, the payment can be considered as for two cases.
v'
ON THE PART OF BOTH PARTIES: up to Karch 30, 1993, ten(IO) cancer patients will be treated close investigation with comprehensive records. under
An assessment might be processed to warrant further research procedures.
ABOUT THE RESULT: The parties agree that the progress and results obtained from this investigation cannot be utilized unilaterally by any of the parties or cannot be utilized unilaterally by any of the parties without the agreement of both parties. This agreement of collaboration written in Chinese and English languages each of which has two copies implements a medical research protocol entitled "malariatherapy of cancer" in Guangzhou, People's Republic of China on the fifteenth day of the month of June in the 1992.
March 24, 1993
2368 VICTORY PAR'(:;NAY SUITE410 CINCINNATI OHIO 45200 513-221-r0J2 fax 513-22HXXl3
Professor Qi Qi Chen Vice Mayor of Guangzhou Canton Medical College Guangzhou, 510182, China Dear Qi Qi Chen: Thank you so very much for being my host at the elegant banquet. I enjoyed being able to meet with you. I am afraid that I am getting old. It had been my intention to thank you in person for your lovely letter and picture that I received at Christmas time. After you left, I realized I had not done so. Please accept now my appreciation for your thoughtfulness. When you come to the united states again, I would very much like you to be our guest in cincinnati. If that is not possible, I would travel to meet you and ask you to be my dinner guest.
enry J. M.D., Sc.D. Presiden Heimlich Institute
The Municipal Institute For Preventive Medicine of Guangzhou

i!l~ i5(!.li! ~ :
.p fliI r-ffi .p lli ---': Jilf23 ~g. 510080 rt! rili : 7771103 ( .(,?,t;1 )
No, 23, The 3rd Zhongshan Road. Guangzhou The People's Republic of China Tel: 7774103 (ext)
Henry J. Heimlich, H.D., Sc.D. Heimlich Institute Foundation, Inc. 2368 Victory Parkway Cincinnati , Ohio 45206 Dear Dr. Heimlich:
April 8, 1993
we have considered thoroughly the use of malariatherapy for treating HI\infected patients. Malariatherapy has proven to be a safe and effective method for treating cancer . There is every reason to be cominced that it can be effective and safe for treating AIDS. we are ready to provide malariatherapy to HIV positive patients at this time. My background experience with AIDS includes: I have worked in the field of infectious diseases for thirteen years and special ill the field of AIDS for fi~e years. I have extensive and deep knowledge on AIDS in the respests of eteology, epidemiOlogy and clinics., Four years ago, I first proposed the hypothesis of HIV orlgenating from human spirm genes in an international conference. In my laboratory, I can do many things on AIDS including HI\ culture. The scientific evidence we possess of the possibility of increasing production of immune substances is ver~ sound. The stud~ sho\o;ing the survival of children who have AIDS and rnalarib, hile 35% of those with AIDS alone died is \er) convincing. It is obviously not possible to predict what our findings will be from our research studies. To not attempt malariathelapy, however, leaves AIDS patients with no possibility of effective treatment. Sincerely yours,
Dr.Chen~~~
The rluuicipal Health and Anti-epidemic St" ation of Guangzhou, No.23 , 3rd Zhong shan Road, Guangzhou 510080, P.R. China
}I~ltr;t
J.
JI~d ~_
/VI/), Sci).
f~)/~h )/V~
2-3Cg [}~J pMk-I~(r'
Su.l:6-. !fl()
~d/flnd:
oL t!-.J"2-tJ6
71)y tkvr
b!f
tid.
J reW-vd 0
lAX
ttrrMUL'x Jl (
tJ17
Ldftr)
k;f rA~
Pr. }ltu- tftY(j5kun
~ i;tr
fr ?! ~twW l6 r r~~ '4 twA ~ r~~ ryj a~r

~J nu-rrd.e,.. J.U>L.~
Apr. 6/
-;6b; ) -:tr~ -:tii u/~~
~ r~~?]?W restorH- . Sf)) >ent rJ&U ~t. J WtncU L& 7T
./dt.ir ahui (f
tt:. CffrrdJ
U5&Y'~ ~m~~ .
u{
<nQct/
~ ~
?7UfIZb
c!f =&;-- -;t-ned -tiu 71.-X7J
rf
~di . ~~~)-tlu ~{{~
/;;;td 1nK'-
~{
(ftrv
~e
Sture-
ok
m~!f~; -t;1u:- ~k &'f ch~l1~ ;" !Jew 'frf
(//~r.e

<P IN i:Hi 'ft 1 1 1-"-: llIr23-<;ru~ i!:{!A!~:
rl!
510080 -~t : 7774103 ( , (Mil )
No. 23, The 3rd Zhongshan Road. Guangzhou The People's Republic of China Tel: 7774103 (ext)
Henry J. Heimlich, MD. ScD. President, Heimlich Institute 2368 Victory Parkway, Suite 410 Cincinnati, Ohio 45206 My dear friend, Dr. HeimlIch:
~Iay
19, 1993
We are applying for the approval of the government for the use of malariatherapy for HIV positive patients. But the situation of using this therapy for this purpose is very different from that for treating cancer patients. The first thing is that HIV carriers are verJ fe~ in Guangdong Plo\ince, we have onh a fe' cases on hand. The secnod thing is that none of the cases ~lllln8 to recei\e the therapy because they have no any symptoms (just HI\' POSItive) and theJ want to keep the secret because of the AIDS discrImination in COlna. If ~e want to persuade them to receive the therapy, we have to paJ all medIcal fee and accomodations for them (all the patients live in the other city, not in Guangzhou). The thIrd thing is that none of the hospitals willing to cooperate with us except we are able to give them an enough quantity of muneJ for all kinds of relative use. The reasons a~e that the AIDS-phobia IS verJ severe in China even among the medical ~rkers of hospitals and not onlJ this is the first time of malariathelapj for AIDS, but also the first time of am therapJ for AIDS in Guangdong Province. Besides of the above reasons, the another important thIng is that we must first get the power to culture HIV, just as you said, the observation of HIV culture result is essentIal for this research. This thing is under the control of our Cen ral Government (like the Federal Govel1lBlel t of [SA). But borne office's of the local go\ernment saId that if GSA give filillncial support to train a doctor of ours in the special field of AIDS in USA for a bholL telm buch ab 3 months, it is a good reason for us to get the power for nI~ ~ulture dnd uther relati\e items (herewith the budget of malar iatherapy for the fir t two Hn' positive patients).
lours sincerel>
cbr
Dr. Chen liaopins The Municipal Health and Anti-epidemi Stalon of Guangzhou. io. 23, 3rd Zhongshan Road, Guangzhou 510080 P. R. China cc: Dr. Hua Hong Shun
iB~ i!iC~lii!J :
The Municipal Institute For Preventive Medicine of Guanozhou c
00 rffl
lll= Blf23-l}
510080
i-l!
5:
7774103(,~, fn)
No. 23, The 3rd Zhongshan Road . Guangzhou The P eople' s Republic of China Tel : 7774103 (ext)
Budget for the First Two Cases
(USD)
Ite ms
1 Case
2 Cases
Hospitalization Routine treatment and Nursing Special Medicine (Albumin. Blood Tr-ansfusion. etal) Medical Workers Reward for the contact with HIV Articles for One Time Use Special Tests (Western Blot.HIV Culture. CD4. etal) Research Activities Ward Equipment
1500 1500
3000 3000
1000
2000
1500 1000
3000 2000
1000 1000 1500
2000 2000 3000
Total
10000
20000
If possible. USA for 3 months.
additional 5000 USD for one doctor training in
at
f,12/'i 3 /,JAi /II. . /I -I; ,.-~~_ "/Lu-e.A v- L ..d
C1
j -c .-</ P9.3 (':'..::~ .-L(!>-er,"1 -Dr. e/'-1:~~ ft'"~';~.- f-l~ " 1

~ ;..Y._ ~~ c,'
IJ-< (/./7Jh~.",( L~ :a .~~";?Yf if"" tt:.,<-~ .I/-< ~eI /U-(~ -/, 'IY'-f! .4 ,,~ t-...='-o I~~ ~v-4 4- / J...4-.---d F /l-)q is' Ij-i.. ..J<~~c~ "" L,; l: (,t {l I j( 1::'.- /1 ! . '-t.-< v-<-J t:t. v-~,--.c-I I'I.--V?-t-<..; o{l r:-t.y, .q...e-z..;......-~'Sr t'.,f.f:~po;/ -t~. /H v <: j t <r.'.? 5/ tr -c'lA---.d ~..I tL-crt ~ (~ ~{Aa~ p-t...,.,...) I/7i -J.-<<-.J. }'-,,~'1_-J
c::..-(
t-f /I
ifZ>
("-if
~~Vi' -~~~ r~J.;.~ . ~ l/l~~~~ ?.....c.~'...-~ i~~~:7":_, :(r~1- '~ /;y!~71.._4<J-I_-".. ~l -1-< <'H.4 . Jay ~t,-", . ;;'lY<.1 ~ . ~ ~ ~/-TAr-"<-j S. ~;(.~~t; . ztCl- '-~.,;:..-:-~ r~~_1-':~ _ 3tH) ': ' \ t-c.'1- /..l--<"'~""" ,cv"..cA.. JI-v.. t:4"')l" -{-~<"'{) ~,./"" J"\..<r ( t<.fl-c/")--c! I elY -jrt.. . . .tLd-'" ' .l'l .:cJ~=:~.~1
.4".1' " .. vi'" b>'-ty -likd-
.Vi t"l. h> 'l
')"
{ { . .-I.e- <N . t'or-i- (J
}-'Y\.~~;;
.;J
Il'J . . .,(--e. . -//l.,~.\).c( Ir4' ~ ~ ;-~.utL~1- V;I~:' /Lv~ jr,.rrrc ?c.--."-;-.-:(. ...~. f ' i<..di:',(!I>j t't 'H".c;>{ .e.~-y ITt~~ r"-'-<- . a4-6 -;Pvcy~~ . .~. . ~ef a;u ?v-r:;-..J-t."';-.,{ a./; -(..",./ .L/.v!~-'J( ,
.4"'7 "j":L..- di(f<A<-J rfJM"> : "':,.{Y). f,,27id; "-"< '(1-1' ';< >-1..(.0-<' F-:..c. ",-,,"d M ''-''-I-~ /l"" ;"'-U>4~'<';- 41
a" n,- lit" (-1./ / ' " ZU": I;
.
"'-'t.L
~Dl: ~i.n A-.0.<-..,.- ~..t:.t-I?..-~ .t- -I.I-'-""'~~'7' r~"-.f.""':'-:~~ (J ,P~;' d,,, ""--l,"'--.....J-p "t1f'r.u'.E;.- . ,
" I;.L.",
,.A./'" - .
.<j(?r~
(7
"/
{_ ifltl-.-
(t ~!' db /~
H-'~ -<1 -t.
'I
L~' c~;.d""Cl.""f- 41: 4'"0 (-{(ti("; )/".?tiZZL:'l; .

1 ;/ (
dJ-Jl<! {l/
()
~t:..:.. ();J.b~,./,
'f )1
~~:~h;"
It..
h
/(rfdIJ (.1 ,,{ ti. c:/,

,/
(.';> (l
~j1::)---e1 . ..t?t6~ '/u-tf./C-A d , // ~. 1:"'-;;""7' PAi"-' /tA~ -;{~~~1 r--<L~-J--':/' ( Iff IflZZ; ..: [ 11 .(..e.L( a!;jn (j>;r,'/.",~,~,4 ,{ (tJ~~ .- l > " ".' (.:.r . .l. "') <-'i.7""1 .....i
)1&.. <. ~J}'\-? ~,,, , , 'c-<-"f ~

(t ,
vii:; .-/
;tt,nH.., ;
."1
'.
()I.
'-t."' ..;{-('.(J /. (..1 ()j./I,t4-()-v---f"
'r" d .<L);,k,,'
1)-M.~{.~""'::/''' ,(~ ..e . ",(/j', -,vv . 4-/..~-l/ 14!
/"1A.t,. . ;;.,..u . A..c.... ~..f- -.(::;C:tt-
,a...( - A-4<---'L-I.. . . . . .-/.-. z. .1 _. .
ir r
..J ?'~'L""t'
,-t-M~~ I_n.~;~ c..I- .-ur .ALh_t/~1..>-~;r ' ~'-3- , "o!.. . -'

~-
'v_ :7;"
r-
p-'1-Cl--v---'d<4 -f)/].-c--a-y
,l~-
--i!.-.U-U1.-7
1\. (?,.i)-.;~j-
ron , ( ~"/'.'
;{.i>
(I . cr l VJ 0 .<.: , ,
Ut- 1ic.(. .(.-"-(..77 'u."" -:'} /~d- e.e.-..J,d ~4.:1i!?1..1- t.(/;~,t..~ 0( fl'-tt_1-1.~/. ,.,>t ~'t " ~-<~1
.0-6" '/
l :'i\'''' ( ~ .;,~,-.(.pUC&{-l
/I1.I."""-II,,,-f-.;(
'1(:; !~)<
..
~".14 k
'-'
.e,.~~ ~
I
1/(0,.,."
HI V (-r)
"
c{ -<---
~ c.tt~"j.Cecf /l-V~l:.4
0 .....7
,e)./
;tiL--.. .
" c/l.
tf
ct.;-c..t;-v- ~-
to- d .... ,t.{, ::>- ,a n , _ ,:. , ~~-e

~t.--~,".
F'i... .l;
':> V
6-.4-, .a:.::r --?-tA:-;:,?iCi.-c.-r ..;;L.J'1''1,"-~,J-.

",'7~L~;"'L~~" r';l
(,_.J.. p""".:.-;c~ ..~-.t;~ /
/JI[)S In'Z<I"'L-I,t ~ ;;""-'-o{ t<!.-e., J...,....&.t;...:t. cft-..-i:.(~'l.:...(.t.- Jt.JI"l.-<-..to(f!-) -o;.. ,,... t.-<.
t-.,t,"
t,;v{
iJ. c...t.;
to ./,-~:t1~.{:::4 C.l-?--r--h--t-//APr
~
0
ti{-C.' ltV,
7AAf-
tb- tA."i<'-l-I'''';lj07~ 17
,..tl-l
(1 ' 1
)10
t .rt
)ll.'(,fAj- 0
~lJtl ~t.., . ) Xt~2)

,d O~(~t ./I.w.~,
:a,'1 . t~~ :tIv.d 9~'l. ~ ~ ..JJ.-tl -l7tJu.

,~~.J:.,
--~
"..d-t..L
I.~~(-b-(.."') ... ... ;-.!t,)." ../:.J;/
?\--H
LLl1.- /t.(..C~'(.-<~
Daar Dr Hua :
ft-~I ])y, c.~
k ~ t~
August.24,1993
1 have alre~dy receivect tbe wired amount USD 10,000 ( ap p ro xim ~ t e lY ) from the HeiMlich Institute, I sent a letter informing Dr. He i mlich that we shall finish the first 10 cases within this ;year As to AIDS project, we do agree to have the sponsored fung provided in separate installments. We would like to know that the sponsored amount will be USD 10,000 for each case, because our budget is proposed according to exact expenditures. Once the fund project is $~ttle0, we could start the treatment. As I have mentioned in a previous letter, the hE.!altl1 department hag already giver us oral approval, that once we have solved the fund problem, we CQuid start treatment and it would be not necessary to wait for the written approval. Because we have malariatherapy experience about two years, we could start the treatment.
Fo~ the H1V infected patients, we ~il1 observe and record mainly the immunological and some clinical data J as T lymph cells ( CD3, CD4, CDS), 19G, 19M, IgA, H1V antibody and antigen titration ( because it is demonstrated that HIV in HiV infected patient could not be irradicated by malariatherapy we o~lydO HIV culture when it is nede~8ary. We hope that we could finish treatment of 10 cancer patients and 2 HIV infected pat1ents within this year.
with our jOint effort
we hope that we could get succe5S.
S 1 l"lcercly,
Chen
Xiao-pin~,
M.D.
September 2, 1993
FOUNDATION, INC.
2368 VICTORY
PAR~AY
HEIMLICH INSTITUTE
SUITE410 CINCINNATI OHIO
THE
Dr. Chen Xiao-Ping The Municipal Health and Anti-Epidemic Station of Guangzhou No. 23, The 3rd Zhongshan Road Guangzhou, 510080 China Dear Dr. Chen: I understand verbal approval has been given the HIV (AIDS) research project by the Health Department. We hope to study 10 patients in this study. Please send us their written approval as soon as you receive it. The final protocol, candidate selection criteria, report and consent forms are enclosed. You should have received earlier drafts from Dr. Hua that you can replace with these. Dr. Heimlich sends his best to you, Dr . Chen, his son. Sincerely,
45206 513-22HXXl2 fax 513-221-0003
September 2, 1993
FOUNDATION, INC.
2368 VICTORY PAR'r-WAY SU ITE 410 CINCINNATI OHIO
HEIMLICH INSTITUTE
THE
Dr. Chen Xiao-Ping The Municipal Health and Anti-Epidemic station of Guangzhou No. 23, The 3rd Zhongshan Road Guangzhou, 510080 China Dear Dr. Chen: I received a letter you sent to Dr. Hua on August 24, 1993 regarding the cancer and AIDS projects which he translated for us. Your letter confirms receipt of the $10,000 for the five cancer patients. . Please let us know the status on the two patients under treatment now. We look forward to your selection of the next three patients. You can fax your replies directly to us now that we have had someone change the fax so we can receive at night. If you provide us with your fax number, we can fax these letters to you as well. In the future, please send separate letters when speaking about the fund information versus project details/status on either cancer or HIV (AIDS) projects. We'd like to be able to use your letters on the project status in newsletters or notes to our supporters, but we can't when they include anything to do with funds. Thank you for your help in this matter.
45200 513-22HXXl2 fax 513-22HlOO3
Susan S udrette Executive Director
September 2, 1993
FOUNDATION, INC.
2368 VICTORY
PAR~AY
HEIMLICH INSTITUTE
SUITE 410 CINCINNATI OHIO 45206 513-22HXXl2 fax 513-22 HXXl3
THE
Dr. Chen Xiao-Ping The Municipal Health and Anti-Epidemic station of Guangzhou No. 23, The 3rd Zhong shan Road Guangzhou, 510080 China Dear Dr. Chen: This letter will confirm our agreement on the fund arrangement for the HIV (AIDS) research project. The Heimlich Institute Foundation will provide you $10,000 for each case studied under the HIV (AIDS) research project protocol. The funds will be wired to your account per the arrangements as follows: $2,500 Downpayment for each case when photos and patient history are received here, and the first malaria shot has been given. When patients have had no less than 30 days of fever and an update and fever charts are sent to us. At completion of malariatherapy when photos and reports have been submitted to us including followup reports per protocol at I, 3, and 6 months.
$2,500
$5,000
In an effort to expedite this project, a $5,000 wire has been sent to you today for the downpayment on the two HIV patients cases. Please send the case histories and photos you have on your first two HIV patients as well as the start date as soon as possible. Dr. Heimlich will come to China during the fevers. If you could give us notice when you plan to begin, we can make his travel arrangements. It is imperative that this project start immediately or the supporters of the project will withdraw their funding. If you have any questions, please do not hesitate to call me. Sincerely,
~dre~t""t-CAe'~""'~"/L.oo"
Executive Director
. _ .:...-, ,,
'
,_ .
'_ ''''
'_ '
__ '
,...., I
I U
,....,
5-L/;f I b . ( 9 93
-rt.:>
irEM.s
I
S~4.;., S~f~
~.I
I
flt.p *
'7-
/rIU-A U"...,~ S~ .. M.:P.

~~
. .
y~ ~
~.
~ /LU.64'~.
c!..J.,I~
~ V,.. C-M,... XI"~ P~ ~~ .../A"..I-- ~v.
/tk.. ~ ~ :d:iJe ~ ~ '-e ~.....4, ~ ~/~ +p~'~'$ ,/h'~ ~~~"'Y.. 7LutWd/

~ /~
IY.1
~ ~..et:i;
1'Uc..... t~
,'~.
7t....,
t!. #"14-0'-1
~~ -~ ~d.A~ ~
~~~~fr~~~.
7"--<~fI-~ ~..w;q~~ ~~
~ ~~~~.d...(-~F~
~t
~
.5';~~~~~.,hA-~tt~,;
w~~ .,&~.I.. ~,...
wU-t ~
~ te:,lJp~ ~ ~~ 4/- S ...p-I),'J.
~ :"'(~E-~rNnt~-' 7k.c...~
,;ft'~1-~ k
(J--J
I
L.
4.~ 5"/.......,1...-.. ~ ~M".."1~
~t) ~ ~f/I"~~' ~ N~~ f2..-~ ~J)
~~~t~1./~ >~~~ L..~, 7~4. ~ l.. A,,~ . $~~' 4- '1~.~~ ~ <91ii-'bJ-...,t-... - ~. A. .&-tSb #' I J"t>t). ~tiL< ~. I~ ~J01]
( '1t-+f .;; .ol.:~'; ~~ .Y4~ ~~~ . .;J
--r.
/~p. _ ~/.
J aW :
(0 :
~t~2.8, 1'f?3
flr.
k.-t.f~ 'e-t,
Htllt H~ ..S~, H ':/J.
R~1t1 q.~J
I( ~
Ck'~ -r;t:U'~ .
tt..~~ ,!c-,.,.~~ HIV-r ~ 6~
J ~~d ~~. ~ 9p..,
. ~~ ~-I'~ ~~ ~
~ ~~ ;l.4""'~.:.r ~.,.
Ji ~~ Dr. y,.,...,
Jh. ~
1!4
/h.:"- . l'
.j~.../ ~ S"~l..t -ftw IJ."""r S
1~-4U.- DJ PtU~4IA""-'" ZL.t').'.c.4..-fM .
."7~t..7 MjA.d1
~ ~ ~~;~In.44~ ..
tftqcf;f~.ft.1M ~~ ~ . ~~ __ ~4~ _~ LC
,~ ~..~ ~.u.I~
~--~ -~ dt(~ .. ~-/vY
~ ~ I~~~ ~r~~~~~p..z~ .....; ~ H:e..r;a~~ II ~-fr~*/~~ ~ ~

~A..~
.1 ~
~ /t.uo~~-~. krr;s ftoJ~k ~~ J ~'~.J- G~l~ ""
~ Q- At:: ~~.I t( ~~. ~'~~j~-hu sr.l)C . ~ n~wJl-.-d ~~ ....t.~"~5

4.
~~~~~~ft~~
~--I?~ 'PIH4" ~
J);. ~ x~!J~ ~ ~~ ~ ~,;t,.;;I-i&1~~ ;t;;...r~
7t4- tJ~ ~~ ~ I~ /.k1)s. II-L

d)-t
~~~tf;~~ ~~. ~If~

?~
~ .-zt-~~~~f~ : ~~~~ ~
~ p-w~"':i. Ilee tt-L

",,(/-1-
~~ 4J~ ~
~J-1tt.-7 ~~.
"H"~ ~ /u4~;"~ f~
~~. ~~~.2$ .,_,;.(. -.r.........it ~;--f (
~e~~:Ja-~':7h~ a-I ;t;;; t't,..~ AJ.,.;//~ O;r%f~
'"'
~-"'--I ,....~!
c:tn,..(
.IV '"
~~
% '""
tt4.r. D /'.
, ~ to-d-{J
1-111/+ jd~.
])~ ~~ (-a.~~
o~ i
-rr~~0>7 b &f14P-.vv~4.J:
: set,.(..~.
~"?l.dHI
d::. ~':'.-..."f tv A-I:-
~ I~~~ .
~~~ dA.ttL~ ..:4~~
(~X:/,~7-.fn,.,~~~
(G ~~.~-o '6~"~~;"
~;
)~ 'f~~ )t14'4"'''' ' ~A.~ ~--...~ ~
~~~? 4/.{ "w.lA!' ~ ~

~ ~ ~ ~~
. ?4~~~~~ .
41>1
?1
lS)
"HJ.'X
~ ~~ ~~ A.l..J44- ~
I
~~.
:If
~~ ~
ltl ',t.j;, IJt~1 \'I1'''\~l~ ~{l

,
~~Wl.ld,I'II)llt, the
('II'.
Ch~!n X\60 Pins.

In~tlt\Jt..o
t'~Vl ChIef of ~l(:r{lblol\Ji~

fot,
Pr'<lventiv!?
~1Jn\ciPtd
~I.HC'lnf; of
R(Jr>ubllc: of China on Nl>velnber 10. '993.
SIGNATORIES OF BOTH PARTIESl
XI~o
Bin Quan
Preventive Medicine
of Gu~nKz.hou,
Pt'o:;id('ll'lt,
The ~un idpa.l lost! t~lt.fl for'
Henry J.
H~f~lich
Prasldent.
Tho !\e1mllch llU1tltuto.
\)f1to of SignIng
To ~ "l>~ ~e1~Uc.J.- ~
MS S~ttre'---t
FtrIM
Roe...
I
O1{Wft-i~~ "M~'4TH~M-4 11(~+)

R~.u--rhN!-.
H~No 'S~VA)
Hv ~
,1:> ,
(flJel~S'~-)J 16 D~P.i t1f. ~f?~6-JT, PRGPA~~b..y'Dr. C'.k~ ,
H' Yt.M
~,,~.
TIi ... l>r HtV1' p~ Wltl-S ~M.l~ ~

f-'\AL4R-lQ
fl/~ Wr'l/ k
;"~~t.tt.d
tt.$
'0'tI'M
I~ YIS/.i~tA I4-,S. ~ a&./-
B~.t1- ~ ~~rka-., -1-~~c..y,Lh~.h s~ ~v::.~~m~""~'.~J . .1'((M~+O LA ~ .!Y~/fa "
~~.
O C T-16-93
S AT
0 7 : 00
P M HUA
8 18
442
8676
. ..7Z!. . ~. :Dr. FI,e.l~/~:~ .. ._".._~_ ~~U4~.e:fI~

~'"
I
IfDNfir$htlN
.... ". . .. .. , ..
Hull. ~. b
. .. . . .. . . a . . . .. . "
R-e..
. ,L t>-'v4PI..""" ~ l ...~. Z4. """ Y-t -1!;l"aH .;~ MoP 'n._~t!-',~ ,U~.3
. . . ... _ .. ... . . . ' . . ' . .... . _.. " . , , --.' -,
C4'1Wt -r1"fA.l~/' ~~/4I"t~ ~ ~v ,
~''''~ J!:i.__ fJrt'j~.d-_~ ~<! ~~n'd1w <>I A.t:.. ~

4J~H.t ~b'UA/ f(N~ 4!"'~~" ...,. rite/" '.... ..; til}!;"~ ;~~.. -..";-"~~ r...;,:,,~~':'"
lu,d-
ph. TAt:; r~
?JiIy ~/"''''''''' II..tJfX--"...... 1-..,f ,;. UN"''-;'" lk~ ",;TIt

..
rnA- ..".,.t-.~ --:.,M ~~"~ . . '. --.-. .. .

/;.It
_J,"IJ~ ~~ ~~""'Itt--,a 2>~ No.
tn<t'l.:J..--fo~ 1'/4$~'~ ~ ~~ . . lJ-e H~I-!;S f4ri> -'1"-~ ---'1
.. foJ'-".S!:~4)~- b ~.
..
WIll
...t;., ~iPf-.tt,.,; S 1/tt.!'ttfl.
~ h-u~ ~. !.-. ~.~f.~C.'!~ ""'~tIf r4ts. ~~ . Mr.. Lt.( /v.JM~.~ tl'-IIIMoW, zu.,.J 'i .]}414"Jr:~ ~J"l"-e .i ' ""},.. ... . . ._ .. ..." .. . . .. .. .... ... ... .. . .
.z AU-,I.-' A.f"", .,tp~~Z>r. a '-....; .~ ~ <Z 11~ (fJl;!A:4/ /,'/(J.1b ~ II:.-.Ittt ~f 0/-- B..... ~~ r~'h,r4.f , 7J, ~~IM~ FI~,-, . ~ . "11-~ .. z.r"77/Z!s"z... % ~~ ....... 1tU~ .
. ,
vtJ"';-;-'~.~~.I..
"
...
.. . . . . .
M "
""
X lt-l G
T lt-lG
EL E .
C.
372
268
e:::
10"
ffll'h 0'
""DR. H'iIM(.JCh
101$ Saud"~#-4!!.
tI(.)A k~A/~ -SHVN 1M. Z, ~

C#IIJ/J MJ#~IUI. 'II *'r"I-f6'1(4p Y
ItJ/2?
R&- .'
.vllrE"--.
1".3
(He 1$1- HIVof P_I;~~1t,1-
bltHJq
"fI....'s ~tI,.,.;~, ifl..I ..D~ eHEW Y;4~ ~Pil'r~ JusJinform&el WI.. 7Ae ~4Ne.J e.cJ:t1 6~ ~.u..r~d -IeJ h AlIt!! ft!!~ ~ 1- 3 d.l ' ; e.. 7 ""-'~t ~AfS .
#
was ;"i'c~
wlM
"'AI.,.,-"
filE
6,..,7'
~~
f 71e-,...rnJ-u.f'Et
~AA.r.f
;F
/'It"n,~
-f 7k
~tJrM ~Atet?M." 1'J.t~ w,'n J,.4? :s~
.fe, y~
6y ~a.;-I. a./se> c.q:/I.~ Wtbu"'r.-l 7iL ~ ~ f i"J""S4,..et)/rtIt,.r ~ c::wf~~ ""~ M..A #: ANI. ~ 7M.!~ ~ r&. firrJ.. #/v.;- #,
1(- y~u n.A-I'e ~ "'r.ff F!rX -fr, j'''-u ~

6~!lUfl$
'I~ V(S~f
<!t1' 41
C~W,IH~,""f.
not
7t<.- 4fh!.l!Jt1t111tliL"I.
~y.).!'- /?.J
Pts (e.J- wt~ ~~,
])r. t:!I-liHJ wtJuld lik-~ -ID '"~ ~1',..tiH-ht $
c1 $IfJ? tltt t:t.tr~lttflKl- 4)'~
G u~ M#IA.
,... ,om ;
::'Ht:r~
HH 1 HU\,j
Case report:
co~c
1.
No. of hospit:3689.
.
.....
Name: _ _ _ \lInle.
~ DDte
Address:
Qf
nd.isscon! Octohor22. 1993. Found HIV positive for 3

month~.
Chief
c01Jp18int~
Hist.oT'~
uf t.he illness and its epioollliology! This patient wont AbroRd
for tourism In _ 1992, Lo Hong Kon5 for one week nnd then to Tid land for two week~. no the hi&tory of homos(lIKuol or hAteros8~U8' int~rcourRH and no the hi~t.ory of injection such os u~os of blood products in Hong Kong and Tai land. Ina? 1993. he went to Phi 1ippines. about 3 IIOnths later he found a job in a clothes manufacturer's in that countr'y. In the time of about"to~. be got l1 high fever about 39t fOT' several days. so he went to see a local doctor and rt}(~ived on(~ injection and one time of blood taking for examination, then the fever disappeared. He said l..htlt. the needles and syringes were not for onetime-use. In the period of staying in Philippines hn found that an oversea Chinese man often used his shav~r without his agreement. lie said the man had the histor~ of sexual intercour~e with many people (heterosexuals) and suffered from STD. He sometimes hert himself with the shaver for shaving. which had been used perhaps by that man. About in~. 1993 (before he came back to China). he fought with a man from Hong Kong and was beaten to hert with bleeding and so was that man. He said that man had skin disease with penis pyorrhea (the man often sho'tf~ his penIs to other people). He denied the history of any sexual intercoutse. Besides of the severe} day's fever roentioned above. he h!:1d no any other' SYlIlPtol8S In th i s two ~ears. When he clime back to Ch ins in July 1993. he was found HIV posit.ive in Ouangzhou Customs.
-"
In 1989. he had appendicitis and received appendectomy in the First

Hospital of Sun Yet-Sen Nedical University. He have the history of allergic rhinitis and denied homosexual. behavior and addiction in his 1ife. lie also denied the history of tuberculosis and malar'ia .
-1-
"...
---=-
Examinat.ion at I:lllilli~slon: ConSicioUBnes~, wall1ht: 56 1{g, vital signs normaL development nurllla}. No JDunuice and edema in general skin. No
petechhlO, ul(:er, whit.ish excrul.lon end II\flSg in the orfll cavity. Thera "ete 1-2 lYlIIPh nudes in two lnguans, each of which WH~ as t.he SiZA of 8 pea. DlQvtiule, 1\0 tender-nes::>. No Anlarge8lent of other- sy~erficiollH l~lnph nodes. No special rlndings in lunF,;s and hcart. l.ivQr and splp.p.n were haps Ipab 1c. Thera Is 8 ~Cttr' I:Ibout 5 CIII long itl tho right low
abdomlml1 wall. no abnunllZ11 findinss in exo-genitllis Hnd in four 1imbs.
' \ " ,J. ,
Lub.:
H~IlIUgralll:
lIb 14d. RBe 4.80 mll./mlll lJBC 5000/mm N 66%.
band-
.,r.
cell 2%. lobulated-cell 65%. F. 1%. L 33%, Ab90lutc lymphocyte count 1650/11 1. Pc 1.4 x 10 /mm. RF negative. CD3:}238/~ 1. CD4:706111 1. CD8:446111 I. IgG;10.4g/L. IgM:O.95g/L, }gA:l.52g/L. IFH : IFNP : IFNrl sorr normal. HBsA& negative. HIV-1 antibody pos it i ve (before adm i S5 ion): El.. ISA (+). Wes tar'n Blot (+ ) . H IV -1 l'int I body titer (ELISA):
Chest X-ray: There was a shadow about the size as a thumb in tho top of the loft lung. "considered as inflammation. lung 18 )'S , to be ,."C Uded.
I>V )
It
Diagnosis: HIV-l infection. asymtomatic carrier, Malariotherapy: malarial blood of 10 c.c. was injected in the Illorning of October 27, 1993, the sizG of Plasmodia vivax Wa~: No inoculum fever. Anti-inflammation (top of the left lung) with cefoperazone IV drip and cefalexin P.O., one week later X-ray re-examination
,.J
, \.1 I
.',"
-2-
('

91 fi4 rfli tp LlJ ::B*23 \}
EU&i.1iIl>'L 510080
"0.
23. The 3rd Zhongshan Road . GuangZholl
it:.
~!i: 7771l03(,~.-...)
The P eop le 's Republic of China Tel: 77741 03 (ext)
Henry J. Heimlich. MD. ScD. President. The Heimlich Institute 2368 Victory Parkway Suite 410 Cincinnati. Ohio 45206
October 28. 1993
My dear friend and dear dad. Dr. Heimlich:
I am glad to tell you that malariotherapy for HIV infection has begun. The HIV positive patient received malarial blood on October 27. 1993. The incubation is about 1-3 weeks. So you can arrange your travel to Guangzhou according to that situation. I hope to see you again in Guangzhou. We will talk on detail with each other in the time of your visiting. Wellcome your wife. my mum. being with you to come to Gungzhou! Your Son.
f
Dr. Chen Xiao Ping
~ ~~
Chief of Microbiology Department. The Municipal Health and Anti-epidemic Station of Guangzhou. No. 23. 3rd Zhongshan Rd . Guangzhou 510080. P.R. China.
DATE:
November 5, 1993 Hong-Shun Hua, M.D. Henry J. Heimlich, M.D. HIV Patient - Malariatherapy
TO:
2368 VICTORY PAR'f::oNAY SUITE410 CINCINNA TI OHIO
FROM:
RE:
45200
513-22HXXl2 fax 513-22HXXl3
I received a report on the HIV -positive patient from Dr. Chen. He says that the patient was HIV -positive in Guangzhou Customs. He does not say whether the tests for HIV were repeated when the patient entered the hospital. Call Dr. Chen and be sure that this is done. If the patient has proven malaria with the plasmodium in the blood, then visit Guangzhou to see the patient and be certain that the tests and fevers are being followed. I will consider visiting Guangzhou if the patient is proven to have malaria, or I will wait until the second patient is treated. Just one page of the Agreement you sent on November 3 arrived, please send the other pages unless you will be back in California soon. I will be going to California on November 18, and we can visit together then.
Benefiting Humanity Through Health and IPeace
X ING
TING
ELE.
INC.
372
2687
P.01
70
I]),r<
I
FIe~~
t(E :
JI~ItI$~$'IftHV
/1- ~ - 'f3.
' J.I~~H.t.r.eJ, t/ M~ SDc:Ire.tt~

HUll , M. D "
lJat~.-
.
#
HIV~ PATlf7I1T Ml9lAJflIArH~~/.

:?Af' lsf II/V+ p4lt-r
mA/4r,'a
1.. ~U.$t- 1"t~/"~eI pI1Hf~. t!a..tI -f6141 "Dr. ~b7 X~-

P:":!.
!/"f lsi-
f<!Vd-
t:CI/4U<
yuludAf[ ~
61-.1 ;rtrj)e-1..fl~. 7~e

WM
f~ ~ IItfNC..../, 6...1- P(MJ"II>~lb/~ yd.

~,( I~ :tii 1/1,;1- fh.u~ 'Z~ k
f~~
])1< . eA~
"-4-1-
f--d ...;
7::< CII~ w".Jd Il~ To htAIu pr~(J')f.S tf-
r'"'"
wa..l"'td, ~t.s
~.d- A.(.
w,..d tI 4#1<
H~N~~ Pr~"'c(...J- *f
M.uUcJ.t!.
J
-~ ~. Iut. zIi:i 7#6- INH1'+r,J.... t>f /MV6-41-rI"'~

tl
#If
G~~. ~ wv..dq "11'1,1
(kt-~~ .t:lu",,14.4f y~r HI~f,

Aft,{
r'/"tl ,.~ !'Ir~~' f ~kH.~
:f1fY 41~-UI ~
iT'>' " / - hJLU{ 1rJe.
d"1 s . .Jf roPst ~~ a.-y ~ pl-,

..f.n
fltsH- ~~~~~.
NC.
Pt-.,~ Id~ K....,.,v .
My P4-x
OI'-8'6--:J.!- 3722'87
THE I NSTITUTE OF PARASITIC DISfASES CHINESE ACADEMY OF PREVENTIVE MEDICINE
Dear Hong-shun
December 6,1993
As we have discussed during your recent visit in Shanghai, if we could establish a plasmOdium banK in China, we are able to treat cancer/AIDS patients at any time. The malariatherapy project could be carried out with a much faster speed. Once malariatherapy is proved to be effective to these disea5es, even limitted to certain stage or certain type of these diseases, that wOUld be a remarkable contribution to medicine. Since your project seems to be promising, the pressing problem ie how to proceed the project in a bigger scale and with a faster speed. I reported this matter to Dr. Fong zheng, the Director of our institute, asking if we could establish such a plasmodium bank in our in8titut~ whenever the Heimlich Institute needs our co-operation. Dr. Fong told me yesterday. that he fully support my suggestion,and authorized me to inform Dr. Heimlich and you. For better application of malariatherapy, 'mosquito transfer' possesses many advanta~es, such as , to innoculate patient with a specified plasmodium of specified quantity, capable to let patient get fever at predicted time and with a predicted number of episodes, or to let the malaria episodes relapse when there is such a therapeutic demand. But at the same time, to establish a plasmodium bank is a complicated team work,and needs plenty of time. By the way, time is of ~&sence. If you want me to co-operate with you, we better start early. If you are considering and planning ,please let me know as soon aB possible, so that I could make plan Of 1994 and make arrangement accordingly. I could make a research program exclusively for malariatherapy~n my lab. After we both convince to establish such a bank, we shall discu8s the project in more detail. TO inform me ,please FAX 86-21-4332670.
Sincerely,
Yang
Bel~11ng,H.D.
Dear Dr Heimlich
December 9,1993
During my recent two months' travel in China, I have visited 5 hospitals in Nanjing,Xuzhou and Guangzhou, where c~n~er patients were treated with malariath~rapy. AS I was Inform~d by physicians ,who treated these patlents, that among ~he 10 patients, 5 demonstrated rather sat~sf~ctory results, 1 with slight favorable result, and ~ wIth nO effect. None of the patients showed adversive effect from malariatherapyThe patients of rather satisfactory results were; 2,br~as~ cancer: 1,Karposi sarcomai l,fibrosarcoma and 1,adenocarclnoma of lung respectively. The patient of slight favorable result suffered from small cell carcinoma of lung. The patients of no effect were of CA of esophagus, nasopharyngeal CA, Ca of head of pancreas and small cell carcinoma of IUng~espectivelY. The result of 'rnalariatherapy of cancer' clinical research might pe sUmmarized as follows:
1 The process of malaria blood innoculation from malaria donor to cancer receptor were handled safely in 5 hospitals. 2 Malaria episodes induced by innoculation did not produce adverse effect, that is, cancer patient could tole~ate malariatherapy. 3 It is very impressing that rnalariatherapy could benefit certain Kind of malignant tumor patient. more than half or the patients of this group got favorable results. 4 Cancer patientsl their family mempers, and hospital staffs are all convinced that malar1atherapy could well be accepted and warrant further application.
since the procedure proved to be promising to cancer patients, we would continue this therapy in cancer patient and also we shall initiate the therapy in HIV+ patient_ Now we have started the first HIV+ patient in Guangzhou. There . are certain reasons that we could not proceed with a
taster speed :
1 To select appropriate patient is not easy. The patient has to fulfill the indication/would willingly accept the treatment and shOUld be at the right time when malaria blood is available. I visited the first HIV+ client and his family_ and I could realize that the amount of work needed. 2 We did not have much malaria donor blood source. Even though provided with a well organized anti-epidemic station network there is not many malaria pabient now-a -days. Sometimes, a whole day is needed to get a malaria donor blood by sending a technician to a far remote rural area. 3 Due to technical or some other reason,our fund could not reach the hospitals in time. And because of increase in expense and inflation, they felt the fund was not enough or barely enough.
,
4 Through all these two years, we ,both
pa~ties, only have a rather loose connection and our communication is not convenient. For example, more than 12 months is needed to sign an agreement after a draft was drawn; Director~ and physicians of Xuzhou Hospital let me examine the two patients and x-ray reports and video taped the proce55 all in one day, but they could not provide the record~,video tapeand X-ray films until
n01'l.
During the recent visit of Jiangsu delegation in LA, I discussed with Mr. Lu Wen-m~n , director of International Communication and Dr. Ctang Hua-chan, Vice Director of Health Department. They we~e grateful for my arrangement for their visit here on behalf of the Heimlich Institute. They said that they will give tull 5upport and promote the malariatherapy project in Jiangsu. Through my connection, they were invited by Dr. Cionci to stay in Phiiadelphia for three days. They visited six hospitals and health facilities,and started the contact between heaith departments of Jian~ and state of Pennsylvania.
I
would like to suggest the following to imalariatherapy of cancer and AIDS'
pro~ote
our project
~n
To contact SOme other medical tacilities where they have more malaria, cancer and Aids patients and they would like to join in the project. For this purpose, I have sent letters to Dr. Gu to contact Health Department of Yunnan Province. 2 To consider the possibility to establish a 'plasmodium bank' to carry out 'mosquito transfer'. I discussed several times with Dr. Yang Bei-ling while I was in Shanghai. Enclosed herewith 1s a FAX received 2 days ago,informing us that he and his institute would liKe to join in our project. I hope that you will take this into consideration and let him ronowyour decision. 3 To accelerate a~d enforce our connection and communication with china. There are so much both administrative and technical work to do. Just by FAX and telephone is barely enough. prObably we have better stay there for a certain period several times a year or even set a standing office over there. Then we miqht entighten our connection with better co~ord1nationiconsulting or even supervision. According to agreement, we were not c~pable even to rinish one year's work in two years, we need to have improvement.
1
Very soon will come the h&liday season, if we have any plan , please start early. As you know, ror orient people, new year lunar new year and spring festival will take months for peopl~ to celebrate and enjoy. Merry Christmas and Happy New Yeari Fraternally
~~~~L?'---
_____
j]j 1:1'1'1T IlJ = lllt23~

~Ii : 7774103 (
al ~ i!&~'H~ : 510080
I{l. .
,{ MfL )
No. 23, The 3rd Zhongshan Road . Guangzhou The People' s R epublic of China Tel: 7774103 (ext)
Henry J. Heimlich, MD. SeD. President. The Heimlich Institute 2368 Victory Parkway. Suite 410b Cincinnati. Ohio 45206
My dear friend. Dr. Heimlich:
Dec. 18. 1993
I want to tell you two pieces of good news . The f irst one is that the second HIV positive patient received malarial blood on Dec. 14, 1993. the incubation is about 6-21 days; and next group of cancer patients will receive malariotherapy very soon. You can make your arrangement of coming to Guangzhou according to that situation. The second one is that the Municipal Health Bureau of Guangzhou approved our application of inviting you as our honorary president. the Municipal Institute for Preventive Medicine of Guangzhou. I hope to see you again very much. Your good friend. Merry Christmas to you!
t
~'P~~
Dr. Chen Xiao Ping . Chief. Municipal Health and Anti-epidemic Station of Guangzhou. . No.23. 3rd Zhongshan Rd. Guangzhou 510080. P. R.China .
O C T-16-93
S AT
0 7 : 00
P M HUA
8 18
442
8676
. ..7Z!. . ~. :Dr. FI,e.l~/~:~ .. ._".._~_ ~~U4~.e:fI~

~'"
I
IfDNfir$htlN
.... ". . .. .. , ..
Hull. ~. b
. .. . . .. . . a . . . .. . "
R-e..
. ,L t>-'v4PI..""" ~ l ...~. Z4. """ Y-t -1!;l"aH .;~ MoP 'n._~t!-',~ ,U~.3
. . . ... _ .. ... . . . ' . . ' . .... . _.. " . , , --.' -,
C4'1Wt -r1"fA.l~/' ~~/4I"t~ ~ ~v ,
~''''~ J!:i.__ fJrt'j~.d-_~ ~<! ~~n'd1w <>I A.t:.. ~

4J~H.t ~b'UA/ f(N~ 4!"'~~" ...,. rite/" '.... ..; til}!;"~ ;~~.. -..";-"~~ r...;,:,,~~':'"
lu,d-
ph. TAt:; r~
?JiIy ~/"''''''''' II..tJfX--"...... 1-..,f ,;. UN"''-;'" lk~ ",;TIt

..
rnA- ..".,.t-.~ --:.,M ~~"~ . . '. --.-. .. .

/;.It
_J,"IJ~ ~~ ~~""'Itt--,a 2>~ No.
tn<t'l.:J..--fo~ 1'/4$~'~ ~ ~~ . . lJ-e H~I-!;S f4ri> -'1"-~ ---'1
.. foJ'-".S!:~4)~- b ~.
..
WIll
...t;., ~iPf-.tt,.,; S 1/tt.!'ttfl.
~ h-u~ ~. !.-. ~.~f.~C.'!~ ""'~tIf r4ts. ~~ . Mr.. Lt.( /v.JM~.~ tl'-IIIMoW, zu.,.J 'i .]}414"Jr:~ ~J"l"-e .i ' ""},.. ... . . ._ .. ..." .. . . .. .. .... ... ... .. . .
.z AU-,I.-' A.f"", .,tp~~Z>r. a '-....; .~ ~ <Z 11~ (fJl;!A:4/ /,'/(J.1b ~ II:.-.Ittt ~f 0/-- B..... ~~ r~'h,r4.f , 7J, ~~IM~ FI~,-, . ~ . "11-~ .. z.r"77/Z!s"z... % ~~ ....... 1tU~ .
. ,
vtJ"';-;-'~.~~.I..
"
...
.. . . . . .
M "
""
--.
January 25, 1994
2368 VICTORY
PAR~AY
S UITE 410 CINCINNATI OHIO 45206 513-221 -00J2 fax513-22HOO3
Dr. Chen Xiao Ping Chief, Department of Microbiology The Municipal Health and Anti-epidemic station of Guangzhou No. 23 3 rd Zhongshan Rd. Guangzhou 510080 People's Republic of China
Dear Dr. Chen: I am working with Dr. Heimlich, analyzing the results of the malariotherapy project. I am now going through your reports on the cancer cases and entering them into a database. I know that your time is valuable, however , there are several points that I hope can be clarified with your assistance. Case 1 Do you have any more information 1992? The success of her
on her progress since May, treatment was very exciting. Case 2 father.
Your last statement indicated that you Have you been able to obtain further infor-
were having difficulties reaching him through his mation regarding his post-treatment status? Case 3 We have not received a copy o f the follow-up report on this patient. Can you provide
Benefiting Humanity Through Health and

Pp.ar.p.
this information? treatment?
Also, do you have measurements to
show the extent of the adenocarcinoma before and after (Your report mentions X-ray results, but we d i d not receive copies of the X-rays.)
Case 4 Hb value. Case 5
We are missing the pretreatment Do you have any tumor measurements, as well Is any follow-up information
as follow-up reports on this patient? available on this patient? Case 6 Dr. Heimlich would like to know if photos are available before malariotherapy. Another point that you might be able to help us with is whether or not the tumor mass showed evidence of cellular necrosis at the time of removal. Again, is any follow-up evaluation available? The results which you have obtained so are interesting. While
there is still much to be understood about the specifics of how malaria interacts with the immune system to kill cancer, the information you have sent us shows the promise of this technique. We hope the follow-up reports will show if immune system stimulation lasts beyond the febrile period. We look forward to hearing about the results with the HIV patients. Meanwhile, please send a copy of the pre-treatment physicals, blood tests and cell counts for the HIV patients. Enclosed are forms for the HIV patients. We anxiously await your reports on them. Dr. Heimlich has told me of your friendship and I look forward to working with you. efforts to appreciated. Sincerely, Thank you for your cooperation. on these projects is Your collaborate greatly
Eric G. Spletzer, PhD
January 27, 1994 Dr. Chen Xiao Ping Chief, Department of Microbiology The Municipal Health and Anti-Epidemic station of Guangzhou No. 23 3rd Zhongshan Road Guangzhou 510080 China Dear Friend: Thank you very much for your holiday greetings. Please accept my best wishes for the New Year and convey that to your colleagues. The desire to make me Honorary President of The Institute of Preventive Medicine of Guangzhou is very thoughtful, and I appreciate the honor. We are pleased that a second HIV+ patient is being treated and hope you will send, at your earliest convenience, his history, physical, and laboratory findings. There are a few changes to discuss concerning the agreement you sent. It should be entitled "Malariatherapy of HIV Infection" as the patients should be treated before they develop AIDS symptoms. The treatment would be more satisfactory if there were 15 paroxysms of hyperthermia, lasting 30 days. Regarding the funding, we agreed to pay $10,000 for each of the first two patients because of the difficulties you described in getting the program started. It is not possible to pay that large amount for each of the additional eight patients, and it should not be necessary since the first two patients have provided sufficient experience for the investigators and the hospital. A fee of $3,000 each, which is $1,000 more than the cost of treating a cancer patient, is within reason. It is very likely we can get additional funds for treating more patients depending on the outcome of the first ten. I am sure these costs are suitable, so please let me know that you agree. Travel to China is difficult for me, but I believe I could do so sometime in February or March at a time when the treatment of HIV patients is in progress. with all my friends,
FOUNDATION, INC.
2368 VICTORY PARKWAY SUITE 410 CINCINNATI OHIO 45200 513-221-00)2 fax 513-221-00)3
HEIMLICH INSTITUTE
Henry J. President: Heimlich Institute
January 27, 1994
2368 VICTOR Y
PAR ~AY
SUITE 410 CINCINNA TI OHIO 45200 513-221-CXX)2 fax 51 3-22HXlO3
Edward W. Probert President Fannie E. Rippel Foundation The Concourse at Beaver Brook P. O. Box 569 Annandale, NJ 08801-0569 Dear Ted: I hope that you are well and that the new year will be a happy one. I have not contacted the Foundation because I was aware of the difficulties that you were undergoing and did not feel it proper to impose. I understand things are now functioning normally. Our malariatherapy project for the treatment of cancer has been progressing with very encouraging results. Enclosed is a picture of a patient treated with malariatherapy for Kaposi Sarcoma, and one of a patient with breast cancer that I sent last year, but which you may not have seen. Charts of some of the cancer patients treated in China are included. Essentially one-half the cancer patients have a positive result. Patients with Lyme disease who were totally disabled, have completely or partially recovered in almost all cases. Most importantly, a fine university with a medical college and hospital just outside of Monterey, Mexico has agreed to accept our patients and carry out malariatherapy. It is an affiliate of Lorna Linda Unviersity in California. Recently I travelled with a doctor from the University to Villahermosa where the Minister of Health of Mexico arranged for us to obtain a steady source of malaria for treatment. Our funds have run out, and I wish to apply for a new grant. If this is possible, please let me know whether I should meet with the Board. In any case, it would be good to see all of you again. Otherwise, I would welcome speaking with you over the telephone. ishes,
Benefiting Humanity Through Health and eace
e9~~J. H imlich, M.D.

P:tesiden Heimlich Institute
1e~~t /J /
-_._--_._--_ .. _--
--
-- _
..
_-- ---_.
----
-_._._-
.. - .
-.--
_._- - - - - - - - - - - - - - - -- - -- - - - ------------------
- '-
----- ---------
_._--- ------
.. -
--
_.
-_._
.. --~--
-----
--
- . - - - ------
,-~-------.
- -- ------ -- ----------- --- - -... -- - ~.
--~
.- -
--'--' -_.--
- - .---_ .... _-- -_ ..
_._--------- -
.
--~
----_.
-_._----- - --
--
_.-
,-~-
Ck:t::' __ __ )))!rcti<c:c:~ # _Ar arh.':<i'1.z,''- ~~ti..-=g~4~~_ ~ ?wL &t-j;{-1)d;dj~ -~/~'&rz~t=-'*'fY

jj-',--21.
--
__._._- -------
- .. -- -- -- -----~
E- -~- - j'~~~~---.-
3 rvl_ 2~?-:Z~/l -M-- __c:74u'f!f-c?~/'

------ :- .---~-- --- ..
Ticer
-.---.
-----
--.-
- - - - --------_._. -------_.
-- ---
- -------- -
--- --- -.-~--
_.-_._-------
-- - -- - ' -"
._-
-- -----.
,- .. _------- - - -
--- ---- -----
--
_.. ----------
-- ----
--~
.---- ----------- -----
--
-----_
..
_---_.- -.-. -_ . . -._-------- '--'---
.------_._-
--_.
__._------------- -_.----- ---'-'-'- ----
-- -
-- ..-
-.----- ----------- -'
_. __ .-
---- _.--------------------------_ ._----- - -
--- - -----
- - - - - - - - - - - - - ---------------
--- -----
-----------_.-----
---- ---
----
- - - ----
- - - - -- ---
_.
__
- -------------- -- .. _------------- - '~
~---------
-----
March 7, 1994 Dr. Chen Xiao Ping

FOUNDATION, INC.
2368 VICTORY P AR'f:'NAY SUITE 410 CINCINNATI OHIO 45200 513-221-CXXJ2 fax 513-22HXXl3
Chief, Department of Microbiology The Municipal Health and Anti-epidemic station of Guangzhou No. 23 3~ Zhongshan Rd. Guangzhou 510080 People's Republic of China Dear Dr. Chen: Thank you for forwarding the case reports so quickly. case reports look encouraging, some of the abbreviations mean. What is ALC? The HIV
but we are not certain what I have asked I
several people, and no one is quite sure what it means. us anything about the HIV titer? show if HIV is in remission.
assume 00 means "optical density", but does this really tell The actual HIV titer will If the HIV titers for these
patients is available, we would like to see how these have changed. Our feeling is that the increase in CD4 is a positive sign. If we can show that the HIV titer has decreased, then we have some very good results. cases? ment? What do you think about the HIV Do you feel the HIV patients show clinical improve-
Again, thank you for your assistance and I hearing from you.
look forward to
Sincerely,
L~, J~~
'I
March 8, 1994 Dr. Chen Xiao Ping chief, Microbiology Department The Municipal Health and Anti-Epidemic station of Guangzhou No . 23, 3rd Zhong shan Road Guangzhou, 810080, China My dear friend, Dr. Chen: Thank you for your excellent reports on the HIV+ patients. There should be no problem to arrange for your coming to the United states as soon as ten or more HIV+ patients are treated. You are now the most authoritative physician in the world on the effect of malariatherapy on AIDS. When ten or more patients have been treated, that fact will be firmly established. We can then, together, along with your colleagues and Dr. Spletzer, submit a scientific paper to a medical journal in China and in the United states to describe our findings. You will have made a contribution which you can teach at an American institution while studying other aspects of AIDS. I met with Dr. Hua last week. We agree that it is urgent, for those patients who can benefit from this research , to treat at least ten additional patients in order to complete the study. It is our plan, if you agree, to increase the number to fifteen. For this reason, we suggest the following . Dr. Hua and I, accompanied by my sister, will arrive in Guangzhou on or about April 6. We hope you can start immediately with the treatment of five HIV+ patients. By the time we arrive , therefore, the five patients will be under treatment , and we can observe them. I had mentioned that we think that the cost of treatment should be less than $10,000 per patient at this time. You can proceed with the treatment of five patients with the knowledge that we will reach an amount that is fair to your organization and the Heimlich Institute when we meet. Please send to me and to my sister, Cecil i a Rosenthal, a letter of invitation by fax as soon as possible so that we can apply for our visas . My sister is not involved in the project and comes as a visitor. Dr. Hua will call you to discuss firm arrangements for our visit. to all my friends, your dear
HEIMLICH INSTITUTE
FOUNDATION, INC.
2368 VICTORY P ARI<:WAY SUITE 410 CINCINNATI OHIO 45200 513-221-00)2 fax 513-221-00)3
M. D. Institute
t~1
rtf Ii
.1?1i. ~
?!t fJJf 1 ,JiJi
lllarC:/{ ll/ IfI;J~ ;?I.H!-:;J- J . ~U ~ fVI.P. fP1V~' f; -;)I~ fo~
~~;Jf~ eVr- j/~~~4',
~/(f,u In- rw ~ dn/~~ $1' r~

f~~ ' ;;:!tc~~~~~
.>cd ~!Q'U- tMt/ J(J1<-r ~ 1:f-- 1'A-;( -:L )~ ~r~. lie ~ ~ u<$ h tfW~~ frU- v</~r __r,i~ ~ .
~/f~~ ~~ C ~t +~~.-
fr 3 riu;f6; t?u~ ~U-~ ~~77J

;,
~ ~l /
.OtL
can
~~..k?? ~~fnJ<:-
~~ .
pta.!? kI fJ)r . JfjI1ff//,/
ALe
tn~J
.,
t~1
-.p. Ii
I?Ji . ~ ~
iJf
JiJi .
~ #b~ {j:/~&4
P-/r'/
(!ur-e-
~nf-./ L c 1/./ '---0 17Z/~~)# k~ an wlbr.,e~!ff/ ;'7 1J~ &ot;( t"J-M' km~tr/L
L{);tf ~ --flu- rJI/z/ ttlzr w;w, 0
;natdlJ~
)/;V/~(}'-tn:r / 7 ~ I~~
J~/s~r# J
:J),. {'~d
y~
f;ir-----
df
M/-~w~ <fIt.
)/I~~~t ~ ~ oUtr~ ~'J
1- dtu/tr~'
6--r
j-;PCM /
dnA--
>l J trJ,,,chvJt.4
--- -- __ _
7)./
_
in'! 1"-C><1 . 71{,(4')

L.
a<d
..
/Ja,f?>fp
ttt.rf" M"'d~7~ , '-. _ -
.-- - - -
- -- - -
Arrangements of Meeting Dr. Heimlich, Dr. Hua Hong-Shun and Mrs. Rosenthal
Date Time 9-11.30AN Apr. 10 2.30-5.30PM Visit Patients Yisou Hosp. Ra il way Hosp. the Institute Xong Lang Min. Malar. Group Items Report Project Progress Place the Institute Participants Ye Guo-Xong. Xong Lang-Min. Malar. Group
8. 30-11 . 30AN Apr. 11 3-4PM
Discuss Next Step
Fan Meng-Hau. Ye Guo-Xong Xong Lang-Min. Malar . Group Vice-mayoress Yau. Fan Meng-Hau Ye Guo-Xong. Xong Lang-Min. Liu Shu-Gua. Major Members of the Institute
Vice-mayoress. et al Meet Guests. Ceremony of the Honoray President
the Institute
Apr. 11-12. 5PM-3PM: Sightseeing.
Evening: Depart to Kunming
<.J
.J
"

<P 00 iri'l <P ili ':::J/!23.f;J1Il ~ i?{i,1iHib:
f!!
510080 ~: 7774103 ( ,~, tJ1)
No . 23, The 3rd Zhongshan Road . Gu angzhou The People's R epublic of China Tel: 7774103 (ext)
Introduction of Dr. Heimlich

Professor of advanced clinical sciences and president of the Heimlich Institute in Cincinnati. Ohio. the United states. a great internationalist. Dr. Henry Jay Heimlich was born in 1920. obtained MD degree in 1943. But his internship at Boston City Hospital was interruped in 1944 by World War IT service in the United States Navy. Volunteering for especially hazardous duty. Heimlich served as a surgeon in the Army of General Fu Zhuo-Yi in the Gobi Desert and Inner Mongolia, to help the Chinese People repel the Japanese invasion. He greatly admired the late Dr. Bathume and the late Dr. Ma Hai-De. Many years later, he was honored in China by the ministry of health, in 1984. Dr. Chui Ye-Li. the Minister of the Health Ministry of China accompanied by Dr. Ma Hai-De. especially invited Dr. Heimlich and his wife to visit China and met them in the Great People's Congress Hall. in recognition of his contributions to the Chinese People during World War II. After the completion of Anti-Japanese War in 1945. Dr Heimlich returned to the United States to continue his medical career. Having worked in the medical field for 50 years. as a well-known thoracic surgeon. he published 'many many scientific papers and have many technological inventions, among them the most famous is the Heimlich maneuver for saving the victims of choking and drowning. Because of the Heimlich maneuver. he has been credited with having saved more lives than anyone else in the world. His name has become a household word in the United states. even though thousands of persons who refer to the "Heimlich maneuver" may not know who Heimlich is or how to perform the simple antichoking procedure that bears his name. Among the honors that he has received are the Albert Lasker Public Service Award (the top award in clinical science) and the Golden

<P IE r-m <P 1lJ ::::!ilf23-\}
i!lB i!t~Jil!:
510080
1774103( ,~. tn)
It!.
li'fi:
No . 23, The 3rd Zhongshan Road . Guangzhou The P eople 's Republic of Ch ina Tel : 7774103 (ext)
Plate Award of American Academy of Achievement. and he has been enshrined in the Engineering and Science Hall of Fame. He is an honorary professor of surgery at the University of Athens. Greece and at the University of Argentina. and in these two years he is the honorary president of the People's Hospital of Jiangmen City. and now he is our honorary president. the Municipal Institute for Preventive Medicine of Guangzhou. Dr. Heimlich Anti-Japanese People and the malariotherapy had a great contribution to the Chinese People in the War. now he have another great contribution to the Chinese People of the World through the cooperation with us on for cancer and for HIV infection.
Dr. Heimlich is a real friend of the Chinese People's. we sincerely give him the best wishes. may him longevity and health forever!
Speech in the Ceremony of Inviting Dr. Henry Jay Heimlich as the Honorary President of the Municipal Institute for Preventive Medicine of Guangzhou. by Vice-president of the Institute. Dr. Liu Shu-Guo. April 11. 1994.
~ ;-::t:.~
_,
' JU N
..._ ,2 _"
06
94 sraaa
MON
i&iALaa
11: 39
PM
HUA _122,-=+=, \
:w=:=
818
4 42
------
P '3 1_ .
! , .
i i
I
MEMO!
Date: 04-13-1994 Attendant8: Public Health Bur@au of YUnpan, F.R.China Yang Qi M.D. Vice Chief of sanitation and Anti-epidemic Division Pl'Ogramme Offici,al in charge Of unan Provincial OFFICE FOR ~IDSControl and Prevention I You Weichang M.D. Chief of the Pharmceutic and Drug Administration Li Xue-zhong M.D. Deputy ~ irector of Eprdermic Disease Prevention Office j Pirecbo f of Yunnan Province Malaria Reseach Committ ~ The Heimlich Institute Henry J. Heimlich M.D. pr J fes8or, President Hua Hong-shun M.D. prdfe55Dr Meeting held at; Kunming, Yunnan iprovince, P.R.China
At first, Dr. Hua made a brief i ~ troduction about the contributions Dr. Heimlich has made in clinica l research and in tIle promotion of friendship and co-operation betw~en the American and Chinese people. The purpose or thi s vi 5 i t of Dr. IHeiml i ch to China is to introduce the theoretioal basis of malaria Itherapy in the treatment of malignant tumor and HIV + patients and abo ~ t the clinical trial undertaken in Jiangsu and Guangzhou since 1991 ~ By communicating and exchange of ideas on those problem5 of malaria the ~ apyin concern, the both parties would lika to find the possibilities t q initiate malaria therapy on malignant tumo,t: and HIV+ patients in yunnax1'
As recommended by the American p ~ Ofessors, for sixty more years, malariatherapy has been used eff~ctivelY in treating neurosyphylis.
Through malaria infection, the i~munity ability of the patients is in~~eased. Tumor incidence was f9und to be low in high malaria incidence area. The mortality rate of chil ~ ren suffering AIDS and malaria was significantly lowered than those :children only suffering AIDS. Among the 10 malignant tumor patiients treated since 1991, Six patients showed improvement in various de J ree,flve of the ' six patients showed marked improvement. Two cases o ~ HIV+ patients,one patient showed the same high level of CD4 count ~fter treatment,as another case his CD4 count increased from low jleVel to a significantly high level. As cons idered by the American proif essors, to Observe the effect of malaria therapy on AIDS patients , ; .A IDS patients could be innoCulated with malaria blood,or by observirt~ the course of AIDS patients who also ~ontacted malaria. That migh~ be easier to observe by the latter method. But tha t would be di ft' ici u l t I to hold the malaria trea tmen t during the course when the AIDS prtien~8Ufferedmalaria episodes. To the opinion of American doctors,the latter trial could only be taken whe~ patient voluntarily ta~e part with full understanding and C'O-Operatlon. I
The
experts of the Chinese party ~eit much inspired and raised questions o~ malaria therapy: the basic therrY, the scientific design, the assessme n t of clinical effectiveness and med cal ethics aspect etc. They considered that ,as a scient fie researc'h , malaria therapy is of
MON
Pt1
HUA
818
442
. . _ ; .. . ' ---. --1
8676
P.02
ME110 (CONTutUED)
significance. but the .itaatioD in Yunnan for the time being i . not entirely mature, they woJld make further consideration. They expressed their hope to on the contact, and to procure fUrther material and information.
~eep
SIGNATURE:
China Party
U.S.A. Party
(sigl1ed)
Yang 01 M.D.
ItL:
Jun 07 94
11:42 NO.UU2
~.Ul
p . t-j l-<:--<YV
'AJ
d--Ll,a".~ ~ 7) t 1-t-e-t~w-..(!-l_('A~
~4~V-;1.j> </ i~-; t. ~:"': ~~~-t.(--:- (~.-.'1

.t~"
. c/D /-.I.J~, .?-v/.A..~-u,a.t...-:.).1 a fcrl!~VL"
Dr'. Ya_-
'--f
/l.rt.:;, 5 (..l~~~'..L;- .
0-.U'\ " ''L.t'-l..~~ '~CI' h1---~'1~'1- ~Y.'r-a. H41.

4
..
Lf)
t.ICb-~ .t/{/~.- .WL~.~~<"L,/

--/Y.(J;4.U /
[;>
.~MJk 'lf.~.-I"'l4..;:,>.fh, t--'~/('_e/~ ~ ~

f!.erv.,.J?~c. .'~ f.::...../ M/(~-L,,-' ~~ 7'
d.A....e.L--<--J
-a--K-tJ'/ --c.~''''-( ~--(J-.:(-"

/.A.--IA-l.A.<
---. J ~
.J.:,/ " f/-{,"1"-Pf
411-Vz,-f:--l'.4/1",
/7
.<-vt..l....(
A.I
-<-t.,~< i!"t-t-. /U.~<-l.-l- ~ /l~"--o( ~'-':r' &~../.~ ~.~ a,j>~'_ -;-CJ_ .

a'i--P-f1A-<- c,< 'f-d.r:d
~
] ) Y-
II--<>', ...-f, (:.-.tl
,.ct,.., .4~-'1 t~f~
.-e:v')
a- ~~ a."lp/U'"qd--.
7 C. )I.<~" d.~. L-.(.~ ),y-""" ..D' C:",l.;'-LlI l-Lf ..A-~f1k--A' ,..c~.j ~ '1/,-1.:((-<:" ~.-~....d i!..dp ~~
P7j.a/I.:!:;;- .. /."';" 't-tA/I'~ I~..

;I;b ---?.-t/)--f1-4-----t'-<--...:t.,
,/1 --/
(Ir
~ --Itc.~.l-' (7\'1
~
,- .~
;-'--t~_ eI ~.-.J-~ c;(
A....f;~.,J~ -
~'~v.~~---f ~ ~'r~~ ,
~A .('-A- ,<..-L'../~tJ ~:
/1t-'1 .(,.<.....,:"<-L-<
(.--1. -t t7
JI-~~~-'1--1 6/ 7 (ry-,
2368 VICTORY
PAR~AY
SUITE 410 CINCINNATI OH IO 45200 513-22HXXl2 fax 513-22HXXl3
To:
~j - ShlNVl
?"~fet!;1fj /
vJA..
fV1"
b"
l-Ar: (R",t)tr(I'l.. -
!67t
P~j~vr Ct> - .:rr~rtP;{crr
~i~t2.~
1994-4-13
t:Lf~~ :
tflOO
~rf~'J2~ff
~&~~~* , ~~~m~~~~0~~~~~
m.tme:
~~~~rp
~~~~*,~~~W~~0~~ff
1E~1Ilfn~ 9tf?~ tf~
ft~~
m. , ~'t!rnmi ~/J \ ~J11}0
~iU~1:F$~ J~'
~OO
iU~1~~rp
M iIH}.1L~ 1Ilf nJiJf

KENRY J . HEMLICH ~~
**J@i
:ttl!. d:i "
J .... ,
~~
~aArP
tflOO
~rf
~*~~$*~~~~mm~ ~%~~~~*tfl~A~~
~~~~~~~1IlfI~tflm~lli~~~.~~~~~~W$~ ~~:~m~~ff~~ff~tt~.&Hlvmtt~A~~~ ~~~&g1991~*~~OOrr~&rffl$*~~m~o
~~~~~~~ff~~*~B~~.m, ~*~~m~*~~
~ff~i117~ttij~~
&H I V~B'11m .A~ 11)ii*~;tiiJf~PJ~'t1o
m~~~ffi~~~m,~*ff~g*~2~ffl~i1ff~~
~~~A+$4m~,~~M~,~~~~~~m~~Am~ E8%N~j], tEtE~~lR~~11~ft~J~*1~, )t?Hm)[UL.f~

1E~8<J, ~~-c*~~1~T .t4!)tr~ffig}!ULj[, 1 9 9 1 4
~~~8<J~tt~.10~, 6~~~~~N&~,~~5~~
ttt3~~8<Jr!1:~,
2i9UH I V ~BttffigA li9umJffi:flfE8$X~8<JCD4

0
mJJffi!7,k-Sf, 1 f9tlCD4~11PH&EB p:f1~t3J3~i1ttm
~~m~~~~~.~TgfifflT)t~ffigA,~*ffl~~
~#~~.)t~mA~~~~~A8<J~~o~T~*$X~*~,
~~~8<J~~~~~.-fi~~~~fi#:flfrn*,m~~~
8<Ji2~J:9:&\~tmA3t5J'-JjtfQ~c~E8)IWt5t T ~~:DQ7f~U
lttfro
~OO~OO~~*~~T~m8<Jm&~~~~tt,~~~
fi~8<JJ~~~M~~~,fi~~~~*~~m~~ili~~o
~~~~M~,~~fi$~t~~~,~~~~~*~~~
~~*~~~~~~, ~~*-~~~**~~~~m~~~
~I{*~. $t{~$8<J~f.4fQ{,@,o
AGREEMENT FOR JOINT PROJECT "MALARIOTHERAPY OF HIV INFECTION"
BETWEEN THE MUNICIPAL INSTITUTE FOR PREVENTIVE MEDICINE OF GUANGZHOU AND THE HEIMLICH INSTITUTE
sUI<fi.(AR Y
B oth sides hold that it is benefic ia l to human race to explore ma lariotherapy for HIV infect ion. The primary objective of this project is to perform a clinical trial by means of blood transfer met hod so as to demonstrat e that the therapy could be applied to HIV infection with no harm. or only with a limited amount of side effects. treatment. Collaborative covenant enact ed by the Municipal Institute for Preventive Medicine of Guangzhou in t his action by President Xiao Bin Quan and the Heimlich Institute by President Henry J. Heimlich. who hereafter for the purpose of this instrument are designated as "Guangzhou" for the first party and as "the Heimlich Institute" for the second party in accordance with the following: PROMISES ON"GUANGZHOU" PART: To designate Dr. Chen Xiao Ping as principal investigator in charge of the project. He is to follow the patients and visit them at least once each week during their hospitalization and examine each patient before each follow-up report. To designate Dr . Xiao Bin Quan. Dr. Lu Vue Hen and Dr. Liu Shu Guo as co-investigators To comply with all the medical. technical and ethical requirements that determine the standards applicable to the protocol. In the respect of concrete measure to do well the management of fifteen patients and guarantee the security of the medical workers on medical activities. prevent cross-infection in hospital and obtain signed informed consent from the patients and respect their confidentiality. The course of malariotherapy is primarily decided to be at least fifteen paroxysms of hyperthermia . But if there are any special conditions occurring. the course can be changed.
-1-
and to assess the effectiveness of this
To send complete and accurate written reports Heimlich months.
(including the histories.
physical and lab. exams. according to the protocal ) and photos to the Institute at start of treatment. end of treatment and three six months. one year. one year and a half and two years after
completion of treatment. There is anothor cooperation instrument between the Municipal Institute for Preventive Medicine of Guangzhou and Guangzhou Yishou Hospital as the internal agreement of "Guangzhou" Part. because of the consideration that there may be more hospitals joining us with the project development. ON "THE HEIMLICH INSTITUTE" PART: To designate Dr. Henry J. Heimlich as principal investigator responsible for the investigation. To designate Dr. Hua Hong Shun as coordinator. To contribute the necessary medical. technical and related for the implementation of the therapy procedure. Funding: at the first two cases. to support a fund of ten thousand USD for each malariotherapy-treated patient with two years follow-up with periodic reports as noted below for the subsequent patients. After that. to support a fund of five thousand USD for each patient for the treatment and follow-up course of two years and submission of patient records and reports. The way of paying is one thousand at the start of malarial fever. one thousand three months after the end of treatment. Then one one thousand six months after the completion of treatment. thousand two years after the completion of treatment. information
thousand one and a half years after completion of treatment and one Total follow
UP is for two years after end of treatment. The patient will be examined
fully physically and with lab. tests and reports sent to the Heimlich Institute at intervals of no less than six months after the first six months posttreatment follow up. Each payment to be made after the Heimlich Institute receives a complete and accurate report of physical and laboratory findings for the previous period. also a recent photo of the patient. if possible.
-2-
For patients
followed for six month, total payment will be three thousand dollars.
~
ABOUT THE RESULT: The parties agree that the progress and results cannot be utilized unilaterally by any of agreement of both parties. the obtained from this parties without the
investigation cannot be utilized unilaterally by any of the parties or
This agreement of collaboration written in the English language which has two copies was enacted in Guangzhou, the People's Republic of China on April 23 , 1994. SIGNATORIES OF BOTH PARTIES:
Xiao Bin Quan President, The Municipal Institute for Preventive Medicine of Guangzhou.
Henry J. Heimlich President, The Heimlich Institute. Date of Signing
-3-

9' [,;j 1m rf'IIJ-=-IIIt2 3%
lli,;i1)(llii 5~ :
510080 iiI, : 7771103 (
,~, ~;1,
No. 23, The 3rd Zhongshan Road. Guangzhou The People ' s Republic of China Tel: 7774103 (ext)
Budget .for Each HIV Patient for Matariotherapy
ItellS
USD
Hospitalization 1000 Routine Treatment and Nursing 750 Special Medicine (Albumin. Blood Transfusion. et al) 500 Medical Workors Reward 1000 Articles for Single-Use 500 Special Tests (Western Blot. HIV Titer. CD4. et al) 750 Research Activities (including Receptions of US Experts) 500 Total 5000

<pOOlffi<plU=~n% tH~ ~i:\ilW :
Q!
~Ii :
510080 777410 3 (
.~, : ' ~
No, 23, The 3rd Zhongshan Road. Gua ng zh ou The People's Republic of Chi na Tel.: 7774103 (ext)
Li Hai-Du Co-investigator. 1964: graduated from Guangdong Medical College. specialized in internal medicine. Vice-president of Yishou Hospital of Guangzhou. visiting doctor. Kuang Fu-Yian Participant. 1964: graduated from Guangzhou Medical College. specialized in internal medicine. visiting doctor. Yau Zi-Li Participant. 1952: graduated from the First Medical Technician School of Guangzhou. specialized in epidemiology. parasitic diseases. expert of malaria. associate chief doctor. Lian \Ie i -Quan Participant. 1973: graduated from Guangzhou Medical College. specialized in internal medicine. President of Yishou Hospital of Guangzhou. visiting doctor.
MAY-23-94
MON
11:17
PM
HUA
818
442
8676
P.01
CHINA TRAVEL
4/1 -4/2 LA to Shanghai i 4/3 Call Beijing, Dr. Fong Yu~-wan. Dr. Fong is making arrangement for our visit to Hain~n. Call Dr. Yang Bei-ling. Hd will introduce m~ to discuss with Dr. ~eng Zhen about '~lasmodium & mosquito bank ror malariatherapy. Dr. ~eng is the director of their institute. i 4/4 Monday I Call Kumm1ng, the provinc~al government of Yunan Province. They have received le~ter from Chinese Consulate General of LA concerning our project. The Health Department of Yunan Province will m~ke decision. Call Beijing & Hainan, they would like to co-operate with us and welcome our vis i t. 1 4/5 Visit Dr. Feng zhen of In~titute of parasitic Diseases & Dr.Yang, they would co-operate with us by furnishing a 'plasmodium bank' but they need f9nd. Ca 11 Kumnling, the Rea 1 th Dep' t of YunCln Provi nce. They are considering. 4/6 Shanghai to Guangzhou Discuss with Chen Xlao- P g and make ready our sched~le in Guangzhou. . I Train tickets from Ho~gkong to Guangzhou are difficult to ~et due to rest i v~l . ' Chen called rriend in HK to get tickets for Dr. Heimlich. Call LA to inform Dr. Hei~liCh. c/o my home. 4/7 Call Kumming, Mr.Xie . of D6f't of International Communication of Health Dep't told me ~hat Dr. YangCi will be in charge Of AIDS project and he i~ going to make decision. 4/8 Call Kumming, a group of experts will discuss with us and they are interested i~ Joint project with us. They asked for our schedul~. Make arrangement for trai~ tickets from fiK to Guangzhou. Our tentatIve China traveV schedule is set except that part of Y~ngt~e boat trip. . . 4/9 Dr. Heimlich and sister a~rived at Guangzhou. 4/10 AM contact Travel Agency ~ith Dr. chen for flight tiCKets &
19
boat trip.
ViSit Yisur Hospital ~nd interview fiIV+ pts. Contact Travel Agency ~ith Dr. Chen for flight tickets & bo~t trip. ! PM Ceremony for Dr. Heim~ich as Honorary President of Guangzhou Institute of prevent1v~ Medicine. 4/12 AM- 3PM Contact Travel ageeCy and got atl schedule decided. Eve Call Kuming & Hainan, o ur schedule for these places. PM 4/11 AM
Guangzhou to Kumming. Discussion with Dr. Yang ,Dr. Yiu & Dr. Li. Visit Stone Forest. ; Eve Sightseeing & dinner i~ downtown Kumming. 4/15 AM Visit National Minorit~ Village PH A report on Discussio~ on malariatherapy in Kumming is
4/13 AM PM 4/14 Al1
ctrafted.
Kumming to Chungking 4/16 to 4/18 noon Boat Trip 4/18 PM Ylchang Visit Gu-zhou, Dam & China Stur-gent Museum. 4/18 Eve - 4/19 AM Y1chang to ~ruhan. 4/19 Wuhan to Haikou, Hainan Eve Dinner & discussion wi~h Drs. 1n Hainan. 4/20 Haikou to Sanya Eve Dinner & discu~sion vi~h Drs. 1n Sanya. 4/21 Sany~ to Haikou . PM Visit Haikou Hospital: Eve Dinner & discussion wi~h Drs. of Haikou.
I
4/22 Haikou to Guangzhou
AM Discussion on agreement : with Guangzhou PM Got flight ticket from puangzhou to Shanghai Got boat ticket from Gu~n9~hou to Hongkong
I
I
4/23 Noon Dr.Heimlich PM Hua
Guangzho ~ to HK Guangzho p to Shanghai
4/25 visit Dr. Yang & Dr. Feng ~ * 4/27 ShanghaI to Nanjing Contact Dr. Chang et al ** 4/28 Contact Dr. Ma et al ** 4/29 Contact Dr. Xu ** Pm Nanjing to Shanghai
5/2
Shanghai to LA Detail on attached page
**
' ~',",
..-....... -..
,-~. ~---~
. . .-------- ." . ---.-.. -,. . . .
--r-----~
..,.. .
-. ~-
'PE
7JL<II.<'~t 1>{ Ra"'/: ~ ..;. f""-t~'. ,9 ~u..hu-Cd Dr. y~ 8.<-:-~ ? Z>r.-'l~ 7-'<- M,,," ~. 7M(j- ~d ~ I '~ ~ ~ ~ ,b>~L;
I
4lAJ7 .d..~ ~ 'F d;.;;- . ~ .' ~~.,f ~ ~,;..

C'!b
~ c:
"(J.l<->?><-<-d..
])/0
"it7
V"""#..;:.,,,;..u duUe.J.:: a.M ~I "';~ ..;., --=Wit 0 ~, 7"-Qt <.v dA ~'d<.A "" ~~ j<n- ~ ~M, wtM ?< = J t;, u-u d.:.~"a ..
w~ ~,lN~ "fJ.,J.<~>c~ e.1m~'c..-J~ b~~ c. Dr InA Yn'-'l- f4uYV/ <I f:..,:.., ~ If, V>A'/><r ~4f- ~ ~ ~
: p" htA
> >
J:Jt-f"Ir/~i&~W- ~ ~ ~,J"-- ~ (9qD.~ec!t-u~7~~
'~ ~ f<r>- '~'f., -Ir-~', ?~~,.t,....,rC-<-<

->
U4 .
~ ~~ 4M'L
,u
~/\f,~ A
~- ~ ~
01-
. .. , , " d<' c;;: l1JaAtf'~ aL-~ .. _.#h~J" -4'~f->r. e~/J...e.~~V9'\~ (~ ~-yo ~8 ~ ~'7 b ugl4p-f'i (I.....ut. -or 13" ~ T~ ll<~ b~ Se..P;,f,'(-,;c ~ i
_ -[11
'hU- , L,..,
;dtM ~ -Nd! ~'ru<.-e. .~ ~ "",~<'<A-";" rtk~ ....I-ru~-
1~' ;a; t<"-),...t. ~ ~.

't6
tA.<J .
rv-f~t ? )-- RA-<,t of ~ ,~. -4 pl-r .

U . /YLC\ w u1 M.).JI~ l/t
i
~d-. -zk.. ~~.l" 71.., ~ k..Vxr 02.[>h <'vuf~t

.4>(.u
t/>o
1-1,,<::,( I-,.,L
e'{:.-i-. ~ ~ ~ ~-<J un
-/
Lf~-1
t;t~ ~~~-I~~d~ J$ ~;/.,..~~ r~ ~ rt~/7 "" /-IN p-/$ . . 1>r.rt'1 WP->< -V...... '"....~ ~~ ./J/,4-<j ~;. 1-1 (V p-f ~ ~ .J.,~<~ i P--&tJ,-..dP-'&<f<f { ~ ?N~ . 'i1- J" IV"""~i~ J ~...d Z>r y~ w.....-y,e..,., !Jho..<d;.... '3 P,..M',Cvt; 77.J-0-M-"""'-&-qr -I 1J~....p 7).-' ~ ..In Fe!; 1-1/11 ~t., W ,,,-- /~
vY1
>
.t:u 4~
4t.d'..,,(~O'Y~> z c/M.~p" J)r,/0.4'( Vv~ ~ ,~M/,t;U ~ f'{-.~ ~7t1P'l-~ <J>'f-bt ~ ~

w/.M t..c /-ltV
u,4A--.,(
1.t4wv frUU.~ "~ ~~-~,<....( ,

~
/-( I v
cl<J.,....,
~d ~ ~
7~ fJ4--C5 ~ 4~ ~w~.u4.- .. 7Jr.X~ ~ J 1>r Ma fI.c4 ..d.<. W<M- ~ c _:! . 4. ~ .t. F .a ~ 4vJ'\ .~t;z ' J......A;;.'tu.I..: oj P-t-r#'-"..ci0i' 1 ~ 'l/i~ ... ~ &0 ~f ~ Dr,/Iu'"../k.h
..l
D)~. X"M
r-t-- L~
.
4 ~ ~ r~ '1 ~ ~f Zd; \ 1L .~ ~ (luG ~ Jtcn-J- eJ.f s~ DJ2>r. hi&l ~ -p~ ~ c&~

.
[)I' ,J1V;t./~\~
/1A.;[;..'&k
$-h s, /
all
--II~~~L-~.
/ti--/l.e 2/ / r?~
2/r. rl-c G. S:~r
/k
rJ!~ :hftZ?Z;
=>
.?-3/;J?
cJ~;Y ?a-~a-:f-
a:z~rufiff/ tJ~ Cfs-.z4
5~ tilt?
~i J'J>/L
)/Ir/
J (f/'~ ~ (?CR- LJ
J'nw
Ulif tfUl-ci
I/IV-ittil',
k;t- reR. I-,)I/I/!us ~
~Iz- ~ ~~,
~ kV.J?(
p.~ ~ t.ftZ"7t", L~~ ~ 7i.
r ~ .uceH7' '4.2. 0/
{?CP7?
a.-r
.J'dnaz
~-tit~
r .
<ff?
?Yj-.
x$1 -t& 7;ir -Zf ~7 Cf ~r

c-tW-.J-e-
) f w..PY
U7<!-
.s:-ne
t/s P
J tL&im;r..e- ~r w.e.-
U<47
tu-e.-
7k-
t~1
/ r
rtf fi
I?Jj ~
?!t if
>
JiJi
~/lq'
t'eVr
rj.4
btkf
-1 :d- ~ nff
[;LI5/J-
tJA/~&J;l ~ /
:vi.)o
()~ --tr;-~
WM-lir11 'J?U
t- rflJI/~I1-ttb~-to rrrUe~rfl/t/ {see " JoLlrtZd 1- JlZ-f,dfiuJ J)-<-~c<-J.e-o (rrt;,

T~
112 (2) -' J-t;-2 - J-Cf-j) .
uJa-
,;w-.-
1H" ~ 'J1.UlrT 54~

7Lb17e
)-1/1/' .
f~ ~ ~ (d:; ~
"r --ph ~fttnVr
17ufJ-.
1Jt'Jo-
?&v.te--t::f( V/" YdmW

~
!~n.
tU/a TCrd.J Pr. ;;; -evmU " .

2)r.
w~k
!fi7U anq zj
cd" ~ ~r
cq.
cur
))11. /'1~b,'4!f- . f{U;1T/~ If.e.vt#b wnt! 1J117r:-r~ ~

rl ..",J!t:J.
f7.~. C,{;'a
.~~
i ~_
, ., , , i,
/'lA-c-!/V\1
(?
~.(,.--J~-e"l ~ ~_,.,{. p k.~--r~;;. ~~ ~ ~ _ _ . ,{ 1-0'21 ~ W
LJ~ :Ch~1 <i~~~~&.'v-<I~ ~ '"""d.

L-<.47'rvvv>
,d"N 4';',
f
1)/, , .A.
';3 .l-~
J
.J .Ak'''"Nf<---v; ~ FAX ~ I ...:,~~&t, C -V r 6"-,-", ~7'~ 4A>-h.-..." .~~ t-z e..t'-h.h e'/-- f.,-(JU/<-f ~~) ,to 'i~......e. ft4-- 4, ~tbV7 4vCA~ A- e.t-t.t~L~_ fur O--U-~ et..,..,1L.t ~,~vI itt+.'~ u..rL ~ t';' {7~'--'I-"'f)'~ v..t
. ./ ' .......-r -&:(/\...:Po.// U"l..-<.-)
4-'(LD,.
-'41 ~ "',vo
/o=-
J,' h
'"
oJ /l-<~. .,(
1
,tL;;.
-
/_
IA! ' L-~~-<'" '1('l.J1.-<-~
?n-</1--
c7(..I'll"L-"'t.
V-~J
_.
.......... ,
c;;>.
.c ,:-!.
.........,....y /
U~-r1-~
+
o
r-v.
,,;, tA.f:..r r'A/YLd ~o

l.a-ti-< a
(j;
/~-~ 'I ~""-'-''1 ~

J.JT-V"O
dL,,--<'d--4, N<- ",..-..Jr;f
c;.(..<-f-7"~-il"-'v~/7 . ~~j ~(,pf~

It:
,,~-"u e.~~n.~.-I
M ..
7.)1- -
o,~. .
~
,
,-ntl?~d"
/ /U"l'l
w ,d,,-
-!ra~
(,'1.jJ"'Y'.
e.r-- ! '
,9 4c~
-:7
et-'l-~{ I1J-!.- ~,_#t-(/v-lk-H4 .t-~.~

4 -'fo~-tA /.IAJ~v ~ I;:~.-l
J,...?' >
,{b..d - ,-f:.(L-d ,LO
~-{/L-t1 (/~",,-~ C-I'Vt-c.-;( 4<"- -c~, !p_ 4-e-V( b ~ . i--<rP.--7.-; ''">Y1--o'i/l- I~)...l, t-t~ C h.~~ ~A_ ~~
-t-<. -&.p~ for vf-O , v:, i e-Uc-.c4~
',/.-/').1
~ Ir,L/\ d'~~7 j'11-.(..~~\t/- 4 7Jr )1-1..M b-ZlZ -f~ <h-1 It;tv--/ ""~ .,g."M.~1
(){>kt.. o-f l ' L.J
t' .
..2~ .~;;J or-;~' L ~~ ('c.~:'__'/ ?f
a_ &ktC 1/ 1''''''' 1<4..-.' ~ /U-A d <4 -C~ b-<d.i..- d",! ,"Dr kh-t .f ~y~ ~~.ft. ~oj,d--I'~~~[~7A~'~~
1<-<--<
IU(~ 1 X - Il'''-]1 ~ " .K-- ~- :< ~ . of /ifw-.cf .,~ . ~.u. ~<~ ,( t;:. /"7v./-$ '! d.-:..- N I--?< t- ~/~ 1 13 K",)'("" w <-L( t!--< ~ .-R-...:z;;v - .d,.-. rt.c ""uJ.,.'MAJ 'J d:... ~~ /~-"1 j>Co ..;., 7i4""" ,,,Up f4 ~,uJ .
~ /:1.T.~v /j'Y4'~~tt:;./~"ry9
.
th o
1t.<'-1-j
t~/{---U _-<L~ ''ad 4 "?~4..-J' ,.tv to/i,,- !J--<A't~ d tA-t.L-9...P'" Q~(

l,jT('V1..L d...eJv Ll>
) h.-<--y
-t-tA-:Jv
.(V-{
t---L--1
''''I-'I..-(JJ}.
~. 7/7~ ~~-... . 7fv.( ~-v-< f-V"l,p-py'J1.'1 /twr. t!_"'vtf-'-..:..L'~ O~-1-~;( l~v>......d, L~- ~ ~;r;~..:.~f'~~"" . &4t."."I, &U-t--t'c-~ -hv?< . f tulTJ-1.~ L-~~ {%
0
tt;;.'L4"-<'
~ tE-<-vt-~..r
() ..[4-;t-
~"'-.--.r ~ ,
~#:c or-~-IA:i
tJ--')-L-d 1,/-f/Vl1 jh-ct-~-f~

.
t1,1
<-,-.,I ,f...-<.
~--9t.,......j
cg~u~--< ~
l/V4!...-
p.:)'
X-I( C4f
1- ife(w.h tVa; 6-e S81-t.f- ~/l: (, /~UA--~ j~'Z.':!..{-Vi ~t.? . -l/7'1.-"Y? :~t:--c~r..~o(....---
i-~ ~v
d. c7<.J~
14 {}.
.
(3-(.,
Kf ~lf..,.,-..{qJ t:n-7 JI.--zAL' &~ ~ ~~/r--t:L1--4 /U ~",-/. ~-/'--t..'-4?

I
A'--/N'-~ ~ . .oJ- "'''fo- ~'''''''1 '
l.
June 22, 1994 Dr. Chen Xiao Ping chief, Department of Microbiology The Municipal Health and Anti-~idemic station of Guangzhou No. 23 3 r Zhongshan Rd. Guangzhou 510080 People's Republic of China Dear Dr. Chen: We received your reply of June 2 and thank you. points require further discussion. Several
FOUNDATION, INC.
2368 VICTORY PARKWAY SUITE 410 CINCINNATI OHIO 45206 513-22HXXl2 fax 513-221-00:)3
HEIMLICH INSTITUTE
THE
With regards to the question of ELISA or PCR for HIV titers, the article that you referenced was very good, but does not answer the question which I posed. If you injected pure HIV antibody into a heal thy person, the ELISA analysis would indicate that the person were HIV infected, although there is no virus. Similarly, if one of our HIV infected patients has all of the virus eliminated after malariotherapy, they will still test positive for HIV antibody despite having no virus. Unless we know that the antibody level will decrease rapidly in response to HIV titer decreases, ELISA analysis won't tell how much virus has been eliminated from the patient's body. Dr. Heimlich recalled that you mentioned it was possible for PCR analyses to be done in Beijing. Can you let us know: (1) How much it would cost to have PCR analyses run there, and (2) Is it practical to have samples sent there? Please note that we would not want PCR analyses done on all cases. These would only serve as a check on the ELISA measurements. You mentioned that you were patients. Have you begun the more details so that we can Guangzhou at the appropriate ready for the next set of HIV treatment or can you give us any arrange for Dr. Hua to come to time?
Do you have any more case data prepared for us? We have the initial data you sent us for the HIV cases, but none of the treament data or follow-up reports as of yet. Could you provide a summary of patient funding which you have received from us, so that we may make the appropriate payments. We have provided a return Federal Express envelope for your reply. I look forward to hearing from you soon.
Best wishes and regards,
~~, ~~c
Jul y 11, 1994 h i r G. Sp l e t ze r , PhD Heimli ch In s titute 2368 Vi c tory Parkway, Sui t f' 410 Cincinnati, Ohio 45206 De ar Or. Spletzer: re ce ived your l e tter uf M ay 20,19 94. Thallk vou. R rna;' be th e best way t o m easu re HIV titer; but it i s not agr ee that PC ava i l able in Gu an gzhou by now . It i s noi conve nie nt t o send samp l es to Be ij ing for doing ?CR 'ifI we can not tel l Beij ing we r ece ived HIV patients from Yunnan Province ( th ey mus t ask us wh er e the pa t ient s are from), be cause we do th at on th e way of und e r g ~und, Or . H eirn! ieh knows about that si tuat ion. Othe rw ise, we should est abl i s h PCR in our labarato ry. But if no PCR, it i s a l so OK to use ELISA for HIV antibod y t o [ppr es en t HIV ti t er because we have known by now th at HI V antibod y i s iden ti cal to HI V in hwnan body, If only we follow up th em for over a half year. Please t el l Dr.Heimlich and Dr. Hua that w e have re ceived seve n HIV patient s in this group. The y wi ll receive malari oth e rapy after giving up their drug addiction, maybe 10 days tater . Bes t wishe s and regards to
I
YOII ,
to Dr.He im li ch and Dr.Hua.
Dr. Chen Xiao Ping hief, Department of Microbiology, C The Muni c ipal Health and Anti-epidemic Station of Guangzhou. No.23 , 3rd Zhongshan Rd . Guangzhou 5100 80, P.R . C hina.
X~~0'-'"~ c:- .
The Municipal Institute For Preventive Medicine of Gua~gzhou

of' fiil r ffl of' lli '=:'!l/f23%
i!I~ i!tIAii Ji!?"
r.l!,
510080 n5 ,7774103( .M!1 >
No. 23, The 3rd Zhongshan Road. Guangzhou The People's Republic of China Tel, 7774103 (ext)
July
28. 1994 Henry J. Heimlich. MD,ScD President, Heimlich Institute 2368 Victory Parkway. Suite 410 Cincinnati. Ohio 45206 Dear Dr. Heimlich: Seven HIV patients received malarial blood yesterday; the incubation is about ten days. you can make your tour arrangement according to that situation. We have used UP all funds from you, because all the seven HIV patients in this group came from Yuili County. Yunnan Province; We three doctors visited them three times in their home town before they agreed to come to Guangzhou to receive malariotherapy. All patients with whom our three doctors (including the doctor who was responsible for giving up their drug addiction) accompanied came to Guangzhou by air (Yuili to Mangshi by bus. Mangshi to Kunming by air and Kunming to Guangzhou by air too). Before they received malarial blood. we had spent a lot of money on giving UP their drug addiction. So we hope you can mail the money to us in advance before you come to Guangzhou so as to carry out the treatment smoothly. The money you should pay this time is:
-.
The Municipal Institute For Preventive Medicine of Guangzhou .p I!I im .p III = Im23~ No. 23, The 3rd Zhong shan Road. Guangzhou
1H~ i!!C!;fC W :
510080
t.l!
~E : 7774103( .~, trt)
The People's Republic of Ch ina Tel: 7774103 (ext)
----------------------------------------------------------------------2000 USD: for the sixth cancer patient 5000 USD: for the first two HIV patients whom we have followed up for a half year 7000 USD: for the seven HIV patients on their start of treatment
Toa 1: 14000 USD
By the way. if you consider the report of seventh cancer patient has some significance. I'll give you the report: but we insist in that yoU should pay for this because we have spent both money and time on his treatment and follow-up even though he just survived one month after the completion of malariotherapy. It is not we selected patient unproperly. instead the patient varied very complicatedly and no effect on this patient. since his general condition was good before the treatment. Wellcome you visit Guangzhou again! Best wishes to you. to Yours sincerely.
D~
Hua. Dr. Spletzer and my aunty. Cecilia.
(/~Xlo
Dr. Chen Xi,o Ping
? ~
I
Chief. Department of Microbiology Municipal Health and Anti-epidemic Station of Guangzhou No. 23. 3rd Zhongshan Rd . Guangzhou 510080. P. R. China
August 9 , 1994
2368 VICTOR Y PAR'f:Y.IAY SUITE410 CINCINNATI OHIO 45206 513-22HXXJ2 fax 513-22HXXJ3
Dr. Chen Xiao Ping Chief, Department of Microbiology The Municipal Health and Anti-Epidemic station of Guangzhou No . 23 3 rd Zhongshan Rd. Guangzhou 510080 People's Republic of China Dear Dr. Chen: We received your letter of July 28 and thank you. We were delighted to know that you have started to treat the new HIV patients. According to Dr. Spletzer, the current status of data for the different patients is: HIV: Patient 1: We have not received febrile data, posttreatment and followup reports. Pat i ent 2: We have not received febrile treatment and followup reports. data, post-
Patients
3-9: We have not received histories, pretreatment physicals and lab results.
CANCER : Pat i ent 3
Was any followup examination given prior to the patient's death? We have recieved no followup reports on this patient. : Was any followup examination given prior to the patient's death? : No followup examination has been returned.
Patient 4
Patient 5
Patient 6
Patient 7
What was the cause of death?
Was an autops y done? Do we have data to show what impact malariatherapy had on his condition? Do we have biopsy information to show that the cancer cells were undergoing necrosis? If you can give us a complete report that shows what happened with the cancer then we will consider paying you for his treatment. I would again stress that in the post-treatment and followup examination that patients' physical appearance and condition be reported in as detailed a manner as the pretreatment physical. The patients' feelings about their condition is also important. As you can see from our agreement (attached), I have highlighted the sections on what data is to be provided to the Heimlich Institute as well as when it should be sent. The payment schedule is also highlighted. You are to receive $1,000 usn for each patient at the start of malarial fevers, and upon our receipt of the histories, preexaminations and lab results. The list provided above by Dr. Spletzer shows where we stand on each patient. When all necessary reports are received by us, the funds will be wired to you, as per the contract. In the meantime, because of your expenses, we have wired $3,000 usn as an advance. We hope that things go well with the new HIV patients. forward to hearing from you soon. Best wishes and regards, I look
7dt1t I , }'
/{ C#id
0 r " UA
~ I~k
A!llllA
Mn,kbn
Henry J. Heimlich,
The Municipal Institute For Preventive Medicine.of Guangzhou

,t [l\j J"til l' IlJ ::: Be23% i1(i if.{lIilfillJ, 51 00 80
J
If:!,
;f,1i , 777 41 03 ( ,~, ii1
No. 23. The 3rd Zhongshan Road. Gua ngzllOu Th e People' s Republic of China Tel, ?i7 t [ 03 ( ext)
,4~. II/' l'Ift(-
J1D f/~YMii1:- JI~Z?tv'd ;h.5i2!?c.&i

2-J6f
/J_I
I
Jlb/1/?/
J . }/~t!U(
(/~ I'~J/5'~4"'"
c;...j1t'
~n&uz/~/
)/r d~ qJ2--~b
>1/11
)flz! r;dtp,L; . b<

6'LW
tftrlf ~~(ever;
r -t:b::r tr.MZ/1Zffi;i1. 8r
'717~~
t ~ me -&It rr
acu~j-<7-
yr
b2
tn.n-T'; 4/n flM({ ~
Pr - /
fi"d/ ~ 1:~Usp
u/ W
~
Cd-tnMv'r-:
/tiza.re-=!c:t(:
;0,ze
ud!f
~JJ,9U-T
~Ji- tV~L ---cr-;;rVL /

{!)r
!lab?' d'=zI f~~

cL;,.,.
C fctl ~ f~2J .
CtiLUj#z.k" s-tvP,P" , f'. I!,
fh,2J. 3r'/2b;#k" 120"
August 17, 1994

2368 V ICTORY PARKWAY SUITE 410 CINCINNATI OHIO 45200 513-22HXXl2 fax 513-22HXXl3
Dr. Chen Xiao Ping Chief, Department of Microbiology The Municipal Health and Anti-Epidemic station of Guangzhou No. 23 3~ Zhongshan Rd. Guangzhou 510080 People's Republic of China My dear friend, Dr. Chen: We received your letter of August 11. We are glad to know that the new HIV patients have begun the fever stage of treatment. We have not yet received the pretreatment histories, physicals, lab results and photos (if possible), as per the agreement. We hope to receive these soon. I have instructed Susan Soudrette to wire the 7,000 USD to you when we receive this information, as per the agreement. We are trying to see if Dr. Hua can come to Guangzhou while these patients have the fevers. I would like to come to Guangzhou soon and visit you, however my schedule is uncertain and I cannot give you any definite information at this moment. Again, we hope that things go well with the new HIV patients. I look forward to hearing from you soon.
Benefiti Humanity Through Health and Peace
August 18, 1994
FOUNDATION, INC.
2368 VICTORY PARKWAY SUITE 410 C INCINNATI OHIO 45200 51:}-221.{XX)2 fax 51:}-22HXXl3
HEIMLICH INSTITUTE
Hua Hong Shun, MD 3708 Baldwin Ave . El Monte, CA 91731
#2
Dear Hong Shun, This is to confirm Dr. Spletzer's conversation with you concerning your trip to Guangzhou, China. Your patients. trip to Guangzhou is to monitor the course of
ma1ariatherapy being given by Dr. Chen Xiao Ping to seven HIV We anticipate that you will be in Guangzhou for one or two weeks, while the patients are s t ill in the fever stage. We would ask you to observe the end of the patients' fevers and visit the patients in the hospital every day to check that they are receiving appropriate treatment and care. being done, and how they are being done. will you also please observe where blood work a nd laboratory tests are Please keep us informed by FAX every few days during the course of your stay. Your trip will not require you to go anywhere other than Guangzhou, and we ask that you not leave Guangzhou until you have completed these things. so, at your expense. you are in Guangzhou. Currently, financially we are unable to make any commitment anywhere to After you have finished in Guangzhou, should you wish to take any side trips, you may do Do not schedule any trips for the time
support
malariatherapy
research
else
other than Guangzhou. still interested in
You may wish to telephone Hainan Island malariatherapy , but we cannot start
or Kunming, to maintain contacts with them and see if they are research there at this time.
We will compensate you for your airfare to and from China and expenses incurred while working on malariatherapy in Guangzhou. In addition, you will be paid $1000 USD for your We would hope Dr. Chen's group will take
time and effort.
care of your lodging in Guangzhou. If any difficulties arise, please let us know so that we may be of assistance. us informed. I hope all is well with your family. Give them my We hope you have a good trip and keep
regards.
Sincerely,
\
I
I
I
I
{
jl
J
"
\ i
1 '
'-
',1_ C(
\ i r't'
i I,
'\
,He~'ry \ ; '~
Himl i ch , MD, ScD

I
,f '-
~ ~
:"
:
) :/
....-
...
I -'
_
I
\. ~ {.
"L
I
I
l,. \( )
t...
I'
'
/. '
1.,1.
/1...
I!~.L,1/
(~I
,,( '
I,'
:;'
_
, ,- J .1 \.., i / i '-"
L . ,_ ..
/U
.
r
)"
I
./~
,
_ ../
--
f.. ,~ :..
/ i ./1, I, f,"
'
FAX:
(513)
221-0003
FACSIMILE TRANSMISSION COVER:
D ATE:
8/1 J/ 9t
2368 VICTORY PARKWW SUITE 410 CINCINNATI OHIO

~~
TO:
LOCATION:
513 221.r0J2
NUMBER OF PAGES TO FOLLOW:
RE:
NAME OF PERSON TRANSMITTING:
If you do not receive all of the pages indicated please call the above-named person at (513) 221-0002.
above,
Jt~ C/}"'. ~ (
'W~~~trS~'~J~~ jjt~ 1kt~~

and Peace
~.'W~~IX ~4~ ~ ~ ~~ ~+ ~ ~ -- kU. "'Ir ;", ~ ~ . ()A. ~ ""-- % ~ ;- ~,.I.N'<. ~ ~ ~ t,. Jr" ~, :JW-l-l,.-.
1k~~~~~~~~HIV~v
t~I~~
Augus t 23, 1994 Henry l.Heimlich,MD,SCD President, Heimlich Institute 2368 Victory Parkway, Suite 40 Cininnati,Ohio 46206
My dear friend, Dr. Heimlich:
I received your letters of August 9 and 17, thank you. I am lorry to know that you have not yet received the reportl (including the follow-up reports) of the first two HIV patients and the cancer patient. you mentioned. Ie must han miued the reports in mailing courses, because I sent them per iodicd h according to our agneement. Last week I lent the reports of the 7 new HIV patients who hafe all got " malarial paroxysms to you by FED. EXPRESS, hafr you received them? Now I sent again the completed reports of the first two BIV patients to you also by FED. EXPRESS. I look foward to hearing from you fery soon so that I confirm you haTe received them. Some time later, I will lend you the completed caneer case reports. From now on, I will mail them to you by FED. EXPRESS on your account number in
order to be life, do )'OU Igree? According to our Igreement, when )'OU rece i red the case repor ts, )'ou shou 1d wire 7000 usn for the 7 new HIV patientsjand Inother 7000 USD for the fir.t two HIV patients, beclule we hale I.nt their a hlU year's follow-up reports to you (20000X '01-6000=7000>So when you recei,e this letter attached the ease reports, you should wire 14000 USD tottlUY to us, 10 II to smoothl), complete the mallriotherap), on the 7 HIV pltientl.
By the WI)" the lib. sheet of CD3, 4, 8 of the els, i on March 1,1994 wis milsed, but we cln cheek it in the lab.
records when Dr. Chai who i. re.ponsible for the telts come back Iffer her summer 'Icltion; IDd the last time ELISA titer will be done ,.r), soon, which dellYs som. tim. due to reagentl llckness. I hl,e I small suggestion that if )'OU ., certainly ,is it GUlnglhou again, you hid better do that nry loon before the comp1eHoll of mallriotherlpy on the 1 BIV paUents.
A'tJtL5f .2~ IrtJtr J/tU1'd' J. lI~nL?;; ~ II p.

2.3t5'<f?
SeD
f~4: JI~;:c/ J/7S~

t/~f /,JirV:;y / .5'zu~ /f-t)
if-f205
~ndZ/ ~k
d/<w-(lOU r~ -tile 7 -new mt/ ~ TibriJ anoi --t,. f,j-f ~ _ H11/ rerrtr tIz4 .J - ~ -iF JIJU reU4-tf:; 0/; Ft=:DEX,? \J ~1:r c.-frm ~t
t;a.k.-
0~!/~~.
tJ/$W c.pk
~e_
ubiarl1 7J~f Mid !iLlsA~fthr k[~
~ / ~ r>e~ ~f- Ul.7ferl7 f/w ./ L,ISIJ allti PA Me all JIiU Ctl-rI >=- dz-, /0"-t~
~ ne-~ Lic-t:.g ~ ~- #kef p-rr ( dt;uhui), ;;1 =ad k tid 'IUI't.J Jle;J!t;fz, and ,4tit.-I~u:.[ 86dte17~~~ CMe! M HIV ~rl1 (&J HtI/~.<-J
w..;ti
"lUre- )
fN rtf M r~ ~ . ~ iJf 1 J9f.
/),dr). ~i- Ju ~J re~d~' 7f~ ~ M CM1 be- M tl-. Hlt/~ ccn:f;-N/ ;" (~ 8tM' fro)ed? fI~ a.i;d JDUrT~Y/ )
I1Ie ~ -it; r~ -ViM, f~mr t/6r 'J SMm fij .!"!1 )Ir ',;k H7);W fr -tA j?ddnn ~MZ4
I
rna's
I~---b;
5l2e
!f1Jtl- 0" V'O~Il.'
7ksi
@.
urdJ~ ""wi r(f~r,
ck~fiJ-~--tu"'~~(J~n
tiki.', ?1J;?rb~t! 2)1:1=:'7
MttM-e:t.l jI-tiA IUtd tvat-r~"-<c g~,
t: . ,.
1- {j'(Jzka~
6~~f1#h Po R. ~
tJ}) .. 2 ..
3I C
7/2 :?Cf).
tJ]):./ tf- 7
: R F (+) /
b Inontiu
( J
1-b-r.
/
(7/22
f! 1-);
]'11
Cl),J -- 7R2 ~ CD~ -'
CH1"
LD,p,\
/1
/q'f)
m17lltiz ~) .
~ We-$tA-ll 8u;{ +; OJ): ;,17 (7P2/1lfj .

~ W/estM--n g~f +- J
()]) : 2
I
0/ ( /!Z2/ttt).
Ca-.se.
Case
W5
s-
.>
WesiZrn -g~f +; OJ) ~ ~()r (7/22/rf).

~ uJ~$1ir/1 2?~t-T ~ OJ): 1,1'1- (7/ 22/ tf lf).
Case 6)
7)
i
.> .>
~ u!est-rl1 '8!..ot T) OJ) ~ 2

W~s~rn l?~tt) OJ)
J)
I (7/2 2 /1ifj
: 2 \ 1]-( 7/22./rtt-)
-.J
Case 1
~ W~s--t-rn BltJt-) l;LISA
Pli-
eD ~ 0 (7/22 /rf)
.
P
BIf
AIoW 'lY
@
71te f~J Mb cases !ottew-uf
6' t7ZdniiJ
~ Iws
bl2n
CJ7tnt&..tLa{ and fC flf irJO.
;r.
Tk 7 .~ Ci:UCL.f' ~ /u'stcT/f) f~p-~d e XtJA11. tvn d Uub . htl-t/e bee 17 f--e 11 f i:tJ
JtlUr dear f~q, 7Jr Cill/ X,:W /~fW' J/z/j'ltt .
A'tJtL5f .2~ IrtJtr J/tU1'd' J. lI~nL?;; ~ II p.

2.3t5'<f?
SeD
f~4: JI~;:c/ J/7S~

t/~f /,JirV:;y / .5'zu~ /f-t)
if-f205
~ndZ/ ~k
d/<w-(lOU r~ -tile 7 -new mt/ ~ TibriJ anoi --t,. f,j-f ~ _ H11/ rerrtr tIz4 .J - ~ -iF JIJU reU4-tf:; 0/; Ft=:DEX,? \J ~1:r c.-frm ~t
t;a.k.-
0~!/~~.
tJ/$W c.pk
~e_
ubiarl1 7J~f Mid !iLlsA~fthr k[~
~ / ~ r>e~ ~f- Ul.7ferl7 f/w ./ L,ISIJ allti PA Me all JIiU Ctl-rI >=- dz-, /0"-t~
~ ne-~ Lic-t:.g ~ ~- #kef p-rr ( dt;uhui), ;;1 =ad k tid 'IUI't.J Jle;J!t;fz, and ,4tit.-I~u:.[ 86dte17~~~ CMe! M HIV ~rl1 (&J HtI/~.<-J
w..;ti
"lUre- )
fN rtf M r~ ~ . ~ iJf 1 J9f.
/),dr). ~i- Ju ~J re~d~' 7f~ ~ M CM1 be- M tl-. Hlt/~ ccn:f;-N/ ;" (~ 8tM' fro)ed? fI~ a.i;d JDUrT~Y/ )
I1Ie ~ -it; r~ -ViM, f~mr t/6r 'J SMm fij .!"!1 )Ir ',;k H7);W fr -tA j?ddnn ~MZ4
I
rna's
I~---b;
5l2e
!f1Jtl- 0" V'O~Il.'
7ksi
@.
urdJ~ ""wi r(f~r,
ck~fiJ-~--tu"'~~(J~n
tiki.', ?1J;?rb~t! 2)1:1=:'7
MttM-e:t.l jI-tiA IUtd tvat-r~"-<c g~,
t: . ,.
1- {j'(Jzka~
6~~f1#h Po R. ~
August 29, 1994

2368 VICTORY PARKWAY SUITE 410 CINCINNATI O HIO 45206 513-221-CXXl2 fax 51 3-221-CXXl3
Dr. Chen Xiao Ping Municipal Health & Anti-Epidemic station of Guangzhou Guangzhou 510080 P.R. China Dear Dr. Chen: Thank you for your letter of August 23, 1994, with the case reports on the first two HIV patients and your letter of August 26 with the ELISA titers . We agree that you should continue sending the patient information via Federal Express using our account number. We have wired $7,000 USD for these first two HIV patients' six-month reports. Once Dr. Cha i returns, please send us the remainder of the lab results for patient 2 . Additional funds will be wired when we receive copies of the signed informed consent forms for the HIV+ patients. Please let Dr. Hua and us know when the fevers will be ending f o r the HIV+ patients. We hope Dr . Hua will be coming to Gu angzhou within the week. Sincerely,
t~~ . ~~
Er ic Spletzer, Ph.D.
DATE:
August 2 9 , 1994 Dr. Hong - Shun Hua Dr. Eric Spletzer Susan Sou drette China Tr i p
FOUNDATION, INC.
2368 VICTORY PAR'{.:NAY SUITE410 CINCINNATI OHIO 45200 513-221-0002 fax 513-221-0003
HEIMLICH INSTITUTE
THE
TO: FROM: RE:
We met with Dr. He i mlich today about the status of the China trip. Dr. Heimlich insists you must see at least the last week of fevers for these HIV+ patients. In order to do this, you must talk to Dr . Chen.
1.
Specifically, you must call Dr. Chen today to find out exactly when the fevers will end. The fevers started approximately August 10 and may be ending early next week. You will need to adjust your travel according to Dr. Chen -- it may be that you will need to leave in the next day or two. Dr. Heimlich suggests that you can leave Los Angeles on one of the daily flights direct to Hong Kong then proceed to Guangzhou as he has done. Please tell Dr. Chen that $7,000 USD has been wired. Also, tell him that we need to have the signed informed consents from the HIV+ patients in order to wire additional funds. Which of the patients was stopped early because of jaundice? Was it the HIV- patient? What was the cause of jaundice? Call Dr. Spletzer after your call to Dr. Chen to discuss the status of the trip. His home number is (513) 7610722.
2.
:3
4.
Th ank you for your help.
FOUNDATION, INC.
2368 VICTORY PARKWAY SUITE 410 CINCINNATI OHIO 45206 513-22HXXl2 fax 513-221-0003
HEIMLICH INSTITUTE
THE
August 30, 1994
Dr. Chen Xiao Ping Municipal Health & Anti-Epidemic station of Guangzhou Guangzhou 510080 P.R. China Dear Dr. Chen: I am sorry I cannot go to China at this time. As you know, I was very sick after my last trip and will have to be fully recovered before I can return. Dr. Hua has just told me that he will be in Guangzhou on september 1. The patients should still have their fevers and be in the hospital at that time. We look forward to his report. Thank you for the very fine records you are sending to Dr. spletzer and Susan Soudrette. In one letter you mentioned that I know about an "underground". I think that is a misinterpretation of an American word. I could not participate in an underground; neither could the Municipal Health and Anti-Epidemic Station of Guangzhou. I do remember you speaking of a network of physicians who are helping with the project and that is admirable. In any case, I wish I could speak Mandarin as beautifully as you speak English. Dr. Hua informed us that one patient became jaundiced and, according to the protocol, treatment was discontinued. That is a correct action.
The ELISA shows that one patient did not have HIV infection. We cannot run controls, but his record may help our later determinations. I am sure that when you sent him home he was grateful, since other physicians had misinformed him that he had HIV.
Your letter indicates that some of the patients were of questionable character and made difficulties for you and the hospital. That is unfortunate. As physicians we must, of course, treat whoever needs our help. As you know, we need the info~med consent forms signed in order to complete our initial records for the 7 patients, as we did for the first 2 patients. Thank you again for your thorough and dedicated work. regards to our friends in Guangzhou. My
Hen y President Heimlich Institute HJH/jlm
10
Ft.. 'ut\1
//cr'VR.. "
l..""U f tVl1
J.
/.IeI'M ficA
I
MD .
D .
/-/ON6 -.'i(.-IuN f.(V'4

7<?fP
lvf-.
ICE
A1/i'Lli,Q/4
!f-i~~4 fly
('IF
H(V(~) ?--ts
P4,/i- :
O~/>?Cf /?~
;" .\e-i-
oc-of
fr
t-'1
I .....;
i;1 t'J1?
0.8/3 r /f'<t
ff
AM
</ /{ R R
'?'!'If
{I/
I~
o.-{- C;flll-I/117 114-(
11,.1
/::VC#,l f '.l
'7
{J, /o/ /11'1- ?11t;v LG-F-T

,
-;(14/'/9(~~1
01\)
oro
a.-I"
A),1(1t1,/ I f 471!t:';1
v~p
a.f-
(~1~4.''1z-fl'~1
rt.:
;;(?
LJ-(
Yf(-illf,y (a/Myl;fX./-r;>c( ~>C> Ii" cf../:l-Ir;e f)..f
,--,-/.. "
' t,,,; t?.Lt-'i -'
i
-/v
M
VI
~i l-e1 y, ~ J (.It-{ /{~I-.'-fa.,1 ~ ~A::.e. /L7tt-<.,- &;-f ~

..
k-'4,.--r;f ,
('~I- 1/..:,,-, 'i 10if

Ofe.
'I'T
~~'1 b i:...t'~
..f I "",_J-(<-' r.tJ. n&.. pd'S" \

I
u. ~ 'r: A""'''1C--f/1Cr 111-4"b..
7r." ~
~ ~ ',flUt <-4h1'tel}'ITJ~'-1 4. ,.~,.,.7t)I'l!.- t,

J)1f11u_ j
fy
~ 1f{1.J4
If
rJ NG7'~~- (/~ ,A
I
80~]) erR.
(.It\lt=
-Z 0 t~M It . {1.'Ir~/e
pe<Jp(<;, ex."-e
clr'lAj
(f./cn:1IN eO) culd1'rJ".....;;:f
..f
mo>-Hy
+-0
cu~ t.rI.A.A.-H''I,lc '1 <-Ie...rCJ 5'.l;y~ .
..?h..l.-tr "'i'~r u4
.~ec.c..;tJ<!f ~
t>r
Or. a, <~-i'l
? 5-()rH~
CJIT~ q"(I-C:~C~ 5
I
6(,1.4 '-1 A.<'~<..I

P/~ih~or.:l.V-"'l
(1U..J-" ;:;,.,.,
.!t
tal Fir.::-I6Ic-rrr::! of
Nal1fe
rt.'l'1
IOG<-;
:(:()- sfop dr;1

.ale.
at:((.---c~I cf-r-\rn'1
MAtlj"~ II,.
z: /K)ofY-<4,'(I!.~}
,
C '( t, (
~,q2/Ot?y~ (~)t~.-1 ;rl.i/~j;-c( (v.W e~e1, c.>f.

bf7'e-/Cy : .)L(.I'1/1~"';Zt;-J) R-~ f.~{I(;'''''''::'''
~.~
':;;'' ;"7 / ~)I- .
7'Aeir- T~'
~,;(S
CdA<: tI
/(c~51J.it
Aj-e..
~.9"" .r;~~ ~-<I

St.;>:
I~r~ I ~
3jJj
vx . .JtI
t9{$
L.W
/.. . L .
\I 1
Mau:f/.1
rt..'-5(<<~1
I
ft-~.r
G--<J<64' r;~ N"d D 'f/7l { ..tf

..
pI-.fuI'~.
,'(
I.
X'
(
,
7
:!d :o'7i /
ilr
~/..}
IS
.?lA-7
S/..7
I
,(
1.7
2,:7
$/ I
'-J -I
i I i!J
X
;,'
X
/
;(
8/1
G. '4
&/J
8~
J!>
<L
.~'/).t
Y,L
'-' 3(!
"
(
ht:J..<--f'
I8
r~
~ /;.;1
;<.
. I , ~~~~~~~~
1
r If!
/11
I
:
:)(
8/
(I
~C
0/;0
tI i ~"'r
rtf- h(JSf~ -I-.r.../ .1-0

.ff .....
f
(I,"pl- tk.- L(1-6

e<.l-i"..tf Z
.
I
Cb""-1~ "-'/
",-';116e
1'11<:
rts; ,dtJefm'J { NP..f) e 5' (,I! ;t,fl}1Vdf~ . ~l-{~~.1'~ f tu~''--lfd(:4.r .Ut ~~,-lj-{~
iaLl< j <"
"
'
HIII' PAl-Hi (+-) F.e,lrf!..r '>11' .fl(~ .T~--iUc;~ e.,lt ov>7 _.

it;
CI
f..-:s;r-I.''' 11.(
l'lf
(Ph
~'/. Co.
A
(l'_
f
"",-...}- 11
f1..
-C1...("
.-'
<
1.....;. (J.ifihJ1.J'. O(fIJ
A('1fL "t."'1
(~ fA Y.
0 /1
fI<!.ed~ (Jo{
it')"
.~ 8'6 - 7-0 .- ]
fr:r /~ ,'rm./ Ihl! -6 - t 7' 6'0 Rolf! R..~1 :# ttJ~/
Iv f
81."'1-:7.-0 -];;:.i...~ i~W8
__
,I j .' ~r-,~l~fd--,r~ __ ~7~
..
y..R.M Pt
f1ALA.RIATHERAPY OF~HT!+ PATIl')~T~ A ml?~t '',.n g., was held on 9/7/9 4 f iTl the In sti tut e
UsP.1' Q<c-~ ~ - ~ ~ i'" f~~ 1- ~;! ~~"

{.)f
......( w..:f,.J/
Pr event t ve
~ -j;;I.. >f~~ ~
1\ ()
() f U'..l~mg7.hou, Guangzhou t Chin Per50nD1 pres~~tl "I.,... .L ',.. - Liu Shou-gou, vice
t~ edicine
of Institute of Preventlve
Dr.
(;h(~n
Xi :?'ao~pj.n Vic e dl:r'ect
Dr'1 Lu Y1.~ t -h~n t
Director of ii Ser H05p Dr. Kuang , Visiting docto

fir. YI.\S
Dr.
H1)8.
r1.;:dic~~1
Dr. 1...1 T set'-51.Ul

t
Yi Ser Hospital , D,trector of Cl nic81 La 0, In sti tute of Preven ti v ~

e
n ~.. t:i tute
Hcngshun. He.imlich
D1' HU8!
E i'or this tlm9 , I am assig; joint projectof malariath :~ II the HIV+ pati ents here of m3.lrt rla e'lQ'(' , h::we th f.H~e ready to go back to the 1: t13ve observed to Dr. Hei bel i eve thnt we a re deepl perforrne:i. It is high tim
ed by Dr. Heimlich to monItor Uit?rapy of HIV+ patients in Guangzhou.
hAve filii 6~led the treatment s'C:::),ge 11' blood drs'fm for leb test, and r hometown. I shall report what li(:b and the Insti tut~, and I ir.lpressee by the work you have now fClr us to revi~w what we h~ve
~re
done. Comments
further
Cornments
o \.U'
and sugge 'ions clinical T'B5e8 eh.
\'lelcome to pl:'C'1mote and
and suggest.ions are swnmarized ~s followl3 The purpose of the projec ts to initiate mAlaria therapy to
HIV+ patients and to asset s t l 1e effect.

t r)le: ' Bted thQ malarJa fev r next? Ttlese
V~
Patients have
stage. What and how shall we do

be
ti ents are examin d <?nd found to
H1V+ by F:LISA
ar'ld wel~e
and "Je$tlrn Blot. They we e IV drug Rddicted

expo SGd to heterosexual, HIV+sinoe 1991 but they 'l'he enlarged lymph gland. .1ere 1 ikely to have tnte IV ,injeotions on extreml
iigh ri sk p3rtnet's. 'rhey we1,'~ re stlll free from cl:1.ntcal symptoms. Itlere not specific, Oecause they tions clue to non-sterile, '11.11 ttple ies by themselves. Their CD4 counts .',
',..,ere nonm).l,
nove 500.
The p$tleots cerne from reT ote OOJ'oP,X" line ci ties near Burma. t"lost of them af'e n;:ttiOnl''l.l mir'lorlties. Havlng Deen d_ t'ug ~"dt;Hatedt they (l0 not mAint(c1in good, mor:':l.l in tegr1.ty. It is hard to
DU:r'i'rlg their st.ElY in Yj, Shou Ho 3Pi ta~ t thoy could not comply well ,..,i th the h05pit8:L 5teff ( did net 11 sten to other phySicl.ans E)nd nurses except Dr. Chen, q ~r r'el with other patients, borrow money from hospital, a s fo):" Detter rflood, etc). Security gu~rds were h~red to m0.i tai~l t.he w~rd in orner. These ktnd. of p~ tients ~re not app opriete candidate for our project. AS required by the proje t, the laD facilities are of importance. The C;Dl~ cells 1tlere mamUB 1y counted. We need ~n Qquipment that CQuld do the counto CDb cells automa tica11y. To perform peR antigen t trotion, a lab of P3 level is needed to set up for fUrth!r tl, c J)l~o,1ect. It \'/111 take Lf days, 2 ays tly train and 2 deys by cor, .for thesE' patients to rea.ch Quangzhou. a temporary lab is needed to set up in their 1101I~e 0''''1) fot' fol lOh'Up. To better undertake tbe mi ~.sj_on, a standing or-geni Zft t,i(m is required. The(} Dr. C . en Xiaoping could devote full time fO!' triG proj ect fl A'ltj. a ~eCJ'9tary will be staffee for the pr1 uerwork. Dr. Liu emph,~ sized thF.i. .. AIDS i~ a very sE~nsit1.ve problem in this country. To un ert:l.ke this LJroject. they shouldered he~vy aocial and polit cal responsioilitias. Because it is not a ll-owed. to do any :regearch except in Yun~m. they had to keep 'the research con! dgnttal. The Institute of Prevootive t1 ed1.ci.n 0 of G1,.\angzhou i 1.1. keep suoportj.ng :for the furthel'"'ing for tne prOl!ct. They ish their effor-t wtll be fully reali"cd nnd full supp rt be provlded.bV 1~ l-1e~k1(:-e~ ..!41.S'-~'hJ-e. .
pt'cdict that they could l< . ~~rJ free from drug.
that CQuld do the coun to f CDb cel ls auto a tics .y . To perform peR antigen. t t t'r'<Jt1on, a lab of P3 ll?vel is. needed to set up for fUrth!l"' tl:, a 1)l~O,1ect. It Hill take Lf days, 2 ays r)y train and 2 d8YS by car, .for thp.se plti eots to rea.ch GUBngzhou, a tempol'cll:'Y 1e b is n ~eded to set up in their horrie OWli fot' fal tovrup. To better undertake the mi~ . sj"on, a standing organtzat.ton is required. Then Dr. C . en Xiaoping could devote full time foc 't,('IO pr'oj ect a nd a ~(lCleta.ry will be staffea for the
uerwork. Dr. Liu emph~ sized thF.!., AIDS is a very sE~nsit1.ve problem in this country, To un ert~l..ke this project. they shouldered he~vy 500ial find polit cal reaponsioilltiQs. Because it is
pt1
not a llowed. to do any keep the research con! r1 edtci.n a of G1,.\angzhou for tne pro i eat. They reali(:cd nnd full supp
:research exoept in
d~Hlttal.
Yun~m.
they had to
Prev~nt:Lve
The Institute of
i 1.1 keep sunportlng for the furthet'ing 1 $h their effot't wt II be fully
rt be
provlded.~V T~'\.. He;h1.(:-~~
.l41-S'--h'hJ-e. .
_-----

iH~ ig(1,ftfil?,;
<P 00 r-m <P lU -=: Blf23% 510080 r11 ali; 777.1103 ( .!;!, T-:' )
No. 23, The 3rd Zhongshan Road. Guangzhou The P eople' s Republi c of China Tel; 7774103 (ex t )
September 19, 1994 Henry J.Heimlieh, MD President, Heimlich Institute 2368 Victory Parkway, Suite 410 Cincinnati, Ohio 46206 My dear friend, Dr. Heimlich: It was a pity you could not come to Guangzhou due to your healthy condition this time. I hope you are healthy forever from now on, and may you be of longevi ty! I mailed the informed consent forms signed by the 7 patients about two weeks ago, please wire the funds for their feTer starts of malariotherapy according to our agreement. Their treatment was completed and we sent them home several days ago. I will mail their detail reports to you. Dr. Hua will also give you some imformation when he go back to USA. Yours sincerely, /
~h~ ~
Dr. Chen Xi Ping Chief, Dept. of Microbiology, Municipal Health and Anti--Epidemic Station of Guangzhou, Guangzhou 610080, P. R. China.
FOUNDATION, INC.
2368 VICTOR Y PARKWAY SUITE410 CINCINNATI OHIO 45206 51 3-22HXXJ2 fax 51 3-221-00J3
HEIMLICH INSTITUTE
THE
September 22, 1994
Dr. Chen Xiao Ping Chief, Department of Microbiology The Municipal Health and Anti-Epidemic Station of Guangzhou No. 23 3 rd Zhongshan Rd. Guangzhou 510080 People's Republic of Ch ina Dear Dr. Chen: In response to your letter of september 19, we have received the informed consents, pretreatment histories, physicals, lab results and photos, as per the agreement. We were sorry to here of the difficulties that y ou had with these patients. Susan Soudrette has wired the 7, 000 USD to you for completion of the first stage. Upon our receipt of the full reports and post treatment lab results, physicals, photos, etc., we will send you the next payment. We look forward to hearing from you soon. Best wishes and regards,
l~./L--L.
7h ,~i- a
b
...
.{.A.--r dc.eo
Ci?"-~ f'
rv-Qrv~?
.-
'-'i
A){J
t't7
(~, fr.-()
"';;' I (N'] .
(qct-y
7lc L~/'- t!7
7tv-
~~<C:- ~- fv>~ <"__~ <<J7<.<> lLz A~;IU;"

(x."1, f
<!. .
i ~ ~-:J.j.~-;-kLf 7~ ,~::J )1;' Sf- (~-N

)
(~r:f9pAf<4 Z4-<~JC4 ~
,"
I\JO . q 7
f~\hJ} ,;~~
,;;../..,......1";'
iF
.cL. H(I!f
~.Jt . ,d~ ~
,
...., s:..p.(Ilt1'1
~~~
r
tA.A
J 4 ,... ,~t< t&. 11A-!><LJIY I - I'jv~, \;'0 f<~1 A ~-t> c.ft~-< <vi;?.....e.. p;.c-f~1 ~ p..T-""'" -4-\' ~
t ...., {;
tL
Itt
I' e. .
q t~~ ~.-w... .
~~s.
k-'"V\A
~',,~ L~ .. r~ / Ri--iA/~
O~
..

.p mr-ffi.p ,L, ::: lllf23"iB;i!t!.fl li!1 : 510080 Ii! a;s : 7771103 ( ,(,HJL )
No . 23, The 3rd Zhongshan Road . Guangzhou The P eople's Republic of China Tel: 7774 103 (ext)
Oc tober 11, 1994 Henry J. Heimlich, MD, ScD President, Heimlich Institute 2368 Vitory Parkway, Suite 410 Cincinnati, Ohio 46206 My dear friend, Dr. Heimlich: I received the letter of september 22 from Dr.Spletzer you the full reports and post treatment and
two paymen t s (2 x 6986USD) fr om you; thanks a lot. Now I send lab results, the physicals and photos. Please wire us the next payment when you receive them if posible. Dr . Hua may have told you detail about the patients' does treatment; the arrangement not enough payment
be unsuitable for patients from Yunnan the patients' treatment of
Province. According to the situation of this time, it was to pay for hospitalization and transportations; we still owe money to Yi shou Hosp i tal after payed it the 14000 USD. So we wi 11 have difficulty to follow up them three months later due to fund lackness if completely follow our agreement. We discussed the plan of our project development when Dr.

<poorffl <PW'=:B!f23Ji}
HI, ;j5U;fj~:
rt!
om:
510080 7774103(,tH./], )
No , 23, The 3rd Zhongshan R oad . G uangzhou The P eople's Republic of China Tel: 7774103 (ext)
Hua visited Guangzhou, he may have told you about that. and from case 2 we can see a hope. By the way, Dr.Xiao Bin-Qian, the president of I myself hope so when the follow up of our
By
now we can say that malariotherapy is safe for HIV patients
station later of
want to send me to USA to study AIDS in the ear ly of 1995, three months as is completed. Could you arrange that for me the cooperation project? We look forward you soon. Best wishes and regards, a part
to hearing from
u/un ~ f21< 1
Dr. Chen Xiao Ping Chief, Dept. of Microbiology Guangzhou 510080, P. R. China.
8tH
L~
>-tnJ
Municipal Health and Anti-Epidemic Station of Guangzhou.
FOUNDATION, INC.
2368 VICTORY PAR'f,)NAY SUITE410 CINCINNATI OHIO 45200 513-22HXXl2 fax 513-221-00J3
HEIMLICH INSTITUTE
october 11, 1994
THE
Dr. Chen Xiao Ping Chief, Department of Microbiology The Municipal Health and Anti-Elidemic station of Guangzhou No. 23 3 f Zhongshan Rd. Guangzhou 510080 People's Republic of China Dear Dr. Chen: We hope that the funds Susan Soudrette wired reached you without difficulty. Dr. Hua returned safely and has sent us the videotapes and audio translations to review. We look forward to receiving the full reports and post treatment lab results, physicals, photos, etc., from you soon. Best wishes and regards,
~ ear
Dr. Heimlich
October 11,1994 with

Dr~ ' Yang,
Enclosed is the Memo of our meeting
Dr.Li and I called
Dr. You, during our visit in Kumin9, Yunan province. and discussed with Dr. Yang several
tim~s
by phone ' 'while ' I was
in Guangzhou about the clinical investigation of AIDS patients. He wrote me this time informing me that he would like to
w;~
follow up AIDS
patients with malaria to compare those AIDS

w~ite
patients without malaria. He agreed tp suppiimentto the original memo.
an addendum as a
Please find the English and the Chinese version of the memo and sign at the pl a ces designated by pencil writing,if you
do convince with the merna. Then we shall FAX of send . by mail to Dr. Yang to ask him to complete his
s~gnatu~e.
Enclosed also is the list of expenditure of my recent China trip. Thank you.
I
"
Yours fraternally,
MEMO 4 - 1 3-1994
_ -_::-e::. -e t s:
'~
? b lic Health Bureau of Yunnan, P.R.China Yang Qi M.D. Vice Chief of Sanitation and Anti-epidemic Division Programme Off,icial in charge ofYunan Provimcial OFFICE FOR AIDspontrol and Prevention ) You Weichang M.D. Chief of the Pharmceutic and Drug Administration Li Xue-zhong M~D. Deputy Director of Eptdermic Disease Prevention Office . '" Director of Yunnan Province Malaria Reseach Committee The Heimlich Institute Henry J. Heimlich M.D. Professor, President Hua Hong-shun M~D. p~ofessor Meeting held at: Kunming, Yunnan Province~ P.R.China At first, Dr. Hua made a brief introduction about the contributions Dr. Heimlich has made in clInical research and in the promotion of friendship and co-operation between the American and Chinese .people. The purpose of this visit 6f Dr. Heimlich to China is to introduce the theoretical basis of malaria therapy ift the treatment of mal i gnant tumor and HIV + patients and about the clinical trial undertaken in ,~ Jiangpu and Guangzhou since 1991. By communicating and exchange of ideas on those problems of -",m alaria therapyin concern, the . .both .parties wpuld, like to find the possoibilities to initiate malaria therapion ma l i-grr:ant tumor and HIV+ patients in Yunnan. . As r~commended by the American professors, for sixty more , years, . malariatherapy has been used effectively in treating neur~syphylis. \ Through malaria infection, the immunity ability of the patients is ' increaseq., Tumor incidence was found to be low in high malaria incidence area. The"1nortality rate of children suffering AIDS and malaria was significantly lowered than those children only suffering AIDS. Among the 10 malignant tumor patients treated since 1991, Six patients showed improvement in various degree,five of the t six patients showed marked improvement. Two, cases of HIV+ patients,one patient showed the same high ' level of CD4 count after treatment,as another case hisCD4 count increased from low level to a significantly hig~ level. As considered by the Ameri c an professors, to .observe the effect of mal,aria ,therapy on AIDS patients, AIDS patients , could be , innoculated wtth;' lnalaria blood, or by observing the . c'ourse of .AIDS patiehts who aiso contacted ' malaria. That lnightbe easier to observe by the latter method~ Bu But that would be difficult, to hold the malaria treatment during the course when the AIDS patien~uffered malaria episodes. To the opinion of American doctors,the latter trial could only be taken when patient voluntarily take part with full understanding ~nd co-operation. The experts of the Chinese party felt on malaria therapy: the basic theory, of clinical effectiveness and medical They considered that ,as a scientif i c much inspired and raised questi~ns the scientific design, the ' assessment ethics aspect etc. researc'h , malaria therapy is of :.:; . ' .ini [' i
\'
~~ ~ i= c a n ce.
~
~-
MEMO (CONTINUED) but the situation in Yunnan for the time being is ~ enti rely mature, they would make further consideration. e ' expressed their hope to keep on the contact, and to pro cure rther material and information. .
J
SIGNATURE: China Party U.S.A. Party
(signed) . . Yang Qi M.D.
,Henry J Heimlich M.D
.'
?r:or t o departure of Dr. Heimlich and Dr. Hua, Dr. Yang made 5 ggestion, i.e. to initiate an inv~stigation to follow up AIDS patients in Yunnan, by making comparison to those with ma l aria, spontaneously infected and later been treated, and those AIDS patients not complicated with malaria. By investig ating this adult HIV+ PATIENTS and to find there is similar result as reported among children in Africa. Dr. Heimlich appreciated the suggestion as a rational - approach. The Heimlich Institute will support this suggestion and would help the experts in Yunnan to prepare the report of clinical research, to have the paper published in major medical journal or presented in appropriate academic meeting.
November 10, 1994

2368 VICTORY PARKWAY SUITE 410 CINCINNATI OH IO 45206 513-221-oo:l2 fax 513-221-oo:l3
Dr. Chen Xiao Ping Chief, Department of Microbiology The Municipal Health and Anti-Epidemic station of Guangzhou No. 23 3 r Zhongshan Rd. Guangzhou 510080 People's Republic of China Dear Dr. Chen: In reviewing and updating the computerized HIV case records, we have been unable to find the fo l lowing information in the materials you have sent us: 1. Pretreatment HIV antibody mea surements for the last group of patients that you t r eated (A side question: Were these patients Western blot positive?) . 2. HIV antibody measurements for the six-month followup examinations on the first two HIV patients. 3. The CD3, CD4 and CD8 data for the one-month followup examination of patient 2 (Wang Wen-Guang). Any help you can provide in obtaining this information will be greatly appreciated. After looking at the results for the first two HIV patients, we think malariotherapy was beneficial. In the the next group of patients (3-8), the trends observed in blood changes between pre- and posttreatment seem to be too diverse to draw any conclusions. Hopefully, the one-month followup examinations will clarify things. What are your thoughts on the results we have gotten so far? Upon our receipt of the missing data, we will send you the next payment . We look forward to hearing from you soon. Be st wishes and regards,
Er ic G. Spletzer, PhD
HEIMLICH INSTITUTE
FD
nfE
January 4, 1995
Dr. Chen Xiao Ping Chief, Department of Microbiology The Municipal Health and Anti-Epidemic station of Guangzhou No. 23
3~
Zhongshan Rd. 510080
Guangzhou
People's Republic of China Dear Dr. Chen: I am writing to ask your help in obtaining some information about the test procedures used in the MT-HIV proj ect. CD3, CD4 and CD8 counts that are being measured Are the soluble
receptor protein or are they cell-bound receptor protein? Also, what method is used for doing these analyses (i.e., is cell bound protein being measured by rosette formation, or is this being done by a fluorescence technique)? details about the analysis procedure. We also are looking forward to seeing the next set of patient reports this month. matters. Regards and best wishes for the new year, Thank you for your attention in these Please send
Benefiting
Humani~
Through Health , and \ Peace
January 30, 1995
Dr. Chen Xiao Ping Chief, Department of Microbiology The Municipal Health and Anti-Epidemic station of Guangzhou No. 23 3rd Zhongshan Road Guangzhou, 510080 People's Republic of China
C2C6 51 3-22 -roJ2 'ax 513-22HXXl3
Dear Dr. Chen: I hope all is well with you. I sent the enclosed paper to you on January 4, 1995, and urgently await a fax from you agreeing that the report be submitted for pUblication in a medical journal. Please let me know your answer as soon as possible. Your comments on the paper will be appreciated. We thought that Dr. Xiao Bin Quan should be mentioned in the acknowledgements for his role in helping this proj ect go forward. What do you think of this? Dr. Hua informed me that you have just returned to Guangzhou after doing follow-up examinations on the patients. We look forward to seeing the next set of patient reports when they are ready. It is not necessary to wait for the reports before sending your permission to publish the paper since the paper concerns only the first two patients. With best wishes to all my good friends.
Sincerel ,
~........
~
I
,~-I
~ ~
u~
Henry J. Heimlich, M.D. President Heimlich Institute ~~
S \If'
/"
Eric G. Spletzer, PhD Heimlich Institute 2368 Victory Parkway Suite 41~ Cincinnati, OR 45206 Dear Dr. Sp letzer:
Feb. 16, 1995
Thank you for your letter of Jaa4, asking about the test method for CD3,.~ and CDS. Now I tell you that the test call APAAP method, a measurement detecting cell- bound protein neither by rosette for.mation nor by ~ fluorescence technique, see Fig.!. The method is very believable since the kits are made by the Chinese Military ~dical Scientific Academy and have been widely used in China for over 10 year s. If you have any other questions about the metho4 it will be my pleasure to tell you the answers. Best wishes and Happy New Year to you Sincerely ~ / /l 'l~ ~71
(// 11
JV~
Dr. Chen Xiao Ping Chief, Department of Microbiology Municipal Health and Anti-Epidemic Station of Guangzhou No. 23, 3rd Zhongshan Roa4 Guangzhou 510080 P. R. of Ch ina
Ce II Receptor (CDS, CIU, CDS) -{ The First MeAb (An t i ~rn3, Anti -ClU, Anti -CDS) -< The Second Ant ibody APAAP Cmlp leI (Bas ic Phosphatase) ( Substance (Red coloration)
CD3+,~+,CD8+
-f
cell APAAP staining Fig. 1
Henry J. He imlich, H), ScD Heimlich Institute 2368 Victory Parkway Su ite 410, Cinc inna t i, (11.5206 My dear friend, Dr. Heimlich:
Feb. 16, 1995
I received your letter of Jan. 30 and the second copy of our paper enclosed I agree to publish our paper as that I mentioned in my last letter. It is important that yon added the sentence'COS cells playa part in controlling HIV replication' in the second coppy. I am sending the reports and photos of follow up of the first two patients for one year and the second group of 6 patients for 3 months. Please send the payment for us to pay Yishon Hospital of Guangzhou for the patients' treatment of hospitalization and pay for the follow up. It was a hard job for us to follow them up village by village in Yunnan Province. We could not weigh them since there was no any scale in their villages. Ie also have no OD values of ELISA for HIVantibody this tbne( but all Were ELISA positive) , because we used up Pasteur ELISA Kits fran France, changing to use the Kits frun U. S. ( cut off value is different fran that of Pastenr Kit) . Fortunately we can do it again when Pasteur Kits arrive, staying their sero-samples in freezer.
We will establish a effective therapy for HIV patients when we complete the follow up of the 8 patients for two year s, I th ink! Best wishes and Happy New Year to you Sincerely f .
unX~
(07
Dr. Chen XiaoPing Chief, Department of Microbiology ~icipal Health and Anti-Epidemic Station of Guangzhou No. 23, 3rd Zhongshan Roa~ Guangzhou 610080 P. R of China
Aprd
4 / Iqq.s-
~ C .
}I~/
Sfl1Jvr / p(J)
:m stt/u;&
/
OH
.23U {/~/J fcuw
a,, ~ndr
/ ~ 01e? d 0.J~6
C l)4 AND CDS CELL RESPONSE IN HIV PATIENTS INFECTED WITH PLASMODIUM VN AX . Henry J. Heimlich and )Ciao Ping Chen, Bin Quan )Ciao, Shu Guo Liu, Vue Hen LIl, Ji Li Yao. Heimlich Institute, Cincinnati, OK USA and Municipal Health & Anti-Epidemic stltion of GuangzhOIl, Guangzholl, Guangdong. China H1V.positive patients are susceptible to secondary infections that prove fatal because of
~~
COlIgrc<>\ (
91h IlIlnll;! itlllill r I iii 11111110"
weaken,d inununity. In controst to other opportuntistic diseases. malaria does not Rccelerate the T2!e of progression of HIV -I disease, nor does HlV infection worsen malaria effects or interfere with respo nse of malaria to treatment. Malaria and HJV coinfetion has been shown clinically, and
m 2:"limaI experiments, to improve Ole course of both diseases. This finding may be related to the
fsa 1hZ malaria infection stimulates Ole body to produce inunUlle substances. CD4 cells are ' -rteled
E:"e 2.3
HlV progresses; initial results of our study, however, show that CD4 and CDS counts
==-"11 in HlV positive patients who have had a planned febrile period of mslaria
tty of the interaction of malaria with HJV infection, two HJV+ patients alBa infected
-~. -
Please read i."15on pa es I II be

com pletin e :his
~.5
. '-
' (p. \.ivax) were allowed to undergo a series of fever paroxysms over a 23 week
>tru1 medical monitoring. The patients have been followed for six months post-
=t'
~"
'orr..
3oL': pa:mus ha 'e had a sustzined increase in CD4 and CDS levels (See Table I). Study
on HlV-positive patients. including further manges in CD4 and CD8
1)0 .... 01 n>LD

I mo.
3 mo.
follow-up
6 mo .
follow-up
follow -up
9361562 4691391
1260/977 6261288
116211129 953/459
rt'"S
lines: do not type on o r clilS ide these lines
Poster ! Worksho p Prefe rence

(see over for workshops) 1 st Choice:
Signature of
tAl 7 .2
11 1 _ )
-;.-,r J.AO ~
~~
PO=UiJOll
pre sentin~or
~!Ic..i '_ =!L':". _-",'..=v--L1-:.... _ _ _ _ _ _ _ _ __
;oIr
-s ~e will be considered assurance of the merit and that all authors listed have had a signifi - ;.'>e = c h being reported.
Complete Mailing Address of Presen ting

(please print o r type)
uthor Important
' ail the Com pleted Abstract Form, Four Photocopies and the Acknowledgement letter to :
Secretariat
9th International Congress of Immunology 9650 Roc \'lIle Pike, Room 3200 Bethesda, MD ., USA 208143998
19
<---"""- --::>
., ... ~Ii
7);;1 ':Yl l-c! new
Ca-5e:
CCL-J-6-
I )
~ 2.
,2-6
~.0Z-2/
: / Iff
, 21/.J
( l L 5-<.
(C<-5
)" -'
2.
2-0
C /
2,2-2-
{a.5~
l /
; 2. 2
{a-s:
2,JO

li!!. :l.!I:: .p OO i 1H.pili=: l!lt23 % 5100 8 0
H ~ ~ ~ (~~3[)
(,
i!I~i;l(~li!b:
f\!i1S: ~('('HJL),
Address: No. 23, 3rd Zongshan Rd. Guangzhou. People's Republic of Ch ina. Post No. 5 1 0 0 8 0 Tel: '/ -; 4 16 :1 (ext.) of G 535 5 (off ice)
J).eflY])r I-f.e-mt~dv I
7w
am
/-I~ ar.e- !~ !
.r
y,;6', 1/7 jtio/P/ flwvfI}jt
5J)r Ch.lM1 w:K atf-tm4 &h~ jt/, In.~h'e-nM
G~r~M
,hpt/f It;, fl1<-
0/
Immtv/l ~L7
" Scm ~rCf'n(/"UJ .
tVf//
wittr~r k "1M ~r~

f>+- g1Vr
r~-7ntt-
Cfflnm@?J
-ef~ 01 ~
frtJl~d'
1 7lI~t(U'loth~ r-/-I1i/ 7edi~

I ;
ho G-u:i~
1f~
1 "- ~~ t~~ .
It
r aUc; atD.i ~~ fo !aif

CAn
j
if i
h .C~2..
1;1-.
p'';iIwr I
71q yo
n~ 40 Wf~
VX (
, t
f})r cJz <iN7 -{;j

@'
t1'n
CcJ<fI~S
i fb~&ld
'PI} ,{" J
J +v
fy'tl
~
t'.JP1J{{,,1J
f??}
vm
vv!1~ '
..
}
~
#1 rtf J!
Wi
ftIi

2 :
q.mrlllq.lll =: ~2 3-!}
;'.(fiii'3 : 510080
El!. ~:,
Ii3
(,~,t!.) .
1"6-&!) 5 5 f~*:: )
Address: No. 23, 3r d Zongshan Rd. Guangzhou. P eople's R epublic of China. Post No. 5 1 0 0 8 0 Tel: "7"1""1110 g (ext.) ~ (office)
745 Fifth Avenue, Suite 700, New York, New York 10151 (212) 223-4040
\/ ~(}-5
q1
,., .... -;V.."i:;>
r ,.)
The Charles A. Dana Foundation
October 4, 1995
Dr. Henry J. Heimlich President Heimlich Institute Foundation 2368 Victory Parkway Suite 410 Cincinnati, Ohio 45206 Dear Dr. Heimlich: David Mahoney mentioned to me that he had a very interesting conversation with you at the Lasker Awards dinner last Thursday. He suggested it would be valuable if I were to learn more about the various research projects you have underway. With that in mind, I would like to invite you to join me for lunch or a meeting in our offices the next time you find yourself in New York City. If you have no travel plans that include New York in the near future, perhaps we could talk by telephone. I will ask my executive assistant, Barbara Peterson, to contact your office to learn of your schedule. I look forward to meeting you in the near future. With regards. .
s~~
Stephen A. Foster President SAF:bp
I /
0/ r- '-I,,,, ----.-----'\
,(I
/J
(\..._
October
10, 1995
FOUNDATION, INC.
2368 VICTORY PAR'f.:oNAY SUITE410 CINCINNATI
HEIMLICH INSTITUTE
THE
Mr. and Mrs. David Mahoney Institute for Brain Initiatives 800 Fifth Avenue New York, NY 10021 Dear David and Hildegarde: It was a great pleasure to be with you last week. We seem to have so much in common. Jane and I both look forward to getting to know you better. The enclosed letter just arrived. Thank you very much for making the suggestion to Mr. Foster. I look forward to hearing from Ms. Peterson to establish a time to meet with them. At present, Friday, November 3rd, looks favorable. I will call when a date is arranged and hope that I can get together with you at that time. Jane and I are both interested in the Institute for Brain Initiatives and would like very much to know more about it. I am enclosing a letter I sent to Mary Fisher just a few weeks ago. Hildegarde brought up her name at the Lasker luncheon -- our minds must be on the same wave length. I have also attached some information on malariatherapy for your inter~
/'
OHIO
45206 513-22HXXl2 fax 513-22HXXl3
r~,
/
nr J. President Heimlich Institute HJH/ms Enclosures

I c,":: /"'-f ,
/ r
M.D., Sc.D.
r
, /) I
AJL/I.-(l-.
;
~\_t(
/~' "
II.
~I
\ (
"
",_,'- i ....
_.>'I .. ~,'
/' (
(7//1
''''
(
\.,
L !!..<//
tfj;
/~. I
'-:, t{ /1' ,
(P
!/C
1 -c: {
'1
-7 __ ,
/J/,r7 /
I ~: /1 ,~
. <;
~';'; ~'
f I
""... t-- \,
'\
"
745 Fifth Avenue, Suite 700, New York, New York 10151
(212) 223-4040

DAvID MAIIONEY, CHAIRMAN
~,j
\
"
(.1.... Q.-/)..\)
october 13, 1995
Dr. Henry J. Heimlich President Heimlich Institute Foundation 2368 Victory Parkway suite 410 Cincinnati, Ohio 45206 Dear Dr. Heimlich: What a delight it was to be with you at the Lasker dinner. I know my wife enjoyed the opportunity also to visit with your bride, as they had much to discuss on alternative medicine. I do hope our paths cross. I have asked our President, Stephen Foster, to be in contact with you regarding some of the matters we discussed. Just for your information, I am enclosing some material on what the Dana Foundation is doing. Please give me a call if at anytime I can be helpful to you. Sincerely,
OM/pm Enclosure
800 FIFTH A VENUE NEW YORK CITY, NY 10021
October 27, 1995
').. " r ,/Z~. - ~ [I :____rf~; 1)1: -; ... ' /i rr /..--, .._/I~'/1
_'
t/ ;Jv
~--~
.~{
Henry J. Heimlich, M.D., Sc.D. President Heimlich Institute 2368 Victory Parkway, Suite 410 Cincinnati, Ohio 45208 Dear Jane and Hank,
11/,).
, /d( "
David and I enjoyed so much meeting you both at the Lasker dinner and having the chance to share many interesting thoughts and stories. We also thank you for sending the information on malariatherapy, which interested me because of the treatment as well of Lyme disease, as one of our grandchildren recently was diagnosed with it at age two and a half. It is also remarkable in what it seems to be capable of doing with the HIV virus. In any event, we will definitely have to plan to meet again and are delighted that you are able to be with us at the Dana Awards dinner on November 8th. David joins me in sending you our very best. Looking forward to seeing you, Sincerely,
+ll;~t-f~
November 13, 1995
FOUNOATION, INC.
2368 VICTORY PAR'f0NAY SUITE 410 CINCINNATI OHIO 45200 513-221-0002 fax 513-221-0003
Mr. David Institute 800 Fifth New York,
Mahoney for Brain Initiatives Avenue NY 10021
Dear Hillie and David: So much has happened since our fateful meeting at the Lasker dinner. Thursday afternoon, I attended the lectures given by Robert Horvitz and Carla Shatz at the Rockefeller University, and was introduced to the fascinating new concepts of programmed cell death in the brain and nervous system development. David's presentation at the Awards dinner, as well as the scientists I met, gave me a better idea of your brilliant accomplishments through the Dana Awards. Dinner was delightful, afterwards. I hope you "Hillie Maneuver". Your to speak at length with and we so enjoyed being with you didn't object to my establishing the bringing us together gave me a chance James Watson about his recent work.
The next day I went to Washington for a meeting of the Medical Consultants to the Armed Forces where I spoke with Surgeon General Vice Admiral Harold M. Koenig. I was pleased to receive the enclosed letter upon my return from the Dana Awards dinner. The Naval Research and Development Command has several scientific bases throughout the world where they study antimalarial vaccines. We are discussing working with their scientists to analyze the malaria parasite in order to determine what substances in the parasite induce the stimulation of immune substances in the body. I had a most pleasant and informative lunch with Stephen Foster on Thursday, November 2. I am sure he has told you about it. His understanding of malariatherapy was most impressive.
M.D.
DEPARTMENT OF THE NAVY

NAVAL MEDICAL RE5!ARCH AND D!VELOPM!NT NATlONAl NAVAL MEDICAL CENTER
ZOI89-S044 BETHESDA. MARYLAND
COMMAND IN REPLY REfER TO
9 November, 1995
From: Dr. Scott B. Halstead Scientific Director, Infectious Diseases To: Dr. Henry Heimlich President, Heimlich Institute
FAX: 513-221-0003
Subject: MALARIA THERAPY

1. I enjoyed our conversation of the Tuesday, November 7, 1995
2. I have spoken to a number of Navy scientists, including some of the world's experts in treatment of HIV. I feel confident that they would appreciate having an opportunity to learn more about your experience with malaria therapy of HIV infections. You understand, I'm sure, that the Navy has no extramural program to support research on the treatment ofHIV. Any lessons learned or research leads from your work would have to be integrated into a rather small intramural program of AIDS treatment. Needless to say the discovery of an effective method of treating or curing mv infections would be of great military importance. 3. Do you have data describing your study design and results to date which I could read and digest to help me assess the possibility of organizing a follow-on meeting? 4. I will be away from my desk from November 15 through December 1,1995. Any materials which you might be able to provide I will review on my return. We can discuss follow up plans at that time.
!.
-.
I.E
515 Park Avenue New York, New York.
10152 (212) 754-2890 FAJ\(212) 754-2892
'Dustees
David Mahoney, Chainnan AJ. Signorile, Theasurer Robert A Good, M.D. Carlos MOseley Robert E. WISe, M.D.
November 14,1995 Dr. Henry Heimlich President Heimlich Institute Foundation 2368 Victory Parkway Suite 410 Cincinnati, Ohio 45206 Dear Dr. Heimlich: I enjoyed our brief conversation the other night at the Dana Awards Dinner. As promised I am enclosing the Eleanor Naylor Dana Charitable Trust guidelines for requesting medical grant support. All the best for your continuing success.
J:
\ ~rncerely, \ ~
;
~
r.
-----------------:~
'5l5 Park Avenue New York, New York 10152
(212) 754-2890 FAJC(212) 754-2892

Trustees David Mahoney, Chairman AJ. Signorile, Treasurer Robert A. Good, M.D. Carlos Moseley Roben E. WISe, M.D. November 29, 1995
Dr. Henry J. Heimlich President Heimlich Institute Foundation 2368 Victory Parkway Suite 410 Cincinnati, Ohio 45206 Dear Dr. Heimlich: This is just a Pour Memoire for The Eleanor Naylor Dana Charitable Trust Christmas Luncheon Tuesday, December 12th at 12.15 P.M to be held at the "21" Club, in the Jack Room, 21 West 52nd Street. David Mahoney and The Trustees of the Trust look forward to seeing you and Mrs. Heimlich.
December
15, 1995
FOUNDATION, INC.
2368 VICTORY PARKWAY SUITE 410 CINCINNATI OHIO 45206 513-221-CXXl2 fax 513-221-(003
HEIMLICH INSTITUTE
Mr. and M1;S~d !1a~ Charles A(,_~ 745 Fifth Avenue suite 700 New York, NY 10151 Dear David and Hillie: Jane and I truly enjoyed the luncheon on Tuesday. Everyone was so pleasant and interesting. Bill Safire's talk was fascinating and has stimulated us to watch his predictions develop. We cherish our friendship with you, and look forward to seeing you in the near future. When I saw the Harvard Mahoney Neuroscience Institute Letter "On the Brain", David, I envisaged how much we could accomplish if our Institute had a similar relationship with you. Your positive response to the possibility of our working together stirs me with expectations of the creative goals we can achieve. I look forward to your further thoughts. Best wishes with
rID
to ~both
//
for the holidays.
-:
;:,egards,
M.D., Sc.D.
HJH/ms
/
December 28, 1995
I
Mr. David Mahoney 1296 S. Ocean Blvd. Palm Beach, FL 33480
2368 VICTORY PAR~AY SUITE 410 CINCINNATI OHIO 45206 513-22HXXl2 fax 513-22HXXl3
Dear David, It was wonderful hearing from you and Hillie. Jane and I are delighted that we will be seeing you in March. I was most gratified to learn that your daughter saved your grandson's life. Please let me have the boy's name and address and I will sign a Heimlich Maneuver poster to him to bear witness to the incident when he is older. So much is happening all at once in regard to malariatherapy, David, that I would like to keep you posted on recent events. CHINA Patient treatment continues. The doctors have agreed to approach the Ministry of Health on the possibility of treating hundreds or thousands of AIDS patients in southwestern China. DOMINICAN REPUBLIC that they are ready to
The enclosed letter indicates get started immediately. COSTA RICA AND GUATEMALA
Both countries are now ready to go. I intend to visit Costa Rica and Guatemala the week following January 27th. At that time I hope to negotiate agreements so we can proceed with treatments. I will then go to the Dominican Republic when the patients there are undergoing malariatherapy. When we last met, the question was raised as to whether the treatment of HIV would require an exception. I have read the Dana Foundation Policies and Procedures that you gave me and was pleased to find that therapy for HIV dementia is included in the Foundation's goals. That is precisely what we are involved in.
Mr. David Mahoney December 27, 1995 Page Two
The Chicago Hope episode on malariatherapy was very positive and made many people aware of what we are doing. I will bring a copy of the tape when Jane and I visit. t for your health and happiness in the new year,
Heimlich HJH/ms Enclosures
Consulado de la Republica Dominicana

Ohio, Kentucky y Indiana 1840 Anderson Ferry Road Suite 109 Cincinnati, OR 45238-3936, USA
December 16, 1995
HenryJ. Heimlich, MD., Sc.D. The Heimlich Institute 2368 Victory Parkway Suite 410 Cincinnati, OH 15202
Dear Dr. Heimlich:
We are delighted to confirm that you have accepted our invitation to commence your Malariotherapy treatment for HW. We confirm that the original phase will commence by January 30, 1996. Twenty four patients will be chosen. The government of the Dominican Republic warmly welcomes you. The hospital, laboratory and medical personnel are gearing up for the start up phase. We estimate that by March 15, this first phase will conclude with the treatment to cure the malaria. The second phase will commence by April 1, 1996, and conclude by May 15,1996. As you well know, medical treatment is expensive. The Dominican Republic will provide you with the best we have to offer. However, we are not a rich country. Your offer to fond the treatment and research is essential for the IfUccessful completion of your Malariotherapy treatment for HW. We await your arrival in the Dominican Republic around the middle of February. We are excited to assist you In this humanitarian effort. you. Feliz N.aviJatl, Prospero Ano Nuevo y Felicidadlt!
.... ". to. ~
We thanJc you for the opportunity
to work with
Amigo's -_ , .. ,P~a Siempre, "

,
Telephone: 513-451-0077 Facsimile: 513-451-0066 e-mail: CONSULRDOHKYIN@MSN.COM
--.
--
--.---------
~.4_4
GUATEMALA
~~P-27-95 WED 18;50 BOB CARPENTER
OJ 1"'50;::~2+777784
F'.
I)
FAX TO WAYNE &: BE"I'rt:
;}JJ-928-0150
FROM BOB: 011-502-2-771784
WE TALKED TO DOCTORA VILl..ATORO THIS HAD THIr.IR 16

Of
MORNlNG WEDNESDAY THE 27th ME:DJCAL C()JIMmlTIES
AND THE'i IN A MEE-TINO
~TORS
FROM 16 nIFl'ERF.m'
YESTERDAY AS PlANNED. DOCTORA VIWTORO COP'! OF: MAk!BIJ.'l'aERAFY !f9t!S~. IN H!V p~rlENTS
THri)f
GAVE EACH DOCTQR IN A'ITENDlmCE A
SliQWS PROMISE AS.. .AIDS .. TBF..A.TMENo:r &:
eM
&;
cDS
CEJ..L RE-
INFroTEp
'WITH J>IASMODIYM VlVAX.
THE DOCTORS .ARE TO STUDY THESE PAPERS AND THERE WII.L BE ANOTHER MEETING
WITH
NEXT WEEK
AND DOCTORA V1LLA.TORO WIll
.AT 005
TIME T1tt PROS &: CONS WILL BE DISCUSSED
MAKE HER DFDrSION AS TO WHEN Tl{g PROGRAM'W!LL BE INITIATED.
rr
APPEARS THAT
THE'{
ARE BEING VERY PRFCISE OF THE PROGRAM.
IN UNDERSTANDING THE PROGRAM.
AFl'ER DOC'l'ORA VIt..LATORO MAKES HER DEX)ISION I PLAN TO HAVE A HF.R 'l'O DISCUSS THE DErAILS
MEFl'n~o WITH
WAYNE CAN YOU SEND ME MORE CO Ql0 &: MELA.'rONIN ? I AM
oor
OF CO Q10.
GOD BLESS YOU BOTH. IN CHRIST.
'J.l,J ':t
I I (_
Nov.
15.
1~95
FAX to Henry Heimlich FAX 513-221-0003 From Wayne Martin FAX 334-928-0150 Hank:
J
have a fAX from Boh Carpenter.

as folJows: and Bob met last night with Dr. from Hospital Especialidad, Aleman and
He reports
DJ',
Jose
Monjes
seven other doctors
He says that they gave a positive yes for your program. lie says that this hospital has an intensive care unit, 35 beds a blood testing laboratory and a doctor on duty at all
times. We have all grown happening, 1 hope
older
that
for a long you have an FAX I hope
time while
interest. to talk
this
has been
After you have phone,

Wayne
read
this
to you on the
San Jos~, May 9 1995
Dr. Henry J. Heimlich, The Heimlich Institute Fax (513) 221-000J

Dear doctor Heimlich:
President Foundation
Many thanks for your letter of April 25. I am very glad that Arnold is our mutual friend and that he suggested that you get in touch with me. am indeed associated with a very serious AIDS organization called Fundaci6n Vida, which is involved in the areas of research, prevention, counceling and other areas related with AIDS. Vida is led by a very rGspected Board, chaired by Dr. Javier Moya, a long time chanpion of the fight against AIDS.
I
Dr. Moya is presently away from the country, but he will be back at the end of the month. In the meantime, I am delivering your letter and information to his office, and we will get in touch with you as soon as he returns.
I am looking forward to a very productive r e Lat.Lcnsti Lp between Fundaci6n Vida and The Heimlich Institute Foundation. Needless to say, I am looking forward to m~eting you during your next trip to costa Rica. Please convey my thanks and regards to Arnold and his family.
sincery,
4~)!/~~~
.~l;;:o UgaldQ~Environmental UNDP-Costa Rica Advisor
cc:
Hans D. Kurz, Resident Javier Moya, Fundaci6n Representative Vida
San JOSe,
August
30, 1995
Dr. Henry J. Heimlich Fax 631-2210003 Dear Dr. Heimlich:
Institute
A few weeks ago I was wondering about the communication between you and Dr. Moya. I was about to call him when your recent letter arrived. I apologize for what happened, but I haven't been able to find him this week. ~parently he moved to another olinio. This time, with all the interesting information you sent on malariatherapy against AIDS, I promise to get involved myself and to do a better job. I have sent copies of your information to the National AIDS Commission, Fundaci6n Vida, the University of costa Rica and to other interested parties. I will continue to do this and make calls and personal visits until I get some action. By the way, if you are planning to visit Costa Rica and if you let me know with a few weeks notice, I could arrange a meeting with several people (physicians, aids support groups, government, etc.). As you can imagine, we have many questions about malariatherapy and probably some individuals would like to take the treatment it possible. What are the precautions that should be taken? Are there legal aspects involved? IS this treatment dangerous for somebody who is already very complicated and sick?
As
you can imagine, your information has lifted my spirit and revived my hopes. I'm sure it will do the same for many people.
I apologize
again and I will be in touch with you soon.
Sincerely,
hcuv/__/~~ --Al~ ugalde/ ~

cc: Hans D. Kurz, Resident Representative Dra. Gisela Herrera, comisi6n Nacional de aIDA (fax 227-7705) Dr. Javier Moya, Fundaci6n Vida (fax 233-3316) Dr. Pedro Le6n, University of costa Rica (fax 289-6746)
~,......"
,',T'"
...... .,..
,-..rrT
lOr-
.,::::.,.....,u
1.11I;>.1-l
ESCUELA AUTONOMA DE CIENCIAS MEDICAS DE CENTRO AMERICA

U
Dr. ANDRES VESALIO GUZMAN CALLEJA "

A LA UNIVEASIDAD AUTONOMA DE CENTRO AMERICA
AFILIADA
November
26,
1995.
HENRY J. HEIMLICH, M.D.

President Heimlich Fax (513) 221-0003 Dear Dr Heimlich As Alvaro Ugalde told you. I disagreed with the terms stated in the last fax from the Ad Hoc Committee on Malar'iotherapy for HIV-AIDS. It is clear for me and for thou6ands of sick people, that there is no cure for the disease although tremendous efforts from the biomedical field have been taken. We need to be innovative 1 open minded and been able to challenge the paradigms that we follow today. Your idees on malariotherapy follow those lines and certainly there is some epidemiological support to encourage them. I don't think is necessary to serotype malarial or HIV 3trains in order to approach malariotherapy although if your Institute decide to help in this regard your participation will be highly appreciated. In5titute ~
To my understanding. studies more in the line to initiate malariotherapy are :

i. Those increasing the knowledge on the immune response induced by malaria in relation to CD4,CDB and other immune cell tag6. 2. Defining if the response can be obtained not with active strains of malaria, but with treated / macereted specimens. 3. Treat HIV cell cultures with serum from active and convalescent malaria. there are more research avenues that can be taken in order to avoid the actual "treatment" of HIV with malaria. Anyhow, above .studies mav ee rve e.e the ao Lid scientific evidence to approach human research.
I believe
If I can be of any assistance to participate. Sincerely
in these
tasks I'll be happy
DR JAVIER E. MOYA
Fax (506) 2~
~
. Fax 296 1545 ~
cc Alvaro
Ugalde
t'ELFONOS: ,APAI!.TADO 638-1007 CENTRO COLON $.,,"" JOSE . COS1''' RIC.",
,FAX
3A2194_ 312860 31-43-68
December
5, 1995
2368 VICTORY PARKWAY SUITE 410 CINCINNATI OHIO 4S200 51J..22Hxm tax 51J..22HXXXl
Dr. Javier E. Moya Escuela Autonoma De Ciencias Medicas De Centro America Apartado 638-1007 Centro Colon San Jose, Costa Rica Dear Dr. Moya: Thank you for your thoughtful and knowledgeable letter of November 26, 1995. I am sending to you a scientific paper we have submitted for publication, and a series of published scientific studies that document the basis for malariotherapy and its safety in HIV+ patients. Unfortunately, most of the U.S. Government's AIDS research funds have gone for drugs over the past ten years. The effect of drugs, such as AZT, on the virus is transient -the AIDS virus rapidly mutates and develops resistance to drugs. Such viral mutations do not alter the effectiveness of a strengthened immune system resulting from malariotherapy -- our body's immune system is constantly overcoming a variety of invading viruses. Your suggestions are well thought funded for such purposes. out, however, we are not
Perhaps I did not make clear the status of our malariotherapy program. A major medical society, after reviewing our successful treatment results to date, granted Institutional Review Board (IRB) approval for the treatment of additional HIV+ patients with malariotherapy. We have limited funding making it possible to offer treatment of U.s. citizens, as well as HIV+ patients in several countries, and are selecting these countries at this time. Treatment will be carried out at the highest scientific level and participating scientists will, of course, be included as authors in scientific reports submitted to medical journals. I would like to have you join in this project as I have the greatest admiration for Costa Rica and its people. I will be visiting one or more countries in Central America during the Week of January 27th. Should you wish to meet with me, and have an interest in treating HIV+ patients with malariotherapy, please let me know and I will plan to set a date to visit you and your colleagues during that period.
Benefiting Humani~ Through Health and

pp.~rp.
Dr. Javier E. Moya December 5, 1995 Page Two
I look forward to meeting you. In the meantime, I would appreciate your thoughts after you review the material I am sendin you.
Henry J. President Heimlich Institute Enclosures
M.D., Sc.D.
/.. .(-\____
I
(Y (q~
FOUNDATION, INC.
2368 VICTORY PARKWAY SUITE 410 CINCINNATI OHIO 45200 513-22HXXl2 fax 513-221-r0J3
~7J~~~J
~ _5) ~
_ ~/S' ~ (/~ __ ~
F ~ /~
~
~~~
~"~."
S~tf"t/~
..d'
l<~ _
!f/~*fidtfrI7~dP
7 '
: L"
:/
h,H;UP~h
'~tkL
r-:>: . ~~
~ v ~
~~
>4j/L.~ 3Wd~~~,
~~
S~
jJw~cv~d~~. d- tfUpw/:t /fi~~1
~~
~p&
~
s. 4Y{; ~ ~
Wr)~
$U.~
/up~
I
JIfM__.~/~~P1~,
o/P
!jcw~
j!};ja 0 Mt ~
" 3~~
.:>
_.::.-
-:
.. ..
f"(~W8. f"{E;WB
~tJ
r..flInu
, .......
'_11
.~
N_V'o[JI
'~'.....:wH'
r'4n.,....... -
NrwtI
NltWG
.............
NI[WH
NlCwfJ Ny"'''
NII:WII N!:WH.
NP.:WA ~."
,
'1
I
Malaria Therapy Shows Promise as AIDS Treatment

Dr. Hcnry J. Heimlich, of the." Heimlich Institute, Cincinnati, Ohio, presented an .... IDS treatment study at the Ninth International Oongrelle of Immunology in Sun Frtu\ci6C(, on July ~4, 1995, Cu'prt:8cnter was Xiao l'1n: Chen, MD, ofthe Municipal Health and Anti-Epidemic Station of Quangzhol1, China, where the reaearcb w as conducted. The study dcacr ibea promising reaults from the use of malaria t.herapy to' trent AW:) virus (lilY) infected patienta by boosting their Immune systems. Two patients with JflV infections were inoculated with 8. curable form of malaria which was cured with medication three weeks later. The patients CD4 (helper Tvcells) and their CD8 (killer Tcells) both increased to hlgh level and haue remained euuated for a full year with no other treatment. In the more advanced patient, CD4 cella rose from 269 to 953; the other's from 889 to 1258. Both patients remain clinically well, .. Drug therapy call weaken HIV virus and increase CD4 cells, but the efl'act 18 short-lived. The vlrue then mutstee, multiplies, and- depletes CD4 cells, resulting in full blown AIDS ... :. .. For 60 yearS, the U.S. Public Health SOMCO provided malaria blood to treat tens thousllnde of neurosyphllts (syphilill of the brain) patlenu with' excellent results. In 1975. malnr'ia thoTapy was discontlnuod .bocAuu neurosyphilis had been. eradicated. Other examples or uatng one dilouo to cure or prevent another include Cowpox .to prevent 8mallpox and Sabin live poUo
or
.. tn conrrast to tho drug approach, 1I\&.lariatherapy strongthoTl8 the body's Immune eyHLuUl,which we belleve wlll ellu\}lo it to control tho virus In all Its mutll.tione. ~lICan;h f'rvm UC Borlwloy, Walter' Reed Reseurch Ccntor, tl~c University of Heidelberg and many other Institutions "hows that malaria stimulates t.he body's production of immune substances, including interleuklns and interferons. Theae substances have been found beneficial in fighting a variety of serious diseases and their reduced supply In AIDS patiente diminishes Immunity, which in turn leads to death. Dr. Henry J. Hefmlich'e use of malaria therapy to treat AlDS is bneod, In part. on Its so-year history of auccess with nmrroayphilts, syphilis of the bruin. Dr. von Jauregg won the Nobel Prize for discovering malaria therapy. In fact, the approach was used for nearly 30 years aner penicillin was discovered because antibiotics could not penetrate the blood-brain barrier, Malaria. therapy we ollly discontlnued in 197~ because it had dono !tt! work: neurosyphilis hR-d been eradicated and nowly acquired lIyph!lfs could be cured in its early stages by penicillin, From 1931 to 1965. the US Public Health Service, the Centers for Disease Control, Johns Hopkine Hoepltal and NIH laboratorioe providod malaria blood to hospitals for injection into tens of thousande of people with neurollyphUls.
mulu rlu bclw(JCII 1.1.0 ol d ldr on with prog roeuivu HIV1 Infoctlon and lh" lJoroncgllt.ivo controla., .. No evido nco Willi i'ound to IIUgftVllt thut. mulo r ln !tn9 uny rolo In "coolorlltlns (.h& r8lIJ of
progrooelon of rrrv-l (!ieelllllJ ... tb'tlrtl 18 no adverse clinical or epidemiological aaaocl e t lon btlt.wu,," Ll.ese two Important public health problems." Other published studies also conclude that malaria is not one of the opportunistic dtsoaaea that endanger AIDS patients.
Additlonnl Evidence of Malaria . The'rapy'8 EtTectivenes8 tor AIDS

A study of 112 children with AIDS, reported from the same hospital where the above CDC study was performed, was present.ed at the 1990 AIDS conference in Florence, Italy. Follow-up data reported that all 41 children Infected with malaria and AIDS were still alive, while 35% of the 71 children infected with AIDS, but not malaria, had diod. ~ Independent research by US Naval Medical Research, Unit No.2 and the Unlveraity of Nebraaka found that people in certain malaria reglons of the world possess HIY. antibodies, but AIDS dOG!not eXist in these locations.
Continuing Research
'rne initial patients will continue to be examined and rested at regular intervals. Additional patients will be treated-with malaria therapy and tested through such measures WI viral loading. Duplicate studios will be conducted in otherloeatJons ... ~"'. 1,:":.'.) 1\:':.IIIu{ , Future research will locus on. th~ process by which the malarie parasite sUmulnt.os the immune system 80 that tho malaria's function can be duplicated through chomtcal means. Coauthors Include Bin Qunn Xino, Ph.D.; Shu G1lu Liu, MD; Yue Hen Lu, MD; Eric O. Spletzer, Ph.D.; and Ji Li Yao, MD. Correspondencel . Henry J. Heimlich, M.D. I' Heimlich Institute ., 2368 Victory PArkway, Suit.e 410 Cincinnati, Ohio 45206 USA
513 221-0002
SRle. Even
with AIl')S Patient.
..
vacclae,
'" .,/." '. .' "';:.

.
Baokground .. The AIDS virus. wa~e. .an unremitting battle with th~ bodY'1J immune system. Immune cella' of the CD4 type docreaee iil number durln:g ; the course of HI\)' Infeetion, ind1cJlting ~ that the virus has an hninediate impact . on CD4 cell doplotion. Whon the CD4 oount falla low enough, symptAlmatio AIDS occurll and opportunistio; infection,)" Cause death. Drugs can . weaken virus and increBBe CD4 cells " temporarily, hut nft.cr two (Ieks the ; virus mutates and multiplies i'n CDC study concludod: -No s!gnlfico.nt patientH. (Nal.ure, January. 19{H~; dltTeronoo! were found In the Incidence. Scientific Anu~clIn. April. 1995.) lIeverlty, or response to therapy of
. ~..
":"<.1
',
~ .'
> .:;".'
"
\'
the
;.' Ell Chemin of Harvard Univorsity'1J School of Public Health atatGs in the lTorlmal of Para,itololfY. October, 1984: "Rooord. oftnmtment-related deaths or extreme deblllty are few relative to the thouaands of patienta treated ... It Is not hard to fmRgine the almost certain fate of the thoulJands of paretics {neuroeyphf1ls patients] who would have eickonod .and died horribly but for malaria therapy." . There exl.st4 no known report in which induood malaria WWl not cured. Confirmation of malaria thempy'llsafety for treAting HIV infeded pationte c()mOIl from !l Conters for DIseI\B6Control study In AfriC'8 pubHBhec:lln the New EnSland Journol of Medicine, July 11,1991. 'Tho
Fax 513-2210003
TOWNSI'!NO
L.fTTl!R for DOOTOR9
.. PAnENTU
- DECEMBI!R
10U
__ !l.ciiCJ~
J. j/~v;,d~~f-L. )v(f2~_~_~ __ _
__ _ ._____ Ei:{J5~c(g/!1. JI~C:71!.<-ch :Z7J~
236* , UCi;;7/ pMr k-wat t--0 0 ='>uliz 410
. _ - - - - - --
------
~akl
-~-----------
---- ---
March
4, 1996
FOUNDATION, INC.
2368 VICTORY PAR~AY SUITE 410 CINCINNATI OHIO 45200
HEIMLICH INSTITUTE
Mr. Stephen Foster President Charles A. Dana Foundation 745 Fifth Avenue, suite 700 New York, NY 10151 Dear Stephen: I enjoyed speaking with you last week about malariatherapy.
513-22HXm fax 513-22HXXl3
In regard to comments that non-specific AIDS treatment has not been successful, we know of no published study that supports that statement. Here are some facts about malariatherapy for those evaluating the treatment. (Numbers refer to the Table of Contents in the looseleaf binder "Malariatherapy for Treating HIV Infected Patients".) 1. In the discussion, Pages 7 and 8 of this paper, there are eighteen references to studies showing that malaria induces ~roduction of immune substances including a variety of 1nterleukins and interferons. 2. This is an abstract of a paper presented at the 1990 International AIDS Conference, Florence, Italy. Of the 112 children with AIDS who were studied, 41 had associated malaria. None of the 41 children with both malaria and AIDS died, and all recovered from their malaria. Of the remaining 71 children with AIDS who did not have malaria, 25 (35%) died. 3. The CDC study by Greenberg that I sent you concludes that co-infection of malaria and HIV does not endanger the patient. Three additional studies confirming that malar1a is not an opportunistic disease that would harm HIV infected patients are included in section 3. The patients in China demonstrate positive findings in treating HIV with malariatherap and they have remained clinically well following malar1atherapy. It is a small series, but preliminary results make it imperative that we treat additional patients. I welcome arise.
t Bes
the opportunity
to respond
to any questions
that
:;tr>ElS J .>
j,
h
.>:
.r:"
H~j~i~l
ch, M.D., Sc.D. Pres1denn / HeimlichEfnstitute HJH/ms
L) If.
-t..
,i"_
March
FOUNDATION,INC.
2368 VICTORY PAR'fJNAY SUITE 410 CINCINNATI OHIO 45200 513-221-<XXl2 fax 513-22HXXl3
5, 1996
Michael Saag, M.D. University of Alabama/Birmingham 700 S. 19th Street Room 2B-113 Birmingham, AL 35233 Dear Dr. Saag: I look forward to our meeting month. in Palm Beach later in the
Mrs. Mahoney suggested that you may have an interest in knowing about our use of malariatherapy for treating HIV infected patients. Some background material is enclosed. You are undoubtedly pleased that the University was ranked number one as an ACTG site. to hearing about your work. of Alabama
M.D., Sc.D. Institute HJH/ms Enclosure
745 Fifth AVt'IIIJt>, Suit!' 700, Nt'w York, Nt'w York
10),')1
(212) 22:J-4040

March 15, 1996 Henry Heimlich, M.D., SC.D. President Heimlich Institute 2368 Victory Parkway, Suite 410 Cincinnati, OH 45206
Dearlli~
Thank you for your faxes and follow-up information of March 1 and 4 on the malaria therapy project. I appreciate the speed with which you sent the information. After reviewing the new information and discussing this project with Jim O'Sullivan, our health program officer, I would like to suggest to you the best way, in our opinion, to proceed successfully with forming a blue ribbon committee and preparing a proposal for Foundation consideration. It seems likely to us that any scientific committee worth its salt would want to see a formal protocol for the proposed trial. Jim did a quick review of protocols for clinical studies from Foundation supported projects and identified the following pieces as key: background and agent rationale; study overview; inclusion/exclusion criteria; treatment regimen; study procedures; adverse events reporting plans; analysis criteria; and ethical, confidentiality, and regulatory concerns. Many of these elements exist in the material you have provided; a few are missing. Putting these pieces together in a formal protocol would also provide you with the opportunity to address some of the CDC's concerns, such as the issue of other blood-borne pathogens in the malaria dose. Jim and I believe that this experiment will generate great media interest, and that the various communities affected by AIDS will have many questions about the study when it is announced. It is our hope that the protocol development process will allow you and the Foundation to anticipate (and defuse) these potential concerns. The Foundation looks forward to developing this study with you. If you agree that a full protocol would be helpful, Jim and I would like to discuss a potential time line with you for developing this process. Please let us know your thoughts. Sincerely, ~
Stephen A. Foster President
SAF/ajh cc: David Mahoney Jim O'Sullivan
MAR, -18' 96 (~lON) 15: 03
MAHO\EY
PAL~I BEACH
TEL:40~ 832 6559
p, 001
MAHONEY
1296 South Ocean Boulevard Palm Beach, Florida 33480 TEL: (407)832-6485 FAX: (407)832-6559
TO:
Dr. and Mrs. Henry Heimlich
DATE: March 18 1996
FROM:
Rillie Mahoney
# OF PAGES INC.COVER: _l_
Dear Jane and Hank, Thanks for your letter of March 5th with the article from Science Magazine and your fax today giving us your flight information with the New York Times article of March 14thattached. We are looking forward to seeing you on Friday and our houseman, Raul, will meet you at the baggage claim area with a sign saying "Heimlich". He will then bring you to our house where we'll have lunch waiting!! As I mentioned earlier, that night we go to the Max Fisher's where you'll meet Mary Fisher. Unfortunately, Dr. Saag had to regret at the last minute. The following night we'll have a dinner here at home and the dress for both nights is much the same - tie and jacket for men - glamorous pajamas or cocktail dress for the ladies!! The weather has turned beautiful so bring bathing suits, tennis clothes, walking shoes, warm-ups - whatever you'd like to do in the sun!! All best,
March
18, 1996
2368 VICTORY PAAy;y.jAY SUITE 410 CINCINNATI OHIO 45200
Mr. Stephen Foster President Charles A. Dana Foundation 745 Fifth Avenue New York, NY 10151 Dear Stephen: The attached March 14, 1996 New York Times article "Panel Offers Sharp criticism of AIDS Research Programs" answers all the questions we discussed concerning the NIH and malariatherapy for AIDS. They are finally recognizing the importance of human studies and the need to restore the damaged immune system. I am advised that the Heimlich Institute presentation "T-Cells Increase in HIV+ Patients After Malariotherapy; Remain High One Year Later", at the International Congress of Immunology last July (see looseleaf binder Section 5) was a factor in the panel's decision. t iscuss your thoughts.
513-22HXXl2 lax 513-221-r0J3
March
19, 1996
Mr. Stephen Foster President Charles A. Dana Foundation 745 Fifth Avenue, suite 700 New York, NY 10151 Dear Stephen: The enclosed protocol, informed consent and scientific paper contain all the information you requested. It is the program we have already been using and the basis for receiving the Institutional Review Board (IRB) approval from the Great Lakes Association of Clinical Medicine. The New York Times article of March 14, 1996, "Panel Offers Sharp criticism of AIDS Research Programs" that I faxed to you on March 18 indicates that the media as well as the NIH are ready to accept restoration of the immune system as a primary means of treating AIDS. Dr. Leanna Standish of Bastyr University in Seattle has received a major grant from the NIH to study alternative treatments for AIDS. We were informed today that she would like to work along with us on this project. If any further information is needed, please call me.
513-221-00)2 fax 513-221-00J3
CC:
David Mahoney Jim O'Sullivan
,;;~ ;_,
... .. ~~,
MAR 201996
I
Clinical
: ,._ Ff~r.();',ifi\'] f,:
lrnmunnloav
Center
of PLA
r ': :~ ..~1:
p~_,.J.
-!or, ft_
ti, 1-,\ : !OrJ003

P. R.
:_:n'''(J!.;.JI
200003.
f-:n
Ch,r.,
0:!;
?,,,:.,Gi
r,' J~8.
:86}i-
'l,7!:'~2~
Dear Dr. Fahey: I am grateful to hear your attention and support to clinical immunology in China. I believe Dr. Renqian Zhong will give you an excellent answer to your hope. The materials sent from you about international meetings program have been received, which can help me to know the procedure of academic activities in recent two years. Thank you very much. "Clinical inununology--A distinct area of18Imanology" is a wonderful article which is of great interest to me. The problems you put forward in this article are also bewildering us. In China clinical immunology is not a medical specialty, such as internal medicine, etc. So it can not be put c ' a proper position in fund application and degree granting. Thus, we will translate this authoritative article into Chinese and publish it in China. I wonder if it is convenient to you. _ Dr. Zhong will complete the training in the -U.S-.l look forward to keeping further contact with you.
Sincerely
yOUI"SJ
~::K~~
Professor, Director Clinical Immunology Center Changzheng Hospital Shanghai 200003
SOM SPEAKING POINTS FOR YOU WITH DR. HEIMLICH
This will be viewed as very controversial research. Before they agree to serve on any blue-ribbon panel, the scientists gathered to oversee this research will need to be assured that all aspects of the proposed clinical trial of malaria therapy have been considered With that in mind there are several items that remain unaddressed materials Examples are. in Dr. Heimlich's
$ \
~ \~ --"
-"From his materials there is no evidence that any of the work already done in China has been reviewed by experts in the field. This makes it difficult to know what weight to place on the results he has reported. -- There is no description of the overall plan of research. For example: How many subjects will be studied? How will the data be analyzed? How will he manage the information flow of data from the Dominican Republic and Guatemala back to the U.S. How will he keep track of patients all over the U.S.
-- There is no discussion of ethical or confidentiality concerns. For example, how will access to the study be controlled? Will citizens of the Dominican Republic and Guatemala be able to maintain the confidentiality of their HTV status and still have access to this treatment? I am sure experts would have other concerns also Dr. Heimlich needs to understand that this research will have to withstand enormous scrutiny from the scientific community, the AIDS activist community, and the NTH and the CDC Any of these groups could effectively block his efforts in the U.S. if they somehow felt their concerns were ignored. The blue ribbon panel will recognize this and, therefore, I am sure have the same concerns and want the same issues addressed.
A problem with all non-traditional AIDS therapies has been their uncontrolled use when there is no strong evidence of their benefit Thousands of AIDS patients have traveled all
over the globe to tryout therapies that have absolutely no scientific backing They have spent thousands of dollars and, in some cases, shortened their lives for no benefit The research protocol for this study needs to be "air-tight" so that it does not become yet another therapy that becomes popular without the appropriate scientific testing before it becomes well-known. need to get some behind the scenes help for Dr. Heimlich to put together this proposal in a way that will be acceptable to such scrutiny. I don't think I am the right person to do it But if he is willing to accept such help 1 think I could find someone for him to work with.
We
0 'd
6E888~1~ 'ONX~j
A3NOH~W a ItWa
(//.
A )
._../
March
25, 1996
Edward Rover, Esq. White & Case 1155 Avenue of the Americas New York, NY 10036 Dear Mr. Rover: Per your conversation 1. 2. 3. 4. 5. with Dr. Heimlich, enclosed please find: letter,
513-22HXlO2 fax 513-22HXlO3
Internal Revenue Service 501(c) (3) determination By-Laws and Articles of Incorporation
List of Directors Form 990 -- ending May 31, 1995 Audit -- ending May 31, 1995 any further information, please do not
If I can provide hesitate to call. Sincerely,
r.
!);'Ly_ ..~.
HENRY J. HEIMLICH, M. D.
17 Elmhurst Cincinnati, Place
Ohio 45208
March
26, 1996
Dear Hillie
and David,
I will never forget the wonders and delights of last weekend. To be in such a beautiful home with caring people like you made me feel happy and relaxed. Meeting so many dynamic people who were friendly reaching out to help others was most gratifying. and
As I said on the phone, David, your ability to assess a situation and accomplish a goal is truly inspiring to me. It was so interesting to learn of your many achievements. Hillie, knowing what you had gone through in the previous days, we were touched that you made us feel so comfortable and wanted. I am enclosing a letter that was on my desk on Monday. Although I receive many letters related to the Maneuver, this one was so unusual that I want to share it with you. Our heartfelt Fondly, thanks for a wonderful visit.
From The Desk Of
James E. Spamm Jr.
March 4, 1996
Mr. Henry Heimlich Xavier University Clinical Science Department Cincinnati,OH 45207
Dear Mr. Heimlich: I am a big fan of your maneuver. I have used it several times to dislodge food from the wind pipes of my family members. We Spamms were born with extra small esophaguses and no uvulas which has spelled disaster in the past Your maneuver has helped to save each of my current family members at least once each. Dad said the small wind pipe gene was passed down from his side of the family and before you invented the maneuver they use to have to mash all their food into a paste to insure that they wouldn't choke. As l'm sure you can imagine this was no kind ofa life. Now thanks to you and your maneuver we can eat whatever we want (even beef ribs, our family favorite) and if the food gets stuck we just reach around the choking victim and pop it out. It's become so common place in our household, its like turning on the television. Even though we've never met you we consider you a family friend. We'd sure like to know more about you. We looked you up in the World Book Encyclopedia, but it listed the maneuver and not the man who invented it. To me that's like listing the Mona Lisa, but not Leonardo Da Vinci. My mother, Pam, is celebrating her 65th birthday on March 29th, could you please send her an autographed picture, pamphlet, or postcard. I think she'd get a real kick out of it. Thank you for saving my family,
U~e:'E:~}
P.O. Box 10232 Fullerton, CA 92635
FOUNDATION, INC.
2368 VICTORY PAR'f,;NAY SUITE 410 CINCINNATI OHIO 45200 513-221-(0)2 fax 513-221-(0)3
HEIMLICH INSTITUTE
March
26, 1996
Mr. David Mahoney 1296 s. Ocean Blvd. Palm Beach, FL 33480 Dear David, since we'll be in touch through April, helpful for you to know my schedule. I thought it would be
The first week in April I plan to be in Cuba. I became an honorary member of Rotary several years ago. Rotary has an international program to inoculate all the children in the world against polio. I have been asked to participate in Cuba that week. I will call my office periodically. April 10 to 15, Jane and I will be at Alta Lodge, Alta, Utah, Telephone: (801) 742-3500, Fax: Ext. 301. April 21st to 25th, I plan to be in the Dominican Republic.
April 25, I return to Ft. Lauderdale. I have meetings on the 26th, give my presentation on the afternoon of the 27th, and then will head for Palm Beach. I look forward to being with you April 27 and 28, departing for Cincinnati April 29 at around 11:00 A.M. Jane will not accompany me at this time, but appreciates your invitation.
_/'
Best lW~s. hes~///

I
i!
,..r ,.
.>.
->
.~--.-~
~~r(~f :/.
!,,~/ ,)/,~.-
,Heimlich, M. D.
1155 AVENUE OF THE AMERICAS
NEW YORK
212-819-8516
May 7,1996
Henry I. Heimlich, M.D. The Heimlich Institute Foundation, Inc. 2368 Victory Parkway, Suite 410 Cincinnati, Ohio 45206 Dear Dr. Heimlich: I am pleased to inform you that the trustees of the Eleanor Naylor Dana Charitable Trust approved a grant of $50,000 for unrestricted support of the Institute. This action was taken at the suggestion of David Mahoney and was unanimously approved. Enclosed is check #5322 in the amount of $50,000 as payment of the grant. At your convenience, kindly return a receipt for this directly to: A. I. Signorile Trustee/Treasurer E. N. Dana Charitable Trust 745 Fifth Avenue, Ste. 700 New York, NY 10 151
It is a pleasure to assist you with your work, and all the trustees join me in wishing
you continued success.
i:}J(
Edward F. Ro er EFR:mem Enclosure cc: David Mahoney
ELEANOR NAYLOR DANA

CHARITABLE TRUST 375 PARK AVENUE NEW YORK , NY 10152
CHEMICAL BANK 277 MADISON AVENUE NEW YORK , NY 10016
1- 12/210
5322
4/28/96 **50,000.00
PAYTOTHE ORDEROF
. l' ' ' T h e Helm lC h Instltute Found atlon,
I nc.
~~
$_------
~~~~~~~~~~~~~
Thousand and 00/100********************************************** ______________________________ _________
MEMO
The Heimlich Institute Foundation Suite 410 2368 Victory Parkway Cincinnati, Ohio 45206 Grant
r!1
.--
OCUARS
Socurtly ........
lloCoII ... bodI.
The Eleanor Naylor Dana Charitable Trust was established in 1982 under the provisions if the !ali! Mrs. Charles A. Dana's Will. In keeping with her lifelong interest in medicine and the performing arts the Tru'lt will foster and finance progress and the pursuit if excellence mainly in these fields. A panel if experts has been engaged fry the Trw;t to evaluate applications and recommend priorities for the allocation iffunds.
~LE
375 Park Avenue New York, New York 10152 (212) 754-2890 Please address correspondence to The Trustees
leanor Naylor Dana, philanthropist, social leader and longtime resident of Wilton, Connecticut, died in New York on May 30, 1982. Throughout her life, and largely through the Charles A. Dana Foundation, she devoted her energies and personal resources to supporting programs in the arts and sciences having far-reaching humanitarian and cultural impact. In 1950, she and her husband, the noted industrialist Charles A. Dana, established the Foundation that bears his name and which, under their joint direction, donated over $105,000,000 to medical research, education and the arts. With an incisive mind that cut straight to the core of any issue and a sense of humor that was appropriately disarming or engaging, Mrs. Dana provided thrust, direction and purpose to many programs. She helped to establish policies and priorities for providing financial support to institutions of higher education . Many advances in preventive medicine, and improvements in the quality of education in this country can be attributed to her efforts and the financial support the Foundation provided. While her perspective was broad, she never lost touch with the traditional values of rural America she acquired in Carthage, Texas, where her family settled after moving from Tennessee, and in which she maintained a continuing lifelong interest.
rants will generally be made to support clinical investigation by established scientists in qualified institutions in the United States , to pursue innovative projects designed to improve medical practice or prevent disease . Grants are generally limited
'.
to no more than three years and not to exceed $100,000 per year, with no overhead costs. The Trust \vill not normally support large scale field studies of a therapeutic or epidemiological nature. Support for instrumentation \, ... iIl be limited to that rcquired for a specific project. Grants \,viII not be made for instrumentation alone.
"
"-
Robert A. Good, :\1.0.
Grants \vill not be made solely to support conference or individual travel nor wiII they be transferrable bctween institutions without the expressed approval of the Trust. Initial inquiries must be submitted as a Le tt e r of Inten t
Robert L Wise , M.D.
not to exceed OIle thousand words. Selected applicants will be invited to submit detailed proposals which must include evidence of approval by the applic3nt\ Insti t lit ional Review Board .
selV'ice and its contribution to the Art involved; (3) demonstrable need for the grant; (4) the financial viability of the program .
In general, grants will not be

made to fund deficits; for exhibits, publications or conclaves; nor will grants be made to individuals. Initial inquiries should be submitted as a Letter of Intent not to exceed one thousand words. Selected applicants will be invited to submit detailed proposals .
n the field of the Performing Arts,
the Trust will make a limited number of grants to qualified institutions within the United States. Generally, grants in response to specific proposals will not exceed $100,000 per year and will consider, among other points:
(1) The anticipated benefit to the
public as a result of the grant, and the long-range potential; (2) the stature of the organization, the history of its public
Trustees David Mahoney. Chairman A.j. Signorile. Treasurer Robert A. Good. M.D. Carlos Moseley Robert E. Wise. M.D.
??
Tel / FAX
570/659-0229
June 7, 1996
Dear Doctor Wang:

It was such a pleasure having you with us. We so admire and enjoy your zest for living, your wonderful knowledge, your friendliness.
I am so thrilled with your beautiful lace tablecloth, and will enjoy using it on special occasions. You were so generous and thoughtful to give this special gift to us.
Thought of you reading the enclosed article, particularly the remark that one's belief plays a role in the outcome of a treatment. Feel sure you're having a lovely time with your son and daughter-in-law. Warm wishes,
Jane Heimlich enclosures
Wang Yi-Tang, M.D. %Hai Wang 4454 Fern Common Fremont, CA 94538
June 17~ 1996
Henry J. Heimlich, M.D. President Heimlich Institute 2368 Victory Parkway Suite 410 Cincinnati Ohio 45206 The United States Dear friend Dr. Heimlich: I sent the enclosed paper in Chinese to you about two weeks ago, now I send its English version to you and await a reply from you agreeing the paper be submitted for publication in a Chinese medical journal and a U.S. journal. ( Prepare to submit to the Chinese Journal of Infectious diseases and the New England Journal of Medicine) Your comments on the paper will be appreciated and English will be very welcomed. your correction of
By the way, it will be the time of next follow up for the second batch of HIV patients in Yunnan Province, therefore we hope you arrange the payment of four thousand U. S . dollars to us for the two years follow up of the first two HIV patients according to our agreement so as to smoothly complete our project.
Best wishes and regards.
Sincerely,
Dr. Xiao Ping Chen Director, Department of Microbiology The Municipal Health and Anti-Epidemic Station of Guangzhou No. 23, 3rd Zhongshan Road Guangzhou 510080 The People's Republic of China
CHARACTERISTICS OF ARTIFICIALLY INDUCED HEMATOGENOUS PLASMODIUM VIVAX MALARIA ON ADVANCED TUMOR PATIENTS Xiao Ping Chen 1 Henry J. Heimlich 2 Shu Guo Liu 1 Bin Quan Xiao l Nai Du Li3 Hong Shun Hua 2 Ji Li Ra0 1 Fu Yuan Kuang-3
1. The Municipal Health and Anti-Epidemic Station of Guangzhou, Guangzhou 510080, China 2. The Heimlich Institute, Cincinnati, U.S.A. 3. Guangzhou Yishou Hospital, Guangzhou, China
Abstract This paper reports the clinic characteristics of artificially induced hematogenous Plasmodium vivax( Pv.) malaria on advanced tumor patients, which were found during the time the authors studied malariotherapy for cancer. The characteristics were that, first, there was a big variation of incubation in these patients. This implies that the variation of incubation of malaria would increase with the digree of individual difference, since tumor patients can be considered as a different host population compared with the health one and different kinds of tumor patients can also be considered as different host populations. This suggests that incubation of malaria will be decided not only by the species, atrains and dose of Plasmodia, but also by the reactive nature of hosts. Second, most patients manjfestated typical every other day's ( tertian) paroxysm of high fever in the early days and then presented irregular every day'a ( quotidian) paroxysm. This is ~ ~~,,;~,~~~ . knowl~e ~d suggests that past ~ knowledge of paroxysmal regu~anty of Pv. malaria should be supplemented or the regular pattern .of Pv. malaria needs to be further studied.
contIw!.1A.
Key words Pv. malaria . Hematogenous infection Fever pattern Advanced tumor Malariotherapy
Incubation
Malaria as a therapy namely malariotherapy was successfully used to treat progressive paralysis and neurosyphilis in clinic, for which its inventer, Dr. Jauregg JWV won the Nobel Prize of Medicine of 1927."1Later some doctors tried it to treat tumors. 2 3 In recent years, we reexplored the clinic values of malariotherapy for advanced malignant tumors (see our another report); during which we had an opertunity to observe the whole courses of artificially induced hematogenous Pv. malaria ( the course from Plasmodium inoculation to clinical paroxysms then to natural disappearing of onsets) and found some new phenomena which were difficultly observed under the natural circumstances. This paper reports the content in the respects so as to provide a reference for colleagues. Cases and methods of Plasmodium inoculation 1. Cases Total 7 patients with advanced tumor volunteerly came to our research cooperation group for malariotherapy during 1991-1993. Now their conditions are simply described as follow: Case 1, female, 38 year-old (Y), lactoadenocarcinoma with multiple osteometastases. Case 2, male, 38y, undifferentiated small cell carcinoma of up right lung with metastasis of mediastinum. Case 3, male, 41y, lung adenocarcinoma with multipl~ 08teometastases. Case 4, male, 40y, nasopharyngocarcinoma, poorly differentiated squamous epithelial carcinoma with metastases of lungs, liver and bonea. Case 5, female, 57y, no pathological confirmation ,in this case, CT showed masses in liver and the head of pancreas,diagnosed clinically carcinoma of head of pancreas with metastasis of liver. Case 6, male, 31y, Carposi sarcoma of left thigh with metastases of lymph nodes and wide infiltration of left thigh. Case 7, male, 4Oy, relapse after resection of rectoInyxoadenocarcinoma with metastasis of pelvic cavity
and multiple osteOmetastases.
2. Methods of Plasmodium inoculation Patients were devided to four batches for-inoculation: Cases 1-2 were the first batch; cases 3-5 were the second batch; case 6 was the third batch; case 7 was the fourth batch. The same inoculations of each batch were at the same time,and the Plasmodia came from the same ' patient of malaria ( the same host, all hosts were the patients of Pv. malaria in the areas of Guangzhou and Shenzhen ). Per time injected suitable quantity of malarial whole blood (all doses of Plasmodia were near to 1.0 X 107 parasites, see table I ). All blood 80urses were 'strictly confh"med no any- other infections especially no syphilis, viral hepatitis, and infection of human immunodeficiency viruses ( HIV ) but only Plasmodium vivax.
Results and discussion 1. lncubation In this study all 7 cases got a typical first paroxysm
of malaria ( chilly tremble, fever and perspiration 80 called" three step melody" ) and all patients were found Plasmodia in blood smears only after presentation of typical onset, therefore the concept of incubation used in this paper refers to clinical incubation namely the period from inoculation of Plasmodium to first clinical paroxysm, see table 1. Table 1 Incubations(days) of artificial hematogenouB Pv. malaria
Bat. No.
2 3
1 2 Case No. 7 1.2 x 107 Dose ofQ)1.2 X 10 7 Plasmo. @1.5 x 10 , 1.5 X 107 18 lncub- C D 22 ation @ 8 6
4 5 7 6 7 7 7 7 1.0 X 10 0.8 X 10 0.8 x 10 1.4 X 10 0.9 X 107 2.9 x l07 2.9 x 107 10 20 28 10 6 18 0
Note: Dose of Plasmodium ,..1) indicates the dose of the first inoculation; @indicates the dose of the second inoculation. Incubation (Dindcates the days from the first inoculation to the first paI'9xysm; @ indicates the days from the second inoculation to the first paroxyEID . ... 0 ... of case 5 indicates the first typical paroxysm was just on the day of the second inoculation, shows this paroxysm was definately caused by the Plasmodia of the first inoculation.
We can see from table 1, inoculation dose of Plasmodium of every case was very closed to each other ( equal or nearby 1.0 X 107 ), but the variation of their incubations was relatively bigger, especially in the Second batch of patients; their difference was most probably between 6 and 28 days compared with that of Pv. malaria transmit~ , by blood transfusion, that was if transfused 1-5 million Plasmodia~~a~ by vein, the incubations would be commanly 8-12 days (Guangdong Provincial Institute for Prevention and Treatment of Parasitic Diseases: Tel(tbook of Parasitic Diseases, published in May, 1982, P91 ). This phenomenon implys doubt of the Theory of Polymorphism of Sporozoites4 for explaining incubation and relapse meChanism of malaria (although the Plasmodium used in this research was not sporozoite but the form of erythrocytic stage, that the host factors could not be ignored it implied was consistent with each other ). The obvious lackness of the Theory of Polymorphism of Sporozoites is its ignoration of exist of host factors.
Under the influence of this idea, most authors studied the mechanism of incubaion and relapse by inoculating different strains and different doses of Plasmodia to the same host population, few payed attention to the differences among individuals and among populations of hosts in their experimental designs; that is to say, few used the same dose and same strain of Plasmodium to infect different bost populations (in our research, the patients with different kinds of tumors can be considered as coming from different host populations). One ( Chen) of the authors proposed the Inhibitor TheOry that not only concerns the Plasmodium but also the host itself to argue with. the Theory of Polymorphism of
Sporowites, and emphatically demonstrated the decisive role of host
factors on the incubation and relapse regularity of malaria.o 2. Clinical onsets and temperature curves The clinical onsets and temperature curVes ( see Fig. 1 ) of artificially induced hematogenous Pv. malaria of 7 patients with basic diseases, different kinds of advanced tumors had a few characteristics as follow: 1, all patients had a typical first clinical paroxysm. 2, every paroxysm manifestated typical chilly tremble, high fever or fever and perspiration so called" three step melody:" 3, most patients ( case 1, 2, 4 and 5) manifestat.ed typical every other day's ( tertian) paroxysm of high fever in the early days and then presented the irregular every day's (quotidian) paroxysm. 4, the second batch patients were inoculated the Plasmodia of coming from the same host and almost the same dose, but some manifestated regular tertian paroxysms ( case 4 and 5 ) and some appeared irregular quotidian one ( case 3). This demonstrates the reactivity of host play an important role iIi the decision of clinical course of malaria. 5, among 7 cases, we observed ,,2 cases' natural disappearing of clinical onsets, with recrudescences after 5 and 10 days resPectively ( contIDUiJig parasiun:ma confirmed by examinations of blood smears); among them one was inoculated two times of Plasmodia, but another just inoculated one time. We also noticed that in our research of malariotherapy for mv infection, 6 lllV positive patients were just one time inoculated with Plasmodia of the same dose and coming from the same patient host of Pv. malaria, some first manifestated typical tertian paroxysms of high fever and then the irregular quatidian paroxysms, but some manifestated other clinical characteristics ( see another report). The results also showed that the clinical regularity of malaria was not only decided by the quality and quantity of infected Plasmodium, but also by the reactivity of host, its exact ' mechanism is to be further demonstrated.
42
41
r-0
40
39
-.......'
(1)
;J
H
30
l;
42
41
~(j
p..
~
8 0
39
38
37
42
41
40
39
38
37
42
41
40
39
Cae 4
38
37
42
41
4~
39
3S
37
~
41 .... ~~~~~~;\~: ~~. .~.

" :' ,( " , ;' 39
, ,42
... .
_ _ 4i
.~;:~~!
-:-.=..
~ ;~
. .~~~.,
..
,/L, ", ~~ \w
: ~y;?_;~ 3~;_ . . " 38
37
' :'i Case 7 1 - , ,~,

"
-' -. ~
- )
.'
--- -
- --.
Fig. 1 Temperature curves of artificial hematogenous Pv. malaria- on adv~~ ..tumor patients ("tv{ indcates the time of use of chloroquine)
@
,
'.
, \
,- ,, .; ~~}:t. <~~;1~:i~.;:~'ik:~: : ~ .:
', :
' ;',:
.,
c '
It,.
'.,:.-;,.- "~' -~ ."
"
-:~ . .
. --~
.... . ;
j
"
\- .
3. Other clinical manifestations Among 7 cases, one (case 3 ) complicated asthma at the times of 8-10th paroxysms, but through the treatment of antisplasmodic and termination of malaria, asthma disappeared soon. One (case 6 ) presented thrombocytopenia, recovered after transfusion of platelets. One ( case 4 ) presented. irregular low fever with slight pain of knee joints during recuperation at home after termination of malaria and discharge, not found Plasmodium in repeated thick and thin blood smears, fever abated when used dichlofenac sodium. Hepatosplinomegaly induced by malaria in all 7 patients was not obvious, most were just palpable under the rib; all recovered to original state after a short time of termina tion of malaria. Anemia was not obvious during the period of fever; one ( case 7 ) complicated quickly progressing anemia after natural abatement of fever, but recovered very soon after termination of malaria and blood transfusion. 4. Therapeutical response to chloroquine All 7 cases of artificially induced hematogenous Pv. malaria were very sensitive to the treatment of chloroquine; all clinical symptoms and parasitemia quickly disappeared after one course of 10 tablets ( per tablet contains 0.15 gram ground substance of chloroquine) therapy , no any cases with recrudescence and relapse after antimalarial administration. Conclusion During the time of researching malariotherapy for cancer, we found that artificially induced hematogenous Pv. malaria on different kinds of advanced tumor patients had some special or new clinical regularity: 1, variation of incubation was big. 2, most patients first . presented ~cal ; tertian . paroxysms . of . high . .re~er. then . irr~. quatidian ParOiysms; this is )contraiy to the traditional knowledge. a, . although patients were infeCted the same strain and the same dose of Plasmodium, it seems that there were different fever pattern of Pv. malaria iIi different kinds of advanced. tumor patients. This phenomenon indicates in one respect that not only advanced tumor patients can be considered as a host population different from health one, but also different kinds of tumor patients can be also considered as different host populations; it shows in another respect that past description on clinics of Pv. malaria should be Bupplimented. So we consider that the research of malariotherapy for cancer not only has important significance on treatment of cancer, but also has a big theoretical value on research of malaria itself, as well as provides a model of research of relation between malaria and tumor. 6
REFERENCES
1. Yang JY, Zhu XM:
2.
3.
4.
5.
6.
Dictionary of Nobel Prize Winners. 1st eeL, Changsha: Hunan Publish House of Science and technology, 1994. P296. (in Chinese) Giugni F: Considerazioni sui risultati della malarioterpia in alcuni casi di tumore malarigno, n Policlinico (Sez Frat), 1965, 72: 197. Greentree LB: Malariotherapy and cancer, Medical Hypoth~ 1981, 7:43. Lysenko AJA, Beljaev AE, Rybalka VM: Population studies of Plasmodium vivax 1. The theory of polymorphism of sporowites and epidemiological phenomena of tertian malaria, Bulletin of the World Health Organization, 1977, 55(5):541. Chen XP, Guan WE: Inhibitor theory: A new exploration of relapse mechanism of malaria, Transaction of Chinese Public Health, 1994, 13: 74. ( in Chinese ) Chen XP, Xiao BQ: Relation between malaria and tumor, Chinese Journal of Preventive Medicine. 1996, 30(4): 61. ( in Chinese )
June 20 1996
J
Henry J. Heimlich, M.D. President Heimlich Institute 2368 Victory Parkway Suite 410 Cincinnati Ohio 45206 The United States Dear friend Dr. Heimlich: Thank you very much for your letter of June 11 and success and your participation of the XI Interational AIDS in Vancouver and the FICIA in Bethesda! congratulate our Conference on
It is too late for me to apply the attendance of Vancouver conference. As you know that it is a complicated procedure for application of going abroad in China especially the application of funding. Three days ago I sent you our paper on cancer in English and I am awaiting your agreement for publication in Chinese journal and US journal, welcome your comment and correction of English. Please give our best to our colleagues in the Heimlich Institute. Sincerely yours,
Dr. Xiao Ping Chen Director, Department of Microbiology The Municipal Health and Anti-Epidemic Station of Guangzhou No. 23, 3rd Zhongshan Road Guangzhou 510080 The People's Republic of China
..
2368 VICTORY PARKWAY SUITE 410 CINCINNATI OHIO
June 25, 1996
45200 513-22HXXl2 fax 513-221-0083
Ms. Valerie Harper Eleanor Naylor Dana Charitable Trust 375 Park Avenue suite 3807 New York, NY 10152 Dear Valerie: Here are some materials for starters. The binder gives extensive background on malariatherapy for HIV. Malariatherapy for cancer is described in the accompanying research paper. When you have had a chance to go through all of this, please give me a call. I look forward to working with you.
I,d'
,'1
.
/,,1
J"'< -:-.;
.'
'1-
~,~
-(
."
,_/
.f.'
",i/_
"
II'
- I
07/25 / 1996
15:48
21275Cl28'32
DAHATRUST
PAGE
02
Memorandum
July 26, 1996
To: Dr. Heimlich From: Valerie Harper
Subject: Confirmation of Dr. Heimlich's Malaria Immunotherapy ProJect- Grant .Road Map
Th~
Eleanor Naylor Dana Charitable Trust (ENDCT) has agreed to the following:
1.
Chlna.. To fund the next ten cases (which will not include needle users). For this
purpose, the ENDeT has agreed to give a grant of $100,000. The ENDeT's $60,000 grant awarded to Dr. Heimlich In April 1996 Should be utilized for Costa Rica, Guatemala, Columbia & India Etc.
2.
3.
It should be understood that further grant mOlleys which would eX(;t:t:..J lht: $150,000 already agreed upon ;by the ENDCT will have to come from other funding sources for the Malaria Immunotherapy project.
Valerie Harper, from the ENDeT, will serve as liaison -"project Manager" for Dr. Heimlich and the Malaria Immunotherapy project and ENDCT. Or. Heimlich and V.lone Harper have a meeting Scheduled at the Trust office on the morning of August 29, 1996
4.
5.
ce. David Mahoney Ed Rover
UNIVERSITY
BERKELEY DAVIS
OF CALIFORNIA,
IRVINE LOS ANGELES .
LOS ANGELES
RIVERSIDE SAN DIEGO SAN FRANCISCO SANTA BARBARA
UCLA
SANTA CRUZ
"Center for Interdisciplinary Research in Immunology and Disease

DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY UCLA SCHOOL OF MEDICINE CENTER FOR THE HEALTH SCIENCES 10833 LE CONTE AVENUE LOS ANGELES. CALIFORNIA 900241747
August 8, 1996
Henry 1. Heimlich, M.D., Sc.D. President, Heimlich Institute 2368 Victory Parkway Suite 410 Cincinnati,OH 45206 Dear Henry:
(310) 825-6568 (310) 206-1318 (FAX)
It was a pleasure to see you again in Vancouver and have a chance to talk further about malariotherapy that you have been exploring. The work is striking and certainly points towards the possibilities for resetting the disturbed immune balances of'HfV infection by major immune stimulation. I wondered if we could help you. Two contexts come to mind. One is our interest in cytokines and their products, especially the soluble markers of activation. We have the capacity to measure most of the cytokines in circulation as well as the capacity of peripheral blood mononuclear cells to produce cytokines under various forms of stimulation. These might be interesting to assess in selected patients treated with malariotherapy. The second context is in the form of a Fogarty International Center (Nlli) AIDS International Training and Research Program (AITRP), which we have at UCLA and which is becoming increasingly involved with studies with intervention and quality control efforts. In this context, we could, perhaps, develop a means of helping your Chinese colleagues in carrying out their studies. Assistance with reagents and quality control samples for CD4 measurements as well as for other parameters of'HfV infection. I would be glad to explore these further with you. Sincerely,
JOML2:
lLF/jm cc:
Director of CIRID at UCLA
Evelyn Najera, MPH Hong Bass, M.D., Ph.D.
b:IHcimlich
WHITE & CASE

UNITED STATES
LOS ANGELES
MIAMI NEW YORK WASHINGTON,O.C.
1155 AVENUE OF THE AMERICAS NEW YORK, NEW YORK 10036-2787 TELEPHONE: (I - 212) 819-8200 FACSIMILE: (1-212)354-8113
ASIA
ALMATY
ANKARA
BANGKOK BOMBAY
HANOI
EUROPE
BRUSSELS BUDAPEST
HELSINKI ISTANBUL LONDON MOSCOW PARIS PRAGUE STOCKHOLM WARSAW
212-819-8516
HONG KONG JAKARTA SINGAPORE TASHKENT TOKYO
MIDDLE EAST
JEOOAH RIYADH
AFRICA
..JOHANNESBURG
LATI N AM ERICA
MEXICO CITY
August 14, 1996 Henry J. Heimiich, M.D; The Heimlich Institute Foundation, Inc. 2368 Victory Parkway, Suite 410 Cincinnati, Ohio 45206 Dear Dr. Heimlich: I am pleased to inform you that the trustees of the Eleanor Naylor Dana Charitable Trust approved a grant of $100,000 for unrestricted support of the Institute. This action was taken at the suggestion of David Mahoney and was unanimously approved. Enclosed is check #5442 in the amount of $1000,000 as payment of the grant. At your convenience, kindly return a receipt for this directly to: A. J. Signorile Trustee/Treasurer E. N. Dana Charitable Trust 745 Fifth Avenue, Ste. 700 New York, NY 10151
It is a pleasure to assist you with your work, and aU the trustees join me iIi wishing
you continued success.
Edward F. Rover EFR:mem Enclosure cc: David Mahoney
September 3, 1996
PO BOX 885 8 CINCINNATI, OH 452 08 5 13-221-0002 ax 513-221-00 0 3 F
Mr. A. J. Signorile, Trustee/Treasurer Eleanor Naylor Dana Charitable Trust 745 Fifth Avenue, suite 700 New York, New York 10151 Dear Mr. Signorile: Your generous contribution to the Heimlich Institute Foundation in the amount of $100,000.00 is most gratifying. Be assured that your contribution will be used to further our research as expeditiously as possible. Your donation will help us continue our quest to save lives through research, education, and creative thinking in solving the problems facing each of us. It is through such caring support that our endeavors can progress in finding treatments for otherwise incurable diseases. Thank you again.
THE
FOUNDATION,INC.
PO BOXB858 CIN CIUAII, OH 45208 513-221-0002 faI513-221-0003
September 4, 1996
HEIMLICH INSTITUTE
Dr. Chen Xiao Ping Chief, Department of Microbiology The Municipal Health and Anti -Epidemic Station of Guangzhou No. 23 3rd Zhongshan Rd. Guangzhou 510080 People's Republic of China Dear Xiao Ping: This is a follow-up to my letter of July 19, 1996. I am enclosing a copy of that letter in case you didn't receive it for some reason. I have sent to your account number 475010101140192114, at the Bank of China, Guangzhou branch, $2,000 for the two year follow-ups for the first two patients. Should you have reason to believe that another $2,000 is warranted, please let us know what it is for. A leading United states university which has a center for immunology has asked to participate in our malariotherapy project. They have a National Institutes of Health center and laboratories to which bloods can be sent for viral loads if necessary. They also said they can help you in China. I believe there will also be an opportunity for you to corne to the united States and study here as the program progresses. Do you agree that we should try to complete such arrangements? We look forward to receiving the results of the tests on the last six patients as soon as possible. Please advise me as to when we might start on the ten new patients, as I would like to visit while they are under treatment. I look forward to hearing your thoughts. family and our colleagues are well. regard , I hope you, your
/tJ-
eimlich, M.D., Sc.D.
Benefiti Humanity Through Health and P eace
Enclosures
HEIMLICH INSTITUTE
FOUNDATION, INC.
p.o. BOX BB5B CINCINNATI, OH 45208 513-221-0002 faI513-221 -0003
September 17, 1996
Mr. A. J. signorile, Trustee/Treasurer The Eleanor Naylor Dana Charitable Trust 375 Park Avenue New York, New York 10152 Dear Mr. Signorile:
o f
/.
We received your generous grant to the Heimlich Institute Foundation in the amount of $100,000.00. Be assured that your grant will be used to further our research as expeditiously as possible. Your donation will help us continue our quest to save lives through research, education, and creative thinking in solving the problems facing each of us. It is through such caring support that our endeavors can progress in finding treatments for otherwise incurable diseases. Thank you again.
I
~ .. ( ~J.--r.
{
~
".,.;> . I, 1)"('1...,.t. I<C

t'L-iI'.-kl
at!.R<.n-~"vr...J- 1L.t.-<-.,.... L.t.._~.'2...~

.. -
/: {_'-<-->1
) +o-f cI
.-
.-
"
4-~.f
.6-t{ -'l_-'
IJ
e~.U
ntA_....~ .."-.:.,L
P.,./t~-r'
Lc.. f-
?U
~<'-I' ~ c-&.<. c.-t...{
/0 (:tf 5' .
/f...-'1-,-,f{ ,1,...(..(..cIv
1~ /~ ,rt..~.r ~.el ~";-L-:> .-i~(;-<-~e. ,f..e... c.~ d>,,;o",-<:Lt; l."-~~"'f' t'.[.--;1 {_"'f-~_..:._.r ,-.,.:'-1 'S' 11. /.....<.r-C..{SIvL-- .-..~~.u. C L-4 " t3.elZi'1_1"t. AJ--UL1.tZd o'f.~... 0 ~t t:)!.--t.~<-hA.. {P-'1\ ..C..{. pot;. a,'l--<._ l;...,~.<~...t2.e4 . ~. Ik;~.,.~<e.t., 1 J <+1;<:/ ~-<~~-<f 6 "-<-'*-.N} ?.L; ,,........ .
,
September
25, 1996
P.O. BOX 8858 CIICIIlATI, 0" 45208 51322HJ002 fiI 513-221-1)003
John L. Fahey, M.D. Director of CIRID at UCLA Department of Microbiology & Immunology UCLA School of Medicine Center for the Health Sciences 10833 LeConte Avenue Los Angeles, CA 90024-1747 Dear Dr. Fahey: At the request of Dr. Heimlich, the Protocol for AIDS. If I can be of any further hesitate to contact me. enclosed please find a copy of
service
to you,
please
do
not
Enclosure
Benefiting Humanity Through Health and
Peace
Malariotherapy for HIV Protocol for Selection and Treatment I. Candidate Selection A. Male candidates only B. Documentation of HIV infection (and classification into HIV-1 or HIV-2) C. Must be WR1 or WR2 stage of HIV infection D. CD4+ T-cell between 300-500 cells/BL Informed Consent A. Knowledge of diagnosis and prognosis B. Mental Competence 1. Understanding of experimental nature and unpredictability of proposed therapy 2. Understanding of risks attributable both to malaria and HIV a) Morbidity b) Mortality c) Recurrence C. Authorization for reporting and pUblication of clinical information (signed and witnessed) D. Ability and willingness to spend prolonged period of time at and in contact with the treatment site Admission studies A. History and physical examination B. CBC, hemoglobin electrophoresis, parasitemia screen C. BUN, serum albu~n, total protein4 immunoglobulin electrophoresis ,interferon assay ,bilirubin D/T, afkaline phosphatase, other enzymes as indicated ( if feasible) D. Urinalysis E. Chest X-ray (pneumonia) F. Electrocardiogram G. HIV titer from PCR H. Whole body photo (swim trunks) Abnormalities requiring possible exclusion from study A. Erythrocyte morphology (standard hematology microscopic examination of Wright/Giemsa stained peripheral blood cells B. Hemoglobin electrophoresis C. Red cell G6PD (glucose-6-phosphate dehydrogenase) D. Renal function E. Seizures F. Active chronic pulmonary conditions 1. Bronchial asthma or bronchospasm 2. Tuberculosis 3. Hypoxemia complicating any other condition G. Cachexia and hypoproteinemia
1
II.
III.
IV.
H. I. J. K. L. V.
Cardiac arrythmia (stress test, if warranted by electrocardiogram) Jaundice, liver function impairment, or portal hypertension Splenomegaly Obesity (more than 30% above ideal body weight) Aortic aneurysm
Treatment A. Induction of therapeutic malaria 1. Selection of malarious donors a) Appropriate plasmodial strain in adequate concentration (1) Plasmodium vivax b) Absence of other blood-borne infectious disease (1) Repeated thick and thin blood smear examination for parasites other than desired plasmodium (2) Negative antibody screens for syphilis, hepatitis, HIV, and any other infections suggested by history and physical examination 2. withdrawal (anticoagulation as indicated) of malarious blood for direct inoculation, for preparation of washed cells, or for plasmodium, culture 3. Patient inoculation (intravenous) with plasmodium source B. Alimentation as indicated with maintenance of 300 gram daily carbohydrate intake C. Monitoring of response 1. Prodrome a) Inoculation fever spike b) Oral temperature charted q. 4 h. during waking hours c) No antipyretics to be taken 2. Malaria syndrome a) Bed rest when fever attains 38C b) Temperatures to be charted (consistent method of measurement) (1) Q. 30 min. during febrile paroxysm (2) Q. 2 h. while awake (3) Temperatures and fever duration to be recorded on report form, as well chart c) Blood pressure recorded b. Ld. (more often if high or low) d) Body weight recorded weekly e) Sodium intake (p.o. or I.V.) of 5 grams daily (for diaphoresis loss) f) CBC, urinalysis, BUN every 4 days g) Acetaminophen 650 mg q. 4 h. p.r.n.
2
..
D. E.
F. VI.
untolerated fever above 41C or repeated tepid sponge baths and aspirin 975 mg p .o . or p.r. q. 4 h. p.r.n. 3. Modification or interruption of troublesome attacks a) Quotidian fever if debilitating b) More than 4 hours and/ or 42 C of fever per paroxysm c) Impending vascular collapse (1) Tachycardia of 130 or more when afebrile (2) Systolic BP below 80 despite intravenous fluid and electrolyte support (combined with digitalis and/or vasopressors as indicated) d) Intractable vomiting e) BUN over 60 mg/dl f) Severe progressive jaundice g) Repeated hypothermia h) Uncontrolled delirium i) Hematocrit below 20% or hemoglobin below 7 grams/dl j) Shock (possible splenetic rupture) 4. Reinoculation if required by inoculation/ hyperthermia failure (defined as either no parasitemia within 6 days of inoculation, or less than 10 paroxysms during malarial syndrome) a) In the absence of chemotherapeutic modification b) Following iatrogenic modification or' interruption of troublesome attacks 5. Termination of malaria after 30 days or 10 paroxysms, which ever comes last Drug treatment of malaria Convalescent care 1. Bed rest until afebrile for 7 to 14 days 2. Resumption of activity * 3. Immupoglobulin electrophoresis, interferon assay , and studies indicqted for comparison with pretreatment serum ( if feasible) 4. Serum chemistries as indicated by abnormalities found on admission or during treatment 5. Final CBC and urinalysis 6. HIV titer from PCR 7. Whole body photo (swim trunks) Discharge and drug therapy for malaria
Follow-up (1, 3, 6 months); no sexual contact preferred, otherwise protected sexual contact (condom) only A. History and physical examination
3
B. C.
D. E. F. G. VII.
CBC, hemoglobin electrophoresis, parasitemia screen BUN, serum albu~n, total protein~ immunoglobulin electrophoresis ,interferon assay ,bilirubin D/T, alkaline phosphatase, other enzymes as indicated ( if feasible) Urinalysis Chest X-ray (pneumonia) HIV titer from PCR Whole body photo (swim trunks)
Analysis of results A. Effect of therapy on HIV 1. Elimination of HIV 2. Changes in HIV titer B. Correlation of HIV changes with duration/intensity of malariotherapy C. Correlation of HIV changes with immune system changes D. Correlation of immune system changes with duration/intensity of malariotherapy
HIV CANDIDATE Candidate must be: HIV positive Male WRI or WR2 class CD4+ T-cell
SELECTION
CRITERIA classified)
(HIV-I or HIV-II
counts between
300-500
PRE-TREATMENT In addition (swimsuit) to full medical
REQUIREMENTS history, full body photographs should for after treatment
will be taken prior to treatment, 2 weeks to occur. prior
and at final follow-up examination. be terminated drug washout
All drug therapies
to start of malariotherapy,
DURING TREATMENT During the course of MT, all precautions contaminated nurses, etc. AIDS-related material complex will be of observed any for dealing with HIV by all, including related to
Development
complications
should be treated
in the normal manner.
CRITERIA
FOR EARLY TERMINATION
OF MALARIOTHERAPY Standard malaria related events indicating need for termination of therapy.
POST TREATMENT Sexual abstinence during follow-up to prevent reinfection (protected sex is acceptable, but not preferred).
Malariotherapy for HIV Treatment Record For Research Only Name of Patient: weight: Age: Physical Appearance Name of Physician: Date of Examination: Sex: M (include photo): F
Patient's
General
Feelings:
Date of Onset
(history):
Date of Diagnosis: Date of Treatments, etc.:
General
Prognosis: of physical impairment due to HIV infection:
Description
Blood Analysis: Hb WBC Pc LT RF CD4+ CD8 CD3
II
IgG IgA IgM IgD IFNa
I
IFN,8 IFNy
II
II
HIV titer from PCR:
II
Malariatherapy Malaria Type: Injection 1- Volume: Date: Observations:
Initiation concentration:
Injection
2-
Volume: Date:
concentration:
Observations:
Malarial
Phase
start of febrile period (date): Record high and low body temperatures and duration of fever (fever should be considered as any temperature greater than 38.3 C or 100 F). Day High Temp. Low Temp. Fever Duration Medlcatlon Reason
1 2 3
admlnlstered:
for medication:
Day High Temp. Low Temp. Fever Duration Medlcatlon
10
11
12
13
14
admlnlstered:
Reason
for medication:
15
16
17
18
19
20
21
admlnlstered:
Reason
for medication:
22
23
24
25
26
27
28
admlnlstered:
Reason
for medication:
Day High Temp. Low Temp. Fever Duration Medlcatlon Reason
29
30 *
31
32
33
34
35
admlnlstered:
for medication:
Day High Temp. Low Temp. Fever Duration Medlcatlon Reason
36
37
38
39
40
41
42
admlnlstered:
for medication: is to be halted after the 30th day of fever, which ever occurs last. Termination of Malaria
* Course of malaria treatment

or 10 paroxysms
Date: Method
of malaria
termination:
Reason
for termination:
..
Post Treatment Name of Patient: Weight: Age: General Condition of Patient:
Evaluation
Name of Physician: Date of Examination: Sex: M

F
Physical
Appearance
(include photo):
Patient's
General
Feelings
About Current
Physical
Condition:
Current
state of Physical
Impairment
Due to HIV:
Blood Analysis: Hb [I WBC Pc LT RF IgG IgA IgM I[ IFNa
IgG [I HIV titer
IgA
IgM
IgD
IFN,8
IFNy I[
from PCR:
'"
Malariotherapy for HIV Follow-up Evaluation (To be given 1, 3, and 6 months after Post Treatment Evaluation) For Research Only Name of Patient: Weight: Age: General Condition of Patient: Name of Physician: Date of Examination: Sex: M
F
Physical
Appearance:
Patient's
General
Feelings
About Current
Physical
Condition:
Current
state of Physical
Impairment
Due to HIV:
Blood Analysis: Hb WBC Pc LT RF IgG IgA IgM
II
IgG IgA IgM IgD IFNa IFN,B IFNy
II
II
HIV titer from PCR:
II
Report on Dr. Heimlich's trip to Los Angeles September 24 - 27 to meet with Professor John L. Fahey, M.D., Director of the Center for Interdisciplinary Research in Immunology and Disease (CIRID) at UCLA, Department of Microbiology & Immunology, UCLA School of Medicine.
PO BOXBB58 CINCIHHATI, OH45208 513-221-D002 faI513221-0003
I met with Dr. Fahey and colleagues at UCLA. On his return from the AIDS conference in Vancouver, he had presented our malariotherapy program to them. T gave them more details and responded to their questions and suggestions. They all are interested and approve. After the conference Dr. Fahey and I met for 3 hours. Our meetings were on 9/24 and 9/25. described his program in four parts: I. Research in AIDS Dr. Fahey (Dr. F)
In 1981, the first three young men to be recognized as having a disease later named AIDS, was reported in the New England Journal of Medicine from UCLA by Dr. Gottlieb, with whom Dr. F worked. Since that time Dr. F has been involved in investigating immunologically, immune deficiency and opportunistic diseases. Dr. F's studies include following the course of a group of homosexual men from 1984 to the present. Of 1,600 men, 800 were sero-positive in 1984, and 800 were sero-negative. The even division of numbers was coincidental, not planned. He has followed the cells and plasma of these individuals every six months since 1984, in addition to cytokine studies and the pathogenesis of the speed of progression of the disease and dysregulation of the immune system. NOW, twelve years later, half of those with AIDS have died. Of the negative individuals 135 are now HIV positive. II. Therapy Efforts
Dr. F is in charge of laboratory studies and does not work clinically with patients. His program is associated with ACTG, and includes adult and pediatric cases. (ACTG is the NIH supported program - AIDS Cohorts Trial Group). He is responsible for standardizing methodologies, in his and other laboratories. Studies include functional testing and flow cytometry. III. International and the supported by the Fogarty NIH. It provides grants
This program International concerning:
is under Center of
-1-
1. 2.
AIDS epidemiology Research support and training of scientists part of the AITRP (AIDS International Training Programs). The location of his work is: a. b. The Asian Pacific Rim, primarily China and India; secondarily Thailand and vietnam. Latin America, Mexico, and Brazil.
as
Dr. F's research for China is headed by Dr. Hong Bass (an American citizen) in Hong Kong and Beijing. Dr. F had brought her to my presentation at the AIDS conference in Vancouver in order for us to meet relative to working together. In the past she has taught at Peking Union Medical College, Beijing Medical University, and the Institute for Traditional Chinese Medicine, all in Beijing, and at the Second Medical Military university in shanghai. Dr. Bass has arranged for Dr. F to carry out his work in all these institutions. Each year trainees from the above institutions and the Chinese Ministry of Health come to UCLA to study in Dr. F's laboratory for three months. The Center also provides to the institutions, at no charge, reagents to carry out laboratory studies. 3. An international effort under the UCLA Fogarty Center to establish controls for measuring CD4 levels throughout Asia. His work includes establishing normal levels for CD4, CDS, and CD3 for all the countries studied, since these levels differ for each country. Dr. F mentioned that Customs in China is very difficult. He sends reagents to China from Australia. He also studies various methods for CD4 testing, including immunofluorescence, ELISA (TRAX 4), and Beads that bind to CD4. He has found that microscopic, ELISA, and flow methods all have validity. Microscopic methods, which we have been using in China, are best for small series.
UCLA and the Heimlich
Institute
1. Dr. F will work with The Heimlich Institute to establish the testing design that will best enable evaluation of the patients we are treating. 2. Laboratory tests that are done in China will be checked by confirmatory testing of the same blood samples UCLA.
at
-2-
3. Our Chinese colleague, Dr. Chen xiou Ping is invited, at the expense of UCLA, to spend three months in 1997 studying in Dr. F's laboratories. Dr. F. will have Hong Bass contact Dr. Chen and provide his laboratories in Guangzhou with training and assistance. He will also provide reagents for laboratory studies to Chen without cost. Dr. F mentioned his interest in training the Chinese military to follow u. S. military methods in treating and arranging discharges for HIV infected personnel. I then informed him that Vice Admiral Koenig, Surgeon General of the U. S. Navy, was going to Beijing for the International Congress on Military Medicine october 11 - 17 and had called me last week hoping to meet my associates. Dr. F advised that he would very much like to have Admiral Koenig meet two Chinese doctors, a General and a Colonel from the Second Military university in Shanghai, who will very likely be at the Congress. The next day I called Harold Koenig, who faxed the Congress program to Dr. F, and arrangements will now be made between them. In addition, Dr. F is scheduled to go to Beijing to teach from October 18 to 23, and both are staying at the same hotel. Dr. F will be in touch with our Dr. Chen in Guangzhou and Chen will likely go to Beijing to meet Dr. F. On Thursday morning, September 25, Dr. Hong Shun Hua and I had a planned meeting in my hotel. Dr. Hua came to me as a Fellow many years ago and has been our contact with Dr. Chen in Guangzhou. Dr. Hua traveled to Guangzhou when our patients were receiving malariotherapy in order to follow their progress. He videotaped interviews with our patients. Dr. Hua telephoned Dr. Chen in Guangzhou from the hotel and we spent a very informative hour speaking with him. (Dr. Chen speaks excellent english.) Dr. Chen was already preparing to include in our patient studies currently developed laboratory tests, including viral loading, lymph factor measurement, interferons, virus gene analysis, etc. He was thrilled with the possibility of working with Dr. F and spending three months in his laboratories. Dr. Chen will be attending an AIDS conference in November in Hong Kong. I later told this to Dr. F who will arrange for him to meet Dr. Hong Bass there. Chen advises that there are 700 HIV positive patients in Hong Kong. He said that on July 1, 1997, Hong Kong will be returned to mainland China, therefore, the Guangzhou Health Station, where our malariotherapy program is centered, will cooperate with the Public Health Department of Hong Kong. Dr. Chen's station has
-3-
...-------:~-------------
--
/'1,
received 2,000,000 Chinese dollars from the Chinese Ministry of Health (ratio to USD is about 8.5 to 1) to expand their facilities and remodel Chen's laboratory. He says he can start the new malariotherapy patient treatments when the remodeling is finished, i.e. after November. (The above was confirmed in a Fax from Chen of 9/27.) On the second day, (9/25), Dr. Hua and I met with Dr. F and advised him of our discussions with Dr. Chen. Dr. Hua is now considering spending the next two months in Dr. F's laboratory. This has been a wonderful year. In summary, our data has been reviewed and accepted by panels of experts of three leading international conferences on immunology and AIDS (San Francisco, July 1995; The NIH, June 1996; Vancouver, July 1996); by university professors who are AIDS authorities; by the u.S. Army Research and Materiel Command; by editors of a medical journal, and was reported favorably in the press. This recognition stems from our carefully prepared protocol, accurate data, and promising results. The future is even brighter. The studies are enhanced by the relationship with UCLA. The affiliation with Dr. Fahey establishes a continuity to our malariotherapy program that assures the ongoing and future progress of our research.
Submitted:
Heimlich, M.D., ScD.
UNIVERSITY
BERKELEY DAVIS
OF CALIFORNIA,
IRVINE LOS ANGELES
LOS ANGELES
RIVERSIDE SAN DIEGO SAN FRANCISCO SANTABARBARA'
UCLA
SANTACRUZ
Center for Interdisciplinary Research in Immunology and Disease

DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY UCLA SCHOOL OF MEDICINE CENTER FOR THE HEALTH SCIENCES 10833 LE CONTE AVENUE LOS ANGELES, CALIFORNIA 90024-1747
October 2, 1996
(310) 825-6568 (310) 206-1318 (FAX)
Hemy Heimlich, M.D. The Heimlich Institute Foundation, Inc. 2368 Victory Parkway, Ste. 410 Cincinnati, OH. 45206 Dear Henry: I want to express my appreciation to you for your taking the time to visit with us at CIRID at UCLA last week. Our group was stimulated by your presentation on malaria therapy. Indeed, several asked me if it would be possible to have a more complete description (CD4 counts, clinical features, etc.) of all of the people treated in China? These may be in a manuscript that is in preparation or submitted but we would appreciate whatever information you can share with us. I very much enjoyed talking to Dr. Hua. He has called and I am sending' him information about a course on mv that is starting next week which, I think, will meet his needs better than spending time with our group. Our working conferences involve laboratory personnel and are not designed for individuals without that kind of background and experience. We will try and help him with an update on mV/AIDs. I must thank you for the reprints of the papers concerning Lyme Disease and the accompanying nervous system manifestations. I have taken tins up with a neurologist and have arranged for a serologic test for the borrelia spirochete infection.
Heruy Heimlich, M.D. October 2, 1996 Page 2
I have also written to Dr. Chen Xiao Ping in Guangzhou to inquire about the possibilities of talking with him during my upcoming visit to China. Also, I have contacted my colleagues in the Chinese Army to see if they are attending the
International Conference on Military Medicine in Beijing.
Many thanks for telling me about so many things that are going on. I am sure they will all turn out to be fruitful. I will be certain to provide you with a follow-up. Sincerely,
John L. Fahey, M.D. Director, CIRlD* at UCLA Chair, Clinical Immunology Committee, International Union of Immunological Societies (lUIS)
JLFIkhl
b:\Heimlich
October
14, 1996
2368 VICTORY PARKWAY SUITE 410 CINCINNATI OHIO 45200 513-221-00J2 fax 513-221-00J3
John L. Fahey, M.D. Director of CIRID at UCLA Department of Microbiology & Immunology UCLA School of Medicine Center for the Health Sciences 10833 LeConte Avenue Los Angeles, CA 90024-1747 Dear John: Thank you for your letter of October 2, 1996. I hope that your arrangements to meet Dr. Chen Xiao Ping work out. You will find him to be a fine young man, well informed, very much interested in your work, and amiable. Your invitation to Dr. Hua to attend your conference is appreciated by him and by me. I understand you had a lengthy with David Mahoney. He is interested in our project. and informative conversation a fine gentleman and very
Dr. Eric Spletzer, my associate, will get together details on our cases and you should have them when you return from your trip. Have a pleasant and productive to help, please let me know. Best ~i !I journey. If I can do anything
j
ich, M.D., HJH: jws Sc.D.
October 22, 1996 Henry J. Heimlich, M.D. President, Heimlich Institute 2368 Victory Parkway Cincinnati Ohio 45206 U. s. A.
Dear Dr. Heimlich:
I -did not receivelt.. Dr. Fahey's letter of October 2 until yesterday. I contacted with him last night and this morning by telephone. It is a pity that it is too late for me to meet him in Beijing because he will return home tomorrow and I could contact him just yesterday. But we talk a lot by telephone. He told me that they win have a HIV training program in Los Angeles from March to April, 1997, just about one month. But I want to stay there for three months to study some things more. Could you please contact him to let me study there from January to April and then return to G118 n gzhou for continuing our clinic trial ? If so, I need your or his invitation letter to deal with my paBBport and visa, the sooner the better. Since in China, as you know, people usually have to spent at least 3 months on dealing with paBBport. So I hope you or Dr. Fahey give me invitation letter as soon as poBBible after you receive this letter. Now I want to let you know my schedule as follow: November, 1996: Attend Hong Kong AIDS Conference and visit Hong Kong Health Department. December, 1996: Visit the second batch of HIV patients for their 2 years follow up to Yunnan Province. January- April, Bring HIV samples to Dr. Fahey' center for testing 1997: and attend HIV training progrom in Los Angeles April, 1997: Return to Guangzbou to treat the 8rd batch of HIV patients ( 10 cases ). During the whole course of next batch patients who will receive malariotherapy, I plan to test their cytokines ( ll-2, 6, IFN-r, TNF ), CD4 by cytometer, HIV load by PCR, HIV sequence and apoptosis. But before doing this, I need study some. things in USA as mentioned above. So I hope you to help me to complete my training for our project to be more perfect.
ltd
I have mentioned in my last letter, you should pay 2000USn each patients each time for the two years follow up of the first two patients ( according our agreement, in the first two patients, you should pay 10000 usn for each ). The part of Guangzhou agrees to continue following up the first two patients, we count the payment to be 1000 usn for each patients each time. Enclosed are the 1.5 year follow up reports of the 6 patients in Yunnan. Case 6 died on July 5, 1996; the cause of his dead is unknown, but I guess there are two possibilities, see the report. We consider 'that you should pay for the follow up this time because we visited his family to get the information about his dead and you did not pay any for his 1 year follow up. We do need enough money to successfully complete our project. We have applied funding from Guangzhou Government to buy flow cytometer and other instruments for our project. We hope your part can pay some if possible. Dr. Fahey suspects our method ( APAAP) for CD4 testing, I have the sense from my talk with him in telephone. We must make our results be widely acceptable in the world, we must use the best instruments to do our tests. So our following research will be much more expensive. We should have this idea.
I agree that Dr. Spletzer is as our coauthor in our paper " Characteristics of artificially induced...". There are some changes in component in this paper, so I hope you or Eric revise it in English wording and grammar and then send back to me as soon as possible.
We are waiting for your payment to complete our each part of the research. We look forward to hearing from you soon. Best wishes and regards to you and my mum, Jane, I miss her very much.
du1~~
Dr. Chen Xiao Ping
Chief, Department of Microbiology The Municipal Health and Anti-Epidemic Station of Guangzbou No. 23, 8rd Zhongahan Road Guangzhou 510080 The People's Republic of China
Malariotherapy for HIV Follow-up Evalultion (To be g hen 1, 3, and 6 month after Post Treatment Ev!luation) For Researeh Only
Name of Patient
Name of Phys ie ian:
Cbn X P
Date of Eumlnallo.:
srI."
I'f'l t
Age: Ganelal Condition of Patient:
Sel:
(]~
Physical Appearance:
/Vormd-
Patient' s Oeneral FaelingG About Current Physical Condition:
Current States of Phyftieal Impairment Due to HIV:

/'1011.4
Blood Analys is:

Hb
WBe
Pc
LT
RF
CD4
IIT/
CD8
CD3
fot liftJIFN
i
IgG
IgA
/,0/0
IgM /\fo
IgD
IFN a.
IFN y
It,oo
IIIV titer from peR:
ELI5A t.l
OP~
I,
92-
Malariotherapy for HIV Follow-up Evaluation

(To be given 1, 3, and 6 month after Post Treatment Evaluation) For Research Only Name of Patient
Weight:
Age:
Name of Phys icTan:
U~
guf::-y
ale of Examinallon:
Sel:
M
sri
)0
r
7)
lu6
General Condition of Patient:
Gf713~
Physical
App~arance:
N~
Patient' s: Genera l '.elings About Current Physical Condition:
Current States of Physical Impairment Due t o HIV:

;\!Of/U!.Blood Ana lysis:
lIb
I I
iBC
Pe
1T
RF
CD 4
CDS
. / }tP
. CD3
".!
/21 /
IgG
JltrO /If
IgA
IgM
/lOO
IgD
2-vlj
IFN a.
~f-t;2
I FN
IFN'y
'0
//i{fO
(Jlt)
HIV titer from peR:
ELISA -t;
OJ)~
/.)6
Malariotherapy for HIV Follow-up Evaluation (To be ghen 1, 3, and 6 month after Posi Treatment Efaluati~n) For Research Only
Name of Patient Name of Physicioan:
Date
. Weight:
Age:
60
J-Ij
Gf
If
C~ X? Examination: 58ft.J / //Irl ,

\
Sex:
G#Jct{ Physical Appearance:
Not"~
Patient' s-General Feelings About Current Physical Condition:
Current States of Physical

t/OflJ2..-
Impair~ent
Due to
HIV~
Blood Analys i s:
-
.
CDS . CD3
.s
Db
WBC
Pe
LT
RF
CD4
2-.1-22-
IJ.2 1Jrrz? I 1ft

{gG
IgD
1/'fO
IFN
." 2.T+)
.
IgA
0 ()
IgM
21j~
IFN Cl
tFN.'Y
20.
/.J-L
Co
HIV titer from peR:
t::::LI5/f-r;
OD~
/.60
Malariotherapy for HIV Follow-up Evaluation (To be given -l;-S;- IS ~ ~Bd &month afier Post Treaiment Evaluation) For Research Only
Name of Pa t ten
Name of Physician:'
eke-11 )( p
/
7 b
I
1
.
Weight:
Age:
Date of ~umina~ ~tJ'7 I'll) /
t/~w I - . , ,,~r Sel: 111 ~ ,
General Condition of Patient: ,}Ie- et:.d tm tf9t.
One. ,')n(mth 6ejc-re-/u.. ~ Iu.lu4 Phys ical Appearance: !/)f fU/..er> ~/z, U/~4 b~ .s!~tWn1/~~ ( ,b~ stAo!) ttA1q ~ / luaA~ tlt4WYe?( ~
Patient' s-General
F~elings
About Current Physical Condition:

u-:e
Current ~iale' of Phye ;.01 Impairment Ifue to HIV: f- . ~
bit-t w~ =uLd n~f J4 ~ ~~ cJ-.f- h;a ~. U~
t1c.:t6eh-t?
h.e.
Hb
ct)d
1 dr"j
J
~ tJvt?r~st?
tJr
~)A~nt/d'?)
c&;d
Blood Analysis:
P'i-;
---'~~
t:Jr
hIPS
ntJbtJofI krw7.0s.
LT
RF
CD4
iBC
Pc
CD8
.' CD3
'",
;c "
IgG
IgA
IgM
IgD
-
IFNa
IFN
I~
IFN y
HIV titer from peR:
Mmlariotherapy for HIV Foll~w-up Evaluation (To be ginn -1,-8,- I\~;J~ ' eel 6 m~ afhr Post T~eatment Evaluation) For Res.arch Only Name of Pa t ien
~
'.1,-,
of Phys ieian: C~n X p of Elaminat ion: ~ff. 7) fl/q {;

ld
Date
Sel:
lIb
Itf.2-
W Be
Pc
L T
RF
CD:!
CDS
CD3
/f4tn?
IgA
/\]
{}
lof
IgD
l!l
/tl?/
IFNa
Iq/
IFN
Is-J7-IFNy
IgG
10,/0
IgM
I
I,
HIV titer from peR:
EL/3fj-t-; OD~/ . 6r:f
MalariGtherapy for HIV Follow-up Evaluation (To be given 1. 8. /'J)~ IDa 6 month after Post Treatment Evaluation} For Research Only
Name of
PhysiciaD~ C/z.w)(p
Weight: Age:
nate of Rumination:
Sel:
M \
Seft?,
.
/,/'16
Physical Appearance:
/fOl'md
Patient' s General
r~elingB
About Current Physical
C~nditiGn:
Current States of PhYBieai Impairment Due to HIV:
None.
Hlood Analys is:
Hb
WBC
q~t:rO
Pe
LT
RF
CD.
CDS
CD3
'3.2,
IgG
11 0
IgM
I( q.o
-r
IgD
J-)O
IFN a.
s-t/f
IFN
~
/lr::
IFNy
.;,
IgA
(, q,o
17 q{)
1
HIV titer from peR:
GLI5"It-t-;
{)j):.1.7f
November 4, 1996
Dr. Chen Xiao Ping Chief, Department of Microbiology The Municipal Health and Anti-Epidemic station of Guangzhou No. 23, 3rd Zhongshan Road Guangzhou 510080 The People's Republic of China
Dear Chen:
Thank you for your letter of October 22, 1996. thorough and informative. Fahey, but I
It was very
I am sorry you missed seeing Dr. spoke with him on the
am pleased that you
telephone.
Dr. Fahey is visiting other countries and will not
be home for another two weeks, at which time I will contact him. It is my understanding that he only gives the training
program in March.
On November 7th I have been invited to visit David Ho's new laboratories. If that looks promising I can ask him to have Perhaps we can
you spend a month with him in New York.
arrange a third month with either Dr. Fahey or Dr. Ho or at another laboratory. Let me know your thoughts.
Should you not be able to come to the united states prior to March, I would like to suggest that you treat two or three That will
patients in the new group before you leave China.
be favorable in the eyes of those who are funding our work. However, I do not think you should treat any new patients
until your new laboratory has been proven to get accurate determinations of all the new tests that you have mentioned and Dr. Fahey has given us a revised protocol.
Your reports of the six patients in Yunnan are very good. They are not really 1. 5 year follow-up reports since they actually completed treatment two years prior to September 7, 1996. Follow-up blood studies should not be done on any of
the seven older patients until we discuss this, probably after you return to China from the united states.
$4,000
has
been
wire
transferred
to
your
account This When
#475010101140192114,
Bank of China Guangzhou Branch.
completes the total payments for the first two patients .
you are in the united states we can discuss the amount that is proper for future laboratory studies.
If we are able to progress as suggested, I have been promised funds to extend our progress, reasonable level. but we must keep them at a
Since the tests will be done in your own
new laboratory, which will be used for treating many other patients, and Dr. Fahey will provide reagents, it should keep
costs down at a lower level.
As always, we will be fair in I am sure that you
meeting our obligations and your needs. will do the same.
My best wishes to my Chinese friends and family,
~.
~--
-....
UNIVERSITY
BERKELEY DAVIS
OF CALIFORNIA,
IRVINE LOS ANGELES
LOS ANGELES
UCLA
SANTA CRUZ
*Center for Interdisciplinary Research in Immunology and Disease

DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY UCLA SCHOOL OF MEDICINE CENTER FOR THE HEALTH SCIENCES 10833 LE CONTE AVENUE LOS ANGELES, CALIFORNIA 900951747
FAX:
(310) 825-6568 (310) 206-1318
November 6, 1996
Henry J. Heimlich, M.D., Sc.D. President The Heimlich Institute Foundation, Inc. 2368 Victory Parkway, Suite 410 Cincinnati, OH 45206
Dear Henry, Ijust returned from my trip that included stops in India and Europe before returning to UCLA. My stay in Beijing was busy and informative. Fortunately I was able to talk with Dr. Chen Xiao Ping on the phone at some length. He was very helpful and certainly speaks English well. I've invited him to take the Fogerty mV/AIDS course at UCLA next spring. The general theme is an update and design of mV/AIDS research. We'll be sending him more information in the coming days, and I certainly hope he can make arrangements in Guangzou to be away for that time. I offered him the opportunity to bring samples from his studies in China so th..,t more detailed can be conducted while h'" 1C' her". at UCLA '"'''~.&.'"' studies t.
U~U" ...
.&..a. _......
tJ
'
"'.
\.i.
''''
.a.,-,_
tJ.&..1.
.... ""
.L.
He identified a method for measuring CD4 T-cell levels that I was not familiar with. Apparently flow cytometry was not used in the malarial therapy studies. I look forward to having more information about the CD4 method that was used. We will try to help him with satisfactory flow cytometry or alternative methods for accurate CD4 T cell measurements. That is part of our course here at UCLA. He assured me that flow cytometry was available at his institute and that he would have access to that for future malarial therapy studies.
He did mention that he would be going to Hong Kong early in November for the 2day AIDS meeting there. I have informed my associate in Hong Kong, Dr. Hong Zhao Bass(whom you also met in Vancouver), about our conversations with Chen Xiao Ping, and hope that the two of them can talk further. She can tell him more about the set up at UCLA and help prepare him to take advantage of that opportunity . I did enjoy my conversation with David Mahoney, who called just before I left for China. I was able to tell him about our plans to interact with your colleagues in Guangzou and the plans to bring Dr. Chen Xiao Ping here to UCLA for six weeks next spring. I hope your work is continuing to go well. Sincerely,
John L. Fahey, Director, CIRID* at UCLA Chair, Clinical Immunology Committee, International Union of Immunological Societies (lUIS)
November
8, 1996
2368 VICTORY PAR'f.WAY SUITE 410 CINCINNATI OHIO 45200
John L. Fahey, M.D. Director of CIRID at UCLA of Microbiology of Medicine Sciences Department UCLA School Center
& Immunology
513-22HXXl2
fax 513-221-((X)3
for the Health CA
10833 LeConte Avenue Los Angeles, 90024-1747
Dear John, I hope you had a successful Chen told me you had phone and interesting contact, trip in Asia. not meet, Dr. and
but could
that he will be spending March 1997 with you. Enclosed patients are recent pictures that have been
I am delighted. data on
and some of the pertinent for two years.
followed
We also have information well as full patient I return to Cincinnati.
on the CD8 counts and other tests, as and will send them to you when
reports,
Should will
you have any questions, be out of town for the
please next
feel free to call. ten days, but will
I be
available
through
my office
and will call you on my return.
Benefiting J' Humanity / . Heimlich, Through/' President Health
M. D., Sc. D.
PS. , r: ~ =r::
4
"I _ ~AJ!
--Cl1
dIf~ .
v-M
~~~ce
fNMW ~
Fax
FOUNDATION, INC.
2368 VICTORY PARKWAY SUITE 410 CINCINNATI OHIO 45200 513-22HXXl2 fax 513-221.r0J3
To: Of:
Dr. John L. Fahey Center for Interdisciplinary Research in Immunology & Disease (310) 206-1318 1, including this cover sheet. December 16, 1996
Fax: Pages: Date:
Once again, thanks for your invitation to Chen Xiao Ping. He asked me to speak to you about his need for a Letter of Invitation as soon as possible. In China, it takes considerable time when dealing with passports and visas. I suggest you send such a letter by Federal Express to Chen at: Dr. Chen Xiao Ping, Chief/Department of Microbiology The Municipal Health and Anti-Epidemic Station of Guangzhou No. 23, 3'd Zhongshan Road Guangzhou 510080 The People's Republic of China You may also wish to attempt a fax, but even if you think it goes through, don't rely on it. His fax number is: 011-86-20-83814993.
My best wishes for a happy holiday
d a new year of working together. .
From the desk of ... Henry J. Heimlich. M.D. THE HEIMLICH INSTITUTE
2368 VICTORY
PAR~AY
SUITE 410 CINCINNATI OHIO 45200 513-22HXXl2 fax 513-22HXXl3
December 16, 1996
Professor Chen Qi Qi Canton Medical College Guangzhou 510182 China Dear Chen Qi Qi: Thank you so much for your thoughtful seasons greeting. It was nice to hear from you. I thought you would be interested in the Heimlich Maneuver now being used to stop asthma attacks. It saves a great deal of money and patients lives. I can send you a video tape of how to do the Heimlich Maneuver for choking, drowning and asthma if you have a compatible VCR for our VHS tape. The Heimlich Institute will be pleased to cooperate with you in disseminating the information for China. 1 look forward to seeing you again in Guangzhou or should you come to the United States.
HJM:jws Enclosures
December 17, 1996
2368 VICTORY PAR~AY SUITE410 CINCINNATI OHIO 45200
513-22HXXl2
fax 513-22HXXl3
Dr. Chen Xiao Ping Chief, Department of Microbiology The Municipal Health and Anti-Epidemic Station of Guangzhou No. 23, 3,d Zhongshan Road Guangzhou 510080 The People's Republic of China Dear Chen: Thank you for your letter of November 28, 1996. Did you receive my fax of November 28th as well as the letter? I suggest you respond to us by fax. Our fax number is: 00-1-513- 221-0003. We are now connected to the computer Internet. If you can also do so through your computer, it is the best way of communication between us. Our E-Mail address is : "heimlich @ iglou.com". I am pleased Dr. Fahey has extended your visit to three months. It will be good if you plan time to visit me at my home in Cincinnati. We may also plan a trip to New York City so you can meet our sponsor. In my letter of November 8th, I recommended you treat two or three patients in the new group before you come to the United States. You could then also bring their blood specimens to Dr. Fahey. That is still recommended, particularly since future treatments will be delayed until July rather than April, as you earlier advised. Should that not be possible, it would then be good for you to select the next ten patients now and take specimens of blood from each patient every week; then bring those specimens and results of your tests to Dr. Fahey. But the best way will still be to treat two or three patients before you come to the United States.
It is a great honor to have our work recognized by Dr. Fahey and for him to extend his
invitation to you. He is one of the most widely known AIDS authorities and I know you will benefit greatly from your visit. I have called Dr. Fahey to remind him of your need for an invitation letter and he is sending it to you.
""'" ) . ,
Dr. Chen Xiao Ping: 12/17/96 Page 2
You and our other Chinese colleagues will be pleased to know our report on our first two patients has been accepted for publication in an international medical journal and should be printed by the time you arrive here. Eric is still working on "Characteristics of Artificially Induced Hematogenous Plasmodium Vivax Malaria on Advanced Tumor Patients". He is also preparing a new paper with the two year results of our eight patients. How was the AIDS meeting in Hong Kong? Did you meet Dr. Fahey's associate? Is your new laboratory functioning? Please let me know your thoughts by return fax or Federal Express, if possible. Your "Mum", Jane, also looks forward to your visit.
FOUNDATION, INC.
2368 VICTORY PAR'f.WAY SUITE 410 CINCINNATI OHIO 45200 513-22HlOO2 fax 513-22H)003
HEIMLICH INSTITUTE
...............
facsimile
TRANSMITTAL
To: Of: Pages: Date:
~----------------------------
VALERIE HARPER THE ELEANOR NAYLOR DANA CHARITABLE TRUST 10, including this cover sheet. January 3, 1997
Should you wish to contact me over the weekend, you may call me at home (513/8717711).
From the desk of ... Henry J . Heimlich , M.D. THE HEIMLICH INSTITUTE
January 3, 1997
2368 VICTORY
PAR~AY
SUITE 410 CINCINNATI OHIO 45206 513-22HXXl2 fax 513-22HXX)3
Ms. Valerie Harper The Eleanor Naylor Dana Charitable Trust 375 Park Avenue New York, NY 10152 Dear Valerie: I have enclosed a tentative three year budget for our project, Malariotherapy for AIDS. Also attached is a copy of the original budget I submitted to Mr. Stephen Foster on February 20, 1996. The original three year budget came to $2,031,245.00. These costs were diminished for the following reasons: 1) Central America is eliminated. 2) The $290,795.00 for equipment, which was designated for China, is now eliminated since the Ministry of Health of China is providing the funds to update and equip their laboratories 3) The number of patients to be treated in years one and two has been diminished. The figures are estimates and are based upon ideal circumstances. I appreciate that the funds may not be immediately available through the Eleanor Naylor Dana Charitable Trust. Should this be the case, there are ways to modify our needs and our rate of progress. For example, we may not meet the contemplated number of patients, thirty for the first year, because treatment will commence upon Dr. Chen's return to China from UCLA. That will diminish the cost by $10,000.00 per patient not treated. Furthermore, our arrangement with Chen is that the cost per patient is spread over a two-year period. The payment per patient, therefore, does not have to be available at the outset as long as we know the installments will be met over the following two years. In fact, since they will start treating the patients in July, approximately 20% of the total costs for patients will be spent during the remainder of the 1997 calendar year (i.e., up to $60,000.00 if they treat thirty patients). Depending on the results we can, anytime, hold off on treating additional patients or, by obtaining additional funds, speed up the process.
Valerie Harper Page 2
As you know, the report on our first two cases is in print in a medical journal. Dr. Spletzer is already working with me on a scientific publication of the first eight cases. As these are presented and published, and our results with new cases are satisfactory, financing and rapidly increasing the number of patients treated will not be a problem. Not stated in the budget are expenses for developing programs in other countries. We are in conversation with the U.S. Army Medical Research Institute and they are establishing contacts for us in Bangkok. This activity can be considered as we progress. I understand that without outside help immediate funding may have to be limited. Further, I understand funding will depend on the discussions you and David will have about availability. I will greatly appreciate your advice and recommendations.
encl.
-,
February 20, 1996 Mr. Stephen Foster President Charles A. Dana Foundation 745 Fifth Avenue, suite 700 New York, NY 10151 Dear Stephen:
VALERIE, FOILCWS ARE 3 PAGES OF 1996 BUDGET SENT TO MR.
FOSTER 2/ 20/ 96 .
IAST THREE PAGES OF THIS FAX IS THE 1997 BUDGET .
2368 VICTORY PARi<:NAY SUITE410 CINCINNATI OHIO 45200
513-221-C002
fax 513-22WXl3
Per our conversation today, enclosed you will find our protocol for the Malariatherapy for HIV+ patients, and a proposed budget. In addition to contributions we receive from individuals, the following are some of the foundations that have supported our research: William P. Anderson Foundation John C. Griswold Foundation Donna Mills Charitable Foundation Fannie E. Rippel Foundation Thrasher Research Fund Combined Federal Campaign Paul Winchell Joseph & Helen Regenstein Foundation Shipley Family Foundation, Inc. We have always been fortunate that additional support comes whenever we have started a project. This has been due to the success and credibility of our various projects. The results generate confidence. Our desire and plan is to treat 100 patients. There is no doubt that if the results continue to be in accordance with those patients in China, this will be a much sought after method. Two physicians with whom malariatherapy project are: you may wish to discuss our
Neal Barnard, M.D. (202) 686-2210 President, Physicians Committee for Responsible Medicine John Parks Trowbridge, M.D. (713) 443-2584 Past President, Great Lakes Assn. of Clinical Medicine
Benefiting Humanity Throug Health and Peace
\::n~~t~t~_ -~-~---M.D. Institute
If wel~n provide f~rmation, please do not hesitate
DETAILED BUDGET FOR INITIAL BUDGET PERIOD JANUARY 1,1996 - DECEMBER31, 1996
PERSONNEL NAME Henry J. Heimlich, M.D. Eric Spletzer, Ph.D.
ROLE ON PROJECT Principal Investigator Research Coordinator Heimlich Institute Research Coordinator & 7-10 Staff China
% EFFORT
ON PROJ.
SALARY REQUEST
FRINGE BENEFITS
TOTAL
75% 100%
-0$60,000
-0$12,000
-0$ 72,000
To Be Named
100%
$50,000
-0-
$ 50,000
To Be Named
Research 100% Coordinator & 7-10 Staff Central America
$50,000
-0-
$ 50,000
TOTAL PERSONNEL COSTS:
$172,000
EQUIPMENT: (Startup costs ONLY for first year of grant) Medical PCR Vironometer Flow Cytometer Centrifuge Flourescence Microscope Analytical Balance Magnetic Stirrers Antigens and Reagents included in patient costs
$ 85,800 $156,000 $ 14,000 $ 10,000 $ 2,395 $ 1,000 $ -0-
Office
2 Fax Machines 3 Computers w/software & modem (includes hardware, statistical and medical software, database management, printers, modems, wiring, setup and programming for compatibility between US, China and Central America) Copy machine
$ 600 $20,000
$ 1,000
TOTAL EQUIPMENT COSTS:
$290,795
- - - -- - ----- ---- - - - - - - -- --
- -
DETAILED BUDGET FOR INITIAL BUDGET PERIOD JANUARY 1, 1996 - DECEMBER 31, 1996 Page Two SUPPLIES: Medical (included in patient costs for all three years) Office $ 5,000 TOTAL SUPPLIES COSTS: TRAVEL Henry Heimlich, M.D. -- trips to China & Central America Eric Spletzer, Ph.D. Research Coordinator - China Research Coordinator - Central America $10,000 $ 5,000 $10,000 $10,000
$ 5,000
TOTAL TRAVEL COSTS: PATIENT CARE COSTS: $10,000 per patient x 100 patients (includes treatment, hospitalization, laboratory tests, follow-up physicals and laboratory tests for 2 years)
$ 35,000
We will be treating the 100 patients in the timeframe below: 40 patients in year 1 40 patients in year 2 20 patients in year 3 $400,000 $200,000
$400,000
OTHER EXPENSES: Central Office Space Central Office Telephones & Faxes Postage & Federal Express for all 3 locations Central Office Bank Charges for wire transfers $ 11,000 $ 3,000 $ 1,500 $ 500
$ 16,000
TOTAL OTHER EXPENSES:
TOTAL COSTS FOR INITIAL BUDGET PERIOD:
$918,795
BUDGET FOR ENTIRE PROPOSED PERIOD OF SUPPORT January 1, 1996 - December 31, 1998
BUDGET CATEGORY TOTALS
1ST YEAR
$172,000 $290,795 $ 5,000 $ 35,000 $400,000 $ 16,000
2ND YEAR
$189,200 $ -0$ 5,500 $ 38,500 $400,000 $ 17,600
3RD YEAR
$ 197,BOO $
-0-
PERSONNEL EQUIPMENT SUPPLIES TRAVEL PATIENT CARE COSTS OrnER EXPENSES
$ 6,000 $ 40,250 $200,000 $ 18,400
TOTAL COSTS FOR ENTIRE PROPOSED PERIOD OF SUPPORT:
$918,795
$650,800
$462,450
JUSTIFICAnONS:
DETAILED BUDGET FOR BUDGET PERIOD JANUARY 1, 1997 - DECEMBER 31, 1997
PERSONNEL NAME Henry J. Heimlich, M.D. Eric Spletzer, Ph.D.
ROLE ON PROJECT Principal Investigator Research Coordinator Heimlich Institute Research Coordinator China
SALARY % EFFORT ON PROJECT REQUEST
FRINGE BENEFITS
TOTAL
75% 50%
-0$30,000
-0$6,000
-0$ 36,000
Dr. Hung Shun Hua (of Los Angeles)
50%
$25,000
-0-
$ 25,000
Secretarial & Administrative
50%
$26,000
$2,000
$ 28,000
TOTAL PERSONNEL COSTS: $ 89,000
SUPPLIES: Medical (included in patient costs for all three years) Office $ 5,000 TOTAL SUPPLIES COSTS: TRAVEL: Trips to China & Medical Conferences Henry J. Heimlich, M.D. Eric Spletzer, Ph.D. Research Coordinator - China $ 10,000 $ 5,000 $ 10,000
$
5,000
TOTAL TRAVEL COSTS:
25,000
Detailed Budget for Budget Period January 1, 1997 - December 31, 1997 Page 2
PATIENT CARE COSTS: $10,000 per patient (includes treatment, hospitalization, laboratory tests, follow-up physicals and laboratory tests for 2 years) We plan on treating patients in the timeframe below: 30 patients in year 1 20 patients in year 2 20 patients in year 3 OTHER EXPENSES: Central Office Space and Equipment Usage Central Office Telephones, Faxes, Computers, Postage & Federal Express Central Office Bank Charges for Wire Transfers
$
$ 300,000
$ 200,000
$ 200,000
13,000
7,000 500
$
TOTAL OTHER EXPENSES: TOTAL COSTS FOR INITIAL BUDGET PERIOD (Year One):
20,500 439,500
**
BUDGET FOR ENTIRE PROPOSED PERIOD OF SUPPORT

January 1, 1997 - December 31, 1999 Page 3
BUDGET CATEGORY TOTALS
1ST YEAR
2 10m YEAR
3 RD YEAR
PERSONNEL SUPPLIES TRAVEL PATIENT CARE COSTS OTHER EXPENSES
$ 89,000 $ 5,000
$ 98,800 $ 5,500
$ lO8,000 $ 6,000 30,250
$ 25,000 $ 300,000 * $ 20,500
$ 28,500 $ 200,000
$ 20,500
$ 200,000
$ 20,500
TOTAL COSTS FOR ENTIRE PROPOSED PERIOD OF SUPPORT:
$ 439,500 **
$ 353,300
364,750
*
**
Actually $60,000 in this calendar year, remainder spread over two years . Actually $199,500 in the calendar year
MEMORANDUM
TO: FROM:
DR. HENRY HEIMLICH VALERIE HARPER
DATE: SUBJECT:
JANUARY 3, 1997 MALARIA IMMUNOTHERAPY PROJECT
Thank you for being my guru on all matters. As I mentioned to you on the telephone, I think the ~ article is fair in that AZT and Protease Inhibitors have for some people prolonged their life and quality, which heretofore, has been impossible. Also, it is well documented. On the positive side, it makes our project easier with the CD-4 levels we received from China to interest, for example, a Mr. Modell. Thanks for doing the "Essential" and "Optimal" cash-flow projection for the Trust. I believe it will be very timely. Best regards, as always, to you and Jane.
attachment
January 8, 1 H9 7 John L. Fahey, M.D. Direct.or

Evelyn G. Najf~ra, MPH
Manager
Fogarty Prngr8rJl
CIRID at UCLA
10833 La Contn Avenue Los Angeles, CA 90024-1747 The UnitAd States Doar Dr . Fahey
Li!)(J
Ms. Najera:
Did you receive my fax attached U . . e operation routine of APAAP
method and the address of Professor Yu Chun Shan on December 30, 1996? I am urgent to have an invitation letter with your signature and the mention of financial support for me to deal with my passport otherwise I would be too late to attend the Fogarty Program because somethings progress slowly in
China . Would you please fax it and then Federal Express its original to me. It wilf be a big help to me. I am Federal Expressing the original letter and the attached application meterials that you request, please checklist:
1. 2. 3. 4. S. 6. 7. 8.
My letter: tow pages . Dr. Xiao Bin Quan's recommendation letter: two pages. Dr. Chen GlJan Jin's recommendation letter: two pages. Assurance letter by my President, Dr. Xiao: one page. The resume "CHEN XIAO PING": five pages. My certificate of degree: one page. My curriculum vitae of graduate student: one page. Application forms: pages 1-5.
-1-
From : , Ci kUcJ=p>ek 5Ud,="( i Zh"m
PHOI1E llo.
0085 20 3828281
Jan, 10 1'397 10: 34AI'1 F'(32
I look toward to IH~ariflg from you.
Sincerely,
Ckr1 rt<'etV j~~) .
Dr. Chon Xiao Pinq <::_-' Director, Dopurtnwnt of Microbiology The Municipal Health and Anti , Epidomic Stc'3tion of Gunngzhou No . 23, 3rd Zhonqshan Road Guangzhou 510080 The people's Republic of China
-2-
MEMORANDUM
To: From:
Date:
Valerie Harper \;\ /
V~\ Henry J. Heimlich, M.D., Sc.D.j ',\ 1\ \ .\,

~ ~
t \
\ ,,} '< } \ . t(
. I
January 8, 1997
'J
Attached is an accounting of the expenditures for the malariotherapy/AIDS program for the period May-December, 1996. Please note, this is from the Heimlich Institute ledgers which have not yet been audited by our accountants, Arthur Andersen & Co. Their audit is based on a June I-May 31 fiscal year. The total expenditures are $69,394.23. As you know, from the recently submitted budget, anticipated expenses for the 1997 calendar year are $199,500.00. Consequently, a grant of $150,000.00 will carry the program through this year and into 1998. However, there are several variables. Thirty patients are scheduled for treatment starting in July. We plan to treat ten patients at a time, with one to three months between patient groups, but the number could be somewhat more or less. The report on the first two patients followed for two years is in print in a medical journal and will be coming out any day. We are also in the process of preparing another report on the eight patients treated thus far and followed for two years or more. They received three weeks of malariotherapy. Seven had an increase in CD4 T cells at the end of the treatment and have sustained the increase without any other treatment! No other procedure for HIV patients has come close to accomplishing this. Based on the results, we are justified in treating 100 patients as soon as is feasible. It is also our goal to initiate inquiries into treating patients within the United States. As we have discussed, these efforts will require substantial funding. I know David appreciates this from his mentioning possible external forms of financing at the Board meeting luncheon and to me.
The Eleanor Naylor Dana Charitable Trust Grant
ElINDS RECEIVED
May 8, 1996 August 16, 1996 Total
$ 50,000 $100,000 $150,000
DISBlJRSEMENTS Use of
Month
May June July August September October November December
Eacil.i4'
433.34 450.00 450.00 450.00 450.00 450.00 450.00 450.00
fhoru:
150.00 120.99 157.72 130.32 144.64 150.00 203.84 75 .0
fus1age 240.50 206.34 908.50 139.00 149.00 110.50 178.50 50.00
Supplies 41.70 189.60 91.55 98.72 30.70 132.02 84.28 30.52
Salaries 4418.24 8240.43 6373.66 4496.07 7129.76 1614.94 5018.84 5949.06
IraYci
1315.75 668.60 1528.95 500.14 337.50
Equip..
-0-0-0-0-0-
Thtal
6599.53 9875.96 8431.43 5914.25 8241.60
1261.63 7942.50 11211.59 1202.06 1104.35 -0323.64 7137.53 7982.34
Totals
3583.34
1132.51
1982.34
699.09
43241
7918.98 8266.14
65394.23 400000 69394.23
Interval Payment to China - 11/19/96 Total Disbursements
FACSIMILE TRANSMISSION COVER:
DATE:
TO:
2368 VICTORY
PAR~AY
LOCATION:
SUITE 410 CINCINNATI OHIO 45200 513-221-00J2 fax 513-22HXXl3
FROM: PERSON . SENDING:
NUMBER OF PAGES TO FOLLOW: RE: If you do not receive all of the pages indicated above, please call the above-named person at (513) 221-0002.
Memo
To: From:
Memo to File Henry ~.. Heimlich, M.D. February 7, 1997
Date:
Last night I spoke to Colonel Brewer in Bangkok. Dr. Brewer said that they had forwarded some material through Washington to me, but I have not received it. He received several replies from the Thai professors with an expression of interest and will have Dr. Ed Brown send them directly to me. Dr. Brown is now in Cambodia. He will be my contact because he originally worked in the field of malaria and now is working in the AIDS project. Brigadier General Zajtchuk arranged the contact with Dr. Brewer.
February 10, 1997

2368 VICTORY
PAR'lYiAY
SUITE 410 CINCINNATI OHIO 45200
513-22HXXl2 fax 513-22HXXl3
Dr. James McIntyre The Reproductive Health Research Unit P.O. Box 1477 Johannesburg 2000 South Africa Dear Dr. Mc Intyre: I am writing to you at the suggestion of Dr. Drew E. Altman, as per the enclosed letters. I am aware of the high level of medical practice in South Africa, and I believe that it would be an excellent place to carry out malariotherapy for HIV infected persons. We have a grant which funds this research, and are prepared to go ahead with it. I am free at our mutual convenience to travel to South Africa if interest is shown. Please advise me of your thoughts through the address, phone or fax numbers shown on this letter, qr to our e-mail <!.ddress:heimlich@iglou.com.
I !
Sinceret,
. I ,
!
I
I
. ~~
~ '
sident The Heimlich Institute Enclosures c.c. Michael R. Sinclair, Ph.D.
1450 G
STIU!ET NW, SUITE
250
WASHINGTON,
DC 20005
January 8, 1997
2023475270 Eu 202 3475274
Mr. Henry Heimlich, M.D., Sc.D.
The Heimlich Institute 2368 Victory Parkway Suite 410 Cincinnati, OH 45206
Dear Dr. Heimlich:
Dr. Altman shared your letter of November 21, 1996 with me. I suggest you contact Dr. James Mcintyre: The Reproductive Health Research Unit P.O. Box 1477 Johannesburg 2000
South Africa Tel: 11-407-6780 Fax: 11-403-3214

Dr. Mcintyre is very well placed to facilitate your further contact with South Africans' in the AIDS field.
Sincerely,
{b~
Vice President
FOUNDATION HEADQUARTERS :
2400
SAND HILL ROAD
MENLO PARX, CALIFORNIA 94025
. .)
" 41585-4 9400
WHITE & CASE

UNITED STATES
LOS ANGELES
M I AMI NEW YORK
1155 AVENUE OF T HE AMERICAS NEW YORK, NEW YORK 10036-2787 TELEPHONE: (1-212) 819-8200 FACSIMILE : (1-212)354-8113
ASIA
ALMATY
ANKARA
BANGKOK BOMBAY ... ANOI HONG KONG JAKARTA SINGAPORE TASHKENT TOKYO
WASHINGTON , D . C .
EUROPE
BRUSSELS BUDAPEST HELSINKI ISTANBUL LONDON MOSCOW PARIS PRAGUE STOCKHOLM WARSAW
DIRECT DiAl: 212-819-8516
MIDDLE EAST
JEDDAH RIYADH
AFRICA
JOHANNESBURG
LATIN AMERICA
MEXICO CITY
February 14, 1997
Dr. Henry Heimlich President Heimlich Institute Foundation 2368 Victory Parkway Suite 410 Cincinnati, Ohio 45206
Dear Dr. Heimlich: I am pleased to enclose a check in the amount of $100,000 representing a grant from the Eleanor Naylor Dana Charitable Trust in support of the work of the Foundation. Please acknowledge receipt on the enclosed extra copy of this letter. Sincerely,
Edward F. Rover EFR:bhr Enclosures cc: Ms. Patricia Mangini Ms. Valerie Harper
February 19, 1997
2368 VICTORY PARKWAY SUITE 410 CINCINNATI OHIO 45206 513-22HXXl2 fax 513-22HXXl3
Edward F. Rover, Esq. White & Case 1155 Avenue of the Americas New York, New York 10036-2787 Dear Mr. Rover: We received the generous grant from the Eleanor Naylor Dana Charitable Trust to the Heimlich Institute in the amount of $100,000. Be assured that your grant will be used to further our research as expeditiously as possible. Your donation will help us continue our quest to save lives through research, education, and creative thinking in solving the problems facing each of us.
It is through such caring support that our endeavors can progress in finding treatments for otherwise incurable diseases. Thank you again.
As requested, I am enclosing a signed acknowledgment of this grant.
~Siun/~:#)
Jo.an Steinberg Duector Enclosure cc: Ms. Patricia Mangini . Ms. Valerie Harper (
February 20, 1997
RlUllIIA1Di.IfC.
2368 VICTORY PAAr::NAY
SUITE 410 CINCINNATI OHIO 45200
HEIMLICH INSTIrUTE
John L. Fahey, M.D. Director of CIRID at UCLA Department of Microbiology & Immunology UCLA School of Medicine Center for the Health Sciences 10833 LeConte Avenue Los Angeles, CA 90024-1747 Dear John: I have heard from Dr. Chen Xiao Ping that he will be arriving at UCLA on March 23. I am pleased that he has this opportunity to work with you. It will greatly enhance the, program when he returns to China. Perhaps I will come out and visit when he is there. Dr. Hua has recently spoken with Chen and I believe it is his intent to bring blood samples of treated patients for analysis. Many people interested in our research would like to know about our affiliation with you, and I am not sure how you would wish to express it. Perhaps you could advise me on that matter, or would care to give me a call so that we can discuss how it can best be described. Hope all is well. Best wishes,
THE
513-221.ffi)2 fax 513-22HXXl3
oHeim!,MoDo
-:
UNIVERSITY
BERICELEY DAVIS
OF CALIFORNIA,
IRVINE WS ANGELES
LOS ANGELES
RNERSIDE SAN DIEGO SAN FRANCISCO SANTA BARBARA
UCLA
SANTA CRUZ
"Center for Interdisciplinary Research in Immunology and Disease

DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY UCLA SCHOOL OF MEDICINE CENTER FOR THE HEALTH SCIENCES 10833 LE CONTE AVENUE LOS ANGELES, CALIFORNIA 90024-1747
March 6, 1997 Henry J. Heimlich, M.D. President The Heimlich Institute 2368 Victory Parkway, Suite 410 Cincinnati, OH 45206 Dear Henry:
(310) 825-65~& _ . (310) 206-1318 (FAX)
I was pleased to have your recent letter. Indeed, we are looking forward to meeting Dr. Chen Xiao Ping and having him here this spring. We had told him that we would be pleased to help him analyze. any specimens that he brings from China in connection with HlV studies conducted there .. It occurred to us that you might like to have him visit you in Cincinnati. We can be flexible here about the arrangements. It might be more interesting if he came after the course here, and you could review the findings and discuss future plans, with the added benefit of the experience he has had here. Of course, you are welcome to visit anytime. I would like to help you in any way that I can. Certainly our association has been stimulating and mutually rewarding. I would be glad to discuss whatever description would be appropriate to meet your needs. I could call after March 17, as I have a pending grant deadline and a meeting 'out of town before that date.
JohllL. F' ~y,:M~D ... .: :'_: .. " . Director CIRID* at UCLA

,.-' ,:.'. " .,' !.' -, .:, ..
'.'
"":
:.::
Chair, Clinical
JLF/dm
Union of Immunological Societies (lUIS)
InllIlunoldgy
','
... ,".
.....
'
'.
.'
.,
",
Committee, International
.,..
v
..........
TRANSMITTAL
2368 VICTORY PARKWAY SUITE 410 CINCINNATI OHIO 45200 513-221.(X))2 fax 513-22HXXl3
facsimile
~------------------
To:
Of:
Valerie Harper The Eleanor Naylor Dana Charitable Trust (212) 754-2892 2, including this cover sheet. March 14, 1997
Fax: Pages: Date:
We keep making progress!
Health
and
From the desk of... Henry J . Heimlich , M.D. THE HEIMLICH INSTITUTE
Peace
<)
,
OHIO DEPARTMENT OF HEALTH
246 N. HIGH STREET Post Office Box 118 Columbus. Ohio 43266-0118 Telephone: (614) 466-3543 GEORGE V. VOINOVICH Governor PETER SOMANI. M.D.. Ph.D. Director of Health
MAR 1 0 1991
Henry 1. Heimlich, M.D., President The Heimlich Institute 2368 Victory Parkway, Suite 410 Cincinnati, Ohio 45206
Dear Dr. Heimlich:
It was indeed an honor and pleasure to have you visit me and other staff at the Ohio Department of Health_I was most delighted to hear first hand about the new application of the Heimlich procedure to treat asthma. I believe that both ODH and Medicaid should be interested in supporting your project. I have talked briefly to Mr. William Ryan, Medicaid Director for Ohio about this project, and shall be sending to him you fiscal proposal as soon as I receive it from you.
I believe that we can find support for your project to carry out a sound clinical study to determine the effectiveness of the Heimlich procedure in management of asthma. I am also intrigued by your preliminary data on the effect of malaria in the treatment of AIDS, and as I indicated to you, I shall be contacting Dr. Hutton of University of Cincinnati College of Medicine to include this topic during our meeting on Monday, March 17. I shall also contact you regarding the possibility of working together on this project in India and Asia.
Many thanks for taking time from your very busy schedule to visit with us. With best regards, Sincerely yours,
~~~,
Peter Somani, M .D ., Ph.D. Director of Health
HEA 6413 (Rev. 5/93)
An Equal Opportunity Employer/Provider
UNIVERSITY
BERKELEY DAVIS IRVINE
i'
OF CALIFORNIA,
LOS ANGELES
LOS ANGELES
RIVERSIDE SAN DIEGO SAN FRANCISCO SAi\'TA BARIlAIIA
UCLA
SANTA CRUZ
*Center for Interdisciplinary Research in Immunology and Disease

DEPARTMENT OF \lICHOBIOLOGY AND IMMUNOLOGY UCL.A SCHOOL OF ~EDICINE CE:"iTEH FOH THE HEALTH SCIENCES 10833 LE CONTE AVE!'<UE
March 27, 1996
LOS A\:CELES
(310) 825-6568 (310) 206-1318 (FAX)
CALIFOHNIA
90024-1747
\(f_v;._~'~
.
~<X:.A ..~~~~
I~
'7. 0~~
\}_~Z~~
-1p~
~~I!c
Dr. Xiantao Kong D~o'l Clinical Immunology Center Changzheng Hospital ) ? L A Shanghai 200003, CHINA Dear Professor Kong:
:-1J
/ I
f'>-_
..
Thank you for your recent letter. We are pleased that the article on, "Clinical Immunology ., A Distinct Area of Immunology," is of interest to you. You certainly have my permission to translate the article into Chinese and to publish it in China. I hope it will be helpful. In the United States, Clinical Immunology is undergoing substantial development and facing new challenges in the area of Clinical Care Immunology. It is generally regarded as a subspecialty of both Internal Medicine and Pediatrics. Thus, it does not compete with these two large areas of Clinical Medicine but contributes significantly to each. There are suggestions that Clinical Irrununology could be accommodated well in conjunction with both Allergy and, especially, the autoimmune aspects of Rheumatology. I am enclosing an article by Robert Rich, M.D., that was published in the December issue of the Journal of Immunology that addresses this issue in a creative manner,
,."
.......
,
'.
~
c
.
{)",.I,.""/,, ../, ......,'" (;,." ,.,.." ..
. " . , ..
April 29, 1997
2368 VICTORY PARor::NAY SUITE 410 CINCINNATI OHIO 45200
513-22HXXl2
fax 513-22HXXl3
John L. Fahey, M.D. Director of Center for Interdisciplinary Research In Immunology and Disease UCLA School of Medicine Center for the Health Sciences 10833 Le Conte Avenue Los Angeles, CA 90024-1747 Dear John: I have spoken with Dr. Chen Xiao Ping and he is greatly appreciative of your program. As per your letter of March 6, 1997, I would like to suggest the following description of our association based on your letter of August 8, 1996: The University of California, Los Angeles (UCLA), and The Heimlich Institute of Cincinnati, have established an affiliation for the treatment of HIV patients using malariotherapy. The Heimlich Institute is carrying out a clinical study, treating HIV patients with malariotherapy, in Guangzhou, China at The Municipal Health and Anti-Epidemic Station of Guangzhou. UCLA has the capacity to measure most of the cytokines in circulation as well as the capacity of peripheral blood mononuclear cells to produce cytokines under various forms of stimulation. These will be used to assess selected patients treated with malariotherapy. Secondly, a Fogarty International Center (NIH) AIDS International Training and Research Program (AITRP), at UCLA, is increasingly involved with studies with intervention and quality control efforts. AITRP is helping the Chinese colleagues of The Heimlich Institute to carry out their studies. UCLA is also providing assistance with reagents and quality control samples for CD4 measurements as well as other parameters of HIV infection.
In March, Dr. Chen Xiao Ping, Chief, Department of Microbiology, The Municipal Health and Anti-Epidemic Station of Guangzhou, commenced studies at UCLA where he is attending lectures and participating in laboratory work. July 1, 1997, the Guangzhou Health Station will take over the duties of the Public Health Service of Hong Kong. John L. Fahey, M.D., is Director of the Center for Interdisciplinary Research in Immunology and Disease (CIRID), UCLA. Henry J. Heimlich, M.D., ScD:, is President of The Heimlich Institute.
I am sure, John, you can put this in better lay terms and I will appreciate your thoughts.
A PHASE I-II STUDY OF MALARIOTHERAPY FOR HIV/AIDS

XlAO PING CHEN, MD
Trainee of Fogarty AIDS Interational Training and Research Program At Department of Microbiology and Immunology, School of Medicine University of California, Los Angeles, U. S. A.
RESEARCH PLAN
May, 1997
Chief, Associate Professor, Department of Microbiology The Municipal Health and Anti-Epidemic Station of Guangzhou ( Public Health Center of Guangzhou ) No. 23, 3rd Zhongshan Road, Guangzhou 510080, the People's Republic of China Phone number: (020) 8382829l. Fax number: (020) 83815255
A PHASE I-II STUDY OF MALARIOTHERAPY FOR mY/AIDS XIAO PING CHEN, MD SPECIFIC AIMS To determine whether malariotherapy (MT, an old therapy used for the treatment of neurosyphilis) changes the clinical and laboratory parameters of mv /AIDS patients. 1. To determine the safety of malariotherapy for HfV /AIDS by observations of side effects and complications. 2. To determine the effects on CD4 counts, HfV loads and cytokines and soluble activation markers during the malarial phase ( MT ) 3. To determine whether after termination of treatment by MT, a. CD4 counts will increase. b. HfV viral loads will decrease. c. Cytokines and activation markers (Ams) will significantly decrease to around normal level.
MT
Termination ofMT
Fig. 1. AMs' dynamics ofMT (Hypothesized by Chen)
._._._._._._._._._._._._._._._._._._._. High level of AMs in mv patients

L.....-
Normal AMs level
4. To determine whether or not changes in CD4 counts, viral loads and cytokines and activation markers after MT are different in patients stratified by CD4 numbers (>500,500-201, 200-51/mm3 ). 5. The extent and duration of changes of the parameters will be determined.
-1-
BACKGROUND AND SIGNIFICANCE 1. Malariotherapy for neurosyphilis Malariotherapy was discovered by Dr. Wagner-Jauregg in 1917. He won the Nobel Prize of Medince in 1927 due to his great success of the therapy for neurosyphilitics. This therapy had been used until 1975 and combined with penicillin since which was invented. 2. Malariotherapy for cancer a. Epidemiology: Malarial prevalence adversly correlates with the prevalence of tumors. b. Clinical trials: During 1950s, 19 advanced cancer patients were treated with malariotherapy in Germany, it was claimed to be effective. During 1991-1993, we treated 7 advanced cancer patients with this therapy, finding that it was effective in treating breast cancer and Kaposi sarcoma. c. Complications ofMT in our cancer patients were not severe: Among 7 cases, one complicated anemia, Hb from 124gIL at pretreatment decreased to 74gIL at termination of malaria; another complicated thrombocytopenia during malarial phase, but both recovered to baseline quickly by transfusions of whole blood and platelet respectively, did not need to terminate malaria before completion of MT' One case complicated bronchial asthma during malarial phase, needed to terminate malaria before completion of the therapy, but recovered quickly after termination ofMT. No complication occurred in other 4 cases. 3. Antiretroviral therapies for HIV/AIDS: a. Nucleoside reverse transcriptase inhibtors: Zidovudine (ZDV, AZT), Didanosine (DDI), Zalcitabine (DDC), Stavudine (d4T), Lamivudine (3TC). b. Nonnucleoside reverse transcriptase inhibitors: Nevirapine (NVP), Delavirdine. c. Protease inhibitors: Saquinavir, Ritonavir, Indinavir (illV). d. Antiretroviral combination therapies: Potential for greater suppression of viral replication than with monotherapy e. Effectiveness: Clinical improvement, viral load decrement for a half to two years; no change of CD4 count ( mv can temporarily increase CD4 count ). f. Gaps of antiretroviral therapies: HIV mutation, drug resistance and transient effectiveness.
-2-
4. a. b. c. d 5. a.
b.
c.
d. e. b.
Immune-based therapies: Interferon-a (IFN-a): Inhibition of Hl V assembly and release. Recombinant soluble CD4 (rsCD4): Blockage ofIllV binding to CD4 cell. Recombinant human interleukin-2 (rhIL-2): Increasing CD4 cell. Combination therapy of immune-based plus antiretroviral therapy: Potentiation of CD4 cell increment with suppression of Hl V replication. Evidences of the proposal of malariotherapy for IllV IAIDS Report 1: 71 AIDS patients died at the rate 35%, but 41 AIDS patients coinfected malaria, nobody died in the same observed period. Report 2: HfV -like virus infection decreases the mortality of experimental animals with malaria. Report 3, 4, 5: In Venezuela, Indonesia and Philippines, malarial endemic regions, HIV -like antibodies existed, but no AIDS patients in these regions and AIDS did exist in nearby non-malarial areas. A lot of reports: Malaria does not accelelate HfV infection progress and neither HfV infection deteriolate malarial patients. Safety of malariotherapy has been confirmed by: Hundreds of thousands neurosyphilitics treated with the therapy. 8 HIV patients treated by us with this therapy, no any complication occurred. PRELIMINARY STUDIES
Our preliminary results of malariotherapy for 8 HIV patients have been recently published in Mechanisms of Ageing and Development: 1997, 93: 79-85. 1. CD4 dynamics: Table 1, HIV 2atient CD4 counts { cells/mnr' }*
CD4 at: Pre-treatment Post -treatment 6 months 12 months 18 months 24 months 30 months Case 1 889 853 1162 1258 1072 941 1697 Case 2 269 527 953 656 864 650 1199 Case 3 1610 979 750 510 1151 Case 4 731 1183 1631 465 2062 Case 5 1868 1248 1813 630 2422 Case 6 1056 1000 875 665 Case 7 924 600 1260 1081 Case 8 705 826 572 842 570
* CD4 measurement
were made by Chinese AP AAP ( enzyme link ) method.
-3-
2.
3.
Dynamics of serum neopterin (NPT, nmollL), beta-2 microglobulin(B2M, mg/L) and Hl V P24 antigen (pg/ml, case 1, 3, 4, 5 and 6 were undetectable in all times; case 8 was 13 pg/ml at pretreatment and 27pg/ml at 3 months follow up) are shown in page 5-7. Plasmodium vivax ( Pv ) malaria manifestations were not more serious than those ( HIV negative) Pv malaria that we observed in our previous clinical practice; no any complication occurred. DESIGN AND METHODS
1. Design: An open label single center phase I-II study of malariotherapy for mv infected patients. 2. Sample size: 10 subjects with entry CD4 counts >50 cells/mnr'. 3. Population: mv infected adults with entry CD4 count >50 cells/mar' ( stratified by CD4 numbers, >500,500-201,200-51 cells/mnr' ) who are anyantiretroviral and immune-based therapies naive at entry, but not excluding traditional Chinese medicine therapy. 4. Pv malarial blood sourses: Thin and thick blood smears confirmed Plasmodium vivax, strictly excluding Plasmodium falciparum exist and blood specimen tests for excluding HIV, hepatitis B virus, syphilitic spirochete and other bloodborne pathogens exist. 5. Regimen: Inoculation of Plasmodium vivax by intraveneous injection of 10 CC malarial blood. Observations and recordings of incubation ( malaria) and clinical manifestation; termination of malaria with chloroquine after 10 malarial high fever episodes and in case any severe complications. 6. Schedule of events: See APPENDIX I.
-4-
-00
"l
Co> 111
\
....
01
"l
m
-00
01
m
111
"l
iO
3::
Q.
iO
\
-,
-,,--, ~-.---
3::
\~\
\
-0
01 ".
:> 0
i.>
0
-0
..
I>
3
Co> 111
"l
Co> 111
"l
3 0
III
.-+ (!)
3::
/1
"'m (j')
3::
0
CD
3 0 m III .-+ 3
Z
""D -of
t
<0
co
t
""D -of
(!)
to
<0
m
3
CD
--10.
N
3 OJ
3
a;
3
"l
....
3
z
"l
Z
""D -of ""D -of
....
30 0 0
"l
Co> 0
....
0
01 0
m
0
Co> 0 30 0
I;)
Co> 0
....
01 0
m
0
Vl
I
-00
....
01
m
111
"l
-00
iO
iO
3::
Q.
:> 0
"C
V.
~
"C
0\
~
111 N
3
3::
0
0
III
.-+ (!)
111 N
3::
Co>
0
03
m (j')
z
t
""D -of
CD
~
Co>
.-+ (!)
III
m
""D -of
o:
z
3
CD
I\) N
3
OJ
3
N
....
z
N
....
""D -of 30
I;)
Co> 0
....
01 0
m
0
Co> 0 30
,.
0 N 0 Co> 0 0
""D -of
m
01 0 0
..
,,0
J>
01 III ?;:
I
O!
,,0
01
O! III ?;:
..
'"
..
'"
" '"
" ~
1/
\ t\
\ \
III
hJ
'" 3
III
'" 3
0
..-+ (T)
!l: '" !l:
Cl
Q:l
..-+ (T)
0 m
(j')
Q:l
\1/
.
0 m
(j')
z
"l1 -I
t
CD
3 '"
-J
t
"l1 -I
3 '"
.! I If
0; 3
.~
~
Z
J>
CD
()l
0; 3
z
"l1 -I 01 0 O! 0
hJ J>
"l1 -I
30
0
a
'"
0 '"
..
'" 30
hJ
J>
01
,,0
0 '"
'"
0\
I
'1:!0
l'l
..
'"
III
l'l
..
!l:
'"
III
hJ
?;:
.. "
'" 3
III
l'l
'" 3
?;:
III
l'l
0
Q:l
0 m
(j')
Z
"l1 -I
!l:
..-+ (T)
0
III
CD
<0
co
S
3
Z
"l1 -I
<0
....
0 m
(j')
(T)
CD
(j)
3
z
J>
z
"l1 -I
"l1 -I
'" 30
l'l
J>
0; 30
0
l'l
J>
'" 0
01 0
O! 0
'" 0
01 0
'"
~o
"'17
"l
..
a a a
'"
a
0
a a
0;
"l
"l
'"
IC :J
Z
'"
:J
0 .~
<,
.. .. ~
0.
:J IC
'0
'""1 (l>
"r
,I
..
'0
'""1 (l>
C>
.'""1
(l>
3 \ 0_
III
"l
(
0
(j)
' I I I
Pl
e-e-
B (l> ~
"'17
"l
:;:l
\\
\
I I
0...
..
<D
3 0; 3
//
CD
I'\)
:;:l OQ
0...
c
:;:l (JQ
::1.
..... '""1
"l
(l>
Pl
.....
B (l> :;:l ......
0
..
a '"
.....,
-.l
I
~ ~~
"0
(J)
.....
'0 0
(J)
a a
'"
...... .....
'""1 (l>
a a
"l
"l
'"
Pl e-e-
"'1J
"l
:J
B (l>
Q :;:l .....
.. .. ..
:J
~
Pl
-.....
e-e(l>
:::::r'
..... (l>
.
0
"'17 III
3 '"
:;:l Pl e-e-
0
P> O
:;:l
"l
..
0 .....,
r+ (!)
o:
CD
to
-.....J
~
'-"
0; 3
o ...... ~ ~~~
~
6 P:> ~-~ ....

+
til
'""1
'#
P - 3 >- 0 No 0..
I r-1-
_- t:
_.
~ ~ ;:J
Po ~
I ......
0\ P:>
_-
g_3~
t:j
r'""1
;:J
3 __ < <
+
+ + + + + + + + + + +
+ + +
+ + + + + + + + + +
'"0
+ + + ~ ;:J
Q~
'""1
P:>
_-
::s
0 0
....... ~
'"
o
'1::! ::::1"-0
- - p;-
;2
t:
+ + + + + + +
+ +
~ ::s ...... ~
0..'1:1
~ ::s 3 ~.
P:>
0..
+ + + + + + + + + + + + + + + + + +
+ + + + + +
~<
0
~ 0
'"0 P:>
?;
'1::!
::s~ o ........ ~ :I. ~
+ + + + + + + + + + + + + + + + + +
0..
~,
trJ
w (t' ......
? ~
8
>< .......
< ~ ~
'""1
.......
tog ~ til S ~
_.
(/)
()
@
(t'~
00
I
< ~ ::r
'""1
+ + + + + + + + + + + +
+ +
(t' .......
<
~ ::r
S?
+
+ +
~ trJ 0
'"r1
trJ
0..0
~g: 0
0
~
'""1
z >-3
(/)
+ + + + + + + + + + + + + + +
0..
r!< .......
0
+ +
+ + + + + + + + + + + + + + + + +
+ +
+ + +
.......
+ + + + + + + + + + + + + + + +
+ +
+ + +
+ + + + + +
+ + + + + + + + + + + + +
0\
3
.......
N
3 ...... 00 3
+ +
N
_J::,..
UNIVERSITY
BERKELEY DAVIS
OF CALIFORNIA,
IRVINE LOS ANGELES
LOS ANGELES
RIVERSIDE SAN DIEGO SAN FRANCISCO SANTABARBARA
UCLA
SANTACRUZ
Center for Interdisciplinary Research in Immunology and Disease (CIRlD)

DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOCY UCLA SCHOOL OF MEDICINE CENTER FOR TIlE HEALTII SCIENCES 10833 LE CONTE AVENUE LOS ANGELES. CALIFORNIA 90024-1747
May 7, 1997 Henry J. Heimlich, M.D., Sc.D. President The Heimlich Institute 2368 Victory Parkway, Suite 410 Cincinnati, OH 45206 Dear Henry:
(310) 825...1)S68 (310) 206-13 18 (FAX)
Thank you for your letter of April 29th. I had some suggestions for revisions of the description of our association included in your letter of April 29 but will have to get some clearances here at UCLA. I will get back to you soon on that. Dr. Chen Xiao Ping has been an active participant in the Fogarty program. He seems eager to learn everything in his time here, and we are trying to provide him with plentiful opportunities to gain both practical, and conceptual knowledge and e~eriel!~.' :.'_, "
. __ . ~ .: .'
~ __
. ~: .
.:-.-"
.. .
. : ~,.~ j
. . ;4'...-_
. "':
.' ~ "_.' .
-,'
_, .
. .
-.
~#1
--'~-.\
~~~_~i~
-~ .;
~ ~-: ;;;.
~.~.~*;:~._:::~~_~.~-:_ .'
~: '.
Dr. Chen brought samples from 8 patients studied previously in Guangzhou. -_ Because of the limited quantities of these samples, we have been very careful to concentrate initial testing in a few subjects and progress to increased numbers of tests as well as increased numbers of samples tested. In 2 individuals examined, so far, they have been found to have elevated neopterin and JhM levels consistent with active progression of HIV infection. We have planned to do further testing of the 3 individuals with additional cytokine measurements and to measure viral load by the acid-soluble quantitative p24 antigen method. The quantities of sample available are not sufficient to do HIV viral load measurements by the RT-PCR or bDNA quantitative methods. One area that has not developed well relates to quantitative assessment of CD4 T cells. We have some reservations about the validity of the CD4 T cell measurements made on the HIV+ patients treated with malarial therapy in China. We asked Dr. Chen to obtain one of the AP AAP kits used in China to quantify CD4 T cells. We hoped that he could compare the method directly with CD4 measurements made by flow cytometry here. However. one of the key reagents did not work, perhaps because the shipment required 10 days, and the ice used for packing had melted. Thus, comparisons could not be made. However, we have had the opportunity to learn the principles of the APAAP method.
We inquired further about the availability of a flow cytometer in Guangzhou, and Dr. Chen told us that there is one at his institution that is used to evaluate transplant patients and some rheumatology patients. For reasons that are obscure to us, Dr. Chen has not arranged to have blood samples from the 3 malaria-treated HIV+ patients in Guangzhou (or other HIV+ patients in his clinic) evaluated for CD4 T cell levels by flow cytometry. That would also present an opportunity to compare the APAAP method with flow cytometry. One aspect of the studies in Guangzhou has presented a major difficulty to interpretation of the findings. That is the absence of pre-treatment, baseline measurements. When we compared date of the plasma sample and "CD4 level" data with the schedule of malarial administration, it was apparent that the first samples were obtained after malaria injection. Dr. Chen confirmed that this was the case for all eight patients. It may be that we do not have the correct facts, but we did want to bring this possibility to your attention. One of the projects required of each Fogarty trainee is the preparation of a research plan for return to home country. This forms the basis for any continuing assistance that the UCLA Fogarty program may provide. In Dr. Chen's case, I have asked him (a) to become familiar with the rationale employed in the current ACTG 328 protocol for evaluation of IL-2 therapy (in addition to intensive antiretroviral therapy) and (b) to develop a plan for evaluating malarial-therapy on return to Guangzhou. I expect him. to present tills plan to you for further development after he completes the program here on May 23rd. We will also send you a copy of the ACTG 328 protocol.
alley, t-.1.D. Direct r, CIRID at UCLA Chair, Clinical Immunology Committee, International Union of Immunological Societies (lUIS) JLF/dm
FOUNDATION, INC.
2368 V IC TORY PAR'f:oNAY SUITE410 CINCINNATI OHIO 45200 513-22HXXJ2 fax513-221-00:J3
HEIMLICH INSTITUTE
May 8, 1997
Mr. Berkley Bedell 1807 Snook Drive Naples, FL 33962 Dear Berkley: Enclosed is a reprint of our recent article and sample requests we are getting for it throughout the world. UCLA asked to be affiliated with us on this project and we have now done so. The Chinese physician in charge of our work iSJre now spending two months updating our laboratory studies.
I.
Hope all is well with you.
if /{t,LA
encl.

'I
i! II!!
3102061318
UCLA-CIRIU
l'IH (
1 ':;1
":::1'/
1'(:
4t::
UNIVERSITY OF CALIFORNIA, LOS ANGELES

IltJlJ(tt.r.:r
OAvr~
UCLA
Si\N nN'/ClSCQ
HIVlNE
u"fi ANCELES
R!VE1lSIOE
SAN 01(;0

DEPARTMENT OF M1Cl\OBIOLOGY AND IMMUNOLOCY UCLA SCl(OOL OF M1!:DIGINE GENTER FOR THE HEALTH SCIENCF-S 10633 LE CONTE AVENUE LOS ANGELES. CALIFOR?-.'lA 00024-1741
May 19, 1997 Henry 1. Heimlich, M .D., Sc.D. President The Heimlich Institute 2368 Victory Parkway, Suite 410 Cincirmati, OR 45206 Dear Heruy:
(310) 825-6568 (310) 206-1318 (FAX)
This follows my letter of May 7, 1997, and contains a correction. I wrote that Chen Xiao Ping had told us there were no baseline samples, e.g., pre-therapy blood samples from the ma1aria treated group in Gual1gzhou. That is what he told 3 of us about 2 weeks ago. We asked repeatedly. Last week we decided to look at the data - the dates that therapies were started and the dates that the first samples were obtained. Last Friday, we reviewed this and it appears that blood samples were drawn on the day malaria was given to 7 of the 8 persons. Patient #2 may also have had a baseline sample if the ftrst sample label date is incorrect. Dr. Chen's ex-planation was that he understood baseline to mean samples obtained some time before the start of treatment. A problem in cOlmnunication.
My regrets regarding the incorrect infoTInation sent to you.
Jolm Lahey, M.D. Director, CIRID at UCLA Chair, Clinical Immunology Committee, Intematiollal Union of InmHmological Societies (lUIS) JLF/dm
May 19, 1997
2368 VICTORY PAR~AY SUITE 410 CINCINNATI
OHIO
45200 513-221-00J2 fax 513-221-oo:l3
John L. Fahey, M.D. Director, CIRID at UCLA Chair, Clinical Immunology Committee, International Union of Immunological Societies (lUIS) UCLA School of Medicine Center for the Health Sciences 10833 Le Conte Avenue Los Angeles, California 90024-1747 Dear John: Your letter of May 7 was most informative. obtain meaningful test results.
It is apparent that your expertise is needed to
I greatly appreciate the preparation of a research plan and look forward to receiving the protocol. The significance of your continued participation in this study is certainly recognized. With best wishes,
lich, M.D., Sc.D. The Heimlich Institute
,.
} i .: .i : J-
DAHATFLIST
PAGE
02
Memorar.ci!! rn DRAFT
June f., 199'
Subject: Heanlich : HiVf MIT
From V.H
Dr Fahey Chcmrnan of thL UCL.A. Dep~1rtr'n8nt of ,rnrnuilo!oqv ,~nd and ChaIr of Immunology Associati(}f)
P res ident
2 l)r. . ahey re4' did Dr Che 1'S
('; hin ;~ ~ a t;
and tJ}fJod
v;n r ~ for
cred!o:lny
OJ:.. J::.ah$)' ia Quotfld a$.. ,ea.ylruL,:Ih~J-i~lnlii\: h MIT ~r9

have jf6eo"( lira! ioa ~s and i.~D 4 counts )
..
iF
t h~
be:$t Hty
n;Sl) lt-$ I,
Dt', Fa hoy Inte r.d~ to take the Heimlic h M!T results to th "" Ni~1
(>
months ~fter the next 10 patients ,should be th o '1Gxt e:lI; ceilerH h rst marker f or testi ng of the- Dre HGimHch'u H1V -MIT follo w2d by two years , D~ . Fahey has asked Dr. C I. 8{ ~ to test me w:"xt le ri pa tient";/ fnr;=I' rncr:th befor admin istering Ni! T ino(;u/&kH1S. This wi!! bC!]in Irnrn~Cl ! mC I ~" v,,'he ': L, Chen return s to Chin(. in m i d ~ J I.Vl1:l .
For Discussion : Future Raquirem9nt9 : The Timing ijf Additi onAl F"um't in g ~~ Va wa s Sources to be cons idered .
~
u2 r2 {~ \Jl re d f()~ Di Mt' ,in'l.--:h <:: ~1 i,: ,' to ~ece 1 ve th& sa,ne le '~Lel of !e(':_Qnltior: t~' y the medical cL ,-.r1 i_Tl!':'/ :,-! ~. Th~' Vaccine and Protease inh ibltorB Th,s ', vou d requ iro $1 an d (j ha l Million Dolla~, the ENDeT grant is included in this figu r~,
'.\'01 '!d
P
100 patient s test resul~
un
M
FOUNDATION, INC.
2368 VICTORY P ARKWAY SUITE410 CINCINNATI O HIO 45206 5132210002 fax 51 3-221 0003
R A
HEIMLICH INSTITUTE
To:
David MahoneyNalerie Harper: The Eleanor Naylor Dana Charitable Trust Henry J. Heimlich, M.D., Sc.D. and Eric G. Spletzer, Ph.D. Report from Xiao Ping Chen, M.D. , following studies at UCLA March 23 to May 31 , 1997 with John L Fahey, Director of the Center for Interdisciplinary Research in Immunology and Disease (CIRID) at UCLA. Chair, Clinical Immunology Committee International Union of Immunological Societies June 6, 1997
From: SUbject:
Date:
Dr. Chen gave four lectures at UCLA to Dr. Fahey, his colleagues and doctors from other countries. He first presented the results of his laboratory findings done in China on the blood of our eight HIV patients. They showed that after malariotherapy, the CD4 cells in all patients increased and remained elevated , at normal levels for two years with no further treatment of any kind. This finding illustrates that the patients' immune systems have been strengthened and have overcome the attack by the HIV (AIDS virus) . Dr. Fahey responded that the results of Dr. Chen's sbJdies in his laboratory in China might be inaccurate. Dr. Fahey tested Dr. Chen's ability by haVing him perform studies in the UCLA laboratories and had a member of the UCLA staff do the same studies on the same material. The two sbJdies came out identicaJ. (See attached graph "Comparision of assay variation between Tech.") Dr. Chen was then asked to carry out studies in the UCLA laboratories on the blood specimens he had brought with him, of the eight HIV patients treated with malariotherapy in China. His work was done under the direct supervision of Dr. Fahey and included tests of greater depth than those done in China. These tests confirmed those done in China, leading Dr. Fahey to say to Dr. Chen that he must be very excited with this kind of results. He congratulated Dr. Chen and asked him to congratulate Dr. Heimlich.
Dr. Fahey asked for a copy of the findings and told Dr. Chen that he would help us to show our data to the National Institutes of Health (NIH). He had Dr. Chen draw up a new protocol to be used for treatment of the next group of patients and Dr. Fahey
reviewed and agreed with it (enclosed). The protocol provides greater in-depth laboratory studies that will suffice to prove the value of malariotherapy for HIV. Dr. Chen has already selected the next ten patients and will proceed with their malariotherapy on his return to China, June 14". Ten patients with results similar to the previous eight will provide strong confirmation of the value of malariotherapy for AIDS. The new protocol calls for performing baseline laboratory tests starting one month prior to malariotherapy. Dr. Chen promises to commence malariotherapy in August or September. Six months thereafter, based on the results of the present series, there should be good evidence of the trend of the new patients. The goal has been to treat one hundred patients. This number, in fact incremental approaches to it, will guarantee that the results are acceptable to all medical authorities if the results are in keeping with the progress thus far. The next ten patients are considered the first group of the one hundred patients. Dr. Chen states he is prepared to treat one hundred patients at any time. The estimate of costs Dr. Heimlich presented originally for treating one hundred patients was one and-a-half million dollars. This included the ENDCT grants to date. It has not changed. Perhaps the NIH or other sources of funding will eventually help in this endeavor if need be. Dr. John C ionci, of Philadelphia, specializes in treating AIDS patients. Drs. Chen and th Heimlich originally met in China through his good auspices. We called him on June 8 and informed him of the above information. He was not surprised and stated that all drugs in all diseases have led to resistance in bacteria and virus infections and he expects the same to happen with Protease inhibitors. Malariotherapy is not affected by this limitation. Vaccines are in early stages of research and have the disadvantage of not being able to overcome every variety of AIDS virus that is developing. Dr. Fahey and his wife accepted an invitation to dinner, on Dr. Chen's last night in L.A., at a Chinese restaurant. The dinner was given by Dr. Hua Hong Shun, the Heimlich Institute's Fellow in Los Angeles. Also present were Dr. Hua's wife and daughter, and Dr. Chen. Drs. Fahey and Chen have obviously developed a good relationship. We believe that the biotherapy - Malariotherapy - is the most likely and most practical method for treating HIV infection and, as has been reported by the media, does not pose the problem of excessive cost for treating the entire world population of such patients. Dr. Heimlich will be calling Dr. Fahey to get a report directly from him.
June 10, 1997: Phone conversation between Dr. Heimlich and Dr. Fahey
Dr. Fahey: There is additional information based on tests done with p24 and activation marker data. It is a step forward, It will warrant a report and he will participate in a joint paper with me. He is going to Amsterdam and Germany this week and, if he cannot get a report to us before he leaves, he certainly will get a full report to me by July I.",
He has offered Chen the reagents he needs (more than he needs) for neopterin, cykotines and all others. He could not provide funds, but could offer reagents and kits as compensation for the use of the flow cytometer by Chen's friends at the University. It is important CD4's be done by flow cytomertry. Chen kept referring to the tests coming back to normal after an initial elevation. Fahey's impression was that, for the most part, cytokines and activation markers came down to or below the baseline but not to normal. In two cases that were normal before treatment, they came down to normal. He said the effect is similar to IL2 administration. Dr. Fahey said he is very interested in the use of malariotherapy and will work with us. He helped Chen write it into a protocol though it took quite awhile to do so,
It is very important to stratify CD4's. In the future we can do also it with viral load and
activation markers. This can be done by simply saving plasma since these substances are stored in the plasma. It is important that no patient was made worse with malariotherapy He is going to stay in touch with Dr. Hua to avoid language difficulties, although he said Chen spoke very well. Fahey got the idea they are hesitant using flow cytometer apparatus for AIDS patients, but Fahey said there is no problem with the spread of disease. NOTE: Ask Fahey about NIH and our results.
June 13, 1997

513-22HXXl2 fax513-22HXlO3
Dr. Najid Aziz Department of Microbiology and Immunology UCLA School of Medicine Box 951747 Los Angeles, CA 90095-1747 Dear Dr. Najid: Dr. Chen Xiao Ping reminded me that I had promised you this book. I am sorry to be late with it. Dr. Chen said he greatly appreciated your support and his stay at UCLA. W.ith
Henry President The Heimlich Institute Enclosure
1</IY~~ ~&, iiQ'.,

Sc.D.
r,est w~,
I /
3102061318
UCLH - '_I f-e I U
J UI.
1"
J r
1. ..:.'; _"
-UNIVERSITY OF CALIFORNIA, LOS ANGELES

61!:IIK~U;Y
UCLA
0 .".\'15
IIIV,,,,,,
LOS A:<C[l.ES
RIVERSIDE
. SAN OIECO
SAN FRANCISCO

DEPARTMENT OF MICR0810LOGY AND IMMllNOJ..OGY UCLA SCHOOL OF MEDICINE CENTER FOR 11-IE HEAI,nt SCIENCES 10833 lE CONTE AVeNUE LOS ....~GElES . CALIFORNIA 90095-1147
June 17, 1997
(310) 825-6568
(310) 206-1318 (FAX)
TO:
Henry Heimlich, M .D. Dr. Hua Oto Martinez-Maza, Ph.D. Evelyn Najera, M.P.H.
CC:
FROM:
lornl L. Fahey, M.D.
J Lr:
RE:
Name of the institutional chief or division chief under whom Chen Xiao Ping works in Guangzhou
I do not have this info011ation and think it would be helpful to have some contact with this perSOll. It would be very helpful if you could provide me with the name and title of such a person or persons ~ TIlls is especially important if we are going to provide continuing assistance in the fonn of reagents or supplies to Dr. Chen Xiao Ping. In this context, we are surprised that he did not request any supplies or materials to take with him nor indicate that he would be writing for some on his retum. I know he was specifically asked by two of roy colleagues and by me ifhe wanted reagents. \Ve tried to be clear to the Fogarty group about this matter. Other UCLA Fogarty program trainees that were here for the same course did take qdv?ntag~ of this (")I)t){n1uu\tY. We de..) have some limits, and we would suggest a $5,000 limit for initial reagents and supplies. The procedure is for us to purchase needed items here and ship them to the UCLA Fogarty trainee. We have successfully done this in a number of other laboratories in China. Yom" assistance in these two matters would be appreciated.
JLF/dm
------------ - ---- - ~-
- --
TRANSMITTALFOUNDATION, INC.
facsimile
- - --- -
- - --
- - --
- - - --
----
INSTITUTE
To:
Of:
John L. Fahey, M.D./CIRID/Dept. Microbiology & Immunology UCLA School of Medicine (310) 206-1318
45206 513-22HXXl2 fax 513-22HlOO3
Fax: From: Pages: Date:
Henry 1. Heimlich,
M.D.~I'
1, including this cover sheet. June 18, 1997
Dr. Chen Xiao Ping's chief is: Xiao Bin Quan, Director Address: The Municipal Health and Anti-Epidemic Station of Guangzhou (Public Health Center), No. 23 3 rd Zhongshan Road, Guangzho, Guandong, People's Republic of China 510080 After you and I spoke, I asked Dr. Chen why he did not request reagents. Apparently he was unclear about what reagents were available and he intended to contact you. I advised him to do so. I do know he is in need of the reagents, particularly for the flow cytometer, and will greatly appreciate them. I hope you have a pleasant trip to Europe and I look forward to speaking with you upon your return.
From the desk of ... Henry J. Heimlich. MD The Heimlich Institute
,~ .::J:
IE
~5
10152 (212) 754-2890 FAJ212) 754-2892

1hlstees
Pclrk Avenue New York, New York
June 25, 1997
David Mahoney,
Chainnan
Treasurer Robert A Good, M.D.
AJ. Signorile,
Carlos Moseley Robert E. WISe, M.D.
Dr. He~ Heimlich President:" Heimlich Institute Foundation 2368 Victory Parkway Suite 410 Cincinnati, OH 45206 Dear Henry: It was nice speaking to you today. All of us are very enthused about the results you are getting. Keep up the good work, and if I can be of help, please call me. warmest best wishes,
4J~
DM/lek
David Mahoney
facsimile
TRANSMITTAL
~------------------------------------------
2368 VICTORY
PAR~AY
To:
Of:
John L. Fahey, M.D ../CIRID/Dept. Microbiology & Immunology UCLA School of Medicine
(310) 206-1318
Henry J. Heimlich, M.D. 1, including this cover sheet. July 22, 1997
I hope you had a pleasant and productive trip to Europe. Dr. Chen spent a few days with me before going to New York and returning to China. I have recently tried to contact him through Dr. Hua who informs me there has been some difficulty in communications due to activities related to Hong Kong. When you have the opportunity, I would greatly appreciate the report of Dr. Chen's stay at UCLA which we discussed when you and I last spoke, and your thoughts as to the next steps in our malariotherapy project. With best wishes,
FOUNDATION, INC.
2368 VICTORY PARKWAY SUITE 410 CINCINNATI OHIO 45206 513-221-0002 fax 513-221-0003
To: Of:
TRANSMITTAL
facsimile
---------------
Valerie Harper The Eleanor Naylor Dana Charitable Trust (212) 754-2892 3, including this cover sheet. July 22, 1997
Fax:
Pages: Date:
I don't recall whether I sent these to you.
From the desk of... Henry J . Heimlich, MD The Heimlich Institute
3102061318
UCLH - '_I f-e I U
J UI.
1"
J r
1. ..:.'; _"
-UNIVERSITY OF CALIFORNIA, LOS ANGELES

61!:IIK~U;Y
UCLA
0 .".\'15
IIIV,,,,,,
LOS A:<C[l.ES
RIVERSIDE
. SAN OIECO
SAN FRANCISCO

DEPARTMENT OF MICR0810LOGY AND IMMllNOJ..OGY UCLA SCHOOL OF MEDICINE CENTER FOR 11-IE HEAI,nt SCIENCES 10833 lE CONTE AVeNUE LOS ....~GElES . CALIFORNIA 90095-1147
June 17, 1997
(310) 825-6568
(310) 206-1318 (FAX)
TO:
Henry Heimlich, M .D. Dr. Hua Oto Martinez-Maza, Ph.D. Evelyn Najera, M.P.H.
CC:
FROM:
lornl L. Fahey, M.D.
J Lr:
RE:
Name of the institutional chief or division chief under whom Chen Xiao Ping works in Guangzhou
I do not have this info011ation and think it would be helpful to have some contact with this perSOll. It would be very helpful if you could provide me with the name and title of such a person or persons ~ TIlls is especially important if we are going to provide continuing assistance in the fonn of reagents or supplies to Dr. Chen Xiao Ping. In this context, we are surprised that he did not request any supplies or materials to take with him nor indicate that he would be writing for some on his retum. I know he was specifically asked by two of roy colleagues and by me ifhe wanted reagents. \Ve tried to be clear to the Fogarty group about this matter. Other UCLA Fogarty program trainees that were here for the same course did take qdv?ntag~ of this (")I)t){n1uu\tY. We de..) have some limits, and we would suggest a $5,000 limit for initial reagents and supplies. The procedure is for us to purchase needed items here and ship them to the UCLA Fogarty trainee. We have successfully done this in a number of other laboratories in China. Yom" assistance in these two matters would be appreciated.
JLF/dm
------------ - ---- - ~-
- --
TRANSMITTALFOUNDATION, INC.
facsimile
- - --- -
- - --
- - --
- - - --
----
INSTITUTE
To:
Of:
John L. Fahey, M.D./CIRID/Dept. Microbiology & Immunology UCLA School of Medicine (310) 206-1318
45206 513-22HXXl2 fax 513-22HlOO3
Henry 1. Heimlich,
M.D.~I'
1, including this cover sheet. June 18, 1997
Dr. Chen Xiao Ping's chief is: Xiao Bin Quan, Director Address: The Municipal Health and Anti-Epidemic Station of Guangzhou (Public Health Center), No. 23 3 rd Zhongshan Road, Guangzho, Guandong, People's Republic of China 510080 After you and I spoke, I asked Dr. Chen why he did not request reagents. Apparently he was unclear about what reagents were available and he intended to contact you. I advised him to do so. I do know he is in need of the reagents, particularly for the flow cytometer, and will greatly appreciate them. I hope you have a pleasant trip to Europe and I look forward to speaking with you upon your return.
,~ .::J:
...............
facsimile
TRANSMITTAL
2368 VICTORY PARKWAY SUITE410 CINCINNATI OHIO 45206 513-221-0002 fax 513-2210003
~----------------------------
To:
Of:
Valerie Harper The Eleanor Naylor Dana Charitable Trust (212) 754-2892 2, including this cover sheet. July 23,1997
Fax: Pages: Date:
The following was sent to Dr. Fahey yesterday.
From the desk of... Vicki Roberts Associate Director The Heimlich Institute
facsimile
TRANSMITTAL
~------------------------------------------
2368 VICTORY
PAR~AY
To:
Of:
John L. Fahey, M.D ../CIRID/Dept. Microbiology & Immunology UCLA School of Medicine
(310) 206-1318
Henry J. Heimlich, M.D. 1, including this cover sheet. July 22, 1997
I hope you had a pleasant and productive trip to Europe. Dr. Chen spent a few days with me before going to New York and returning to China. I have recently tried to contact him through Dr. Hua who informs me there has been some difficulty in communications due to activities related to Hong Kong. When you have the opportunity, I would greatly appreciate the report of Dr. Chen's stay at UCLA which we discussed when you and I last spoke, and your thoughts as to the next steps in our malariotherapy project. With best wishes,
FOUNDATION, INC.
2368 VICTORY PARKWAY SUITE 410 CINCINNATI OHIO 45200 513-22HXXl2 fax 513-22HXXl3
HEIMLICH INSTITUTE
THE
..............
facsimile
TRANSMITTAL
To:
Of:
Fax: Pages: Date:
~---------------------------
John L. Fahey, M.D. Center for Interdisciplinary Research in Immunology and Disease (CIRID)IUCLA School of Medicine (310) 206-1318 2, including this cover sheet. July 30, 1997
Dear John, I just received a message from Dr. Chen and I am sending it to you as it pertains to your question as to why Chen did not take reagents with him. I trust this is self explanatory, but would appreciate receiving your thoughts. With best wishes,
From the desk of... Henry J. Heimlich. MD The Heimlich Institute
July 23, 1997 Henry 1.. Heimlich, M. D. President, Heimlich Institute 2368 Victory Partway Suite 410 Cincinnati, Ohio 45206 The United States of America Dear friend, Dr. Heimlich: I reached home Guangzhou on June 15. Thank you for your hospitality when I was home in Cincinnati. I received a fax letter from Dr. Hua, attached the letter Dr. Fahey wrote to you on June 17. Dr. Fahey did mention that he would supply a part of reagents to us and his colleagues, Dr. Najib Aziz ( the fellow who asked you to send him a book of Heimlich's Home Guide to Emergency ) and Dr. Pari Nishanian respectively mentioned that they would provide us with a part of reagents for cytokine testing, CD4 rosette forming testing ( or ELISA testing) and P24 testing and I told them that we did not need P24 reagent and the CD4 reagent other than that for flow cytometry. I also told Dr. Aziz our need for cytokine reagents and he promised to ship them to us during our preparation of next 10 patients due to expiration of reagents. As Dr. Fahey said in his letter for you that they did have some limits and they suggested a $ 5,000 for initial reagents. So the situation is basically the same as our talks in Cincinanti, Even Dr. Fahey provides us with the reagents for flow cytometry, the cost for test procedures and equipment upkeep and mantenance is still very much because flow cytometer is very expensive and the cytometer we will use in Guangzhou has not yet been used for HIV samples.
UNIVERSITY
BERKELEY DAVIS
OF CALIFORNIA,
IRVINE . LOS ANGELES
LOS ANGELES
UCLA
SANTA CRUZ
Center for Interdisciplinary Research in Immunology and Disease (CIRID)

DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY UCLA SCHOOL OF MEDICINE CENTER FOR THE HEALTH SCIENCES 10833 LE CONTE AVENUE LOS ANGELES, CAUFORNIA 900951747
August 6, 1997 Henry J. Heimlich, M.D., Sc.D. President The Heimlich Institute 2368 Victory Parkway, Suite 410 Cincinnati, OH 45206 Dear Henry:
(310) 825~6.~68. ~
(310) 206- 1318 (FAX)
Enclosed are tables of the data obtained on the samples provided by Chen Xiao Ping. We have problems with interpretation because of uncertainty as to when the samples were obtained in relation to therapy in most of the patients. Hopefully, you have more exact data. Chen Xiao Ping gave us shifting information at different times during his stay here. Patients 4003 and 4004 are probably the clearest. Presumably, the first samples were obtained before malariotherapy, the second samples during malariotherapy and the subsequent samples were after malariotherapy. 4003 had a baseline neopterin of 6.97 (within the normal range). P2M was normal and sTNF-RII was at the upper end of normal. A marked rise is seen about 3 weeks later during therapy. About 11 days later, there is substantial subsidence. Subsequently, values are in the normal range (but gradually falling) in 1994 and progressive increases in 1995 and 1996 until abnormal levels are recorded 9/11/96. Patient ID 4004 follows a similar course with the exception that his baseline was elevated in 1993. His post therapy values were generally below baseline and were mostly in the normal range in 1995 but were increased again in the 1996 sample. The other patients present the problems of not knowing if the first values were pre-treatment or were obtained during or soon after malariotherapy. The absence of certainty about these first values (Do they represent just disease or disease plus malariotherapy or disease plus some other infection?) presents difficulties for interpretation of the subsequent values,
In the accompanying graphs, please understand that the "0" time point only indicates the first sample that we had for patients 4001, 4002, 4005, 4006, 4007 and 4008. We are uncertain about their relationship to malariotherapy. Please feel free to use this data in reports and publications. We would appreciate an acknowledgment and credit to the support provided by NIH grants TW 00003 and AI 36086. The difficulties outlined above contributed to our concern that Chen Xiao Ping have a carefully 'Written out experimental plan (in English and in Chinese) in advance of future malariotherapy studies. Both versions of the plan should be available to you (I would be glad to review these). As you know, I believe that malariotherapy may act by similar mechanisms to those operating in the 5-day continuous intravenous IL-2 treatments developed by Lane, Kovacs and their colleagues. Both malaria and IL-2 stimulate marked increases in all or almost all cytokines. IL-2 induces CD4 increases without reductions in viral load. That is why we have been concerned to help Chen Xiao Ping have accurate CD4 measurements. He still has to develop a working relationship with the persons who have a flow cytometer at his institution. Sincerely
John L. ahey, M.Do Director" CIRID at UCLA Chair, Clinical Immunology Committee, International Union of Immunological Societies (lUIS) JLP/dm
MEMORANDUM
August, 11, 1997 To: John L Fahey M.D. From: Najib Aziz M.D.
Department of Microbiology and Immunology UCLA School of Medicine Center for the Health Sciences 174718
N . 1\
./}
Re: CMTS ID# and CSM Normal Plasam Levels; ID#
ID# 4001 4002 4003 4004 4005 4006 4007 4008 NORMAL
Int. GHYM LW
wnw
WWG
XBP XLL
YL YXW plasma Level 25% 1.05 4.10 1.40 50% 1.18 5.10 1.64 75% 1.42 6.29 2.19 90% 1.61 8.45 2.74
Analytics
B2-M
Neopterin 11-2 sTNF-RII
10% MeanSD 1.27O.34 0.94 3.56 5.743.16 fila 1.87O.80 . 1.13
'" '"
:2
0
C\I C\I
'<t 0 0 '<t E . E :..

Q)
c: 0
0 0 '<t
0
CO
:2
c: 0
-0
,
E
0 0
-0
Q)
..
o
o
.1.dN
.1.dN
'" '"
:2
0
C\I
C')
0 0 '<t E .
Q)
c:
0 0 '<t
-0
r-...
:2
0
C\I
c: 0
-0
,
)
0
=
<D :;::;
c:
E
0
08
09
Ot>
0 09 09
O~
Ot> .1.dN
Oc:
.1.dN
'"
C\J
'"
:2
j
1:J
<D
0 0 '<t
0
C\I
c:
<0
:2
0
C\I
E .
0 0 '<t
1:J
c: 0
=
<D
c:
09
09
ot> .1.dN
o~
08
09
OV
OC: .1.dN
~ ~
0 0 '<t
1:J
'"
,....
0
C\I
'"
:2
c: 0
io
:2 E
=
<D :;::;
c:
0 0 '<t E
a
0
C\I
c: 0
:2
0
e.
Q)
09
09
ot> .1.dN
0(:
09
09
ot>
'>
.1.dN
0
CO) CO)
"<t 0 0 "<t
N N
0 0 <:::Q)
:2 C 0 E
CO c
0 0 "<t
:2 C 0 E
"'0
0
""
0
::!:!
CD
-=-
""
0
CO) C')
C')
0 0 "<t
N
0
0
:2 C
E
2CD
r-, 0 0 "<t
:2
0
c
N
2Q)
"'0
::!:!
0
o
V'lZ8
0
CO)
0
CO)
:2
C\J
j
"'0
CD
0 0 "<t
N
CD
:2
0
C\I
E .
0 0 "<t
"'0
2CD :;::;
E
0
E:
0 V'I<:S
V'lZ8
0
CO)
0
CO)
1
.0 0 "<t "'0
0
N
:2 C 0 E
2Q)
0 0 "<t
in
0
C\I
:2 C 0 E
::!:!
0
2Q)
c{
c/)
E:
0 V'I<:S
E:
'z.
V'lZ8
'<
o
(')
'i3:
~~ g
. '<t",
c:
en
:!23
,.c
ro
o
0<:
O~ <:l::INl.S C'dNl.S
o
os
0<:
(')
CI)
:;::;
"0
CI)
:;::;
0<:
<:l::INl.S
o
O 0<:
O~
<:l::INl.S
o
(')
'i3:
o
(\j
c: 0
E
CI)
:;::;
os
0<:
cl::lNl.S
O~
o 01: <:l::INl.S
o
(')
..'<t "0
'i3:
o
(\j
o o
c:
LO
0
'i3: o
(\j
c: 0
.
'<t
CI)
:;::;
os
0(;
O~ <:l::INl.S
os
0<:
<:l::INl.S
O~
-:::2'0
"
r '
CMTS
PID DATE NPT(runol/l) B2M(mgll) STNRll(nglml) IL2(pglml) P24(pglml)
WHW WHW WHW WHW WHW WHW WHW WHW WHW WHW WHW WWG WWG WWG WWG WWG WWG WWG WWG WWG WWG YXW YXW YXW YXW YXW YXW
10/27/93 11115/93 11126/93 114/94 311/94 4/5/94 8/1/94 1110/95 6/6/95 2/6/96 9111196 12/16/93 1/11194 1125/94 3/1194 4/5/94 8/11/94 1110/95 6/6/95 2/6/96 9/11/96 7/27/94 9/1/94 1/2/95 5/27/95 1/27/96 9/7/96 7/27/94 9/1194 112/95 9/7/96 7/27/94 9/1/94 1/2/95 5/27/95 1127/96
6.97 46.92 12.2 8.14 8.43 7.35 5.39 6.67 8.13 9.05 11.78 15.33 82.56 26.54 11.75 16.18 10.02 7.39 10.52 7.34 14.76 41.35 52.24 30.66 52.01 33.6 31.37 24.32 19.39 9.33 11.84 27.95 19.9 21.85 22.96 10.94
1.77 2.78 2.26 1.51 0.58 1.94 1.37 1.92 2.12 2.36 4.32 3.55 4.76 3.4 3.56 3.16 2.07 2.13 2.54 2.19
2.61 22.68 4.82 2.85 2.54 2.19 3.44 2.99 2.91 2.82 5.3 32.05 16.9 6.5 7.2 4.8 5.2 5.5 5.55 5.95 6.11 7.2 11.29 5.91 5.34 5.46 4.2 2.49 2.54 4.92 5.29 7.3 7.35 4.91 4.86
0 0
0 0 0 0 0 0 0 0 0 0 0 32 121
0 2
107 159 165 95 250 2 18 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
3.31 5.04 4.4 4.33 4.05 3.74 2.11 2.66 2.04 2.29 1.96 2.04 2.5 1.78 2.05
XBP XBP XBP XBP LW LW LW LW LW
4 11
7 10
06/24/97 NA CIRID at UCLA
CMTS LW XLL XLL XLL XLL

GHYM GHYM GHYM GHYM GHYM GHYM YL YL YL YL YL YL 917196 7/27/94 1/2195 5127/95 1127/96 7/27/94 911194 112/95 5/27/95 1127/96 917196 7/27/94 911194 112/95 5/27/95 1127/96 9/6/96 14.11 31.61 14.07 17 10.96 27.39 23.4 13.8 10.31 10.51 28.9 49.89 32.79 28.21 25.99 22.83 31.61 2.08 2.23 3.31 2.79 2.66 1.81 2.84 2.32 1.97 2.13 3.34 3.71 3.43 3.36 3.59 3.62 3.3 4.74 9.43 5.08 6.37 4.91 7.24 4.85 4.58 3.29 10.34 11.34 4.76 6.13 6.65 7.36 7.09 5.27 8 22 0 0 0 0 0 19 24 17 21 29 73 13 0 27 0 0 -
06/24/97 NA CIRID at UCLA
mai l b~x: / C%7c / p rogram% ... ms.edu.cn%20&number=26
mailbox:/C%7C/prog r am% ... ms.edu.cn%20&number=26
Subject: Re: Letters and E-mail Date: Wed , 20 Aug 1997 15:40:33 +0900 From: "Chen Xiao Ping" <chenxp@gzsums.edu.cn> To: "Heimlich" <heimlich@iglou.com> CC: "Eric G. Spletzer" <egspletzer@hotmail.com>
Dear Dr. Heimlich: I have received your two express letters and email and I have told Dr. Xiao Bin Quan your descriptions about funding issue. He requested me to review our agreements and our case reports and then to report to him. Now he let me tell you his points based on our agreements: "It is understood that an occasional patient may survive only four or five months but will still warrant inclusion in this series" ( ON GUANGZHOU PART ) . We have S cancer cases who survived at least 4 months ( easel: 22 months; case2: he refused to be followed up; case3: 4 months; case4: 8 months; caseS: 4 months; case6: over 36 months; case7: 3months ). It is unpredictable how long to survive a patient who suffers from an "incurable" disease to receive an unconfirmed therapy ( clinical trial, not routine treatment ). It is possible that a trial therapy may promote the progress of an "incurable" disease. So you should pay us at least for S cancer patients according to our agreements. Dr. Xiao said that you did not overpay for cancer patients but owe us 1,000 USD. He says that we do not ask for the 1,000 USD any more, but we have to receive the 6,000 USD that you owes us for HIV/AIDS project. Please remember that we have totally treated eight HIV patients, instead of seven patients that you mentioned in your letter. ( In fact, we treated 9 HIV patients; do you remember that case 9 complicated jaundice, we terminated malaria before finishing therapy and then we did Western Blot again with negative result? But I brought his blood sample to UCLA for further testing. It showed postive and we did it again recently in Guangzhou, the result was positive, but we have cancelled this patient). We do not want to delay our nex clinical trial , if only you complete your payment on the project. Dr. Xiao also mentioned that any financial support from UCLA can not be deducted from your payment. The reasons are that, 1) 7,000 USD for one patient is the least, not the enough according to our new protocol. 2) We can not accept UCLA as a joining part if its payment is deducted from yours; for example, Dr. Fahey has to be as a member of Heimlich Institute if he wants to join us. As a joining part, Guangzhou payed a lot, took a lot of responsibility and faced high risk. So, any additional payment should be used to improve our resea rch conditions. Above are Dr. Xiao's point s. Dr. Xiao also let me tell you that a university in Italy is willing to pay a great deal of money to cooperate with Guangzhou, but we refuse it, because we have set up a gre at friendship between us for a long time. As you know, my dear friend, Dr. Xiao is a very important person in our project. I am unable to change any point of his this time. What time we can do next clinical trial, it is completely decided by you, my friend. I hope all things are going well with you. Best regards. Dr. Chen xiao ping, from Guangzhou, Ch ina
> > > > > > > > > >
>
From: Dr. Henry J. Heimlich <heimlich @iglou.com> To: chenxp@gzsums.edu.cn Subject: E-mail and other communicat i ons Date: Tuesday, August 19, 1997 5:42 AM Dear Dr. Chen, We received your e-mail at both heimlich@iglou.com and egspletzer@hotmail.com. We hope that you have no problems getting this e-mail.
> An important American organiza t ion will be holding seve ral AIDS > conferences in China in March, 1998 . Dr. Heimlich has been asked to lead > a delegation for a possible meeting in Guangzhou. This would be a great > opportunity for you to show your wor k to a group of American AIDS > doctors.
> >
We sent two letters to you rega rding MT-cancer and MT-HIV projects
. 0:
08/21/97 08 : 43:26
mailbox : /C%7C/program% ... ms.edu.cn%20&number=26
mailbox:/C%7C/program% ... ms.edu.cn%20&number=26
> which you had apparently not received when you sent your e-mail. Copies
> of these are attached to this e-mail note. We hope that this addresses
> the matter so that we can go ahead with the next batch of patients.
> > Please advise as to what dates you will start the work-up and > treatment of the next 10 patients. The foundation providing the funds > wishes to know this as soon as possible. > Sincerely, >
>
> >
- 2
08/21/97 08:43:26
~1~2~bl~1~
ULLH-ClkIU
HUI.)
c: 1.
'=' (
eJ :
t:J"l
UNIVERSITY
BERI:ELEY O.ll\')$
OF CALIFORNIA,
UIVINE ' LOS ANCtLES '
LOS ANGELES
RIVERSIDfr
UCLA
HNTt 1 .. 11116("
I
M,'J 1?!J:;vQ ' MN fll"'!'ir.r.~r.o
UlWT'rllI1'7

DCl'ARTMENT OP MlCR0810LOGY AND IMMVNOLOGY UCLA. SCHOOL OF MEDIClNE CEN'TER FOR THE HEAUf{ SCIENCES 10833 LECONtEAVENUE
August 20, 1997 Henry J. Heimlich, M.D., Sc.D.

President
lOS ANGeLCS,
CAUFORNlA
900?31747
(310) 825-6568
(310) 2061318 (FAX)
The Heimlich Institute 2:108 Victory Parkway. Slllip,410

Cl.l1(,~J.lla.t~,U11 4~206
Dear Henry: Twas ploased to have Y01l1' 110tP: nhout the planned visit to China that YOU will be chairing next March. I am sure the Citizen Ambassador Program has a mailing list
!~~lhUItt tDnjtmlb~l1fb!~tnmm!Q ~ruP.rvt~ ~~JlqeJ\!Q~6Qrt!lqiIll\JQ~~U~r My

oVlI1 visits are built around research sites where we have ongoing or potential collaborative work, so Ihave not been able to take advantage of this kind of opportunity.' I am sure they will benefit enormously from your past experience
and interests.
1 hnpn )fnll hmrn nn intnnorrting gnOtlp of pnnticipnnto.
Sincerely,
John L. ." ey, M.D. Director, CIRln at UCLA Chair, Clinical Immunology Committee, International Union of Immunological Societies (lUIS) JLF/dm
facsimile
TRANSMITTAL
-------------------------------------
PO BOX BB58 CINCINNATI, OH 45208 513-221-0002 fill 513-221-0003
To: Of: Fax: Phone: Pages: Date:
John L. Fahey, MoD. UCLA School of Medicine 3102061318 3108256568 7, including this cover sheet. August 26, 1997
Dear John,
Dr. Spletzer found the accompanying article. It confirms our results and suggests an approach for our studies.
From the desk ot.. Joan Steinberg Cincinnati, OH 45206
.,-
...............
TRANSMITTAL
facsimile
~~~~~~~~~~~~~~-
2368 VICTORY PARKWAY SUITE 410 CINCINNATI OHIO 45200 513-22HXXl2 lax 513-221-rol3
To: Of: Fax: Pages: Date:
Valerie Harper The Eleanor Naylor Dana Charitable Trust (212)754-2892 2, including this cover sheet. August 27, 1997
'.
' ,~
Where are we now?
FOUNDATION, INC.
HEIMLICH INSTITUTE
Our results have been presented at the International Immunology Conference in San Francisco, the International Immunology Conference at the NIH in Bethesda, and the International AIDS Conference in Vancouver. Each presentation represents approval by the leading AIDS experts. We also received very positive press. Those presentations led to the interest of Professor John Fahey of UCLA. He invited and paid for Dr. Chen, our Chinese counterpart, to study at UCLA for two months. Chen has prepared a very complete protocol for the next series of patients and is ready to treat them. We are arranging to send funds to him. Dr. Fahey is providing an initial $5,000 of laboratory reagents to China from his NIH grant, and is confirming our Chinese blood tests at UCLA. Dr. Fahey, in a recent detailed report on our work, asked that we acknowledge the support received from his NIH grants in scientific papers we write. He is taking an active part in our project. Dr. Eric Spletzer, Heimlich Institute's researcher, found an in depth study of the relationship between malaria and HIV published in the Pasteur Institute of France journal. It reviews the medical literature, and reports on their own detailed animal studies, concluding that the effects of malaria and HIV infections on each other are protective rather than harmful. The scientists recommend long term studies comprising a large number of human subjects be done - which is what 'we are about to do. We have published our early results in a scientific paper and received requests for reprints from all over the world. -Our work is widely recognized. Furthermore, as reported in a front page story in the New York Times, August 8, 1997, failures with drug treatment of AIDS are increasing as we predicted When we started our research, it was challenged by several doctors. Yet David believed in the work, because he understood it, and provided funds. There is no known evidence of opposition at this time.
PO BOX BB5B C INC INNATI, OH 45208 513-221-0002 Fax 513-221-0003
Where do we go from here?

We have spoken of treating a hundred HIV patients and budgeted $1.5 million for this when the next 10 patients have been treated and also have good results. Our work is successful; we cannot afford to delay. We should not wait for further results, that wastes valuable time and lives. Nor need we wait until we can gather the entire $1.5 M. Instead, we start raising funds right now, and for each $10,000 raised treat an additional HIV patient.
I have been invited to go to South Africa with a delegation of American AIDS specialists, which is further evidence of the acceptance of our research. It is my hope that we will be asked to carry out malariotherapy treatment of AIDS patients there. That would be ideal.
September 8, 1997
FOUNDATION, INC.
INSTITUTE
513-221-0002 Fax 513-221-0003
P .o . BOX B858 . CINCINNATI, 0" 45208
John L. Fahey, M.D. Director, CIRID at UCLA Chair, Clinical Immunology Committee, International Union of Immunological Societies (lUIS) University of California, Los Angeles Center for the Health Sciences 10833 Le Conte Avenue Los Angeles, California 90095-1747 Dear John: I have just returned from my week of relaxation. Thank you very much for your fine report of August 6, 1997. I appreciate your efforts and contribution to this work. We will certainly acknowledge and credit the support provided by your NIH grants in any report that is issued. Would you please send me the appropriate wording for the acknowledgment. I hope that "you will participate as an author of such a report and look forward to our drawing it up. I will send the protocol that Chen Xiao Ping had worked out with your colleagues. I am asking him to send a copy in Chinese to you. I agree with your statement that malaria and IL-2 treatments may act by similar mechanisms. You raised the question whether the first values were pre-treatment. It was my impression, from your letter of May 10, 1997, that had been a problem in communication that was now settled. Please advise. I would greatly appreciate your thoughts on what our next steps should be in working on this project together.
.Benefiting Humanity Through Health and Peace
John L. Fahey, M.D. Director, CIRID at UCLA September 8, 1997 Page 2
I note in an Associated Press article of September 5,1997 that others are working on a virus to target HIV-infected cells as rei>Orted in Cell. Another effort to give a disease to cure another disease. We will get hold of the article when Dr. Spletzer returns from a conference he is attending.
I~~
2368 VICTORY PARKWAY SUITE 410 CINCINNATI OHIO 4S2OO 513-22HXX)2 fax 513-221-<Xm
HEIMLICH
To: From: Location: Pages: Date:
From the desk of...
September 8, 1997
FOUNDATION, INC.
INSTITUTE
513-221-0002 Fax 513-221-0003
P .o . BOX B858 . CINCINNATI, 0" 45208
John L. Fahey, M.D. Director, CIRID at UCLA Chair, Clinical Immunology Committee, International Union of Immunological Societies (lUIS) University of California, Los Angeles Center for the Health Sciences 10833 Le Conte Avenue Los Angeles, California 90095-1747 Dear John: I have just returned from my week of relaxation. Thank you very much for your fine report of August 6, 1997. I appreciate your efforts and contribution to this work. We will certainly acknowledge and credit the support provided by your NIH grants in any report that is issued. Would you please send me the appropriate wording for the acknowledgment. I hope that "you will participate as an author of such a report and look forward to our drawing it up. I will send the protocol that Chen Xiao Ping had worked out with your colleagues. I am asking him to send a copy in Chinese to you. I agree with your statement that malaria and IL-2 treatments may act by similar mechanisms. You raised the question whether the first values were pre-treatment. It was my impression, from your letter of May 10, 1997, that had been a problem in communication that was now settled. Please advise. I would greatly appreciate your thoughts on what our next steps should be in working on this project together.
.Benefiting Humanity Through Health and Peace
John L. Fahey, M.D. Director, CIRID at UCLA September 8, 1997 Page 2
I note in an Associated Press article of September 5,1997 that others are working on a virus to target HIV-infected cells as rei>Orted in Cell. Another effort to give a disease to cure another disease. We will get hold of the article when Dr. Spletzer returns from a conference he is attending.
mailbox:/C%7C/program%
.ms.edu.cn%20&nurnber=38
mailbox:/C%7C/program%
.ms.edu.cn%20&nurnber=38
Subject: Re: Aug 26 E-mail Date: Mon, 22 Sep 199715:56:43 +0800 From: "Chen Xiao Ping'v-cchenxptgigzsums.edu.cn> To: "Dr. Henry J. Heimlich" <Heimlich@iglou.com> CC: "Dr. Eric G. Spletzer" <egspletzer@hotmail.com>
Dear Dr. Heimlich: We are pleased that you agreed to send us the 6,000 USD according to our agreement. As you know, this payment is very important for us, because we need it to ballance our account vs our agreement and to start our next clinical trial. Please wire transfer this payment to our account (475010101140192114 ). Please notice that the 2,000 USD you wired to our account ( 4776213-01140007599 ) on the date 9/8/95 was included in the Table 2, Fundings of Malariotherapy for HIV/AIDS in my E-mail of 8/6/97 and in my recent letter by FedExpress. Yes, it is gratifying that we can both discuss the questions and relationships openly because of our great trust and mutual respect. We do cherish our great friendship that has been established by us since 1990. Yes, we have over 10 patients in Guangzhou. 1. They are definitely HIV positive. 2. But they are all drug users. 3 ..We have not yet tested their CD4 cells. 4. they are interested in our malariotherapy. So I would like to discuss the issue on patient selection with you. In my impression, these HIV patients in Guangzhou are much better than those previously from Yunnan Province in the case of patient selection because they have good health now and have much more higher education level as well as have good veins for their b,lood being taken. They agreed to avoid sharing needles with others and promised to cooperate with us. It will be much more easier for us to follow them up. So I trend to select the patients in Guangzhou even though I have' contacted other HIV patients who'are not drug users but they will corne from other provinces including Sichuan Province and Henan province. As you know, in China, most HIV patients are drug users. If we want to treat 100 patients in China in the coming years, we have to select them. But, to tell the trues, I am able to get 10 patients who are not drug users from other provinces this time. Therefore I hope to see what is your opinion. Another thing I want to talk to you is that on the basis of our new protocol made in UCLA, our patient selection is not limited to those CD4 counts between250-500 but the HIV infected adults with entry CD4 count over 50 cells/mm3 ( stratified by CD4 numbers, over 500, 500-201, 200-51 ) who are any antiretroviral and immune-based therapies naive at entry, but not excluding traditional Chinese medicine therapy ( Please see the DESIGN AND METHODS of our new protocol ). ~Dr. John L. Fahey agreed to this protocol and you agreed too in my impression when I was in UCLA and at home in Cincinnati. Dr. Xiao wants to know whether you have promised that 1, you will pay 7,000 USD for each HIV.patient in the coming 'clinical trial; 2, you will not deduct the financial supports by UCLA from your payments because 7,000 USD/each is just the least budget. He said that he would welcome UCLA to join us if it pay some and take some responsibility in the project. He promised once more to pay for a -80 centigrade freezer and pay some for improving ourAIDS laboratory special for the research of malariotherapy. He added that if you promise both mentioned above, he would pay and let the clinical trial start immediately. If you and Dr. Xiao both agree and promise, trial immediately. I look forward to hearing from you. Sincerely, Dr. Chen xiao Ping Chief, Associate Research Professor I am able to start the clinical
of 2
09/22/97
08:53:41
M
To:
2368 VICTORY PAAr:wt{{ SUITE 410 CINCINNATI OHIO 45200
M
Valerie Harper Henry
o
MD
J. Heimlich,
Interim Report on Malariotherapy and AIDS: Please transmit to David Mahoney Date: September 25, 1997
513-22HX02
fax 513-221-00:J3
Resume of our conversation:

Re: John L Fahey, M.D., Director Center for Interdisciplinary Research in Immunology and Disease (CIRID), Chair, Clinical Immunology Committee, International; Union of Immunological Societies (lUIS)
I. Dr. Fahey is providing Dr. Chen Xiao Ping with $5,000 worth of reagents to carry out CD4 levels with a flow cytometer, the latest method. 2. Dr. Fahey sent us laboratory data obtained from the blood of our patients in Guangzhou and states we should feel free to use this data in reports and publications. The results confirm Dr. Chen's analysis. Dr. Fahey says he would appreciate an acknowledgment in our publications of the work done on our patients at UCLA and asks that we give credit in our reports to his two NIH grants that supported this work. 3. Dr. Fahey states that he believes malariotherapy may act by similar mechanisms to those operating in the 5-day continuous intravenous IL-2 treatments tested by the NIH. He says both malaria and IL-2 stimulate marked increases in all or almost all cytokines (immune substances produced by the body). I told him I agree. Malariotherapy is superior since IL-2, an expensive, genetically engineered interleukin that causes severe reactions, and must be repeated every month or two. 4. Dr. Fahey is going to send me his recommendations for the next steps in our continuing work together to expedite the malariotherapy program.
A two-year follow-up of our eight patients has been prepared for submission to a medical journal. It reports on the seven of our eight patients who continue to be in good health and mentions the one who died at twenty-one months, unrelated to malariotherapy.
Valerie Harper Page 2 September 25, 1997
Our work has become more urgent since The New York Times revealed there are limitations in the response to protease inhibitors indicating the drugs are failing, at a rate approaching 50%. As you know, I have always said the drugs will fail due to resistance of the HIV virus; whereas boosting the immune system with malariotherapy continues to succeed. We now have a protocol developed by Dr. Chen in conjunction with Dr. Fahey suitable for the treatment of 100 patients. The sooner we attain that figure, the quicker our work will be accepted and the benefits extended to the world's population. You will recall the opposition to malariotherapy that occurred when David Mahoney first presented the concept to several doctors. I know of no opposition now .
.:J ~.
.'
M E M o
To:
2368V ICTORY PARKWAY SUITE410 CINCINNATI OHIO 45206 513-221 -0002 fax 513-221-0003
R A
Valerie Harper Henry J. Heimlich, MD
From: Subject:
Interim Report on Malariotherapy and AIDS: Please transmit to David Mahoney September 25, 1997
V
-'
v '
Date:
Resume of our conversation: Re: John L. Fahey, M.D., Director Center for Interdisciplinary Research in Immunology and Disease (CIRID), Chair, Clinical Immunology Committee, International; Union of Immunological Societies (lUIS) I. Dr. Fahey is providing Dr. Chen Xiao Ping with $5,000 worth of reagents to carry out CD4 levels with a flow cytometer, the latest method. 2. Dr. Fahey sent us laboratory data obtained from the blood of our patients in Guangzhou and states we should feel free to use this data in reports and publications. The results confirm Dr. Chen's analysis. Dr. Fahey says he would appreciate an acknowledgment in our publications of the work done on our patients at UCLA and asks that we give credit in our reports to his two NIH grants that supported this work. 3. Dr. Fahey states that he believes malariotherapy may act by similar mechanisms to those operating in the 5-day continuous intravenous IL-2 treatments tested by the NIH. He says both malaria and IL-2 stimulate marked increases in all or almost all cytokines (immune substances produced by the body). I told him I agree. Malariotherapy is superior since IL-2, an expensive, genetically engineered interleukin that causes severe reactions, and must be repeated every month or two. 4. Dr. Fahey is going to send me his recommendations for the next steps in our continuing work together to expedite the malariotherapy program.
A two-year follow-up of our eight patients has been prepared for submission to a medical journal. It reports on the seven of our eight patients who continue to be in good health and mentions the one who died at twenty-one months, unrelated to malariotherapy.
"'-r - - -I
- - -- - - -- - -
- - - r --
- -.--._ --.. _ - ..--.--.
Valerie Harper Page 2 September 25. 1997
Our work has become more urgent since The New York Times revealed there are limitations in the response to protease inhibitors indicating the drugs are failing, at a rate approaching 50%. As you know, I have always said the drugs will fail due to resistance of the HIV virus; whereas boosting the immune system with malariotherapy continues to succeed. We now have a protocol developed by Dr. Chen in conjunction with Dr. Fahey suitable for the treatment of 100 patients. The sooner we attain that figure, the quicker our work will be accepted and the benefits extended to the world's population. You will recall the opposition to malariotherapy that occurred when David Mahoney first presented the concept to several doctors. I know of no opposition now.
September
26, 1997
2368 VICTORY PAR~AY SUITE 410 CINCINNATI OHIO 45206 513-221-{XX)2 lax 513-22HXXX3
George D. Lundberg, Editor JAMA 515 N. State St. Chicago, IL 60610 Dear Dr. Lundberg: Enclosed patients:
M.D.
is a manuscript entitled "Malariotherapy Two years of follow-up experience."
for
HIV
We certify that we have participated sufficiently in the conception and design of this work and the analysis of the data, as well as the writing of the manuscript, to take public responsibility for it. We believe the manuscript represents valid work. We have reviewed the final version of the submitted manuscript and approve it for pUblication. Neither this manuscript nor one with substantially similar content under my authorship has been published or is being considered for publication elsewhere. Furthermore, we attest that we shall produce the data upon which this manuscript is based for examination by the editors or their assignees if requested. I certify that affiliations with or involvement in any organization or entity with a direct financial interest in the subject matter or materials discussed in the manuscript (e.g., employment, consultancies, stock ownership, honoraria, expert testimony) do not exist. In consideration of the action of the American Medical Association (AMA) in reviewing and editing this submission, the undersigned authors hereby transfer, assign, or otherwise convey all copyright ownership to the AMA in the event that such work is published by them.
We look forward to your decision regarding pUblication in Journal of the American Medical Association. If changes are required, please notify Henry J. Heimlich, at 2368 Victory Parkway, Suite 410,
---
__
3102061318
UCLA-CIRID
022 P02
SEP 29 '97
15:23

BERKELE DAVIS IRVINE LOS
.~NGELES
UCLA
SANTA B.~RI!ARA . SANTA caul,
. RIVBIISIOIl
SANOIl!:GO SAN I'IIANCISCO
Center for InterdiSciplinary Research in Immunology and Disease (CIRlD)

Or-PARTMF-NT OF MICROBIOLOGY AND IMMUNOLOGY UCLA SCHOOL OF MEDIClNE CENT6R FOR nJl:: HEALTH SCIENCES 10833 i.E CONTE AVENUE COS ANGELES. CALIFORNIA 9(j)95-1747
September 26, 1997 Henry J. Heimlich, M.D., Sc.D. President The Heimlich Institute 2368 Victory Parkway, Suite 410 Cincinnati, OH 45206 Dear Henry:
(310) 825-6568 (310) 206-1318 (FAX)
I have your recent letter of September 8. I have been working on a schedule that will allow me to visit China near the end of October and, specifically, to be in CantoniGuangzhou on October 24. I am writing to Chen Xiao Ping about this bec.ause the principal reason for going to Canton will be to discuss how he is progressing with plans for the malarial therapy trial and to become acquainted firsthand with the setup at his institution and to meet some of the other people that are involved in AIDS and immunology research there. Of course, I will want to discuss the plans for the new protocol. If you could make a copy available to me in the next week or two, that would be very much appreciated. The citation to credit the work that we have contributed would be "assisted in part by NIH grants TW-00003 and AI-35040." There is no need to include me among the authors but an acknowledgment would be quite sufficient. I do still have some reservations about the relati011ship of his first samples to the adntinistrati<)1l of malaria. These impinge on my confidenc.e about interpretation of the data. TIlere were a nwnber of switches on specific. infonnation from Chen Xiao Ping while he was here that caused this unease. Perhaps, I can settle my qualms after the visit to Guangzhou. I have several appointments in Beijing (prior to going to Guaugzhou) at the Peking Union Medical College, the Beijin.g Medical School, and the Academy of Preventive Medicine. Is there anything that I could do on your behalf at any of these sites? I would be glad to try to help.
Director. Chair, Clinical Immunology Committee, lUIS JLF/dm
mailbox:/C%7C/Program% ... ms.edu.cn%20&number=41
SUbject: Re: E-mail Date: Tue, 30 Sep 1997 16:43:59 +0800 From: "Chen Xiao Ping" <chenxp@gzsums.edu.cn> To: "Dr. Henry 1. Heimlich" <Heimlich@iglou.com> CC: "Dr. Eric G. Spletzer" <egspletzer@hotmail.com>
Dear Dr. Heimlich and Dr. Spletzer: Thank you for your E-mail of 9/24/97. I agree with you that we should select HIV patients who are not drug users this time even though there are more difficulties to do so. Yes, it is true that there are more than 700 HIV patients in Hong Kong, but the Health Department of Hong Kong was unwilling to introduce the patients to us ( I visited the Department two times on this issue ) and I have not yet been able to contact the patients directly. I am continuing my effort on keeping touch with Hong Kong. On the other hand, we can find other patients in other cities in Guangdong Province and in other provinces. It will take one to two months to re-organize them to come to Guangzhou to receive our therapy. We delayed some time in our discussion of funding issue; but we are pleased that we reach our agreement finally. There are some points that I want to discuss with you. In my opion, first, malariotherapy ( MT ) is not IL-2 therapy; because IL-2 can not induce production of CSFs including multi-CSF( IL-3 ), GM-CSF, M-CSF and G-CSF which promote stem cells regeneration, but MT can do so theoretically, see Appendix. Second, malariotherapy is not natural malaria. Many doctors consider that malaria suppress immune system. It is not all true. A lot of data show that in the early stage of malaria, it definately boosts immune system; the decrease of peripheral white blood cell ( WBC ) in some patients with malaria is due to redistribution of WBC, especially concentrating in the spleen and liver, not real decrease of WBC. But it is true that the late stage of malaria suppresses immune system. As we know, our malariotherapy is just to use the early stage of malaria ( no more than 15 fever episodes ). Third, there are no any forms of relapsing Plasmodia in our MT, this point was discussed by us before we started our MT for cancer. Forth, high fever can inhibit RNA synthesis and HIV belongs to RNA virus. So we should widen our patient selection so that we are more earlier to confirm that MT is much better than IL-2 therapy. But if we do not want to take any risk, I agree with you this time. Appendix. MT: P.Ag---> Macrophage--->IL-l, CSFs--->stem cells ---> Macrophage --->IL-l, HLA-DR, IL-6 --->resting T cell --->activated T cell--->IL-2, IL-4,IL-6,IFNs --->T, B cell-->-->--> IL-2 therapy: IL-2--->T, B cell-->-->--> Note: P.Ag: Plasmodium antigen. Sincerely, Chen Xiao Ping, M.D.
1 of 1
09/30/97 08:52:25
HEIMLICH INSTITUTE
2368 VICTORY PARKWAY SUITE410 CINCINNATI OHIO 45206 513-221-()()()2 fax 513-221-()()()3
Fax
To: Valerie Harper The Eleanor Naylor Dan
Of:
From: Fax: Pages: Date:
(212) 754-2892 5, including this cover sheet. September 30,1997
The following article, front page in The Cincinnati Enquirer, is also in today's New York Times, (Science Times section). Also being sent is a fax received today from John Fahey and his letter of May 19, 1997. Last is an e-mail received today from Chen. Give me a ring this morning when you have read these, as I will be at your favorite spot the dentist - this afternoon.

Health
and
Peace
THE CINCINNATI ENQUIRER

A GANNI II N Ws/'AI'Ek . 501.100 RuJ' ERS DAI LY
'\JI .~ "AY . !:'(I' II(MII " k 30,1 997
FlNAJ. Enm oN/EAsT 50 er.N"!';
Study: AIDS cocktails failing half of patiel

BY DANIEL Q. HANEY
The Associated Press
New drug
TheFDA has OK'd an anti-HIV combination pill that will cut down on "drug cocktails." A4
TORONTO Widely heralded new AIDS treatments that seemed to stop the virus' advance and revive patients from near death are now beginning to fail in about half of all those treated, doctors said Monday. The disappointing reports suggest the tough virus is coming back after being knocked briefly into submis-
sion, just as many experts feared it would. Dr. Steven Deeks presented data from the University of California at San Francisco' s large public AIDS clinic at San Francisco Gen-
eral Hospital. Patients whose diseasePrescriptions of so-<:alIed fighting T cells were ravaged three-drug cocktails - two by HIV have regained normal older AIDS drugs plus one of uves and even gone back to the new class of medicines work. However, many worried the virus would eventualcalled protease inhibitors have clearly revolutionized ly grow resistant to the protease inhibitors and resume its AIDS care. In many places. more than insidious destruction, 90 percent of AIDS patients New data. presented Monare taking these combina- day at an infectious disease tions. and typically people conference sponsored by the start on them even before American Society of Microbithey get sick, ology, suggests this is indeed
happening regularly. "There is a whole mixture of explanations," said Dr. David Ho of the Aaron Diamond AIDS Research Center in New York City. Dr. Ho said that for people who had relatively low virus levels when they started taking the drugs and had not used other AIDS medicines. failure almost always means they did not take their pills on schedule.
"Compliance is critical," Dr, 0" "When we say we mean rigid adh over 20 pills a day, Also at high risk who were on oll drugs before start! ase inhibitors or wI' counts were very I, Dr. Deeks sai, ments by ph ar O! companies show couraging resullS,
mailbox:/C%7C/Program% ... ms.edu . cn%20&number=41
mailbox:/C%7c/program% ... ms.edu.cn%20&number=41
SUbject: Re: E-mail Date: Tue, 30 Sep 1997 16:43:59 +0800 From: "Chen Xiao Ping" <chenxp@gzsums.edu.cn> To: "Dr. Henry J. Heimlich" <Heimlich@iglou.com> CC: "Dr. Eric G. Spletzer" <egspletzer@hotmail.com>
Dear Dr. Heimlich and Dr. Spletzer: Thank you for your E-mail of 9/24/97. I agree with you that we should select HIV patients who are not drug users this time even though there are more difficulties to do so . Yes, it is true that there are more than 700 HIV patients in Hong Kong, but the Health Department of Hong Kong was unwilling to introduce the patients to us ( I visited the Department two times on this issue ) and I have not yet been able to contact the patients directly. I am continuing my effort on keeping touch with Hong Kong. On the other hand, we can find other patients in other cities in Guangdong Province and in other provinces. It will take one to two months to re-organize them to come t o Guangzhou to receive our therapy. We delayed some time in our discussion of funding issue; but we are pleased that we reach our agreement finally . There are some points that I want to discuss with you. In my opion, first, malariotherapy ( MT ) is not IL-2 therapy; because IL-2 can not induce production of CSFs including multi-CSF( IL-3 ), GM-CSF, M-CSF and G-CSF which promote stem cells regeneration, but MT can do so theoretically, see Appendix. Second, malariotherapy is not natural malaria. Many doctors consider that malaria suppress immune system. It is not all true. A lot of data show that in the early stage of malaria, it definately boosts immune system; the decrease of peripheral white blood cell ( WBC ) in some patients with malaria is due to redistribution of WBC, especially concentrating in the spleen and liver, not real decrease of WBC. But it is true that the late stage of malaria suppresses immune system. As we know, our malariotherapy is just to use the early stage of malaria ( no more than 15 fever episodes ). Third, there are no any forms of relapsing Plasmodia in our MT, this point was discussed by us before we started our MT for cancer. Forth, high feve r can inhibit RNA synthesis and HIV belongs to RNA virus. So we should widen our patient selection so that we are more earlier to confirm that MT is much better than IL-2 therapy. But if we do not want to take any risk, I agree with you this time. Appendix. MT: P.Ag---> Macrophage--->IL-l, CSFs--->stem cells ---> Macrophage --->IL-l, HLA-DR, IL-6 --->resting T cell - - - >activated T cell--->IL-2, IL-4,IL-6,IFNS --->T, B cell-->-->--> IL-2 therapy: IL-2--->T, B cell-->-->--> Note: P.Ag: Plasmodium antigen. Sincerely, Chen Xiao Ping, M.D.
1 of 1
09/30/97 08:52 : 25
3102061318
UCLA-CIRID
022 P02
SEP 29 '97
15:23

.~NGELES
UCLA
. RIVBIISIOIl

(310) 825-6568 (310) 206-1318 (FAX)
SUbject: Re: E-mail Date: Tue, 30 Sep 1997 16:43:59 +0800 From: "Chen Xiao Ping" <chenxp@gzsums.edu.cn> To: "Dr. Henry 1. Heimlich" <Heimlich@iglou.com> CC: "Dr. Eric G. Spletzer" <egspletzer@hotmail.com>
Dear Dr. Heimlich and Dr. Spletzer: Thank you for your E-mail of 9/24/97. I agree with you that we should select HIV patients who are not drug users this time even though there are more difficulties to do so. Yes, it is true that there are more than 700 HIV patients in Hong Kong, but the Health Department of Hong Kong was unwilling to introduce the patients to us ( I visited the Department two times on this issue ) and I have not yet been able to contact the patients directly. I am continuing my effort on keeping touch with Hong Kong. On the other hand, we can find other patients in other cities in Guangdong Province and in other provinces. It will take one to two months to re-organize them to come to Guangzhou to receive our therapy. We delayed some time in our discussion of funding issue; but we are pleased that we reach our agreement finally. There are some points that I want to discuss with you. In my opion, first, malariotherapy ( MT ) is not IL-2 therapy; because IL-2 can not induce production of CSFs including multi-CSF( IL-3 ), GM-CSF, M-CSF and G-CSF which promote stem cells regeneration, but MT can do so theoretically, see Appendix. Second, malariotherapy is not natural malaria. Many doctors consider that malaria suppress immune system. It is not all true. A lot of data show that in the early stage of malaria, it definately boosts immune system; the decrease of peripheral white blood cell ( WBC ) in some patients with malaria is due to redistribution of WBC, especially concentrating in the spleen and liver, not real decrease of WBC. But it is true that the late stage of malaria suppresses immune system. As we know, our malariotherapy is just to use the early stage of malaria ( no more than 15 fever episodes ). Third, there are no any forms of relapsing Plasmodia in our MT, this point was discussed by us before we started our MT for cancer. Forth, high fever can inhibit RNA synthesis and HIV belongs to RNA virus. So we should widen our patient selection so that we are more earlier to confirm that MT is much better than IL-2 therapy. But if we do not want to take any risk, I agree with you this time. Appendix. MT: P.Ag---> Macrophage--->IL-l, CSFs--->stem cells ---> Macrophage --->IL-l, HLA-DR, IL-6 --->resting T cell --->activated T cell--->IL-2, IL-4,IL-6,IFNs --->T, B cell-->-->--> IL-2 therapy: IL-2--->T, B cell-->-->--> Note: P.Ag: Plasmodium antigen. Sincerely, Chen Xiao Ping, M.D.
1 of 1
09/30/97 08:52:25
HEIMLICH INSTITUTE
2368 VICTORY PARKWAY SUITE410 CINCINNATI OHIO 45206 513-221-()()()2 fax 513-221-()()()3
Fax
To: Valerie Harper The Eleanor Naylor Dan
Of:
From: Fax: Pages: Date:
(212) 754-2892 5, including this cover sheet. September 30,1997
The following article, front page in The Cincinnati Enquirer, is also in today's New York Times, (Science Times section). Also being sent is a fax received today from John Fahey and his letter of May 19, 1997. Last is an e-mail received today from Chen. Give me a ring this morning when you have read these, as I will be at your favorite spot the dentist - this afternoon.

Health
and
Peace
THE CINCINNATI ENQUIRER

A GANNI II N Ws/'AI'Ek . 501.100 RuJ' ERS DAI LY
'\JI .~ "AY . !:'(I' II(MII " k 30,1 997
FlNAJ. Enm oN/EAsT 50 er.N"!';
Study: AIDS cocktails failing half of patiel

BY DANIEL Q. HANEY
The Associated Press
New drug
TheFDA has OK'd an anti-HIV combination pill that will cut down on "drug cocktails." A4
TORONTO Widely heralded new AIDS treatments that seemed to stop the virus' advance and revive patients from near death are now beginning to fail in about half of all those treated, doctors said Monday. The disappointing reports suggest the tough virus is coming back after being knocked briefly into submis-
sion, just as many experts feared it would. Dr. Steven Deeks presented data from the University of California at San Francisco' s large public AIDS clinic at San Francisco Gen-
eral Hospital. Patients whose diseasePrescriptions of so-<:alIed fighting T cells were ravaged three-drug cocktails - two by HIV have regained normal older AIDS drugs plus one of uves and even gone back to the new class of medicines work. However, many worried the virus would eventualcalled protease inhibitors have clearly revolutionized ly grow resistant to the protease inhibitors and resume its AIDS care. In many places. more than insidious destruction, 90 percent of AIDS patients New data. presented Monare taking these combina- day at an infectious disease tions. and typically people conference sponsored by the start on them even before American Society of Microbithey get sick, ology, suggests this is indeed
happening regularly. "There is a whole mixture of explanations," said Dr. David Ho of the Aaron Diamond AIDS Research Center in New York City. Dr. Ho said that for people who had relatively low virus levels when they started taking the drugs and had not used other AIDS medicines. failure almost always means they did not take their pills on schedule.
"Compliance is critical," Dr, 0" "When we say we mean rigid adh over 20 pills a day, Also at high risk who were on oll drugs before start! ase inhibitors or wI' counts were very I, Dr. Deeks sai, ments by ph ar O! companies show couraging resullS,
mailbox:/C%7C/Program% ... ms.edu . cn%20&number=41
mailbox:/C%7c/program% ... ms.edu.cn%20&number=41
SUbject: Re: E-mail Date: Tue, 30 Sep 1997 16:43:59 +0800 From: "Chen Xiao Ping" <chenxp@gzsums.edu.cn> To: "Dr. Henry J. Heimlich" <Heimlich@iglou.com> CC: "Dr. Eric G. Spletzer" <egspletzer@hotmail.com>
Dear Dr. Heimlich and Dr. Spletzer: Thank you for your E-mail of 9/24/97. I agree with you that we should select HIV patients who are not drug users this time even though there are more difficulties to do so . Yes, it is true that there are more than 700 HIV patients in Hong Kong, but the Health Department of Hong Kong was unwilling to introduce the patients to us ( I visited the Department two times on this issue ) and I have not yet been able to contact the patients directly. I am continuing my effort on keeping touch with Hong Kong. On the other hand, we can find other patients in other cities in Guangdong Province and in other provinces. It will take one to two months to re-organize them to come t o Guangzhou to receive our therapy. We delayed some time in our discussion of funding issue; but we are pleased that we reach our agreement finally . There are some points that I want to discuss with you. In my opion, first, malariotherapy ( MT ) is not IL-2 therapy; because IL-2 can not induce production of CSFs including multi-CSF( IL-3 ), GM-CSF, M-CSF and G-CSF which promote stem cells regeneration, but MT can do so theoretically, see Appendix. Second, malariotherapy is not natural malaria. Many doctors consider that malaria suppress immune system. It is not all true. A lot of data show that in the early stage of malaria, it definately boosts immune system; the decrease of peripheral white blood cell ( WBC ) in some patients with malaria is due to redistribution of WBC, especially concentrating in the spleen and liver, not real decrease of WBC. But it is true that the late stage of malaria suppresses immune system. As we know, our malariotherapy is just to use the early stage of malaria ( no more than 15 fever episodes ). Third, there are no any forms of relapsing Plasmodia in our MT, this point was discussed by us before we started our MT for cancer. Forth, high feve r can inhibit RNA synthesis and HIV belongs to RNA virus. So we should widen our patient selection so that we are more earlier to confirm that MT is much better than IL-2 therapy. But if we do not want to take any risk, I agree with you this time. Appendix. MT: P.Ag---> Macrophage--->IL-l, CSFs--->stem cells ---> Macrophage --->IL-l, HLA-DR, IL-6 --->resting T cell - - - >activated T cell--->IL-2, IL-4,IL-6,IFNS --->T, B cell-->-->--> IL-2 therapy: IL-2--->T, B cell-->-->--> Note: P.Ag: Plasmodium antigen. Sincerely, Chen Xiao Ping, M.D.
1 of 1
09/30/97 08:52 : 25
3102061318
UCLA-CIRID
022 P02
SEP 29 '97
15:23

.~NGELES
UCLA
. RIVBIISIOIl

(310) 825-6568 (310) 206-1318 (FAX)
3102061318
UCLA-CIRIU
l'IH (
1 ':;1
":::1'/
1'(:
4t::

IltJlJ(tt.r.:r
OAvr~
UCLA
Si\N nN'/ClSCQ
HIVlNE
u"fi ANCELES
R!VE1lSIOE
SAN 01(;0

DEPARTMENT OF M1Cl\OBIOLOGY AND IMMUNOLOCY UCLA SCl(OOL OF M1!:DIGINE GENTER FOR THE HEALTH SCIENCF-S 10633 LE CONTE AVENUE LOS ANGELES. CALIFOR?-.'lA 00024-1741
May 19, 1997 Henry 1. Heimlich, M .D., Sc.D. President The Heimlich Institute 2368 Victory Parkway, Suite 410 Cincirmati, OR 45206 Dear Heruy:
(310) 825-6568 (310) 206-1318 (FAX)
This follows my letter of May 7, 1997, and contains a correction. I wrote that Chen Xiao Ping had told us there were no baseline samples, e.g., pre-therapy blood samples from the ma1aria treated group in Gual1gzhou. That is what he told 3 of us about 2 weeks ago. We asked repeatedly. Last week we decided to look at the data - the dates that therapies were started and the dates that the first samples were obtained. Last Friday, we reviewed this and it appears that blood samples were drawn on the day malaria was given to 7 of the 8 persons. Patient #2 may also have had a baseline sample if the ftrst sample label date is incorrect. Dr. Chen's ex-planation was that he understood baseline to mean samples obtained some time before the start of treatment. A problem in cOlmnunication.
My regrets regarding the incorrect infoTInation sent to you.
Jolm Lahey, M.D. Director, CIRID at UCLA Chair, Clinical Immunology Committee, Intematiollal Union of InmHmological Societies (lUIS) JLF/dm
American Medical Association

Physicians dedicated to the health of America Journal of 515 North State Street Chicago, Illinois 60610 312 464-5000 312464-5824 Fax httpJ/www.ama-assn.org
The AmeriC8ll
M~dical Association
October 1, 1997
Henry J. Heimlich, MD Hemilich Institute 2368 Victory Parkway, Suite 410 Cincinnati, OH 45206 USA RE: MS# JPC710l9, MALARIOTHERAPY FOR HIV PATIENTS: TWO YEARS OF FOLLOW-UP EXPERIENCE Dear Dr. Heimlich: Thank you for giving us this opportunity to consider your manuscript. Please refer to the manuscript number and first author in all subsequent communication. Your manuscript has been assigned to Carin M. Olson, MD, who can be reached at 312-464-2442. We agree to consider this manuscript with the understanding that its content, figures, and tables have not been published or submitted elsewhere in print or electronic format, and will not be submitted elsewhere during the period of review by THEJOURNAL. Your manuscript will be reviewed by Carin M. Olson, MD, and possibly by two or more peer reviewers. Every effort will be made to expedite the review process and to notify you of our decision as soon as possible. It is the policy of THEJOURNAL not to return manuscripts that have been rejected (unless the author has specifically requested the manuscript's return). Only the original artwork, if submitted, will be returned. The original manuscript and any copies will be destroyed and recycled . . cerezyyoureD~
E~~~berg,
MD
~-:frfD/f
Scientific Publications
Fax
2368 VICTORY PARKWAY SUITE 410 CINCINNATI OHIO 45206 513-22HXlO2 fax 513-22HI003
To: Of: Fax:
Valerie Harper The Eleanor Naylor Dana Charitable Trust (212) 754-2892 Henry J. Heimlich, M.D.
From:
Subj:
(/
Summary of E-mail of 9/30/97 from Dr. Chen Xiao Ping 1, including this cover sheet October 7, 1997
Pages: Date:
1.
2.
Dr. Chen agrees that we should not treat drug users. He is continuing his effort to try to work with Hong Kong to obtain patients. In addition, he has patients in other cities in his and other provinces. It will take one to two months to organize them to come to Guangzhou to receive treatment.
3.
The remainder of his message is scientific.
Regards,
::~ -)
1B/27/97 18:35:11
RightFAX NT-)
513 221 BBB3
Page
BB1
FROST & JACOBS LLP

CIN CINNATI, OHIO COMMUNI CATIONS CENTER FAX COVER SHEET
Facsimile Transmission Date and time of transmission: MOll 10/27/97 10:34AM Number of pages: 05 (Including this cover page.) TO Name: Company: Location: Fax Number : Voice Number: FROM Name: Fax Number: Voice Number: COMMENTS Dr. Heimlich , Attached is a draft of the letter to the IRS requesting that the Institute be reclassified as an MRO. Please take a moment to review and let me know if you have any questions or comments. As Joan and I discussed, the information from the Institute's 990 will be inserted. Doug Thomson
Dr. Heimlich Heimlich Institute
92210003
DOUGLASD . THOMSON
(513 ) 651-6935
THE INFORMATION CONTAINED IN THIS FA.,'{ IS INTENDED FO R THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDR ESSED AND MA Y CONTAIN INFOR MATION THAT IS PRIV ILEGED. CONFIDENTIAL. ATTORNEYS' WO RK PRODUCT .-\ND!O R EXEMPT FROM DISCLOSURE UNDER APPLICABLE LA.W. IF THE READER OF THIS MESS AGE IS NOT THE INTEN DED RECIP IENT (O R THE H IPLOYEE OR .'\G ENT RES PONSIBLE TO DELIVER IT TO THE INTEN DED RECIPI ENTl. YOU ARE HEREBY NOTIFIED THAT ANY DISSE!v!I NATION. DISTRIB UTION OR COPYING OF THIS COM MUNICATION IS PROHIB ITED. IF YO U HAVE RECEIVED THIS COMM UNICATIOl\ IN ERROR. PLEASE NOTIFY US BY COLLECT TELEPHONE.
CINCINNATI FAX NUMBER

(513) 651-6981
OTHER OFFICES (FAX NUMBERS)

COLUMBUS (614) 464-1737 MIDDLETOWN (51 3) 422-3010 LEXINGTON (606) 253-2990 NAPLES (941) 261-2083
SH OULD YOU HA VE ANY PROBLEMS RECEIVI NG THIS TRANSMISSION , PLEASE CALL (:' 13) 6:' I -677 :'
1B/27/97 18:35:45
RightFAX HT->
513 221 BBB3
Page ElEI2
DOUGLAS D. THOMSON (513) 651.6935

d thomson@frojac.com
October 27,1997
Internal Revenue Service EPIEO Division P .O . Box 3159 Cincinnati, Ohio 45201 Re : The Heimlich Institute (23-7303161). Request for change in non-private Institute status to a medical research organization.
Dear Sir or Madam This letter is to request a change in the status of the Heimlich Institute (the "Institute") from an organization described in Section 509(a)( 1) and Section 170(b)(1)(A)(iv) to an medical research organization described in Section 509(a)(1) and Section 170(b)(1)(A)(iii). A copy of the Institute 's determination letter is attached recognizing the Institute as a Section 501(c)(3) organization cla ssified as a non-private Institute described in Section 509(a)( 1). In order to assist your determination of the Institute ' s c lass ification as a r-v1RO under Section 170(b)(l)(AXiii) a completed Schedule C, Section 2 from Form 1023 is attached to this correspondence . Also attached is a Form 2848 naming the undersigned as power of attorney for the Institute . Should you have any additional questions, please contact the undersigned . Very truly yours,
Douglas D . Thomson
DDT/gvs
Enclosure
457723.0 1
18/27/97 1B:36:13
RightFAX HT->
513 221 B883
Page BB3
DRAFT 10/27/97
The Institute's Affiliation with the UCLA Medical Center
The Institute has for many years been engaged in the continuous active conduct of medical research . The Institute's most notable activities relate to research and the promulgation of information concerning the I'Heimlich Maneuver" developed by Dr. Henry J. Heimlich the is material describing the Institute's research about Institute's President. Attached as Exhibit the Heimlich Maneuver. While the Institute continues to engage in research concerning the Heimlich Maneuver, the Institute's primary research focus is currently the treatment of HIV (AIDS) patients using malariotherapy . The Institute's malariotherapy research is being conducted by the Institute in conjunction with two hospitals . Patients are treated and results initially analyzed at the Municipal Institute for Preventative Medicine (the I'Municipal Institute") of Guangzhaou, China. An agreement (the "Agreement") describing the relationship between the Municipal Institute and the Institute is attached as Exhibit The Agreement requires that the Municipal Institute provide medical treatment and testing (using the clinical protocalls developed by the Institute and modified with the assistance of the UCLA Medical Center) to the patients involved in the malariotherapy clinical trials . The Municipal Institute forwards the test results from the clinical trials to the Fundation and the UCLA Medical Center for review and analysis . The Institute finances the cost of the clinical trials, has established and continues to revise clinical protocols and analyzes the data from the clinical trials . Results of the Guangzhaou clinical trials are also analyzed by the Center for Interdisciplinary Research in Immunology and Disease at the UCLA Medical Center. The chief researcher for the Institute is Dr. Heimlich. The chief researcher for the Municipal Institute is Dr. Xaio Ping Chen and the principal contact at the UCLA Medical Center is Dr. John L Fahey . The Institute has arranged for Dr. Chen to spend significant time working with Dr. Fahey's staff at the UCLA Medical Center. The close cooperation between the UCLA Medical Center (through Dr. John Fahey), the Institute (through Dr. Heimlich and Dr. Chen) is evidenced by the material attached as Exhibit The first sentence ofTreas . Reg. Section 1.170A-9( c)(2Xvii) states that an MRO need not be formally affiliated with a hospital. Likewise, the last sentence ofTreas . Reg. Section 1.170A9(cX2Xvii) provides that not all of an MRO's research efforts need to occur on the hospital's premises, only that there be "cooperative of appropriate [MRO and hospital] personnel and the use of facilities of the particular hospital. whenever it would aid such research." It is clear that there is an affiliation between the Institute and the UCLA Medical Center contemplated by Treas . Reg. Section 1.170A-9(c)(2)(vii)
18/27/97 18:37:87
RightFAX HT->
513 221 8883
Page 884
The Institute Devotes a Substantial Amount of its Assets to Medical Research

In order to qualify as a MRO, the Institute must devote a substantial amount of its assets to medical research. Treas . Reg. Section 1. 170A-9(c)(2Xiii) defines medical research as " ... the conduct of investigations, experiments and studies to discover, develop, or verifY knowledge relating to the causes, diagnosis, treatment, prevention, or control of physical or mental diseases and impairments of man."
A.
The Institute's Medical Research
As discussed above, while the Institute continues to engage in research concerning the Heimlich !\.1aneuver, the Institute 's primary research focus is currently the treatment of HIV (AIDS) patients using malariotherapy. HIV-infection weakens patients ' immune systems by outstripping the ability of the body' s immune cells to respond to the virus. This effect of HI V infection leads to the equivalent of rapid ageing of the immune system, resulting in decreased ability of the body' s immune system to respond to secondary infections that can prove futal. Restoration and preservation of the immune system are crucial elements in the successful clinical management of HIV infection. The aim of malariotherapy is to restore immunological function by providing a general stimulus to the immune system. Strengthening the immune system allows for the {X}tential elimination of the virus . A 1996 article from A1echanisms of Aging and Development (a medical and scientific journal) discussing the Institute's malariotherapy treatment ofHIV is attached as Exhibit _ . Based on the foregoing it is clear that the Institute conducts medical research 'within the meaning ofTreas . Reg. Section 1.170A-9(c)(2)(iii).
B.
Use of the Institute's Assets for Medical Research
Not only must the Institute conduct medical research, but it must also devote a substantial part of its assets to the conduct of such medical research. According to Treas. Reg. Section 1.170A-9(c)(2)(v)(b), the Institute will be considered to devote a substantial part of its assets to the conduct of medical research if it expends funds equaling 3.5% or more of its endowment for the conduct of medical research. The determination of whether the Institute has spent the required 3.5% is based on the Institute ' s expenditures for the prior year (i.e ., for 1997, a review of expenditures for 1996) or for the prior four years (i .e., for 1997, a review of 1993-1996) .
1B/27/97 1B:37:56
RightFAX HT->
513 221 BBB3
Page BBS
The analysis below, drawn from the Institute's Form 990 for 1996, 1995, 1994 and 1993 clearly show that the Institute devotes a substantial part of its assets to medical research. The calculation of the Institute 's endowment is a combination of the cash and investment totals from Part IV of the Form 990. The detennination of the amounts the Institute spent for medical research is determined by totaling lines (a) and (b) of Part III of the Form 990.
1996
[To be provided]
1995
Endowment = $502,3 83 3.5% of endowment is $17,583 Amount spent on medical research is $106,178
1994
Endowment = $593,623 3.5% of endowment is $20,777 Amount spent on medical research is $82,969
1993
Endowment = $570,337 3.5% of endowment is $19,962 Amount spent on medical research is $60,496
457723.01
MEMORANDUM
2368 VICTORY PARKWAY SUITE410 CINCINNATI OHIO 45206 513-221-0002 fax 51 3-221-0003
To: From:
Valerie Harper Henry J. Heimlich, M.D. Interim Report on Malariotherapy and AIDS: Please transmit to David Mahoney November 4, 1997 John L. Fahey, M.D., Director Center for Interdisciplinary Research in Immunology and Disease (CIRID), Chair, Clinical Immunology Committee, International; Union of Immunological Societies (lUIS)
Subject:
Date: Re:
Resume of Dr. Heimlich 's conversation with Professor John L. Fahey, M.D. , November 4, 1997, shortly after Dr. Fahey ' s return from China:
1. Dr. Fahey believes malariotherapy may act by similar mechanisms to those operating in the 5-day continuous intravenous IL-2 treatments tested by the NIH. He says both malaria and IL-2 stimulate marked increases in all or almost all cytokines (immune substances produced by the body). I told him I agree. Malariotherapy is superior since IL-2, an expensive, genetically engineered interleukin that causes severe reactions, and must be repeated every month or two.
2. Dr. Fahey was positively impressed concerning the laboratories, and other facilities, in China and said they can carry out all tests as well as those done at UCLA. 3. The medical personnel working with Dr. Chen were impressive and the Municipal Health Group impressed Dr. Fahey with their interest in malariotherapy. They supported Dr. Chen 's work. 4. Dr. Fahey is in agreement with using intravenous drug users and reported most of the clinical trials in the U.S. include such individuals. He suggested, if possible, two HIV positive non-drug users would be worthwhile including.

Health
and
Peace
DAVID MAHO~EY
745 FIFTH AVESUE
SUITE 700
NEW YORK, NEW YORK 10151
212/838-3710
November 6, 1997
Dr. IIel'l:}:" !rt::..i.~i1l.l:. cit
17 Elmhurst Place Cincinnati, Ohio 45208 Dear Hank: I write this for two reasons. First, to congratulate you on the wonderful news from Dr. Fahey. It seems you are really on track, and should be indeed proud. My second reason is to inquire why a man of your demonstrated brilliance can possibly consider touring Africa in any form at this time. We need all of your efforts behind this major breakthrough, and your family and friends don't look forward to you doing bongo dances when they're not necessary. Keep in touch. Know how much we miss you. Warmest best wishes,
~
DM/lek
David Mahoney
UNIVERSITY OF CALIFORNIA , LOS ANGELES

BERKELEY DAVIS IRVI NE LOS ANCELES . RIVERSIDE SAN DI ECO . SAN FRANCISCO SANTA BARBARA
UCLA
SANTA C RUZ
Center for Interdisciplinary Research in Immunology and Disease (CIRID)

DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY UCLA SCHOOL OF MEDICINE CENTI:R FOR TIlE HEALTII SCIENCES 10833 LE CO/'ITE AVENUE LOS ANGELES. CAUFORNIA 90095 1747
November 13, 1997 Chen Xiao Ping, M.D. Department of Microbiology The Municipal Health and Anti-Epidemic Station of Guangzhou No. 23, 3 rd Zhongshan Road Guangzhou 510080, P.R. China Dear Dr. Chen:
(310) 825-6568
(310) 206-1318 (FAX)
I must thank you for a very pleasant and enlightening visit to Guangzhou and to The Municipal Health and Anti-Epidemic Station. Both are very impressive. You and Dr. Shi Wen lun were very kind to meet me at the train station and to take me to the hotel and then see that I had lunch, and later in the evening to take me on a driving tour of Guangzhou. The Pearl River, especially at night, is quite impressive, and all of the lights and activity of the streets are quite amazing in that it goes on and on with other activities such as the huge trade fair. Clearly, Guangzhou is a major and dynamic center in China. The afternoon meetings with Dr. Xiao Bin Quan and his associates Dr. Wang Ming and Professor Xiu Qiong of the AIDS laboratory and Dr. Raoji Li, the parasitologist, were quite impressive colleagues of yours. Also, I particularly enjoyed talking with Dr. Xu Hui Fang, the epidemiologist, who clearly has an important role in AIDS research in The Municipal Health Group. They were kind to answer my many questions. It is clear that Dr. Xiao Bin Quan is a dynamic leader. AJso, the Municipal Health and Anti-Epidemic Station is an interesting place to work with many resources that should be of great assistance to you. I was impressed with their interest in your proposal for Malarial Therapy. It . seemed to me that there was substantial support for your work. The opportunity to talk with so many of your colleagues was very valuable. They represent many resources. Unfortunately, with all of the activities, there were one or two questions that I had not had a chance to discuss with you. One has to do with
where the HIV+ patients in your Malarial Therapy study would be seen during the febrile periods with malarial infection. Will they also be at a single hospital during the time that they have malaria or will they be at home? Is there a physician at one of the hospitals who is involved in this study, or are you entirely responsible for the health of the patients during the time of the experimental induction of malaria until its cure? A clear delineation of responsibilities and roles of individuals participating in studies is important for the success of clinical trials such as the one that you have proposed. I do understand that you have the capacity to get the blood samples and see people in follow-up through the facilities of the Anti-Epidemic Station. I can see that you have established a good relationship with Dr. Yu Chun Shan, Chief of the Central Laboratory at the Sun Yat-Sen University of Medical Sciences and Hospital. It is not clear to me, however, that his technician has agreed to accept HIV positive samples. He seemed extremely reluctant during the time we visited there. I have seen this sort of problem before from technical people. I am sending, separately, information about handling the samples in relation to the machine. I hope that there are no further difficulties in having CD4 tests done there. Indeed, it would be very important to have blood samples from some of your patients tested by flow cytometry and be sure that testing runs smoothly before you start your critical induction of malaria. I believe Dr. Heimlich will want reassurance on this point. It is possible that Emily Huang, who is a very knowledgeable person in the Central Laboratory group, might be of help. Certainly, she is more comfortable with spoken and written English than Professor Yu. Indeed, we will all be interested to know what the CD4 levels are in your patients before therapy as well as in control subjects. You remember, I am sure that all clinical trials in the USA obtain CD4 T cell measurements on two (2) blood samples before starting the treatment. I am writing to Dr. Heimlich about the use of intravenous drug abusers in the study. I have talked to one of the leaders of the AIDS Clinical Trial Group in the United States who assures me that most of the clinical trials in the United States currently involve some HIV+ individuals with drug abuse. The requirement, of course, is that they be able to stay on the protocol. I think this is less of a problem in your case when the treatment period is a defined period of time. Could you include at least 2 HIV+ non-IV drug abusers in the whole study, with the bulk of
2
the patients being drug abusers. It is important that you have a protocol for serial evaluation before, during and after the Malarial Therapy and that the evaluation includes assessments for other diseases such as TB, hepatitis or other infections. Be sure to save plenty of plasma on each date, as you will need it for viral load testing as well as other studies. Again, I want to thank you for your courtesy and for a very stimulating visit in Guangzhou.
'Dt fL~~
John L. Fa ey, M.D. Director, CIRID at UCLA Chair, Clinical Immunology Committee, International Union of Immunological Societies (lurS) JLF/dm P.S. Enclosed are copies of several pictures I took during my visit. cc: Henry Heimlich, M.D. Hong Bass, M.D., Ph.D. Evelyn Najera, M.P.H.
<..~
John L. Fahey , M. D.
UNIVERSITY OF CALIFORNIA . LOS ANGELES
MICROBIOLOGY &. IMMUNOLOGY UCLA SCHOOL OF MEDICINE CENTER FOR THE HEALTH SCIENCES 10833 LE CONTE AVENUE LOS ANGELES. CALIFORNIA 90095. 1747
---"':;t::-~i
".~
MG-13
.
J-
'.,
.. ..
~ --'
I. "
: . ..
, ~ :t~
Henry J. Heimlich, M.D. , Sc.D. " President The Heimlich Institute 2368 Victory Parkway, Suite 410 Cincinnati, OH 45206
"'rl .,
"" ,
o.'S'2.Clr,,-'2.~\Cl
Cl~
1111.111 .111111111111111111111111111111111111111111111111111 1 1
MEMORANDUM
November 20,1997 To:

David Mahoney
Ed Rover
cc:
From:
Valerie Harper
.~
, . , .' . :
"
1.
The enclosed material Is a documented progress report on Dr. Heimlich's MIT. The November 4th telephone conversation between Dr. Heimlich and Dr. Fahey and the letter from Dr. Fahey to Dr. Chen which reviews his trip to China as well as his continued support and involvement with MIT. In addition, I am including the latest NIH news release re: HIV which says that HIV persists and "can replicate despite prolonged combination therapy". The next ten patients to be treated with MIT are available and the specific protocol requested by Dr. Fahey is being organized. ~ ;;,;4vovtV g~ flcc
2.
~~
It.};
3.
Dr. Fahey believes that MIT has a sound, scientific rationalef"nd is "~yperio"" since IL-2 is an expensive. genetically engineered interieukin that causes "Severe reactions and must be repeated every month or two in addition to being more costly.
It is clear that the Protease Inhibitor drugs have been successful in giving HIV patients remlsAion without cum.
4.
5.
In conclusion. Dr. Heimlich would appreciate the opportunity for the three of us to discuss either in person or on a conference call in December, some of the ideas he feels strongly about re: the future strategy for MIT.
mailbox:/C%7C/Program% .. ms.edu.cn%20&number=12
mailbox:/C%7C/Program% . ms.edu.cn%20&number=12
SUbject: Send reagents Date: Fri, 21 Nov 199708:03:39 +0800 From: "Chen Xiao Ping" <chenxp@gzsums.edu.cn> To: "Najib Aziz" <naziz@ucla.edu> CC: "Dr. Eric G. Spletzer" <egspletzer@hotmail.com>, "Dr. Henry 1. Heimlich" <Heimlich@iglou.com>, "Henry 1. Heimlich" <heimlich@juno.com>, "Debbie" <dmathies@microimmun.medsch.UCLA.edu>
Dear Dr. Aziz: Dr. Fahey'S visit to Guangzhou last month was very helpful to our project of malariotherapy for HIV infection. Now we will start the next batch of clinical trials very soon. So I hope that you send us the following reagents as soon as you can by Federal Express or other express. 1. Kits for flow cytometry including CD4, CD8, CD25, HLA-DR and CD4 PCD (apoptosis) testings. 2. Kits for activation markers including NPT, B-2-M, TNF-a, IFN-r, sTNF-aRII, sIL-2R and plus sing IL-2 ( if possible, plussing IFN-a, IL-6 and IL-10 ) testings. By the way, I have now another hypothesis that malaria stimulates a shift from Th2 to Th1 pattern of immune response in HIV patient. I believe that it will be confirmed by our coming trials. Best regards. Dr. Chen Xiao Ping Research Associate Professor
1 of 1
11/21/97 09:18:54
...............
facsimile
TRANSMITTAL
2368 VICTORY PARKWAY SUITE410 CINCINNATI OHIO 45206 513-22HlOO2 fax 513-221-0003
~----------------------------
To:
Of: Fax: Pages: Date:
Valerie Harper The Eleanor Naylor Dana Charitable Trust (212) 754-2892 2, including this cover sheet. November 21,1997
Dr. Aziz is Dr. Fahey's assistant.
From the desk of... Henry J. Heimlich, MD The Heimlich Institute
mailbox:/C%7C/Program% . ms.edu.cn%20&number=12
SUbject: Send reagents Date: Fri, 21 Nov 199708:03:39 +0800 From: "Chen Xiao Ping" <chenxp@gzsums.edu.cn> To: "Najib Aziz" <naziz@ucla.edu> CC: "Dr. Eric G. Spletzer" <egspletzer@hotmail.com>, "Dr. Henry 1. Heimlich" <Heimlich@iglou.com>, "Henry 1. Heimlich" <heimlich@juno.com>, "Debbie" <dmathies@microimmun.medsch.UCLA.edu>
Dear Dr. Aziz: Dr. Fahey'S visit to Guangzhou last month was very helpful to our project of malariotherapy for HIV infection. Now we will start the next batch of clinical trials very soon. So I hope that you send us the following reagents as soon as you can by Federal Express or other express. 1. Kits for flow cytometry including CD4, CD8, CD25, HLA-DR and CD4 PCD (apoptosis) testings. 2. Kits for activation markers including NPT, B-2-M, TNF-a, IFN-r, sTNF-aRII, sIL-2R and plus sing IL-2 ( if possible, plussing IFN-a, IL-6 and IL-10 ) testings. By the way, I have now another hypothesis that malaria stimulates a shift from Th2 to Th1 pattern of immune response in HIV patient. I believe that it will be confirmed by our coming trials. Best regards. Dr. Chen Xiao Ping Research Associate Professor
1 of 1
11/21/97 09:18:54
Juno e-mail printed Fri, 12 Dec 199709:49:44, page 1 From: "Chen Xiao Ping" <chenxp@gzsums.edu.cn> Return-path: <chenxp@gzsums.edu.cn> To: "Evelyn" <enajera@microimmun.medsch.UCLA.edu> Cc: "Mathieson, Deborah" <dmathies@microimmun.medsch.UCLA.edu>, "Henry J. Heimlich" <heimlich@juno.com>, "Dr. Eric G. Spletzer" <egspletzer@hotmail.com>, "Dr. Henry J. Heimlich" <Heimlich@iglou.com>,"NajibAziz" <naziz@ucla .edu> Date: Fri, 12 Dec 199711:04:42 +0800 Subject: Reagent package Message-ID: <199712120300.LAA01200@ gzsums.edu.cn > X-Status: Read X-Mailer: Microsoft Internet Mail 4.70.1155 Dear Evelyn: We have just received the reagent package for testing sTNF-RIl and NPT and the enclosed letter model that you wrote to New Delhi Customs authorities. We have to pay customs tax this time. I suggest that you do not send other reagents untill we have delt with the customs tax-free procedure. It is complicated in China and different from India. But I will let you know this as soon as possible. Thank you. Merry Christmas and happy New Year! Dr. Chen Xiao Ping
HEIMLICH INSTITUTE
2368 VICTORY PARKWAY SUITE 410 CINCINNATI OHIO 45206 513-22Hl002 fax 513-221-Q003
..............
facsimile
TRANSMITTAL
To:
Of:
Valerie Harper
~--------------------------
The Eleanor Naylor Dana Charitable Trust (212)754-2892 2, including this cover sheet. December 12, 1997
Fax: Pages: Date:
Just received this e-mail from Chen. It's a copy of a letter to Evelyn, John Fahey's secretary. This will make it possible for Chen to get started with the patients.
From the desk of ... Henry J. Heimlich, MD The Heimlich Institute
Juno e-mail printed Fri, 12 Dec 199709:49:44, page 1 From: "Chen Xiao Ping" <chenxp@gzsums.edu.cn> Return-path: <chenxp@gzsums.edu.cn> To: "Evelyn" <enajera@microimmun.medsch.UCLA.edu> Cc: "Mathieson, Deborah" <dmathies@microimmun.medsch.UCLA.edu>, "Henry J. Heimlich" <heimlich@juno.com>, "Dr. Eric G. Spletzer" <egspletzer@hotmail.com>, "Dr. Henry J. Heimlich" <Heimlich@iglou.com>,"NajibAziz" <naziz@ucla .edu> Date: Fri, 12 Dec 199711:04:42 +0800 Subject: Reagent package Message-ID: <199712120300.LAA01200@ gzsums.edu.cn > X-Status: Read X-Mailer: Microsoft Internet Mail 4.70.1155 Dear Evelyn: We have just received the reagent package for testing sTNF-RIl and NPT and the enclosed letter model that you wrote to New Delhi Customs authorities. We have to pay customs tax this time. I suggest that you do not send other reagents untill we have delt with the customs tax-free procedure. It is complicated in China and different from India. But I will let you know this as soon as possible. Thank you. Merry Christmas and happy New Year! Dr. Chen Xiao Ping
mailbox : /C%7C/Program% ... ms.edu.cn%20&number=18
Subject: Re: Patient selection Date: Thu, 18 Dec 1997 08:27:41 +0800 From: "Chen Xiao Ping" <chenxp@gzsums.edu.cn> To: <heimlich@iglou.com> CC: "Dr. Eric G. Spletzer" <egspletzer@hotmail.com>, "Henry J. Heimlich" <heimlich@juno.com>
Dear Dr. Heimlich and Dr. Spletzer: We have 20 HIV patients at hand, among them 3 are sexually transmitted and others are drug users. The most important thing right now is that we are waiting for the reagents from UCLA ( and we are dealing with the customs issue ) to screen CD4 levels of the patients due to other criteria of patient selection. According to the principal of scientific research, we need the same batch ( or the same resource ) of reagents to test patients before and after treatment. All things are progressing here in Guangzhou. The number of tested and officially reported HIV positive patients in China is about 2800 by now. All other numbers are estimated and I believe that nobodies know the exact number. But we can say that HIV/AIDS has been a real problem in China; in some regions such as Yunnan Province the problem has been really severe. Yes, we have received the funds from the Heimlich Instiute. Merry Christmas! Dr. Chen Xiao Ping
> > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > .> >
From: Dr. Henry J. Heimlich <heimlich@iglou . com> To: chenxp@gzsums . edu . cn Subject: Patient selection Date: Thursday, December 18, 1997 6:57 AM Dear Dr. Chen, We received copies of the e-mail concerning the import of test reagents, and are glad to see that things are proceeding. However, we are still interested in knowing how patient selection is going, especially for the sexually transmitted cases. A recent lecture by R. Peter Piot , Executive Director of the UNAIDS program, stated the following: "In China - on the other hand, dramatic developments with consistent increase in HIV infections may be expectedin the coming future. The national AIDS committee in China just released estimates projecting the number of people living with HIV/AIDS rising from 400,000 at the end of 1997 to about 1.2 million by the year 2000. Whereas most of the HIV infections in the past occurred in in j ecting drug users, the dramatic increases in sexually transmitted diseases in China suggest that the main mode of transmission of HIV may rapidly change in the coming years. STDs are becoming particularly widespread in China's coastal regions with their booming economies, growing disparities in wealth, and vas t population movements. A study in Yunnan Province, for example, has already shown how easily the epidemic can break out of the drug user group to their sex partners and ultimately their children. Here around 7% of the spouses of infected drug users are already infected with HIV. As elsewhere in Asia and the Pacific, where the tiger economies are bringing in new wealth, the potential also exists for an acceleration of the epidemic . " Do you feel this is accurate?
1 of 2
12/19/97 08:48:12
rnailbox:/C%7C/Proqram% rns.edu.cn%20&number=18
> Happy holidays! > > > Eric G. Spletzer. Ph.D. > > P.S. Did the funds we wired make to your account?
> We hope that everthing else is going well for you and your colleagues. > ~
2 of 2
12/19/97 08:48:12
Dr. Chen has sent the enclosed progress report stating he has twenty patients ready for treatment and is awaiting reagents from UCLA. His recent exchange with UCLA indicates reagents have arrived. As you wrote in your last letter, we have both been anxiously awaiting treatment of the ten patients. The delay has been worthwhile because it is due to success of our project beyond my greatest expectations. In addition to publishing our first paper, we have gained acceptance of malariotherapy and affiliation with one of the leading experts on AIDS immunology, Dr. John Fahey of UCLA. This recognition led to the NIH-sponsored, two-month trip of Dr. Chen to UCLA for training in the latest laboratory studies for AIDS and to development of a protocol for testing patients that is so thorough it must be accepted by all experts in the field. The NIH, through Dr. Fahey, is now providing reagents to Dr. Chen. Dr. Fahey made a special trip to China and, as you know, wrote a glowing report on the facilities and the caliber of scientists working with Dr. Chen. During this period, it was officially documented that the highly touted drug treatment of AIDS is not a cure and is failing to hold back the virus in fifty percent of cases. We have the only existing treatment with the potential for cure. When we first spoke, I advised it would take one-and-a-half million dollars to prove the effectiveness of malariotherapy and I have no reason to change that figure. The sooner we can obtain the balance of that amount, the quicker we can treat one hundred patients and prove we have the ability to cure HIV infection. The Chinese will act much more rapidly when they know we are prepared to do this since it takes just as many professionals and, just as much laboratory and clinical equipment, to treat ten patients as to treat one hundred, particularly since the reagents are available. I hope you will consider raising these funds through those who hold you in such high regard for your knowledge and accomplishments in the world of medical science. With warm regards and friendship,
,
i ~)
mailbox : /C%7C/Program% ... ms.edu.cn%20&number=18
Subject: Re: Patient selection Date: Thu, 18 Dec 1997 08:27:41 +0800 From: "Chen Xiao Ping" <chenxp@gzsums.edu.cn> To: <heimlich@iglou.com> CC: "Dr. Eric G. Spletzer" <egspletzer@hotmail.com>, "Henry J. Heimlich" <heimlich@juno.com>
Dear Dr. Heimlich and Dr. Spletzer: We have 20 HIV patients at hand, among them 3 are sexually transmitted and others are drug users. The most important thing right now is that we are waiting for the reagents from UCLA ( and we are dealing with the customs issue ) to screen CD4 levels of the patients due to other criteria of patient selection. According to the principal of scientific research, we need the same batch ( or the same resource ) of reagents to test patients before and after treatment. All things are progressing here in Guangzhou. The number of tested and officially reported HIV positive patients in China is about 2800 by now. All other numbers are estimated and I believe that nobodies know the exact number. But we can say that HIV/AIDS has been a real problem in China; in some regions such as Yunnan Province the problem has been really severe. Yes, we have received the funds from the Heimlich Instiute. Merry Christmas! Dr. Chen Xiao Ping
> > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > .> >
From: Dr. Henry J. Heimlich <heimlich@iglou . com> To: chenxp@gzsums . edu . cn Subject: Patient selection Date: Thursday, December 18, 1997 6:57 AM Dear Dr. Chen, We received copies of the e-mail concerning the import of test reagents, and are glad to see that things are proceeding. However, we are still interested in knowing how patient selection is going, especially for the sexually transmitted cases. A recent lecture by R. Peter Piot , Executive Director of the UNAIDS program, stated the following: "In China - on the other hand, dramatic developments with consistent increase in HIV infections may be expectedin the coming future. The national AIDS committee in China just released estimates projecting the number of people living with HIV/AIDS rising from 400,000 at the end of 1997 to about 1.2 million by the year 2000. Whereas most of the HIV infections in the past occurred in in j ecting drug users, the dramatic increases in sexually transmitted diseases in China suggest that the main mode of transmission of HIV may rapidly change in the coming years. STDs are becoming particularly widespread in China's coastal regions with their booming economies, growing disparities in wealth, and vas t population movements. A study in Yunnan Province, for example, has already shown how easily the epidemic can break out of the drug user group to their sex partners and ultimately their children. Here around 7% of the spouses of infected drug users are already infected with HIV. As elsewhere in Asia and the Pacific, where the tiger economies are bringing in new wealth, the potential also exists for an acceleration of the epidemic . " Do you feel this is accurate?
1 of 2
12/19/97 08:48:12
> Happy holidays! > > > Eric G. Spletzer. Ph.D. > > P.S. Did the funds we wired make to your account?
> We hope that everthing else is going well for you and your colleagues. > ~
2 of 2
12/19/97 08:48:12
VALERIE HARPER
139 E. 94tb Street 212-289_0747
New York, New York 10128
<.
~{I-
~m\~,~
QW
OW'
~~ ik~~~ ~ B 'l~ ~l ~
OM
~~Q( ~\}j 6~t(\\j ~ \iL~4~

C\D
O(G \~( ~1JQf(
~ d~~\)c~\O
f
D().r
OU(
~(~'7
D8C4t " u.\
\(\n~ Ut~ {~ .r( ~
Juno e-mail printed Tue, 13 Jan 199820:16:46, page 1 From: "Najera, Evelyn" <ENAJERA@microimmun.medsch .ucla .edu> Return-path: <ENAJERA@microimmun.medsch .ucla.edu> To: Chen Xiao Ping <chenxp@gzsums.edu .cn> Cc: "Mathieson, Deborah" <DMATHIES@microimmun.medsch.ucla.edu> ,"HenryJ. Heimlich" <heimlich@juno.com> Date: Mon, 12 Jan 98 12:04:00 PST Subject: Reagents and customs Message-ID: <34BA77A9@deans.medsch.ucla .edu> X-Status: Read X-Mailer: Microsoft Mail V3 .0
Dear Dr. Chen: I hope you are having a pleasant beginning in 1998. Thank you for the photos and for your wishes. I will also forward the photos to Matt which
I
am sure he will be pleased to receive . Thank you for sending such thorough explanation on your customs situation. You may also want to speak with 2 of our trainees in China conducting work there. They have been able to obtain clearance through customs with the same documentation I provided to you and DHL. They may be able to provide some advise on the procedure from their end : 1) Dr. Hong Wang-School of Basic Medical Sciences Tel. 86-106-209-1155 Fax 86-106-209-1436 2) Dr. Xudong Lin-Chinese Academy of Preventive Medicine Tel. 86-106-353-8621-71 Fax. 86-106-302-2960 In the meantime, I will discuss this issue with Dr. Fahey and we will be in touch with you. Best Regards, Evelyn
From: Chen Xiao Ping To: Mathieson, Deborah Cc: Najib Aziz; Dr. Eric G. Spletzer; Dr. Henry J. Heimlich; Evelyn; Henry J. Heimlich Subject: Reagents and customs Date: Wednesday, January 07,1998 9:18AM Dear Dr. Fahey: It is complicated to deal with customs duty-free in China . We have not known the procedure until just now. We need in advance your donation letter ( by express, not by fax) in which all reagents and their values should be
.)
January 23, 1998

45200
513-221-(0)2 lax 513-221{(X)3
John L. Fahey, M.D. Director, CIRID at UCLA Chair, Clinical Immunology Committee, International Union of Immunological Societies University of California Department of Microbiology and Immuno!ogy\UCLA School of Medicine Center for Health Sciences 10833 Le Conte Avenue Los Angeles, CA 90024-1747 Dear John: It was good speaking with you the other day. Enclosed is the paper we have written and Peter Piot's speech. I anticipate your comments. We seem to be progressing nicely in China and I am looking forward to my visit there. What would you think of extending the treatment to other Asian countries such as India, Thailand or the Philippines? Would any of the doctors with whom you work in those areas be interested? To bring you up-to-date on my health, enclosed is one article that appeared after Election Day. The picture makes me look as if I am in a straight jacket! Some write-ups and TV reports sounded like an obituary, but as Mark Twain said more than 100 years ago, in 1897, "The rumors of my death are greatly exaggerated." My cardiac exams came out 100% normal, but I missed my trip to South Africa. Having had a week of skiing two weeks ago, and my reg~ennis games, I can't complain.
/7
Wi
best wis!le(/
~Jl J. Heimlich, M.D., ScD . .IPresident
encl.
..............
facsimile
TRANSMITTAL
2368 VICTORY PARKWAY SUITE 410 CINCI NNATI OHIO 45206 513-22HXlO2 fax 51 3-221-0003
~--------------------------
To:
Valerie Harper The Eleanor Naylor Dana Charitable Trust (212) 754-2892 2, including this cover sheet. April 21 , 1998
Of:
Fax: Pages: Date:
From the desk of ... Vicki Roberts Associate Director The Heimlich Institute
Dr Alan 8 Stone
Medical Research Consultant

38 Hollycroft Avenue LONDON NW370N mail alan.stone@headoffice.mrc.ac.uk Telephone & Fax: 01714318532
Dr Henry J Heimlich MD DSc The Heimlich Institute Foundation Incorporated 2368 Victory Parkway Suite 410 Cincinnati, Ohio 45206 USA Dear Dr Heimlich
People to People Ambassadors Program: AIDS expert delegation to China

I was very sorry indeed to hear that you were unwell, but your being unable to lead the above delegation gave me the opportunity to do so! I have just returned from China and thought you might like to have a copy of my brief report (enclosed). I thought you might be especially interested in our experience of the malariotherapy work which you yourself initiated. Our view of this is covered in Section 13 of the report. It is of course difficult to carry out a proper clinical trial in China, not least because the necessary patient numbers are not available. What struck me most about this approach is that (a) there is a solid rationale for it and (b) ifit works in HIV infection it may be the only available treatment for most of the developing world, where drug ' cocktails ' are too expensive to contemplate. I mentioned to our colleagues in Guangzhou that I would approach the UN AIDS Programme and WHO about the possibility of collaboration (and funding) for a welldesigned malariotherapy trial. I have no idea at this point as to how they might react to this suggestion. Naturally, nothing is guaranteed, but I will certainly try my best. With best wishes Yours sincerely
Alan Stone
",
LE
375 Park Avenue New York, New York 10152 (212) 754-2890 FAJ212) 754-2892
TrusteeS
David Mahoney,
June I, 1998
Chainnan A.J. SignOlile,

Treasurer Roben A. Good, M.D. Carlos Moseley Roben E. WISe, M.D.
Dr. Henry J. Heimlich The Heimlich Institute The Goetze Center 415 Straight Street Cincinnati, Ohio 45219 Dear Hank: Valerie has advised me that your Institute has now become affiliated with The Deaconess Hospital in cincinnati. It is a fine organization and you should be very pleased. Keep up the good work. I am glad you are back safely from Iran. Give our best to Jane. Warmest best wishes,
~~
DM/pm cc: Ms. Valerie Harper
...............
facsimile
TRANSMITTAL
I St-RA:lqltr 01 off i~~11
V.sr~ -J.~ql
~----------------------------
To:
Of:
Valerie Harper The Eleanor Naylor Dana Charitable Trust (212) 754-2892 2, induding this cover sheet. June 23, 1998
Fax: Pages: Date:
The following is FYI.
From the desk of ... Vicki Roberts Associate Director The Heimlich Institute

BERKELEY DAVIS IRVINE LOS ANGELES RIVERSIDE SAN DI EGO SAN FRANCISCO SANTA BARBARA
UCLA
SANTA C RUZ
June 15, 1998 Dr. Henry J. Heimlich Deaconess Hospital 311 Straight Street Cincinnati, OH 45219 Dear Henry,
DEPARTMENT OF MIC ROBIOLOGY AND IMMUNOLOGY UCLA SCHOOL OF MEDICINE CENTER FOR THE HEALTH SCIENCES 10833 LE CONTE AVENU E LOS ANG ELES . CALIFORNIA 90024-1747
(310) 825-6568 (310) 206-1318 (FAX)
I was interested to catch up on your many activities. The move to Deaconess Hospital sounds like an advantageous change for you. The trip to Iran must have been interesting. I was glad to hear that things were opening up there again but not surprised to hear that you were again leading the way. I was pleased to discuss the progress that Chen Xiao Ping is making in Guangzhou. We do look forward to seeing the data that he has supplied to you and Eric Spletzer. The issue of the viral load measurements is one which we will be glad to help with. We can do the tests at UCLA but we need 2ml of plasma. I do not know if Chen Xiao Ping has made other arrangements for viral load measurements in China. If he has, we would like to know that the lab is experienced and satisfactory. We certainly would want to check some of the samples at UCLA. However, we can do them all but they could be sent to us perhaps 4-6 months into the study so that the samples could be tested in a batch style. We will be in contact with Chen Xiao Ping about arrangements to send the samples. Of course, we would want a small number of samples to be sent first to be sure the process of shipment works all right and I think it will take several months to work this out. We have supplied reagents to him in the past. However, we would appreciate assistance with the cost of the viral load test. They cost about $175 each because of the cost of the reagents and the equipment. We will be glad to share this with you 50:50. It would certainly be of great help to us. In considering other possible sites for malarial therapy, I would like to wait until this study is further along and we have good data on the findings in the current study. I will be glad to discuss this with you a bit further on. With best regards, I remain sincerely yours,
John L. Fahey, M.D. Director, CIRID at UCLA Chair, Clinical Immunology Committee, International Union oflmmunological Societies (lUIS) JLFlkw
cc: Naj ib Aziz
QL -!

BERKELEY DAVIS IRVINE LOS ANGELES RIVERSIDE SAN DI EGO SAN FRANCISCO SANTA BARBARA
UCLA
SANTA C RUZ
June 15, 1998 Dr. Henry J. Heimlich Deaconess Hospital 311 Straight Street Cincinnati, OH 45219 Dear Henry,
DEPARTMENT OF MIC ROBIOLOGY AND IMMUNOLOGY UCLA SCHOOL OF MEDICINE CENTER FOR THE HEALTH SCIENCES 10833 LE CONTE AVENU E LOS ANG ELES . CALIFORNIA 90024-1747
(310) 825-6568 (310) 206-1318 (FAX)
I was interested to catch up on your many activities. The move to Deaconess Hospital sounds like an advantageous change for you. The trip to Iran must have been interesting. I was glad to hear that things were opening up there again but not surprised to hear that you were again leading the way. I was pleased to discuss the progress that Chen Xiao Ping is making in Guangzhou. We do look forward to seeing the data that he has supplied to you and Eric Spletzer. The issue of the viral load measurements is one which we will be glad to help with. We can do the tests at UCLA but we need 2ml of plasma. I do not know if Chen Xiao Ping has made other arrangements for viral load measurements in China. If he has, we would like to know that the lab is experienced and satisfactory. We certainly would want to check some of the samples at UCLA. However, we can do them all but they could be sent to us perhaps 4-6 months into the study so that the samples could be tested in a batch style. We will be in contact with Chen Xiao Ping about arrangements to send the samples. Of course, we would want a small number of samples to be sent first to be sure the process of shipment works all right and I think it will take several months to work this out. We have supplied reagents to him in the past. However, we would appreciate assistance with the cost of the viral load test. They cost about $175 each because of the cost of the reagents and the equipment. We will be glad to share this with you 50:50. It would certainly be of great help to us. In considering other possible sites for malarial therapy, I would like to wait until this study is further along and we have good data on the findings in the current study. I will be glad to discuss this with you a bit further on. With best regards, I remain sincerely yours,
John L. Fahey, M.D. Director, CIRID at UCLA Chair, Clinical Immunology Committee, International Union oflmmunological Societies (lUIS) JLFlkw
cc: Naj ib Aziz
QL -!
June 22, 1998
311 STRAIGHT STREET CINCINNATI OHIO 45219 513-559-2391 FAX 513-559-2403 heimlich@igloucom
Mr. David Mahoney The Eleanor Naylor Dana Charitable Trust 375 Park Avenue, Suite 3807 New Yor~ New York 10152
Dear David: Thank you very much for your good wishes. Being affiliated with Deaconess greatly expands our research potential. Most importantly it establishes The Heimlich Institute as a permanent institution. We have been provided with a fine facility and moved in June I S[ .
An e-mail from Dr. Chen today says "A piece of good news is that the results ofposttreatment CD4 tests by flow cytometry are very good with no clinical complication in our 10 new cases." Laboratory studies are being done in China and in Dr. Fahey's laboratories at UCLA
Iran was a most interesting and gratifying experience. Everyone knew the Heimlich Maneuver, and the people were warm and friendly to me. I spoke at nine institutions The Iranian Life Saving Federation, Universities, Hospitals, and Medical Colleges. Congratulations on the national attention your fine book is getting. Seeing the picture of you presenting a copy to Hillary Clinton was most impressive. Janejoins me in sending our love to you and Hillie, and hope to see you soon. Sincerely,
c.c. Valerie Harper
Affiliated with The Deaconess Associations, Inc.
DEACONESS AssOCIATIONS
311 Straight Street Cincinnati, Ohio 45219 (513) 559-2100
CONTACT: Barbara Lohr or - Bryan E. Wright
(513) 559-2760
FOR IMMEDIATE RELEASE
National Health System Steps up to Promote Work of Renowned Lifesaver

(JUNE 30, 1998) -- A joint endeavor unveiled today will ensure the long-term continuation of the work of one of the century's most influencial physicians. The Heimlich Institute, directed by founder and namesake Henry Heimlich, M.D., recently became a member of Deaconess Associations, Inc., a national health system based in Cincinnati. Through the partnership, Deaconess will assume responsibility for advancing and promoting the mission and vision of the Heimlich Institute in perpetuity. Why? According to Deaconess president and chief executive officer E. Anthony Woods, inviting the Institute on board gave the health system a rare opportunity to positively impact people throughout the world. "Deaconess and the Heimlich Institute share a common commitment to values such as compassion, creativity and service," Woods said. "We felt that Dr. Heimlich's innovative spirit and caring tradition should be preserved and advanced for the benefit of future generations." Dr. Heimlich is best known for developing the Heimlich Maneuver, a technique used since the 1970s to save choking victims worldwide. He also invented the Heimlich Chest Drain Valve, which was first used during the Vietnam War to save the lives of soldiers and civilians on both sides. The device continues each year to save thousands of people with chest wounds who would otherwise die from fluid and air buildup resulting in a collapsed lung. Originally founded in New York in the 1960s, the Heimlich Institute moved to Cincinnati 30 years ago. Now located on the campus of Deaconess Hospital in Cincinnati, the Institute continues to conduct scientific, cultural and social research into issues of importance to the medical and scientific community, as well as addressing social concerns in the United States and abroad.
(MORE)
HEIMLICH / DEACONESS JUNE 30, 1998

2-2-2-2
"I welcome the opportunity to work with Deaconess Associations," said Dr. Heimlich. "This affiliation ensures that the Heimlich Institute will always be led by creative scientists who will continue to seek logical, frequently simple, methods of saving lives." Through the Heimlich Institute, Dr. Heimlich is now researching new treatments for AIDS and cancer, and he is teaching the use of the Heimlich Maneuver to save drowning victims and asthma sufferers. Dr. Heimlich is also working to promote peaceful solutions to international problems through the Heimlich Institute's "A Caring World" program. In May, he traveled to Iran to speak with Iran Life Saving Federation members and healthcare professionals, as well as college students and faculty, to gather their insight on the relationship between Iran and the United States. His visit was subsequently detailed in the Iran News. Deaconess Associations, Inc. is a multi-faceted, not-for-profit healthcare system which provides a diversity of health services nationwide. In addition to the Heimlich Institute, key divisions include Deaconess Hospital of Cincinnati, Deaconess Long Term Care, Inc., Deaconess HomeCare, Inc., MCH Services and the Deaconess Health Associations Fund.
-- 30 --
July 8,1998
311 STRAIGHT STREET CINCINNATI OHIO 45219 513-559-2391 FAX 513-559-2403 heimlich@iglou.com
Ms. Valerie Harper The Eleanor Naylor Dana Charitable Trust 375 Park Avenue New York, NY 10152 Dear Valerie, In keeping with our telephone discussion last week, I have, as you requested, summarized for the files our progress re Malaria Therapy (MT uses Malaria Vivax which is curable, as opposed to the virulent Falciparum Malaria.). Background The following is a brief recap of the past two years: The initial funding began in June of 1996 by the Eleanor Naylor Dana Charitable Trust. The $250,000 granted to date covers the second group of ten patients presently undergoing treatment. Presentation of the MT abstract at the Worldwide AIDS Conference 1996 in Vancouver. At the Worldwide AIDS Conference, Dr. John Fahey of UClA, approached Dr. Heimlich to request a collaboration between himself, UCLA and Dr. Heimlich. In 1997, Dr. Chen, who spearheads the Heimlich MT clinical trials in China, at the invitation of Dr. Fahey of UCLA, spent two months at UCLA to establish a uniform blood-testing protocol for MT treatment in China. MT boosts the immune system increasing the CD4 T-cells of the HIV patients we treated. With no other treatment given, this increase of CD4 T -cells persisted for two-to-three years after the three-week course of MT was completed.
Present Status
Dr. Chen, who has been in charge of the Heimlich MT clinical trials in China, has been appointed Director of the Center for AIDS Control and Research in Guangzhou.
As of June 1998, nineteen patients have been treated with MT in China.
Eight of the first nine HIV-positive patients treated with MT are, clinically free of HIV after three years (one died of unrelated causes).
As of July 1998, the results of the CD4 test flow cytometry of the ten patients treated with MT in June of 1998, are very good with no evidence of clinical complications. '
If the ten patients currently being treated with MT are clinically free of HIV after six months, Dr. Fahey has agreed to treat U.S. patients with MT who have not responded to the present drug therapy now available in the U.S. This would perhaps be an appropriate time to approach your friend, Dr. Henri Meier of Hoffman La Roche in Switzerland, with the idea of trying to chemically replicate the curative properties of malaria parasites (Vivax) which strengthens the immune system.
You will recall my saying that drugs have never cured a virus, even a cold. Recognizing the failure of drugs, the NIH scientists and others who have spent billions researching drugs, immediately came up with developing a vaccine, another billion dollar expenditure. Scientists estimate that developing a vaccine will take ten years or more. In any case, a vaccine will not cure the thirty-four million already infected with HIV. In reporting on the 1998 Worldwide AIDS Conference in Geneva, The New York Times headline stated, "AIDS MEETING ENDS WITH LITTLE HOPE OF BREAKTHROUGH - Drugs and Vaccines Have Had Setbacks, and Politics Has Hindered Other Efforts". MT has the strongest rationale for the successful treatment of HIV infected patients and it can be offered to the world at little cost. As mentioned above, we have started treatment on ten new patients. Early results are favorable and the treatment has proven safe. When I first spoke with David, I said it would take $1.5 million to complete studies that prove the value of MT. That figure has not changed. We owe it to the millions who are dying of HIV infection to obtain those funds now and treat enough patients to prove the validity of MT. With additional funds, we can make arrangements to treat HIV patients in the U.S., particularly those who have undergone drug treatment that failed. Dr. Fahey agrees with this. In the early 1950's, U.S. medical authorities tried to prevent Jonas Salk from testing his
polio vaccine. Clinical trials were undertaken because Basil O'Connor, founder of the Polio Foundation, fought the medical establishment on Salk's behalf. MT requires the same kind of courage. As you know, The Deaconess Associations, Inc., a national health corporation which consists of twenty-seven institutions in eleven states, invited The Heimlich Institute to become a part oflhe prestigious Deaconess Hospital in Cincinnati. We moved into our new quarters last month. This affiliation established the Institute in perpetuity and our work will continue after I am gone. In the event David obtains the use of the VA hospital he has in mind for treating patients, the Deaconess Associations, Inc., will be invaluable in organizing staff and administration of the hospital. I hope you will discuss with David the importance of raising the funds needed at this time. Such funds will enable us to enlarge our clinical trials and save the world from this epidemic.
Henry 1. Heimlich, M.D., SeD. President
DEACONESS FOUNDATION
3 11 Straigh t Street C incinnati, Ohio 452 19 (5 13 ) 559-2323 Fax (5 13) 475 -5057
July 14, 1998
Ms. Valerie Harper The Eleanor Naylor Dana Charitable Trust 375 Park Avenue New York, NY 10152 Dear Ms. Harper, I thought that you might be interested in receiving a copy of our recently published 1977 Annual Report in addition to several articles regarding Dr. Heimlich. They will provide you with an introduction to our corporation prior to your visit. We are very excited about Dr. Heimlich and The Institute joining us and look forward to meeting you next week. Have a safe and pleasant trip.
Sincerely,
Charles P. McDowell President
Serving Th e Deaconess A ssociaLions, Inc.
July 20, 1988
liEIMUCH
FOUNDATION, INC.
INSTITUTE
Mr. Eric R. Rippel, President Fannie E. Rippel Foundation Post Office Box 758 Madison, NJ 07940 Re: Dear Eric: The $25,000 fourth installment of the grant for the clinical trial in Mexico, "Malariatherapy for Cancer," has been received and is greatly appreciated by ~he Heimlich Institute Foundation. Enclosed are the detailed reports of expenditures and copies of cancelled checks for $30,000 to the Instituto Nacional de Cancerologia (I.N.C.). All expenses other than payments to the I.N.C. are made Under the auspices of Xavier University and are solely tied to the Mexican research. Note that personnel salaries have diminished in recent months as less time has been required of employees. Expenses are within the framework of original expectations and will last for the 18 months budgeted. Substantial grant funds have had to be utilized, however, due to delays beyond our control or that of the Mexican physicians; during that period, salaries and ongoing expenses continued, as did research. The medical literature is regularly scanned by Dr. Carr and analyzed, and a research paper is being completed that you will soon receive. The delays encountered could not be anticipated and are consistent with medical exigencies related to start up of original research where clinical experience must be gained as treatment progresses. First, the Mexican City physicians had to establish a source of Plasmodium vivax malaria in other provinces, arrange for obtaining malarial blood donors, and create a system for preservation and transfer of the malarial blood. Cancer patients were then selected in keeping with the protocol. Over a period of time the first three terminal cancer patients volunteered for malariatherapy. Patient #1, a female with extensive rectal cancer, metastatic, received the first malarial blood transfusion in December. Malaria fever did not occur and after a month a second malarial transfusion was given. A total of four attempts to induce malaria were unsuccessful and after three to four months the patient left the hospital and, as a result of the advanced stage of her cancer, died at home two weeks later. Difficulty in inducing malaria may be related to an inadequate concentration of parasites in the donor blood, damage to cells during transfer, or the patient's resistance based on previous bouts of malaria. Another possibility in line with our concept is that the massive tumors conveyed an immunological response against the malaria in the same manner that the malaria works against cancer. Patient #2, male, had melanoma with metastases to the groin and lungs. Patient #3, male, has colon cancer with recurrent cancer in the pelvis, plus lung metastases. Both patients over a period of several weeks Report for the year ending June 30, 1988.
OHIO
45207 513 7451099
r
Page 2
received three malarial blood transfusions without induction of clinical malaria. The fourth transfusion induced malaria in both patients. Our Mexican colleagues attribute the successful innoculation to intravenous injection of very fresh malarial blood and the increase in malarial parasites in the blood obtained during the rainy season. Patient #3 completed malariatherapy and has returned home. Chest xrays showed possible shrinkage of cancer nodules. He will be reporting to the National Cancer Institute, Mexico City for follow-up. Patient #2 expired as he was completing a month of malariatherapy. Death was due to existing widespread metastases. Autopsy provided valuable information. Metastatic tumors in the lungs showed extensive necrosis (death of tumor cells). This necrosis involved extensive areas in the periphery of cancer nodules. Tumor cells remained only in the center of the nodules. Dr; Abelardo Meneses Garcia, pathologist at the I.N.C., projected the slides of tumor nodules, and stated that in their institute, which has extensive experience with melanoma, peripheral necrosis has never been seen. The slides were shown to Dr. Lawrence VonKoster, Professor of Pathology, University of Cincinnati, specialist in melanoma, without first telling him of the malariatherapy. He was shown slides of tumor biopsies before treatment and then subsequent to malariatherapy. Dr. VonKoster had previously seen neither peripheral necrosis of melanoma nodules nor such extensive necrosis. Dr. Carr has been researching texts and medical literature concerning melanoma and found that peripheral necrosis is rare and occurs in relation to immune reactions. The findings in Patient #2 strengthen the concept that malaria therapy destroys cancer cells, and that it may act through immune reactions as well as hyperthermia. The successful results have encouraged Dr. Beltran, Director, Instituto Nacional de Cancerologia, to offer to select patients with less advanced cancer and with cancers known to react favorably to stimulation of immunity. Although there were unavoidable delays, we have gained this valuable information that might not have been forthcoming had 20 patients been treated carelessly. Our Mexican counterparts have exhibited courage, brilliance, and persistence in the face of seemingly adverse circumstances. We can all be proud of our relationship with them. In previous communications you have received letters from the Beijing Cancer Institute, Beijing, China and a telex from India indicating interest in participating in these clinical trials. These communications illustrate the increasing acceptability of the principles of our project. India advises that many of their cancer patients requiring blood transfusion receive malarial blood, therefore, preparatory time can be avoided and retrospective information gathered and analyzed. China offers a degree of experimental control not available elsewhere. On Monday, July 18, 1988, I received a phone call from Dr. Xu, director of the Beijing Cancer Institute, who is in Washington, D.C. as guest of our National Cancer
Page 3 Institute of the N.I.H. Dr. Xu wishes us to visit Beijing in October to discuss establishing malaria therapy for cancer there. He will have 'an official invitation sent from the government of China on his return next week. The Rippel Foundation has supported this work patiently. We have all had some trepidation as it seemed to falter -- awaiting CDC cooperation, I.N.C. approval, and initial clinical results -- then each step resulted in acceptance and progress. How long does it take to find a cure for cancer? We are already ahead of methods for which billions of dollars and decades were spent with no decrease in the cancer rate for 50 years. I believe in this project and, as always, will continue to participate without compensation. I hope and trust that, in the next few years, we will see the successful results toward which we appear to be headed, and that the Rippel Foundation will continue to graciously support this work.
enry Heimlich, M.D., Sc.D. resident, The Heimlich Institute Professor of Advanced Clinical Sciences Xavier University HJH/nc Enc.
VALERIE HARPER THE ELEANOR NAYLOR DANA CHARITABLE TRUST Visit Schedule - Wednesday, July 22,1998
Time
9:00 - 9:30 a.m.
Host
Charles McDowell President, Deaconess Foundation
Activity
Review Foundation, Deaconess History, Organization Structure, Connection with Heimlich Institute
9:30 - 10:00 a.m.
Tim Crowley Chief Operating Officer
Deaconess Hospital Operations and Services
10:00 - 10:30 a.m.
Barbara Lohr Director, Corporate Mktg. & Communications
Tour - Hospice and Hospital Operations
10:30 - 11:30 a.m.
Dr. Heimlich and Eric Spletzer
Research Project
12:00 - 2:00 p.m.
Jim Pahls Chairman, Board of Trustees
Lunch, Board of Trustees Review, Deaconess Associations, Inc. Mission and Future Plans
2:00 - 3:00 p.m.
Heimlich's Residence
3:00 - 4:00 p.m.
Open House
OPEN HOUSE JULY 22,1998
Bardes, June Barrows, Winnie Bernstein, Shirley Briggs, M/M Peter Budig, Otto M., Jr. Capuder, Corrine & Daughter Carr, Ray & Kathy Collier, Peggy Collier, Phyllis Crowe, James Dehner, Joseph HI Board of Trustees
6J (~.:fltINI J v /) I i1-t
(?)
HI Board
Economou, Bob & Carole Gall, John & Nydia Gandersman, Nancy Gardner, Ted & Naomi Gertrude Goodwin, John Harper, Valerie Harrington, Sr. Jean Patrice Hatki, Anna Mae
President, HI Board of Trustees (Deaconess)
Phil Heimlich's Assistant
Dana Foundation
Deaconess
Heimlich, Jane Heimlich, Phil Helfrich, Reverend Herman J. Horwitz, M/M Harry (?) Jones, Dorsey & Kathy Collins Jones, Judge Nathaniel Kenworthy, Marlene McDowell, Charlie Malloy, Terri Messer, Mari Moll, William Moore, Jacqueline & Alex M l/ JeS ( '1)~-;tt N eergaard, M/M Richard Nerish, Dorothy Pahls, Jim & Kathy Richardson, Melody Sauer, Shirley Sternberger, M/M Claudio Stolley, M/M Alex Vogel, Rick President, Deaconess Auxiliary Deaconess President/General Mgr. Channel 12 (Deaconess)
"
VP HI Bd of Trustees,Cincinnati Council Member Deaconess
President, BankOne
HI Supporters HI Contributor
HI Board
July 22, 1988 Mr. Eric R. Rippel, President Fannie E. Rippel Foundation Post Office Box 758 Madison, NJ 07940 Dear Eric, Thanks for faxing me the letter from Pettit. It only takes three days for a fax to reach me since it goes to a friend who mails it to me! Dr. Pettit's description is quite typical of those who are invited to lecture in China, but, of course, he is not aware of my relationship with that country. As he indicates, we don't expect to learn much from the trip, but that is not our purpose, nor, with my experience in China, do we need "cultural infusions." Weare going toChina. to set up the malaria therapy program. When I was last in China, I saw a iaser therapy treatment for skin cancer being carried out in Henan Province in collaboration with the University of Rochester and it was progressing well -- there are so many patients available. There are invitations and there are invitations. It is one thing to know something about China and another to know Chinese friends. The Chinese have never forgotten my work with them in World War II and, in 1984, honored me with a dinner at the Great Hall of the People two days after President Reagan had his dinner there. The Chinese never forget -- they reach out with greater warmth and cooperation than even that we have received in Mexico. As you know, Dr. Hua (referred to by Dr. Pettit by his first name, Hong Shun -- Chinese family names are stated first), a highly respected Chinese surgeon, came to Cincinnati two years ago as a fellow to observe my work. He was responsible for spreading the Heimlich Maneuver in China and my name is known throughout the country as a result. His friends head various medical schools as well as the Ministry of Health. As I wrote in my recent report, Dr. Hsu, Director of the Beijing Cancer Institute, recently stopped to visit Dr. Hua (who now lives with his family in Los Angeles -- his wife is an obstetrician). Dr. Hsu took time to phone me from Washington when visiting the National Cancer Institute. Dr. Hua translated our malariatherapy protocol into Chinese (enclosed) and it was reviewed by medical colleges in Shanghai and Canton, the Beijing Cancer Institute, and the Ministry of Health. The hospitals we will visit in Canton, Shanghai, and Beijing have determined that malariatherapy for cancer is a viable study and are inviting us to establish a program comparable to Mexico. Dr. Hua's associates have already located a source of malaria in Canton Province.
OHIO
45207 5137451099
I am prepared to personally pay my own expenses and those of Dr. Hua, if necessary, because I am certain Dr. Hua's preparations have paved the way to accomplish our malaria therapy project. You are an essential participant in the project and must surely join us. It is also an opportunity you will appreciate that occurs once in a lifetime. ' Please call and let me know your thoughts.
\'vl~
HJH/nc Enc.
Heimlich, M.D.
facsimi l e
TRAN SM ITT A L
311 STRAIGH T STREET CINCINNATI OHIO 45219 513-559-2391 FAX 513-559-2403

heimlich@iglou.com
To: Fax: Pages: Date:
Mr. & Mrs. David Mahoney 011 -4121-613-4424 1, including this cover sheet. July 23, 1998
Dear David & Hillie, Jane and I offer our best wishes and love on your anniversary. May you have many, many more. We are so sorry we were unable to attend. Yesterday, The Heimlich Institute had a reception to mark our affiliation with Deaconess Hospital. Moving here has been very gratifying. It was particularly pleasant to have Valerie Harper attend the functions. Prior to the afternoon reception, she met with Trustees and officials of the Institute and the hospital, and gained a great deal of knowledge about the enthusiasm and status concerning our malariotherapy project. I am certain she will have a thorough report in your hands shortly. There is no question we are on the right track and will progress toward the final proof. The affiliation with Deaconess is a great plus in that direction. Sincerely,
8enefitin Humanity Through Health and Peace
DEACONESS fOUNDATION
311 Straigh t Street C incinn ati , O hio 452 19 (513) 559-2323 Fax (513) 475 -5057
July 23, 1998
Ms. Valerie Harper Administrator The Eleanor Naylor Dana Charitable Trust 375 Park Avenue New York, NY 10152 Dear Valerie: I enjoyed the opportunity to meet you and look forward to working together for the benefit of Dr. Heimlich's research. If you need any additional information regarding Deaconess, please don't hesitate to call me. In the meantime, I will work with Dr. Heimlich to prepare a project business plan including budget and timetable of events for your and David Mahoney's review. If you have a sample copy of a preferred format, please send it to me. Also, any information regarding either ofthe Dana Trusts for our files would be helpful. Again, it was a pleasure to see you and I hope you have a wonderful vacation in France. It sounds like a delightful time. Best regards,
Charles P. McDowell President
Serving The DeocoI7ess A ss()cioLions. I nc.
I~
DEACONESS FOUNDATION
\ 311 Straight Street*Cincinnati, Ohio 45219*Phonc (513) 559-2323*FAX (513)475-5057
TO:
Hank
FROM:
Charlie
DATE:
July 27, 1998
This fax transmission is 4 pages, including the cover sheet. If you have any difficulty with the reception of this transmission or have any questions, please call me (513) 559-2323 for assistance.
COMMENTS: Hank: Please review and comment. I will be at home (860-2717) if you need to discuss tonight. Loretta can make any changes on her word processor. The U. S. patient cost is based on $1,500 per day for 30 days ($45,000) plus four viral load tests at $500 each ($2,000). That leaves a $3,000 per patient buffe~,. the same as China for unanticipated ./ costs. Thanks
MALARIOTHERAPY PROJECT BUDGET Year One
A. STAFF
ROLE ON PROJECT
SALARY REOUIRED
FRINGE BENEFITS
TOTAL
Henry 1. Heimlich, M.D.
Principal Investigator
-0-
-0-
-0-
Eric Spletzer, Ph.D.
Research Associate Heimlich Institute
$21,000
$3,600
$24,600
Secretarial and Administrative
Administrative and clerical duties
$18,000
$3,200
$21,200
TOTAL STAFF COST:
$ 45,800
B.
SUPPLIES: Office $5,000
TOTAL SUPPLIES COST:
$5,000
C.
TRAVEL: Trips to China & Medical Conferences $10,000 Henry J. Heimlich, M.D. Eric Spletzer, Ph.D. $ 5,000
TOTAL TRAVEL COST:
$15,000
Page 2
Year One (Continued) Malariotherapy Project Budget
D.
OTHER EXPENSES: COSTS TOTAL
Institute Office Space & Equipment Usage Institute Office Telephone, Faxes, Computers, Postage & Federal Express Institute Office Bank Charges for Wire Transfers TOTAL OTHER EXPENSE:
$ 8,500 $ 4,000
500
$13,000
TOTAL NON-PATIENT CARE ONE YEAR COST:
$ 78,800
Page 3 CONSOLIDATED MALARIOTHERAPY THREE YEAR BUDGET
BUDGET CATEGORY
1st YEAR
2nd YEAR
3rd YEAR
TOTAL
PERSONNEL
$45,800
$ 50,400
$ 55,000
SUPPLIES
$ 5,000
$ 5,500
$ 6,000
TRAVEL
$15,000
$18,000 $15,000
$ 21 ,000
OTHER EXPENSES
$13,000
$ 18,000
TOTAL ANNUAL EXPENSE
$78,800
$88,900
$100,000
TOTAL NON-PATIENT CARE EXPENSE:
$267,700
PATIENT CARE COST $1,000,000
100 Chinese patients including treatments, hospitalization, laboratory tests, follow-up physicals and laboratory tests for 2 years; compliation, analysis, and pUblication of data. or
10 U.S. patients in addition to 50 Chinese patients including treatments, hospitalization, laboratory tests, follow-up physicals and laboratory tests for 2 years; compilation, anaylsis and publication of data.
TOTAL EXPENSE & PATIENT CARE COST:
$1,267,700
10 / 14 / 1995
19:39
2127542 892
DAtlATRUST
PAGE
01
The Eleanor Naylor Dana Charitable
Trust
FAX
Date:
.July 27, 1.998
Number of pages including C0ver sheet:
3 ---
To:
From:
Dr. Heimlich
Valerie Harper
PERSONAL CONFIDENTIAL
Phone: Fax phone:
Phone:
212-754-2890
Fax phone:
212-754-2892
CC;
REMARKS:
Urgent
!81 For your review
Reply ASAP
8J Please comment
1 0 / 1 4 / 1995
19 : 39
21 27542892
DANA TRUST
PAGE
02
July 24. 1998
375 Pari Avenue New Yorlr.. N~ Yon

10152 (212) 75+2890 FAX (212) 7542892
Thlstccs David Mahot\ty. Chairman AJ Signorile. Trt:"a.Surcr
Dr. Henry Heimlich The Heimlich Institute The Goetze Center 415 Straight Street Cincinnati Ohio 45219
Dear Hank:
Thank you and Jane for making me feel so at home in every way . It made all the difference to my visit. It was impressive even though well deserved to witness the enthusiasm of everyone I met at the Deaconess for The Heimlich 's Institute's achievements . and their commitment to assure the continuity and future of your vision.
Robot A. Good. M.D. CarlWMoscley Robert E. W~. M.P

. -1- .
, 1.
I hope that my candid approach In the various meetings we had was constructive . An honest and practical entente is critical for all the parties concerned to provide MT with an optimal environment for success. I do not th ink it unreasonable as we are only talking about a few months that we give Dr. Chen 's latest ten patients Inoculated with MT the consideration necessary. This yardstick is important. The Trust committed funds for this.
Thank you for working on the budget projection so swiftly w ith Charles McDowell. which should include the continuation of our work in China and the initial tra ils in the U.S. It was exdting to hear that the Deaconess would consider using the unoccupied space of the Vitas Hospice facility for the treatment of HIV /MT patients. Just th ink if we could eventually add UCLA's failed Protease inhibitors drug patients and the V& A Hospitals in the future . As you remarked It has only been two years and we have come a long way to achieving a solid foundation for such an enormous undertaking as MT. You truly have the support of David Mahoney . The Deaconess executives. Trustees . John Fahey. I can appreciate your impatience, the last stretch always appears to be the longest and the most demanding . Visionaries like yourself must find patience and due diligence trying
10 / 14 / 1995
19 : 39
2 1 27542892
DAI-IATRUST
PAGE
. Our diner meeting with John Gall was in my opinion most important. For you to have such a staunch ally as head of your board of Trustees, who has such a penetrating business mind to interface with The Deaconess as we proceed , as well as your best interest at heart is an enormous asset
I am sure you know how involved and committed I am to your latest "Brain Child ". I do appreciate that every day that passes must seem like an eternity when you have such a creative and compaSSionate mind set as yours ,
This is a rather long thank you letter for the privilege of knowing and working with you .
st regards as always,
LE
375 Park Avenue New York, New York 10152
(212) 754-2890 FAX (212) 754-2892
Trustees
July 27, 1998 Mr. Charles P. McDowell President Deaconess Foundation 311 Straight Street Cincinnati, Ohio 45219 Dear Charles: Thank you for taking time out of your busy schedule to expose me to the Deaconess's myriad activities to promote and provide community-centered services to improve the health of people across the nation.
David Mahoney,
Chairman A J. Signorile, Treasurer Robert A Good, M.D.
Carlos Moseley
Roben E. WISe, M.D.
It was impressive even though well deserved to witness the enthusiasm of everyone I met for Dr. Heimlich's achievements and their commitment to assure the continuity and future of his vision . Thank you for giving your immediate attention to creating a much needed project business plan, timetable of events and budget projection , which as we discussed should include the continuation of Malaria Therapy in China and initial trails in the United States. It was exciting to hear that the Deaconess would consider using the unoccupied space of the Vitas Hospice facility for treatment of HIV/MT patients. Dr. Fahey of UCLA, as you know had suggested to Dr. Heimlich that he would consider administering MT to HIV patients who had failed to respond to the protease inhibitors. David Mahoney would be willing to explore using The V&A hospitals should the ten patients now being treated respond as successfully as the first ten patients treated. I requested that Eric Spletzer send me a synopsis of Pertinent findings to Malaria Therapy from the XII Worlds Aids Conference, I I think you would find it very interesting. I enjoyed so much our first evening together with you and Mrs. McDowell and the Heimlich's. What a festive introduction to what I hope will be a productive and successful cooperation for all
co~cerned.
t regards,
DEACONESS AssOCIATIONS
311 Straight Street Cincinnati, Ohio 45219 -1")--9 ,"} :) J (:)
-_
noo u,
August 5, 1998
Ms. Valerie Harper The Eleanor Naylor Dana Charitable Trust 375 Park Avenue New York, NY 10152 Dear Valerie: Thank you for your letter of July 27. I am happy to hear that you were impressed with the enthusiasm and commitment that we all have for Dr. Heimlich's work. I can assure you that what you witnessed is genuine! Mr. McDowell and Dr. Heimlich continue to make progress on enhancing the plan, timetable and budget you have already received. I am also looking forward to reviewing the synopsis of findings on Malaria Therapy that you referenced. Valerie, Kathy and I very much enjoyed the opportunity to lunch with you, and I look forward to our future cooperation leading to extremely successful results. Thank you for your continued interest!
5L:~
James L. Pahls Chairman of the Board cc: Mr. C. McDowell Dr. H. Heimlich tvlr. E. A. Woods
August 10, 1998
311 STRAIGKT STREET CINCINNATI
OHIO
45219 513-559-2391 FAX 513-559-2403 heimlich@iglou.com
Ms. Amy Irving 2034 La Mesa Drive Santa Monica, CA 90402 Dear Amy, Considerable time has passed since you put your faith and support behind our malariotherapy program for treating HIV patients. That is the nature of original research; it is done deliberately and thoroughly. You will be interested to know our HIV research has progressed very well. We have begun malariotherapy treatments on a new group of HIV patients in China, and once again, the results are very promising. In 1996, after we presented the results of the first group of patients at the National Institutes of Health (NIH) and the International AIDS Conference in Vancouver, our findings were so good that the University of California in Los Angeles (UCLA) asked if they could join our program. They have done so. As a result, UCLA brought our head doctor from China to spend two months in their laboratories. We are now carrying out the very latest studies on the new Chinese patients both in China and at UCLA. Our work incurred interest, as you know from the enclosed news article I previously sent you. It was overshadowed, however, by the hype about new drugs as a cure for AIDS. That seemed unlikely to me because no virus has been eradicated by drugs, including the common cold. This year, at the AIDS conference in Geneva, the primary reports were, unfortunately, on drugs not being a cure, their failure and complications in HIV patients, and the fact that drugs create resistant forms of the virus. Now they are talking about a vaccine ten-totwenty years away. The probability of a success is questionable, however. Should a vaccine work against an American HIV virus, it will not necessarily do so on one from Thailand or Africa. The latter will then spread rapidly through travel. In any case, a vaccine is of no use to the forty million HIV patients.
Consequently, my concept of building up the immune system with malariotherapy is gaining increased respect. When the present group of patients has been followed for six months, we intend to treat HIV patients in the United States whose treatment with drugs has failed. They have no other hope. Another big piece of news is that The Heimlich Institute was invited into Deaconess Hospital in Cincinnati, thereby fulfilling my hopes of making the institute a permanent institution. Please note our new address and telephone number should you wish to contact me. I hope to hear from you and see you should I get out to California. Best regards,
08/18/1998
17:28
310-2E15-1318
C:IPID
AT UCLA
PAGE
132
MEMORANDUM
Center for Interdisciplinary Research in Immunology and Disease (CIRlD) DATE: TO: August 18, 1998
Depanment of Microbiology & Immunology UCLA School of Medicine Center for the Health Sciences
Dr. Henry Heimlich - VIA FAX

Dr. Eric Spletzer - VIA FAX
FROM:
John L. Fahey. M.D. ~
(:f-
Do you have a more detailed protocol for the current malaria studies of Chen Xiao Ping? Enclosed are 2 pages of a larger documents he gave us in May 1997. I hope to go Guangzhou in late October 1998 and need an update on the study plan. Many thanks.
enclosure
facsimile
IIIIIIIIIIIIIII~------------------~---------
TRANSMITTAL
To:
311 STRAIGHT STREET CINCINNATI OHIO 452 19 513-559-2391 FAX 51 3-559-2403
heimlich@iglou.com
www.heimlichinstitute.org
Valerie Harper The Eleanor Naylor Dana Charitable Trust 212/754-2892 6, including this cover sheet. January 28, 2000
Of: Fax: Pages: Date:
This is an amazing day. We have approval to begin treatments in South Africa. The letter from Michael Burke resulted from contact made from the Bishop of Southern Ohi() to the Archbishop of Tanzania. They are ready for collaboration on treatments in 13 hospitals. David Mahoney enabled us to get to this point through the original grants provided from the Eleanor Naylor Dana Charitable Trust. I am asking you to forward this information to David. We are on the road to curing AIDS and I am asking him, from my heart, to help us obtain funds from whatever sources to complete this project as quickly as possible. This will be David's greatest legacy for humanity.
Benefitting Humanity Through Health and Peace
From the desk of...
Affiliated with The Deasconess Associations, Inc.
, .: Malariotherapy
Subject: RE: Malariotherapy Date: 11m, 27 Jan 200015:29:21 +0200 From: "Frannie Albertse Dr (Shared Serv)" <FAlberts@jci.co.za> To: "'Henry J. Heimlich'" <heimlich@iglou.com> CC: "Koos Oostuizen Dr (Shared Serv)" <MOosthui@jci.co.za>
Dear Dr Heimlich Thank you for your letter of January 14, 2000 and the relevant information. Again my apology not for answering promptly, but I could only see the yesterday. CEO
The company has given us the permission to start the process and to do the Trial . a) I will revisel rewrite protocol to meet all international and local standards b) Thereafter - get MRc/MCC approval as well as Ethical Committee approval c)Then we are in the position to invite you out here I vice versa. Please give me your thoughts on this. Kind regards Alberts, Nicolaas F MBChB MFGP(SA) MPharm Med
I
suggest the following :
Henry J. Heimlich[SMTP:heimlich@iglou.com] > Sent: Friday, January 14, 2000 12:12 AM > To: Frannie Albertse Dr (Shared Serv) > S ubject: Malariotherapy
>
> From:
> ----------
I hope you both had an enjoyable holiday. I am writing because of a January 9, 2000 article from the Associated Press which focused on the > AIDS crisis in South Africa. > > The article noted that 10% of South Africa's population is infected with > HIV and that this epidemic poses a huge challenge to the health system. > The AP reported that some hospitals in the Johannesburg area are > limiting lab tests and releasing HIV patients earlier in order to > stretch their budgets. They are also training HIV patients' families to > care for them at home. A researcher from the University of Natal in > Durban stated it honestly - "We can't afford to spend money on people > who are going to die." > > The article also reported South Africa's Health Minister, Manto > Tshabalala-Msimang, said, "The government will never be able to cope > with it (AIDS) alone." > > As we all know, even with new expensive drugs, HIV infection remains a > death sentence. It is hard to convey my great sorrow regarding the > situation in South Africa; I can only imagine how very hard and > frustrating it must be for you. > > Although genetically engineered IL-2 has been proposed for the treatment > of HIV, it is expensive, ha s significant side effects, and will take a > minimum of 20 years (if ever) to be developed into a viable cure. > Malariotherapy is proven to stimulate the production of a variety of > immune substances, including interleukins (IL-6, IL-2R), interferons
> > > > > >
Ja nuary 13, 2000 Dear Drs. Oosthuizen and Alberts,
1 0f2
1/28/00 11 :29 A ll
l<.E:' Malariotherapy
> (IFN- ,
Our results of treating HIV patients with malariotherapy continue to be > positive; CD4 counts remain elevated and the patients remain clinically > well. Your study that was mentioned in the e-mail of August 3, 1999 > confirms that CD4 counts are increased in those HIV patients who had > contracted malaria. There is no doubt that malariotherapy is > scientifically sound, will do no harm, and is inexpensive. > Malariotherapy, at this time, is the only possible means for controlling > and possibly curing HIV infection. > > As you know, the Heimlich Institute is responsible for significant > advances in medical treatment: the Heimlich chest drainage valve, the > Heimlich MicroTrach for transtracheal oxygen delivery, and the Heimlich > maneuver for choking, drowning and asthma. If we press ahead with this > research, malariotherapy for the treatment of HIV infection can be the > next significant advancement. This would be a good time to press > forward with this project. How can we expedite starting this project, > so that we can provide the only available hope for South Africa's HIV > patients?
> > We look forward to your thoughts. > > Sincerely, > > Henry J. Heimlich, MD , ScD
> > > > >
IFN- ) and sCDB. These are the substances that can produce a cure. Malariotherapy has been shown to be safe in treating tens of thousands of neurosyphilis patients. We can send a copy of a report from the Harvard School of Public Health which documents that fact.
> President > Heimlich Institute

> >
> > > > > > >
PS: We can send the following articles which may be o f some i nt erest: "Heimlich tri es using malaria as low-cost HIV treatment. vlashington Time s, July 15, 1996. Cherni n E. J Parasitol 1984;70:611-617. If y ou can send us your surface mail addresses, we will then send copies of these.
20f2
1/28/00 11 :29 AM
Re: Malariotherapy for HIV
Subject: Date: From: To:
Re: Malariotherapy for HIV Thu, 27 Jan 2000 19:35:19 -0800 Mjburke@maf.org (MJBURKE) "Henry J. Heimlich" <heimlich@iglou.com>
Dear Dr. Eric G. Spletzer, PhD Thankyou so much for your reply. My work is basically a public health task. I am an Australian. I have been working here since 1992. I will attach a copy of my DEC 99 report. This has addresses etc. This will give you a brief picture of what we are attempting from this office. We are interested in collaboration. There is a National Institute of Medical Research - I attend their annual conference next month. There is a National Aids Control Program. Research protocols need to be approved by the Ministry. I know the Minister. Do you have any other contacts in the Tanzanian Ministry of Health or in WHO? Yours sincerely, Michael Burke Reply Separator Subject: Malariotherapy for HIV "Henry J. Heimlich" <heimlich@iglou.com> at INTERNET Author: Date: 1/26/00 3:47 PM January 25, 2000 Dear Mr. Burke, Thank you for your letter of January 6, 2000. In regards to more recent information, our treatment of HIV-positive patients with a three-week course of malariotherapy, following which the malaria is cured, continues in China. An additional 20 patients have been treated. Like our previously treated patients, these 20 patients also experienced an sustained increase in their CD4 counts and remain clinically well without further treatment of any kind. At this time, malariotherapy is the only possible means for controlling and possibly curing HIV infection. We are currently obtaining viral load measurements. Our Chinese collaborators are the Public Health Department, headed by the Director of AIDS Research for Guangzhou province. They have recently obtained the scientific laboratory apparatus to perform viral counts and DNA factors. You will find two papers attached: the first is our electronic version of a paper from the Harvard School of Public Health showing safety and efficacy of malariotherapy for neurosyphilis, and the second is a draft of a paper showing the two-year results of our first 8 patients, which has been submitted for publication. Both are in Corel WordPerfect 6.0 format. We have additional information which we would like to send you. will you please send us your surface mailing address so that we can send this to you. Dr. Heimlich will travel to Tanzania when arrangements for collaboration and treatment of patients is established. Sincerely, Eric G. Spletzer, PhD Researcher Heimlich Institute
lof2
1/28/0011 :43 AM
ACT HEALTH Anglican Church of Tanzania P.O. Box 899 Dodoma, Tanzania Ph: (255) 061-21437/21860 Fax: (255) 061-324565 Email: cpt@maf.org ACT Health December 1999 Report. Dear Bishop / Diocesan Development Officer / Diocesan Health Officer/ Medical Officer in Charge A Health Office within the Provincial ACT Health Office is being established. Our agreed basis is VISION STATEMENT A sustainable health care system delivered with the compassion of Christ, characterised by Quality, Affordability and Respect for Creation resulting in happy, healthy and peaceful communities. MISSION STATEMENT To further the healing Ministry of Christ through promotion, collaboration and provision of quality, wholistic curative, preventative and rehabilitative health care for all, especially to those most in need. GOAL To facilitate the provision of quality and sustainable health care to the people in Tanzania by 2002 PURPOSE Improved health services provided by the Anglican Dioceses in Tanzania. The last few months have been busy in the ACT Health office. Please note the following :1. The "ACT HEALTH Quality Health Care Programme 2000 - 2002" has been submitted to a range of donors. Answers are awaited.
2. The ACT Provincial Synod was a great time of fellowship and talking about health opportunities with senior people from many dioceses. Thank you for your encouragement. We look forward to continue to work together. 3. Community Based Health Funds (CBHF). CBHF are pre-payment health funds that a famil y or community joins and then is able to gain a range of health services at a much reduced cost later in the year. It would allow people to invest in their health after a harvest when money is most available. This initiative is being implemented in other churches in Tanzania. The Ministry of Health is also pilotting a similar program in various districts. * A French donor is looking for a partner diocese to pilot an Anglican CBHF.This would initially be a research phase of three to six months. If you are interested please contact ACT Health Office. 4. Health Sector Reform(HSR). The Government of Tanzania is implementing a process of Civil Service Reform. The Health sector is at the forefront. HSR has several parts. This includes decentralisation, privatisation, democratisation and the Ministry of Health concentrating more on policy and quality issues and less on implementation. There will probably be continuing changes in the mix of the public / private non profit / private for profit services. One key element for the churches is the formation of District Health Management Teams (DHMTs). The church health institutions are entitled to have one member on each DHMT. Different church health services will have to work together to choose a member to represent them on the DHMT. In order to influence district health policies and allocation of district health funds, please ensure you are represented. There is much to be gained by being represented. There is much to lose by not being represented on the DHMT. The Government will commence implementation in 35 thirty five local government authorities from 01012000. The list is included of these 35 authorities. ACT Health Office has already discussed this with Mpwapwa, Masasi and Tabora Dioceses.
* ACT Health Office in partnership with Christian Social Services Commission (CSSC) are willing to offer support during this important change in the health sector.
*Please make sure you participate in your District Health Management Team from the earliest opportunity. The benefits of doing so are potentially very high. 5. ACT Health office has commenced to negotiate with a bednet (vyandalua) provider. Research shows that an Insecticide Treated Nets (ITNs) are able to reduce malaria attacks by 30 - 40%. This is a very big public health gain. Pliot programs have been in place. The Ministry of Health (MOH) now wants to implement this acrosss Tanzania. ACT Health office in partnership with the MOH, partner organisations and other NGOs wants to support diocesan health services implement this program so our communities are healthier.
onference in San Francisco
mailbox:/C%7C/Program%20Files/Nets .... 914D1D76@gzsums.edu.cn&number=329
Conference in San Francisco Mon, 14 Feb 200016:27:19 +0800 Chen Xiao Ping <chenxp@letter.gzsums.edu.cn> "Dr. Henry J. Heimlich" <Heimlich@iglou.com>
Dear Dr. Heimlich: I attended the 7th Conference on Retroviruses and Opportunistic Infection on January 30-February 2, 2000 in San Francisco. I called your office but the number had changed and then called your home but you were not in, so only leaving you a message. The time schedule was very tight, so I was unable to visit you in Cincinnati this time since I needed to return to China immediately after the conference because as you know, the dates were in the Chinese New Year holidays-Spring Festival, the most important holiday in China. And -also, I was not sure whether I could go or not in that I got my visa from US Consulate just three hours before my departure time from Guangzhou to San Francisco. So please excuse me that I did not tell you this in advance. I did not present any paper in the conference, I was just one of six Chinese representatives invited by the conference committee two weeks before the conference dates. It was an excellent national AIDS meeting of USA. I learnt a lot and got to know many new friends during the conference. Today is the first working day after the Spring Festival, I will email you again on other issues. Happy Spring Festival and give my best regards to my mom, Jane and Dr. Spletzer. Sincerely yours, Chen Xiao Ping, M.D.
2/14/008:13 AM
Thank you for your greetings cards
Subject: Date: From: To: CC:
Thank you for your greetings cards Fri, 25 Feb 2000 15:39:20 +0800 Chen Xiao Ping <chenxp@letter.gzsums.edu.cn> "Dr. Henry 1. Heimlich" <Heimlich@iglou.com> "Dr. Eric G. Spletzer" <egspletzer@hotmail.com>
Dear Dr. Heimlich: Thank you very much for your beautiful electronic greetings cards. If it had not been the Holiday of Chinese New Year this time I would have flown to Cincinnati to visit you again after the US AIDS meeting in San Francisco. But I would find an opportunity to visit you again in a not far future and you are warmly welcome to visit Guangzhou again at any t ime. Good luck and best wishes to you, your family and all my f ri e nds in Cincinnati. Chen xiao ping, M.D.
2/25/00 8:22 AM
The Municipal Health and Anti-Epidemic Station of Guangzhou

r-ffl510080, if'1lJ==J&23
No. 23, 3n1 ZhongshanRoad, Guangzhou510080

~J! (Fax): 020-83815255
ft!~ (Telephone): 020-83802426
March 3, 2000 Hemy J. Heimlich, M.D. President, Heimlich Institute 311 Straight Street Cincinnati, Ohio 45219 U.S.A Dear Dr. Heimlich: Enclosed is our paper "Phase-l Studies of Malariotherapy for mv Infection" published in Chinese Medical Sciences Journal (Attached are also the first page and the catalog page of the journal). The abstract win be cited in Medline Database. Please note: There are some things wrong with the editing such as some numbers of the References and the word "assay" wrong as "essay." But I think the main results and ideas are clear enough to audiences. By the way, I need the first page and the catalog pages of the journal of Mechanisms of Ageing and Development in which our paper Malariotherapy for mv Patients is published. Please send me a copy of these pages. Best regards and wishes to you and all my friends in Cincinnati.
Sincerely,
Director
oj;;! ;:kif2~'
/
Chen Xiao Ping, MD.
C/
'"/' ~
.:>
Center for AIDS Control and Research at The Municipal Health and Anti-Epidemic Station (Centers for Public Health and Disease Control) of Guangzhou No. 23, 3td Zhongshan Road Guangzhou 5] 0080 The People's Republic of China Tel: 8620-83802426
Fax: 8620-83815255
mailbox:lC%7C/Program%20FileslNetscapelNa ...38DB IF93.EC745303@gzsums.edu.cn&numl.:'-'r=94
ubject: Dat, e: From: To: CC:
Express Fri, 24 Mar 2000 15:56:03 +0800 Chen Xiao Ping <chenxp@gzsums.edu.cn> "Dr. Henry 1. Heimlich" <Heimlich@iglou.com> "Dr. Eric G. Spletzer" <egspletzer@hotmail.com>
Dear Dr. Heimlich: Please email me whether you have received my Federal Express enclosed our paper Phase-1 Studies of Malariotherapy for HIV Infection published in Chin Med Sci J or not. Please send me a copy of the cover page and the catalog page(s) of the journal in which our paper Malariotherapy for HIV Patients was published. I remember that Dr. Spetzer attended the XII International Conference on AIDS in Geneva in 1998. I want to know if he had a presentation on malariotherapy for HIV/AIDS in the conference and if the presentation was signed the names of the Guangzhou part of the cooperation researchers as the authors or co-authors. If so, please send us a copy of the abstract with the cover page of the proceedings. Please send them via express to us. We need these documents. Unfortunately, Dr. Fahey has ended the reagent support to us including those for cytokines testing and HIV viral load measurement. So we have a big gap in funding in our second study of malariotherapy for HIV/AIDS. So we hope you make an effort to support us according to our agreement when I was in Cincinnati so that we can complete the project within two or three months. Thank you. Sincerely yours, Chen Xiao Ping, M.D.
lof!
'<4/{)o
!J
I .
cI
dies
Subj ect: Date: From: To:
Further studies Wed, 05 Apr 2000 16:35:50 +0800 Chen Xiao Ping <chenxp@gzsums.edu.cn> "Dr. Henry J. Heimlich" <Heimlich@iglou.com>, "Dr. Eric G. Spletzer" <egspletzer@hotmail.com>
Dear Dr. Heimlich and Dr. Spletzer: We should not give up malariotherapy! We have spent nine years long on and got a lot of findings from the studies. But as you know, Guangzhou is not a good site for phase-II studies of Malariotherapy for HIV/AIDS, because there are no so many HIV-infected persons found in Guangzhou at present time. We need at least 200 selected HIV-positive patients for phase-II studies, among them, 100 for treatment group and additional 100 for control group. I think we should find a way for further research in the USA if we wan to do phase-II clinical trials. If this needs, I will to go there. But at the moment, we are facing a problem in measurement of HIV viral load even though we have made a great effort to set up bDNA system, the reagents are too expensive to us. So we really need your financial support based on our previous cooperation agreement. We the Guangzhou part have taken all responsibilities in the research project and we hope that you the Heimlich Institute part take too. I found a few paper abstracts very interesting and useful via Internet, but I could not find their original articles at libraries in Guangzhou. Could you please help me to find out these articles at libaries in Cincinnati and send me a copy of them? These articles are: 1. Chougnet C, et al. Kinetics of lymphocyte subsets from peripheral blood during a Plasmodium falciparum malaria attack. Clin Exp Immunol 1992; 90: 405-408. 2. Worku S, et al. Lymphocyte activation and subset redistribution in the peripheral blood in acute malaria illness: distinct T cell patterns in Plasmodium falciparum and P. vivax infection. Clin Exp Immunol 1997; 108: 34-41. 3. Wahlgren M, et al. Adhesion of Plasmodium falciparum-infected erythrocytes to human cells and secretion of cytokines. Scand J Immunol 1995; 42: 626-663. 4. Kalyesubula I, et al. Effects of malaria infection in human immunodeficiency virus type I-infected Ugandan children. Pediatr Infect Dis J 1997; 16: 876-881. 5. Allen S, et al. Human immunodeficiency virus and malaria in a representative sample of childbearing women in Kigali, Rwanda. J Infect Dis 1991; 164: 67-71. 6. Tswana SA, et al. The relationship between malaria and HIV. Cent Afr J Med 1999; 45: 43-45. Thank you very much. Chen Xiao ping, M.D.
lofl
4/5/00 8:09 AM
Tue, 11 Apr 200017:13:30 -0700 "Fahey, John" <JLFahey@medneLuc1a.edu> "'chenxp@gzsums.edu.cn '" <chenxp@gzsums.edu.cn> "'heimlich@iglou.com III <heimlich@iglou.com>
Center for Interdisciplinary Research in Immunology and Disease (CIRID) April 11, 2000 Chen xiao ping, M.D. Department of Microbiology The Municipal Health and Anti-Epidemic Station of Guangzhou No. 23, 3rd Zhongshan Rd. Guangzhou 510080, P.R. China chenxp@gzsums.edu.cn Dear Dr. Chen, I have reviewed the manuscript on Procedures and clinical assessments etc. I have made some changes in the text. The new Table 2 is very clear. Please regard them as suggestions. I changed the title. The phrase (Experience in treating patients with HIV infection) indicates the treatment effects will be reported. But that is a separate paper. Thus, I suggest - "Recent Experience in 20 HIV+ patients" which indicates that it is a great deal more than a case report. I took out the references to HAART therapy. That is not relevant to the thrust of this paper which is about the effect of malarial therapy and the clinical conduct of malarial therapy. It is distracting and incomplete. The comparison can corne after the paper on malarial therapy effects on HIV infection is published. I took out the references to tuberculosis because that also did not seem to be important from the standpoint of the contributions in the present paper. In addition, there was no reference to the interaction of tuberculosis and malaria. Parts of the abstract were reworked to provide more emphasis on the contribution of this paper. The changes in the Results were only to regroup the presentation into formats that seem somewhat easier to follow. On page 5, there was a sentence referring to treatment of acute HIV infection and to not using malarial therapy at that time. I did not realize that any of the people studied in this study were in the acute phase of HIV infection. If there is no experience with acute HIV infection, then a recommendation should be based on some rationale which you would have to provide. Meanwhile, I deleted that part. Also, in the credits for support, I thank you for thinking to include reference to support from the National Institutes of Health. However, I would ask you to delete that since we did not apply for NIH HSPC approval. It can be included, however, in the paper on immunologic changes associated with malarial therapy. I do look forward to seeing the manuscript on immunologic changes in malarial therapy. I suspect that you have done all the analyses. Viral load information is not critical to that report. The additional freezing cups are being sent soon and you will have word from Barbara Hered when they are shipped. In relation to the problems of detecting intracellular cytokines, I have
of
4/12/009:33 AM
asked Dr. Najib Aziz to respond. I can tell you that problems are very common in carrying out these tests. They require some skill and practice. Your colleagues at the Guangzhou Provincial People's Hospital should contact Dr. John Bradley, Flinders Medical Center, Adelaide, Australia at email: imjb@flinders.edu.au to receive the samples of the flow cytometry proficiency testing program. I am alerting Dr. Bradley to save a sample for them. The shipments are going out now so they should contact him promptly. Finally, how is the HIV viral load testing proceeding? I would suppose there was a period needed to become familiar with the procedures, and to be sure about the analytic results. Keep the manuscripts coming. Sincerely, John L. Fahey, M.D. Director, CIRID at UCLA p.s. Reference numbers 7 and above need to be changed in References and in the text. Also, reference is needed for problems with palsmodium faciparum. Attachment - manuscript Cc: Chen Xiao Ping.doc
Dr. Henry Heimlich (heimlich@iglou . com)
t~~Chen Xiao Ping.doc
Name: Chen Xiao Ping.doc Type: Program File (application/msword) Encoding: base64
4/12/009:33 AM
Final version of manuscript
Final version of manuscript Fri, 21 Apr 2000 17:59:56 +0800 Chen Xiao Ping <chenxp@gzsums.edu.co> "Dr. Henry J. Heimlich" <Heimlich@iglou.com>, "Dr. Eric G. Spletzer" <egspletzer@hotmail.com>
Dear Dr. Heimlich and Dr. Spletzer: Attached is the final version (if you agree) of our paper manuscript Procedures and Clinical Assessments of Malariotherapy: Recent Experience in 20 HIV+ Patients reviewed by Dr. John L. Fahey. If you agree, I would like to first try to submit to AIDS journal in the form of FASTTRACK of the journal which publishes papers within four months if accepted. Please sign the form of Submission to AIDS Journal--Authors' Confirmation and then send back to me by fax or email if you agree the final version and agree to submit to the journal. I will to take your suggestions into account. You are also welcome to introduce to a British or American journal other than AIDS. By the way, have you received my last E-mail of April 5? I am looking forward to hearing from you and receiving your signatures of the attached form. Best wishes and regards. Chen xiao Ping, MD
c:
Name: Recent experience in 20 HIV+ patients.doc r~:'Recent experience in 20 HIV+ patients.doc Type: Micr?so~ Word Document L~_I (apphcatlOn/msword) Encoding: base64
~~~Form of Authors,doc
Name: Form of Authors.doc . Type: Microsoft Word Document (application/msword) Encoding: base64
of 1
4/21/00 11:03 AM
SUbj ect: Date: Thil, 27 Apr 200015:52:57 -0700 From: "Fahey, John " <JLFahey@medneLucia.edu> To: n'chenxp@gzsums.edu.cn"' <chenxp@gzsums.edu.cn> CC: n'heimlich@iglou.com"' <heimlich@iglou.com>
Ce n ter for Interdisciplinary Research in I mmunology and Disease (CIRID) April 27, 2000 Chen xiao ping, M.D. Department of Microbiology The Municipal Health and Anti-Epidemic Station of Guangzhou No . 23, 3rd Zhongshan Rd. Guangzhou 510080, P.R. China chenxp@gzsums.edu.cn Dear Dr. Chen, I am pleased that you are prepared to send the manuscript for publication. If you and Dr. Heimlich could identify a general medical journal I would suggest that would be better than AIDS. The editors and readership of AIDS want to know the relationship of the study to the effect on AIDS. That is not in this paper. Your pape r is really about malarial therapy. Again, if you could identify some type of journal where this could reasonably go, such as the British Medical Journal. I am quite sure that it will not be accepted by the New England Journal of Medicine. I would suggest you put it in appropriate format. The nature of the paper is not the sort of thing that usually warrants a fast track publication. However, the main thing is to get it accepted by a reput able journal. We have sent off today by express delivery copies of 5 of the 6 articles that you requested last month. I regret the delay but I hope it will help you in presentation of immuno l ogic effects of malarial therapy. I promise to respond more rapidly with comments about future manuscripts . Sincerely, John L. Fahey, M.D. Director, CIRID at UCLA Cc : Dr. Henry Heimlich (email: heimlich@iglou.com)
of 1
4/28/008:14 AM
Z e :yo ur email
Subject: Re: your email Date: Fri, 28 Apr 200010:10:41 +0800 From: Chen Xiao Ping <chenxp@gzsums.edu.cn> To: "Fahey, John" <JLFahey@medneLucla.edu> CC: "Dr. Henry J. Heimlich" <Heimlich@iglou.com>
Dear Dr. Fahey: Thank you for your suggestion. I have found the British Medical Journal (BMJ) to which the manuscript can be submitted via E-mail . I will first try the BMJ based on your suggestion if Dr. Heimlich agree (I will contact him soon). Sincerely, Chen xiao p i ng, M.D. Fahey, John wrote: > Center for Interdisciplinary Research > in Immunology and Disease (CIRID) > > April 27, 2000
>
> Chen Xiao ping, M.D. > Department of Microbiology > The Municipal Health and Anti-Epidemic Station of Guangzhou > No. 23, 3rd Zhongshan Rd. > Guangzhou 510080, P.R. China > chenxp@gzsums.edu.cn > > Dear Dr. Chen,
>
> I am pleased that you are prepared to send the manuscript for publication. > If you and Dr . Heimlich could identify a general medical journal I would > suggest that would be better than AIDS . The editors and readership of AIDS > want to know the relationship of the st udy to the effect on AIDS. That is > not in th i s paper. Your paper is really about malarial therapy. Again, i f > you could identify some type of journal where this could reasonably go, such > as the British Medical Journal . I am quite sure that it will not be > accepted by the New England Journal of Medicine. I would suggest you put it > in appropriate format. The nature of the paper is not the sort of thing > that usually warrants a fast track publication . However , the main thing is > to get it accepted by a reputable journal. > > We have sent off today by express delivery copies of 5 of the 6 articles > that you requested last month. I regret the delay but I hope it will help > you in presentation of immunologic effects of malarial therapy. I prom.ise > to respond more rapidly with comments about future manuscripts.
> > > > > > >
Sincerely, John L. Fahey, M.D. Director , CIRID at UCLA Cc: Dr. Henry Heimlich (email: heimlich@iglou . com)
, of 1
4/28/00 8:14 AM
,e: Latest paper
Re: Latest paper Fri, 28 Apr 2000 10:37:38 +0800 Chen Xiao Ping <chenxp@gzsums.edu.cn> "Henry J. Heimlich" <heimlich@iglou.com>
Dear Dr. Heimlich: I have changed my mind that we should first try our latest manuscript to the British Medical Journal (BMJ) based on Dr. Fahey's suggestion. What is your opinion? If you agree, I will change the format matching the AIDS journal to the one matching the BMJ to which the manuscript can be submitted via E-mail (both formats are very similar). I am looking for your response. Best wishes and regards, Chen Xiao ping, M.D. Henry J. Heimlich wrote:
> Dear Dr. Chen, > > We received your e-mail and y our fax. Dr. Heimlich will be in tomorrow > (April 26, 2000). I will get him to look at the paper then and we will > respond as soon as possible. > > Best wishes, > > Eric G. Spletzer, PhD > Heimlich Institute
of!
4/28/008:14 AM
Program
'on
bject: Program discussion Date: Thu, 08 Jun 200011 :12:02 +0800 From: Cben Xiao Ping <chenxp@gzsums,edu,cn> To: "Dr. Henry J. Heimlich" <Heimlich@iglou.com> CC: "Dr. Eric G. Spletzer" <egspletzer@hotmail.com>, "John L. Fahey" <jlfahey@microimmun.medsch.ucla.edu>
o ar Dr . Heimlich:
Xl' b ead, Dr . Xiao Bin Quan entrust me to talk with you very openly on
~
of the idea of malariotherapy for HIV/AIDS. I admit tha t you b e first person who proposed the idea of malariotherapy for HIV ~~ = ect ion early in 1992. But you are not the unique one who had this ~ ' e a i n early 1990s. I also admit, I have never told you before t hat I t a' the ide a too separately in early 1993 (but I told this to Dr. Xiao 3~n Q an). After our first discussion on the topic of malariotherapy for ::: _ - in fec tion in mid 1993 in Guangzhou, we got to know, you advocated ~ ar i othe rapy for cancer, HIV infection and Lyme disease, but I favored - ~e th erapy for cancer, HIV infection and systemic lupus erythematosus S ~ ) . I told my colleagues that I never considered the therapy should be given to patients with Lyme disease even though the disease was ea e rni c in northern China during that period. To tell the true, I really ~e spect ed you, I did not want to argue with you. We can trace to early ~ 0 when our good friend, Dr. Cionci visited Guangzhou and told me that 70 advocated the therapy for cancer and I told him that this idea was 7 e=y r easonable. But we knew very quick this was not really your ~~opo sal, because some other authors had proposed this idea or practiced ~~ b efore y ou. Nevertheless, anyone should admit the fact that Dr. Ee~~ ch first proposed the ideas of malariotherapy for HIV infection c= ' ~yme dis ease and Dr. Chen separately proposed the ideas of the ~~ e~apy for HIV infection and SLE e ven though Chen h ad the idea of -;~ar ~oth erapy for HIV infection later than Heimlich about a half year . 5~ e = had got some data that t here was no harmful interaction between ::: ~; and Pl asmodium based on my knowledge and exper ience of working in ~e = ~ eld of infectious disease for 13 years (13 y ears on malaria and 5 7E~S on AIDS ) and on obtaining new information by read ing reported ~~c es till early 1993. And also, I had been quite familiar with the - - s~o ry of malariotherapy for neurosyphilis by t heoretical study and the :=-=-:: ~ i.c e of clinical research of malariotherapy for cancer through the .:. ::~ ration with you by early 1993. My brain often naturally came up _~ ~ e q u estion that why we did not try malariot herapy to tr eat ~=-~~e~ s with HIV infection during the months in early 1993. I was very =x .:.~~ ~ h en you told me through a letter you would come to Guangzhou to -- ~ __ s with us the feasibility on cooperation of malariotherapy for HIV -:===~o and I immediately told my head, Dr. Xiao that Dr. Heimlich had - -e s=,Q i dea! But when we discussed the feasibility in Guangzhou in mid ~ecogniz ed that you had the idea earlier than I had about a half =~ . ~ rtbermore, I realized that you got stronger ev idence than I did =_~_ =-t t h i s idea when you gave me a copy of the paper abstract = =--S<i:.n t h e VI International Conference on AIDS in 1990. This is a ; ~ s~o=-y. So I would admit forever that Dr . Heimlic h is the first e u nique ) person who proposed this idea. This is similar to =~ ~ =- ~o that Dr. Montagnier in France and Dr. Ga llo in USA ~ ~~e~~ =0 nd HIV (LAV/HTLVIII) in 1983 and 1984 respectiv ely.
e are
~ ssue
_:==, =
after our disc u ssion in mid of Guangzhou organized a couple ==-~ ( t he membe r s included clinicians, epidemi ologists, ,~__~_- =~~S , _ arasitologist s, virologists, social and ethical ~. __~ __ - - ~ ~ka=s a s well as governme nt officers) discussions. In t he i scuss ion, about 70% board member s opposed this =-_ -sed o n th at malar i a induces variety of cytokines and =~ ~.:. ~s ~hi c h ar e ha ~ ul to HIV/AI DS patie nt s. But in ard di scuss ~o s , it was that I proposed the ~~~-E - - = ~ - ~ ~se - -- ~, e re l a ted f actor s would do increase d r ' 9 .:._~ ~.:. e.:: '-o .:: d s arp::'y decreased to base li .:.:=e:- - e :E 7e~_ a =t e r t ermina tion o f a l a ria g t
---~e= ~ery importa nt thing is that, ~ e __ ~ i pal Depar tment of Health
- -'" ==
00 ,_ Al\ t
Program discussion
a feedback mechanism of immune system. It was this hypothesis that reversed the percentage of the board members who originally opposed us from about 70% to about 30%, which leaded to the final approval of phase-I studies of malariotherapy for HIV infection conducted in Guangzhou. Of course, Dr. Xiao Bin Quan played a very important role in the discussions. I remember that you did not attended any board discussions. So it is uneven if you persist in mentioning Dr. Heimlich proposed the idea of malariotherapy for HIV infection in any manuscripts of ours. We strongly consider that it is enough when Dr. Chen wrote the first paper abstract presented in the 9th International Congress on Immunology in San Francisco in 1995, putting the name of Dr . Heimlich first; Dr. Heimlich presented a paper abstract as the first author in the XI International Conference on AIDS in Vancouver in 1996; Dr. Heimlich wrote the first paper as the first author published in Mech Ageing Dev 1997; Dr. Chen wrote the second paper published in Chin Med Sci J 1999 i 'n which Dr. Heimlich first proposed the idea was mentioned. It is absolutely enough as a history document. Dr. Xiao also entrust me to talk with you very openly on the issue of our Cooperation Agreement. According to our New Cooperation Agreement made in Cincinnati in 1997, the Heimlich Institute part (HI) needs to pay 84,000 US dollar ($7000 per case, 7000 times 12 = 84000) for the Second project of Malariotherapy for HIV/AIDS if Dr. Fahey does not provide reagents for HIV viral load testing (note: if Dr. Fahey provides reagents for viral load testing, the payment will be $5000 per case). Nevertheless, HI only paid $14,000 for the whole project. My colleagues (all are new to you except Dr. Xiao) said that HI did nothing in the second project except the 14,000 dollar payment. Therefore they argued with me that we might take HI out from authors in our new paper manuscripts, we just need t o say thanks to HI in the sec t ions of acknowledgement. But I e x plained that Dr. Heimlich first proposed the idea of malariotherapy for HIV infection early in 1992 even though I had the same idea separately in early 1993. I excuse them because they do not know the history (I would like to let you know that they are all young fellows). And as you know, most colleagues of mine who joined the Projects of Malariotherapy for cancer patients and for the first eight HIV patients including Drs. Rao JL, Liu SG, Lu YH, Li NO and Kuang FY retired one to three years ago . But anyway, I would pers i st in putting Dr. Heimlich in the position of second author in our new manuscripts on the 12 HIV patients who received malariotherapy. But Dr . Xiao and I also persist in that this will be based on the responsibility taken by HI in the project according our Cooperat i on Agreement However, in the deep hearts of Dr. Xiao and I, Dr. Heimlich is our good friend and we hope to keep the friendship forever which has been established since 1990 when we started to discuss cooperation on the program of malariot herapy for cancer after introduction of Dr. Cionci. By the way, the HIV viral load has been measured through a great deal effort in borrowing the bONA reagents from Dr. Yunzheng Cao working at the National AIDS Research Center of China in Beijing (she returned to Ch ina in 1998 from the Aaron Diamond AIDS Research Center in New York). W i th my bes t wishes and regards to all colleagues at Heimlich Institute. Chen Xiao Pin g , M.D.
2 of 2
6/8/008:28 A M
Re: Your letters of June 8, 2000 and July 6, 2000
Re: Your letters of June 8, 2000 and July 6, 2000 Fri, 07 Jul 2000 12:53:23 -0400 "Henry J. Heimlich" <heimlich@iglou.com> chenxp@gzsums.edu.cn JLFahey@medneLucla.edu
Dear Dr. Chen, Concerning your note of June 8, Dr. Heimlich appreciates your statement that Dr. Heimlich is "the first person who proposed the idea of malariotherapy for HIV infection early in 1992." A small correction should be noted in this regard - Dr. Heimlich first proposed this concept and made it known in the late 1980's when his nephew died of AIDS after receiving an injection of infected plasma for hemophilia. It is interesting to now learn you conceived of the idea of malariotherapy for AIDS seven years ago. Traditionally, in scientific articles, the first person to conceive of a treatment is always mentioned in this regard in the historical background. It is not unusual for others to have the same idea at a later date. You are the originator of suggesting the use of malariotherapy for systemic lupus erythematosus (SLE) and credit should certainly be given to you in any papers on malariotherapy for SLE. We agree with Dr. Fahey's statement to you in his letter of June 8, "Regarding authorship, it is incontrovertible that you and your colleagues have done the work carried out in these projects." The acknowledgments in our first full paper state this. Certainly, if it were not for our joint efforts, we would not have achieved what we h~ve . Your e-mail of July 6 caught us somewhat by surprise since we did not know the paper had been submitted for publication, and had not received any message from the British Medical Journal. Upon looking at your e-mail closely, we found that Dr. Martyn had spelled our e-mail address incorrectly (igloo instead of iglou). We cannot open some portions of your attached manuscripts since you have switched to Microsoft Word fr om Corel WordPerfect. Please fax a copy of the manuscript that was sent, so we can respond appropriately. Our FAX number is 513-559 -2403. We will respond to the rest of your June 8 e-mail shortly. forward to continuing our mutual friendship and research. Best wishes and regards, Eric G. Spletzer Researcher Heimlich Institute cc: John L. Fahey, MD We look
1 of 1
7/7/00 12:53 PM
Subject: Date: Fri, 22 Dec 2000 09:25:30 -0800 From: "Fahey, John" <1LFahey@medneLuc1a.edu> To: "'chenxping@netease.com It, <chenxping@netease.com> CC: "'heimlich@iglou.com It, <heimlich@iglou.com>
Center for Interdisciplinary Research in Immunology and Disease (CIRID) December 22, 2000 Chen Xiao ping, M.D. Department of Microbiology The Municipal Health and Anti-Epidemic Station of Guangzhou No. 23, 3rd Zhongshan Rd. Guangzhou 510080, P.R. China chenxping@netease.com Dear Dr. Chen, I read the paper and am sending it back with some suggestions. However, I did want to raise again the question of which journal is most suitable. We looked at the information available at website http://www.thelancet.com/info/info.isa?nl- authorinfo&n2=Writing+for+The+Lanc et. In reviewing that and then looking at a recent issue of Lancet, it seemed that there were two possible difficulties with the paper. First of all, Lancet seems interested in the clinical reports rather than laboratory science and this paper is really reporting on the immunologic consequences of malarial therapy in HIV+ persons rather than the clinical procedures and clinical outcomes. A second point relates to the style of the narrative. It seemed to me that the narrative is fairl y discursive. For example, the Summary really contains almost all the information in the paper. Journals usually require a very concise summary with the main points, not all of the issues or data in the paper. It occurred to me that Nature Medicine -might be more suitable. The information on Nature Medicine can be obtained at http://www.nature.com /nm/info/guide authors/#authors. I hope this is helpful. But, certainly you must trim the abstract . I will try and do that so that you can get a n idea of what I am thinking of. I am not sure if you have access to the journal Nature Medicine . I can understand that could be a problem for you. Howe v er , the point about trimming the summary or abstract applies to any western journal that you might submit your papers to. Nature Medicine limits abstracts to 100-150 words and the main text to 3000 words maximum. Sincerely, John L. Fahey, M.D. Director, CIRID at UCLA Enclosure - manuscript Impact of acute vivax .doc CC: Henry Heimlich, M.D. (heimlich@iglou.com)
_ Name: Impact of acute vivax .doc ~~~Impact of acute vivax .doc Type: Winword File (application/msword) Encoding: base64
10fl
12/26/008: 11 At'-
Re: Re: Discussion conclusions Fri, 23 Feb 200117:54:27 +0800 chenxiaoping <chenxping@netease.com> Henry J.Heimlich <heimlich@iglou.com> "John L. Fahey, M.D." <jlfahey@microimmun.medsch.ucla.edu>
Dear Dr. Heimlich: Thank you for your email response of Feb. 22, 2001. We agree that we did all things in our previous research projects according to our agreements and we were happy during the cooperation. This leaded to that in our first study of malariotherapy for HIV infection, we totally presented two abstracts in two important international meetings and published two papers in science journals. But there is no use to talk the previous issues including funding, because all participants in Guangzhou part have known the past through a couple of discussions. We should take a time to resolve the current problems in our second HIV -malariotherapy project. You should remember that in our very difficult time, we asked for the funding from the Heimlich Institute, but we failed to get it due to the agreement obligation. We had to spent a lot of time on dealing with the funding and make a great effort to persuade the governments to fund the research. Finally, we got it from several departments. The project, therefore has been completed, but this also leaded to a change of the major funding originally from Heimlich Institute later to the local governments and other institutions. I suggest that, you do not need the authorship of the paper titled "Impact of acute vivax malaria on the immune system of HIV + patients" which focuses on the early immune response (only 3 months data), not really on the efficacy of malariotherapy, but we would still like to thank you in the acknowledgements section like: "We acknowledge Dr. Henry 1. Heimlich for his successful cooperation with us in the pilot study of malariotherapy for HIV infection during 1993-1996. He independently proposed the idea of malariotherapy for HIV infection in 1992 (note: in the contributors section: Dr. Chen independently proposed the idea of malariotherapy for HIV/AIDS in early 1993 will be mentioned). He also helped us to get a part of funding from Eleanor Dana Charitable Trust in our present study. Dr. Heimlich works at the Heimlich Institute in Cincinnati, USA." I hope you accepted this acknowledgement. Doing so is very important for me to comfort my colleagues and the officials. Because the conflict of funding and authorship issues made me a deep embarrassment, this directly leaded to the intervention of officials. I am afraid that I will lose my colleagues and then lose the opportunity for our future cooperation. Please note, the situation here in China is very different from that in the USA, even though China is in progress. My another suggestion is that you should make a supplement to fund the research so that your authorship remains in the next paper which focuses on the data of CD4 level and HIV viral load for two years follow up. It will be the most important paper up to now in the research of malariotherapy for HIV infection. I will explain in my greatest effort to my colleagues that Dr. Heimlich should be the second author in this paper and I will insist in making a notification like: Dr. Heimlich and Dr.
Chen independently proposed the idea of malariotherapy for HlV infection respectively in 1992 and in early 1993 or like: Dr. Chen and Dr. Heimlich equally contribute to this paper. But your funding is very important for comforting either my colleagues or the officials. Our future study will be a very big project, needing a huge funding: a multiple-center phase-II study of malariotherapy for HlV infection which includes 100 patients for the treatment group and 100 patients for control group. This needs to screen over 400 patients for their CD4 count level for patient selection. We also need to sign a new agreement in a research funding style (that means funding go ahead of data obtaining) if we come together again in the future. By the way, a private company in China and an institution in Italy are willing to fund the phase-II study, but I have not yet accepted, because this will let the research goes a business way and I am waiting for the cooperation with you. We do not hope to contact with any embassies or consulates or directly with the officials, because our cooperation is completely scientific but absolutely not political. Regarding to the letter from Dr. Cionci to Dr. Heimlich, it is not true for saying that Dr. Heimlich spoke to my group on the use of malariotherapy for HlV. The fact is that in 1990, Dr. Cionci as a representative of Philadelphia Red Cross Society visited to Guangzhou. I met him in the White Swan Hotel where he stayed. We talked very friendly, when I told him about my hypothesis on that HlV might originated from the molecular hybridization of SlV and human sperm gene (I published this idea in early 1990), then he told me the idea of malariotherapy for cancer proposed by Dr. Heimlich, when my response was "this idea is very reasonable" since I had been a physician for infectious disease for many years and had treated over one hundred malaria patients. Then Dr. Cionci returned to USA and told Dr. Heimlich about my interest in malariotherapy for cancer even though I had been worked at AIDS laboratory since 1988. Dr. Heimlich came to Guangzhou in 1991 to talk with us on the cooperation of malariotherapy for cancer. Dr. Heimlich did give lectures in Zengcheng County People's Hospital and Dongshan District Hospital, and I did be there as an interpreter for Dr. Heimlich, but Dr. Heimlich never mentioned malariotherapy for HlV in his lectures and thereafter until the middle 1993. It was that I first time spoke to Dr. Xiao, the Director of my station about the idea of malariotherapy for HlV in early 1993 on the first working day after a long vacation of Chinese New Year holidays. Three months later I received a letter from Dr. Heimlich by which I first time knew Dr. Heimlich had the same idea and I told Dr. Xiao about this. Then we came together again after completion of malariotherapy for cancer. Then Dr. Hua Hong Shun came a couple of times on behalf of Dr. Heimlich (he also visited us a couple of times for our cancer research project). The unique document telling us that Dr. Heimlich proposed the idea in 1992 is a written letter from Dr. Heimlich to me in 1994. Any statements saying Dr. Heimlich proposed the idea prior to 1992 are unacceptable. Simultaneously, any statements denying Dr. Chen independently proposed the same idea in early 1993 are also unacceptable. These statements will lead to no way to go for our cooperation, because these statements are not true. We also had different ideas on malariotherapy for different diseases: Heimlich's
L _"II1 di ease idea and Chen 's SLE idea which I mentioned before.
It is unrea onable for saying that the immune system manuscript is in Dr. Heimlich's house computer not in the office one, because these computers link to the internet: not only Dr. Heimlich but also I can email to your office if I have your email address. In addition, a floppy disc can be used from the house to the office.
I look forward to hearing from you, especially the answers on the acknowledgement in the immune system paper and the funding and authorship in the efficacy paper as well as the future cooperation. I suggest that we should talk and resolve any problems between us before the intervention of officials which complicates any existed problems. So timely communication is very important because we have computers which link to the internet. Please give me your new office and Eric's email addresses. Please excuse me to CC this message to Dr. Fahey, because I think we should talk very openly, and Dr. Fahey helped us a lot in HIV-malariotherapy projects. Best wishes and regards to you, your family and colleagues. Chen Xiao Ping, M.D.
Reply to your e-mail of Feb 23, 2001
SUbject: Date: From: To: CC:
Reply to your e-mail of Feb 23, 2001 Fri, 23 Mar 200117:16:49 -0500 "Henry 1. Heimlich" <heimlich@iglou.com> chenxping@netease.com lLFahey@mednet.ucla.edu
Dear Dr. Chen, We received your e-mail of February 23, 2001. It is so complete and thorough, it is best if we cover one item at a time. Let us first resolve the matter of whether you conceived of malariotherapy for HIV in early 1993 before hearing about it from Dr. Heimlich. Dr. Heimlich had presented his concept at meetings in the United States for several years starting in the late 1980s. As Dr. Cionci wrote, he clearly remembers Dr. Heimlich spoke about malariotherapy for HIV and cancer at a large meeting at the Municipal Health and Anti-Epidemic Station of Guangzhou where you were present. Dr . Cionci was then escorted to another room in the building where he and seven other doctors saw a short video of a man described as the first AIDS patient to die in China. Dr. Cionci then told Dr. Heimlich about the film. Dr. Heimlich, once again in the presence of other physicians, mentioned that pe intended to treat HIV patients with malariotherapy . You informed Dr. Cionci and Dr. Heimlich at that time that HIV was not a problem in China. That is why you started treating cancer patients. It is not unusual for a person to hear of something, forget about it, then, at a later date think it is his original thought . Here is a suggestion. You sent Dr. Fahey copies of your last letter, therefore, we will send a copy of this letter to him. We both have a great deal of respect for Dr . John Fahey; furthermore, he is independent of both of us. Dr. Heimlich arranged for you to spend several weeks at Dr. Fahey's laboratories in 1997, before this misunderstanding arose. Through the copy of this letter, we us ask Dr. Fahey to tell us whether you told him malariotherapy for HIV was your independent concept during that visit. If he says you did so, and you told him the date, Dr. Heimlich would consider that fact in resolving this matter.
Af~er
this is cleared up, we can proceed to discussing other matters.
Best wishes to you and your coworkers . Sincerely, Eric G. Spletzer, PhD Heimlich Institute
1 of 1
3/23/015:17 PM
Subject: Re: your e-mail of March 23, 2001 Date: Thu, 29 Mar 2001 16:26:34 +0800 From: chenxiaoping <chenxping@netease.com> To: Henry J .Heimlich <heimlich@iglou.com> CC: "John L. Fahey, M.D." <jlfahey@microimmun.medsch.ucla.edu>
Dear Dr. Heimlich: We can not accept the statement "As Dr. Cionci wrote, he clearly remembers Dr. Heimlich spoke about malariotherapy for HIV and cancer at a large meeting at the Municipal Health and Anti-Epidemic Station of Guangzhou where you were present." Because this is not true. Nobodies knew in Guangzhou part "Dr. Heimlich spoke about malariotherapy for HIV" during his visit in 1991. But Dr. Heimlich did speak about malariotherapy for cancer to the audiences at that time. This has been documented in a letter from Dr. Heimlich to Dr. Chen in 1994: Dr. Heimlich proposed the idea of malariotherapy for HIV infection early in 1992. This is also documented in our second published paper entitled "Phase-1 studies of malariotherapy for HIV infection", in which Dr. Heimlich requested to write down the same thing before submitting to the journal. Therefore, there is no witness to say Dr. Heimlich spoke about malariotherapy for HIV to the audiences in Guangzhou in 1991. Professor Xiao says that Professor Heimlich wants to made more stories about malariotherapy in his email to Dr. Chen in March 23, 2001, but these stories are absolutely not true, nobodies accept them. Dr. Chen not only independently proposed the same idea in early 1993, which I mentioned many time before, but also proposed the possible mechanisms of malariotherapy for HIV infection (this is documented in our second published paper) in the same year in the review board discussions, otherwise the research could not be approved by the board (please remember, Dr. Heimlich did not attend any review board discussions during the whole course). It is absolutely unreasonable to ask our friend, Dr. John L. Fahey to clarify our dispute, because I got to know Dr. Fahey and then became his friend in 1997, four years later after the concept was conceived in early 1993. Please remember, when we talk the possibility of cooperation on malariotherapy-HIV project in middle 1993, Dr. Cionci was not in. Professor Xiao says that it is no need to talk further if Heimlich Institute deny the fact that Dr. Chen independently proposed the idea of malariotherapy for HIV infection. Because Professor Xiao heard the idea first time from Dr. Chen. In fact, we can not
confirm Dr. Heimlich proposed the same idea in 1992, but we do not deny it, and wrote it down in our second published paper while Dr. Heimlich requested to do so before he permitted to publish the paper. The Guangzhou part decide not to talk any more if Heimlich Institute persists in denying Dr. Chen independently proposed the same idea of malariotherapy for HIV infection in early 1993. The cooperation therefore discontinues due to this issue and funding event. Because these indicate that we do not trust again each other. Sincerely, Chen, Xiao Ping, M.D. , Ph.D. Director, Center for AIDS Control and Research Municipal Health and Anti-Epidemic Station of Guangzhou
November 18, 2002
311 STRAIGHT STREET CINCINNATI OHIO 45219 513-559-2391 FAX 513-559-2403 heimlich@glou.com
WoMN.heimlichinstitute.org
Ms. Barbara R. Sporck-Stagmaier 2401 Ingleside Avenue #IID Cincinnati, OH 45206 Dear Barbara, You have always been so kind to remember and support our work each year. I feel the enclosed report I received a week ago will be as gratifying to you as it is to me. The archbishop of the Anglican church of Nigeria met with me originally when he visited Christ Church in Cincinnati. Dr. Wakama, and another physician from Nigeria, came to The Heimlich Institute in October under the auspices of the Anglican church of Nigeria. They spent a week learning how to carry out our treatment of malariotherapy for HIV/AIDS. The doctors expect to commence treatment of HIV/AIDS patients in Nigeria this month. In addition, two physicians from South Africa spent the past week with us. They also intend to initiate treatment in that country. During the first week of December, physicians will be arriving from Ghana for the same purpose. The ineffectiveness of drugs for HIV/AIDS was established this year. Our malariotherapy is the only hope at this time and is receiving wide recognition. I am going out of town for Thanksgiving, but will call you upon my return in the hope of getting together before the end of the year.
Encl.
Affiliated with Deaconess Associations Inc.
jy
/~~/--
fJ~'1
--- ~ '-c
December 18,2001
.----~/ JtJ
..
\
Ms. Barbara R. Sporck-Stagmaie~ 2401 Ingleside Avenue #IID Cincinnati, OH 45206 Dear Ms. Sporck-Stagmaier: Thank you for your generous contribution to The Heimlich Institute. commitment and support of The Institute's efforts. We are grateful for your
Dr. Heimlich and the Institute continue to actively pursue research into issues which are important to the medical and scientific communities, including cancer, AIDS and Asthma. In addition, we continue to invest in a nationwide educational effort to increase the public's awareness of the Heimlich Maneuver's effectiveness and success in saving choking and drowning victims. Support such as yours will help ensure that these important efforts continue. Ms. Sporck-Stagmaier, I know Dr. Heimlich personally appreciates your significant support and recognition of his achievements and talents. Thank you again for helping Deaconess foster his work ... and best wishes for a delightful holiday season! Sincerely,
E. ANTHONY WOODS President & CEO cc: Dr. H. Heimlich
Dear Dr. Heimlich: Due to many things to do in the new year, I just have time to finish the abstracts and translations related to Chen Xiao Ping's affair. All the related materials are summarized in the enclosed package. I believe the material are suffice to prove Chen's attitude. I really feel ashamed of it. Anyway, if there is any need, I can be your witness. Please send my best regard to your family. Fraternally,
~
Hongshun 0110412002
~/
APPENDIX
Dr. Heimlich's letter to me, December 31,1990, with a letter written by Chen Xiao Ping to Dr. Cionci.
Chen' s letter said, ''Thanks for your information and letter. I am also interested in the malaria therapy on treating people with cancer and AIDS." Chen knew about malaria therapy of cancer and AIDS after Dr. Cionci's visit to Guangzhou in May 1990. 2 Chen Xiao Ping's letter to me, March 5, 1991, with a translated abstract of that letter in English by me.
Chen asked us to provide him materials concerning malaria therapy carried out in Mexico and also about malaria therapy on neurosyphilis. When Dr. Heimlich, Dr. Cionci and I went to Nanjing to observe Dr. Ma Yongquan's initial several cases of malaria therapy of cancer, Chen came to Nanjing to learn how Dr. Ma started. After malaria therapy got approved by the Ministry of Health of J iangsu Province, then Chen Xiao Ping was able to got approval from Guang Dong Province, Which supervised Guangzhou. 3 Agreement on the Cooperative Project of Malaria Therapy of Cancer by Guangzhou Institute of Preventive Medicine, Yisou Hospital and the Heimlich Institute, signed by both Chinese and US parties at June 15,1992
Chen Xiao Ping was among the Guangzhou Party. They promised to provide manual labor and equipment. Dr. Heimlich represented the US party, promising to provide all the necessary related medical and technical material. 4 Chen Xiao Ping's letter to me, October 11, 2001
Chen mentioned in his letter,"Dr. Cionci visited Guangzhou in 1990. That was for the first time mentioned to me about malaria therapy of cancer. I agreed that is a very reasonable assumption. Not until the Spring Festival of 1993, I proposed to the Director of the Municipal Health & Anti-Epidemic Station of Guangzhou, Dr. Shao Bin Quan that malaria therapy of HIV might be a more valuable treatment method and later I got Dr. Shao's full support. Two months later, I received Dr. Heimlich's letter suggesting that malaria therapy might be used in treatment of AIDS. This was a co-incidence. Chen Xiao Ping independently proposed malaria therapy in treatment ofHlV infection." 5 Combating AIDS by Using Malaria Therapy (abstract)
Dr.Ho Da Yi discovered Cocktail Therapy ,but the therapy can not eliminate virus in the storage site. Dr. Chen Xiao Ping of the Municipal Health & Anti-epidemic Station of Guangzhou using his malaria therapy can help patient increase CD4 cells and discovered some of its mechanism. Chen proposed a new treatment regime by combining malaria therapy plus cocktail therapy. <Followed by a brief review of malaria therapy of neurosyphilis and reports of AIDS patients with malaria> In the 90's of 20 th century, Chen Xiao Ping proposed the malaria therapy of AIDS. In 1993, The health system of Guangzxhou discussed and assessed the feasibility of malaria therapy on AIDS. Finally, Chen got approval from various related organizations of Guangzhou government. Chen started the world's first attempt. From 1993, Chen with his research group started to treat a group of20 patients and in 1955 Chen published his essay and read before an international meeting.
<Followed by Chen's explanation of how CD4 cells count increased> In conclusion, the paper said that if the integration of malaria therapy and cocktail therapy got success, then AIDS patients will be tremendously benefited.
Note: There is no author of this article. A very interesting thing is that th name of Chen Xiao Ping appeared 21 times throughout the article. No single word about Dr. Heimlich, Dr. Cionci or the Heimlich Institute.
D. Heimlich:
Thank ou fo r your email response of Feb. 22, 2001. We agree that we did all things in our previous research projects according to our agreements and we were happy during the cooperation. This leaded to that in our first study of malariotherapy for HIV infection, we totally presented two abstracts in two important international meetings and published two papers in science journals. But there is no use to talk the previous issues including funding, because all participants in Guangzhou part have known the past through a couple of discussions. We should take a time to resolve the current problems in our second HIV-malariotherapy project. You should remember that in our very difficult time, we asked for the funding from the Heimlich Institute, but we failed to get it due to the agreement obligation. We had to spent a lot of time on dealing with the funding and make a great effort to persuade the governments to fund the research. Finally, we got it from several departments. The project, therefore has been completed, but this also leaded to a change of the major funding originally from Heimlich Institute later to the local governments and other institutions. I suggest that, you do not need the authorship of the paper titled "Impact of acute vivax malaria on the immune system of HIV+ patients" which focuses on the early immune response (only 3 months data), not really on the efficacy of malariotherapy, but we would still like to thank you in the acknowledgements section like: "We acknowledge Dr. Henry J. Heimlich for his successful cooperation with us in the pilot study of malariotherapy for HIV infection during 1993-1996. He independently proposed the idea of malariotherapy for HIV infection in 1992 (note: in the contributors section: Dr. Chen independently proposed the idea of malariotherapy for HIV/AIDS in early 1993 will be mentioned). He also helped us to get a part of funding from Eleanor Dana Charitable Trust in our present study. Dr. Heimlich works at the Heimlich Institute in Cincinnati, USA. " I hope you accepted this acknowledgement. Doing so is very important for me to comfort my colleagues and the officials. Because the conflict of funding and authorship issues made me a deep embarrassment, this directly leaded to the intervention of officials. I am afraid that I will lose my colleagues and then lose the opportunity for our future cooperation. Please note, the situation here in China is very different from that in the USA, even though China is in progress. My another suggestion is that you should make a supplement to fund the research so that your authorship remains in the next paper which focuses on the data of CD4 level and HIV viral load for two years follow up. It will be the most important paper up to now in the research of malariotherapy for HIV infection. I will explain in my greatest effort to my colleagues that Dr. Heimlich should be the second author in this paper and I will insist in making a notification like: Dr. Heimlich and Dr. Chen independently proposed the idea of malariotherapy for HIV infection respectively in 1992 and in early 1993 or like: Dr. Chen and Dr. Heimlich equally contribute to this paper. But your funding is very important for comforting either my colleagues or the officials. Our future study will be a very big project, needing a huge funding : a multiple-center phase-II study of malariotherapy for HIV infection which includes 100 patients for the
treatment group and 100 patients for control group. This needs to screen over 400 patients for their CD count level for patient selection. We also need to sign a new agreement in a research funding tyle (that means funding go ahead of data obtaining) if we come together again in the future . B the way, a private company in China and an institution in Italy are willing to fund the phase-II study, but I have not yet accepted, because this will let the research goes a business way and I am waiting for the cooperation with you. We do not hope to contact with any embassies or consulates or directly with the officials, because our cooperation is completely scientific but absolutely not political. Regarding to the letter from Dr. Cionci to Dr. Heimlich, it is not true for saying that Dr. Heimlich spoke to my group on the use of malariotherapy fo r HIV. The fact is that in 1990, Dr. Cioncj as a representative of Philadelphia Red Cross Society visited to Guangzhou. I met him in the White Swan Hotel where he stayed. We talked very friendly, when I told him about my hypothesis on that HIV might originated from the molecular hybridization of SIV and human sperm gene (I published this idea in early 1990), then he told me the idea of malariotherapy for cancer proposed by Dr. Heimlich, when my response was "this idea is very reasonable" since I had been a physician for infectious disease for many years and had treated over one hundred malaria patients. Then Dr. Cionci returned to USA and told Dr. Heimlich about my interest in malariotherapy for cancer even though I had been worked at AIDS laboratory since 1988. Dr. Heimlich came to Guangzhou in 1991 to talk with us on the cooperation of malariotherapy for cancer. Dr. Heimlich did give lectures in Zengcheng County People's Hospital and Dongshan District Hospital, and I did be there as an interpreter for Dr. Heimlich, but Dr. Heimlich never mentioned malariotherapy for HIV in his lectures and thereafter until the middle 1993. It was that I first time spoke to Dr. Xiao, the Director of my station about the idea of malariotherapy for HIV in early 1993 on the first working day after a long vacation of Chinese New Year holidays. Three months later I received a letter from Dr. Heimlich by which I first time knew Dr. Heimlich had the same idea and I told Dr. Xiao about this. Then we came together again after completion of malariotherapy for cancer. Then Dr. Hua Hong Shun came a couple of times on behalf of Dr. Heimlich (he also visited us a couple of times for our cancer research project). The unique document telling us that Dr. Heimlich proposed the idea in 1992 is a written letter from Dr. Heimlich to me in 1994. Any statements saying Dr. Heimlich proposed the idea prior to 1992 are unacceptable. Simultaneously, any statements denying Dr. Chen independently proposed the same idea in early 1993 are also unacceptable. These statements will lead to no way to go for our cooperation, because these statements are not true. We also had different ideas on malariotherapy for different diseases: Heimlich's Lyme disease idea and Chen's SLE idea which I mentioned before. It is unreasonable for saying that the immune system manuscript is in Dr. Heimlich's house computer not in the office one, because these computers link to the internet: not only Dr. Heimlich but also I can email to your office if I have your email address. In addition, a floppy disc can be used from the house to the office.
I look fOf\vard to bearing from you, especially the answers on the acknowledgement in the immune :stem paper and the funding and authorship in tbe efficacy paper as well as the future coopera ion. I suggest that we sbould talk and resolve any problems between us before the interven ion of officials whicb complicates any existed problems. So timely communication is very important because we bave computers which link to the internet. Please gi e me your new office and Eric's email addresses. Please excuse me to CC tbis message to Dr. Fahey, because I tbink we should talk very openly, and Dr. Fabey belped us a lot in HIV-malariotberapy projects. Best wisbes and regards to you, your family and colleagues. Chen Xiao Ping, M.D.
Dear Dr. Hua:
M arch
5, 1991
I have rec eived your two l etters and several articles about 'Malaria- the r apy of c a n cer project". Because of Chinese new year holida ys , I h a v e to wait until this month' then to contact t h e v ar i ous related government office, oncology hospital a nd mal aria clinics . No w I got th e reply from Guangzhou municipal government that they full y s up por t this joint project. The director and experts of cancer hospital showed much interest in this experimental research, and doctors of malaria clinics would supply malaria patients' blood for' blood transfer'. For the time being, we still need more supporting materials before we can make a definite decision and a working schedule. We would lilke to know the detailed progress of malaria therapy carried out in Mexico, e.g. the number of cases, what kind of cancer patient are been treated, their preliminary results etc. Also, we would like to get materials about malariatherapy on neurosyphilis. A meeting will be held under the direction of the Municipal Ministry of Health ,participated by government officials, cancer exper t s and doctors of infectious diseases to discuss this project. With all these convincing materials, that would help them to make the decision. We are looking forward to the next visit of Dr. Heimlich and Dr. Cionci. Please let me know the date and schedule of their visit. Sincerely,
Chen, Xiao-ping
~l~
~q~~b~~
... - . . . . .....
r.
-'-'\~"'"
.......... '-.. ... . I I ;
~ _
4:.
-.
The Co~lition: $0 ynite ~e~gle ....

-.~
!!!I!! ' !!.!!!!!A~..!!:2!!!!~:~:~
A~I S
t 1l'.A.
~<lO11 A~., 'f~m ru-
Dr. Juk ('O"ei. ltaul'ldc:f. 2'5.6~'.360 UI~/\p '.(lInf' r.rson~t CIJ-~lIfr - 3uaa~~~ fte)'tUtdn Ri"~riol, ("~Chlltr 4t0-3~J8!lf.
",hClP p,In
,"(.;,rs C::l!l'lP-b~ l. l' APRPid Ip.\nn
~t.. 1JQU,
\ \;'1:.JV\:LtD
n" II"~ C",Ollr . 6tll J~24'r,.,
A4~rnIJlIJ 0",1,.. r-c.c~\lt.v e nil ~\N ACUJ..(O

AU~1 J~,~ A~ ~tro.::l.:!'
'eUe...~p 0{ I:MA ri~ n

~~(\t(' NlU)~II.
C.,A. n. wd M"!IIb.:, ~lr~l'!l~ M~cc\l Vot.:rs l~iJC ufP;'IX',.yI utNa

\ It,l ~ C"'I<.~I~I\ Nn~rie4'" A~ .;,'I1"I"ltl
l\\i1! ~111
net. 'on, ?t.~<JC'I\I.

Scp t~ tUbe:
7. 20f)U
Dr. H~lUY J, H.;:icnli<;:h

Thl' Heimlkh InslilUh' 311 Strl\igh1 Str~el
Cilldnnuti, OH
4S~19
Dt:a r Dr.
As
Hcimli;;h~
yO'J r~que,~leJt
I huvc
rC\'l:w~d wy re;,'oJlel't ion
of (llll discuc;.5 i (ln~ c()1lccmini malariotht-L,py, as you
)ugg~litc:d , Tn Novernb..:r. 1991, you and I neW 0\11 of San Francisc(\ to Mainland China to conduct i! ( a(~l;nIS usin~ maluri(Hhel ~py, During th~ ual'$-Pddfi~ {:rossing. we once ugain discussed your hope
tb.lt n/41ari')lht-IIIFY cculd h~lpt
.10d
pm..~ihl y \~urt; c\;'(Tain typ~s of t'Cln(~'r .

1
111i::i was my third trip to Chin,'\, My fi.rst was in \9S0, wheu 1 WilS inviTed alt.'ng with 3t other phySicians, c :duc!tors and varil:\.1 pTl)re!i.sional~ fo!' a. VII' medical and ,uJtural ~xch8ng~, It was then that 1 intmdu ..--:d the llei.ll1lit:h M41t'1t:'uvt'r t<:. Dr, HClng Shu1'I Hua in th..: N a.o.l ina 'Pt'opk, Hospital
In MIlY, 1990, 1 W~\~ in ....i~cd ty lh~ Chim~6c l~ed Cli.l S~ \0 present iOl'mallt:ctures on AILlS (0 hund1'cd!.' of m..;dlcal dOt,;ttlr~ in six or China's main cith~~. I was lold I was the fir~t Western doctor It') do so.
10 help pa!)s the. tin1t: dUling ()U! lcm~ flig.ht. yO\~ aod I earn~i\l)' explored the pn"ls and cons of maluriolht::rap)". Quit" 1utllr<~lly, you advised me Ihnt for s~veut yeats you hi1d bee!, researching Ule USt: of malariotherupy for AIDS ;:md you a~ked what r thoughl abvul the po$.\ibility of Ir~i\tillg peor1e with
HIVIl\IDS.
A few day" b\tt".r in Chi!'!:!, W'. s:\~, Otnd h(,Md ~L,~ i c Johl1i~n un TV annou.n c e to rha 1'ned;~4 that he telOted pt,,)sitiv~ (or lh~ AIDS vin.l!,;, Ooa agiJi!l, we agw;:d ho\v \\'(lodtdul it would bt if m~Ja.ri()therapy could
SEP;:-.
$')-'!-t:
l '~ : "J' ~..
H("
L I k..
.' H 1.- t~ L
1 II r" ' t. t
FeY !8.
\ dls: il1;; ly [c . embc,
.,. , ~~ of th ~
bw .J '
~raph1c ,' ~ it dll-:um,n l..:-<l th~ \a:;l six mO:lth~ of tht' p;tlicm'5Iit'~ .
wh<.' .a
to d /l .t' it
~,;il \<)0 0' wil h t\ TV . With (~boot seven o\h.:r dCX,'.h.1TS pf(;S~nt, the~ popped ir. a video ilnd ',-~~ lhe firs : pe :son vihv die.d in Ch:,n~\ 1'r;)))1 A 10S con1i-,J)<,'utionS, it W(lS iii color and very
();t
g on ' of Y lUI lectures W ph~ siciall:; in Guangzh<)u, th<lt 1 wa~ qui~tly asked de ,,- .ors 10 b\\'e tb~ l.;crure hAll \Wi!. ~ him. lit' ,ouk m~ to &notlw wing ot th~ medical
I.ni
~Glll\n inaav~n()us dru~ user and a mllk prostitute . II ~,,(l,S ~~d, gruc,~om~ "nd p;1thelic.
\o\'~rc info(w~d, at thilt tiDi~, AIDS \\'l.I~ not n plOblelli in CbIH\ .
He "vas a. ymmg man from Thail and
FC'II:, i.lg YQUl k.:tun::. Trcla~\:J fC

w:th HI\ . Wt:
w j1hysicl<in~. NI,,' .;Igllin YO 'l mentionel,1 to(I" Y(lU hoped ,(.1 <,\,medilY lise mala.riotherapy on people infected
y\)~ wrat I had ~t:en on lh;; vldet'. In Iht' prcsen<.:e \)( the otl1er
Fr:ncrually.
In Jack Ctouci ,.'
4!-A'~~'
I
200 1if.12 A 12 BCWJ1Joff'fhN)
ft )d:JHiE~Ht~ W3IY:J~~ ~-A9EL
$J
~~~W3A~fa' ~m ~!!iff ~
cp . fi~f4*~{OJ* -~BA IY:J~~ IY:J r~~ml~ $J '

1Y:J~ ~W3~(A~l'5t ~U3W3
;]:-@';I*~JJi51re.71;jIUj, t::~1'~~1Y:J
. ~A~~~
!I@>500),
CDC CDC
I ~(CD4 roJ ijHinV11n~W3iUtt:!i1Y:J II ~(CD4roJ ~). f5J&f. Wffi:~M~~

!tcpl~m -F.t.'t!l$'U'i,!l$~fOlIlJ&~ )
, '!itt!-J(illE,*"~$3@Fl
ZP:1Y:J~,'lS,I,. {t!!JlJitig~~L ~i:tEt~1tt:: r1'Ai~L A~~~iiffl r~19~
!I@~m200-500)fOCDCm~ ,f'1~HJIJlJ7q~~I*liE,'/;!\~,W
~AfrnHIJ7~~;g-J1n ~CP ff-{~Ht~ijiliElY:J r~19~
(CD4Wj!l<200).
$J
f!nJ;)Am1J$~,f,;g-@\
$J
IY:JfiXJ}]JU~ ,~p.ilUJ'ZP: ~M~~W3,f,;g-(CD4Wj!l~
m~ ,CD4 Wj!l@ tE 15 7t :
$)~j[ lY:Jlli~T~ f11J1Y:J~fJl
?!'\ffff'
~~19' fffff&~ITm~19i'iJ ~!t~~ti~ffi;;P~
1993 .RffI5) , "'Bt5ftt-F.t.'t!l$~ 41
, {f ; r ~19~$ J i'iJ~ ffl IO-207(~fjlY:J r ~19~ 'Jt r ~~~$ J *iff&9E : R tzo4' CP~~1iHfjm~ ~!f-~ffl r~19~$J IY:J~ ~~W3~rrIDfij~ ~ L ,~ $J 7f5~' f!nAI~~gti ~fiiU[IY:Jm!~ti@\!~H& 1 1i15l'5t!i6IY:JIlJil/Fp lWtE~- ~i:tEfljmij/$W3f49~ , 83m- mmm~HJjl'5t!i6I\'%t#i!i6~ J1nlW-ra9 B j!(li : ~it1'~g~ r:p ~ ~ * 51 ~ r m ~ i@ : @ff~1'EJ~1ffl~~ , !:)!tCr ~ {t!!.fiXJ}]ftg~JIt~$fflm-i'iJ~ ~~W~:hSU~ !t~& ,~* ffl~ti~) @';*LM~~IO~~ $J ). 19~$ J 1lf~ 7~ ,f, ;g-CD4 ~$*!l!tifij~ , 1927if{t!!.1l~~ ~m~l!' J1i*~f4;; '~19~~~~~&ffl~oim~~ J1n~r:plJws~~:!ifOC D roJ!I@t~.1JDIJ~* ,!it~JJi7 7g~gfi~m~ ~ r~19 mmm~f.DfOJ1i1Hmf4;;t~ 19i&' WSAJ1n~CPIJWS$~ Wj!l@H~~~5E~~W3A ; ~;]:fiWj!l~.1JolY:Jlm7tm! ~$J fflm-~~wslJi'iJ~' &:tfHiJB'C' f~aH1t<ftrz:~ j!Jl:i*T~' @:7~,f,;g-,& fM~mlJ~@I~m~ ~ , ~ ffff i'Ufj 7 r~ 19 ~ ~;;P~J&q{~i'iJ~~*!l!tim m-~' r~19~$J fflm-i'iJ @\~:g-~J7qIJCD4mI!lIfflMi ilU;g-&:B9c!tws~tt~*ZP: $J + rm~ml~$J IJ~ ~WfflJ~*Oftl?~~Afr' ~~~wslJliHJEPX:mli~jK~ t~.1JD cpM(CDC IIW,f,;g- f&;g-mi~!t92.l'5t**1C,'/;!\i5L ~~H' )i1'~iti r~19~$J IJ~ f~m.'MJ~IUl~El 'J!j.f/j~iQ ~IjOJ~~1*W~fi,'/;!\75L' g: ElWI~~wsi'iJ~IY:J~El I r1i!&m.;~J ~~~~m~ wsm!~' @;l't~~~~ilf Ifflro7;]:-t!tWkOO~ ~{f-~~8ira~P9' CD4roJ ~ , ~i&*OJ~g~ws~~ : . l11i1990iffl~-@l$IH~' ft ftlJ m-~, 20t!t*.e. 90 if{-t tE 1993 if1fflMi, J!j.f/j'ZP:$ n?l~UiH~tUffSt~*ZP:(li: =.t:. ~T*' ~92.l'5tWj!l@7t . ~{j'~W.lU~tl*~:ttfO~) m ' J!j.f/j, zP: ttl:17 ~ ~ J;) ~JtlJliHJE+Ml.it20:g$~* if 11Fl <gff-~~MJ;) (~ 1;.. ffruJ~;g-,*"iilJ-~ j '
tJt!tWRUH~ tEffij~lWfh5iji191Y:J ElIY:J ~g1'~gffl
~f&~~ $1'~gm~ W3iH~ ~
, J;)i}Jt~~,;g-@';I*liE,'/;!\' if,
cp~~1if$~~tH1Cit fi!l$~' g~it;]:J!!;~A1* @JItf&W3AW311iil~
IJ-~~~~ ''ii~fr'~~ rf!19~$J g15~~WSIJ 1t rf!19~$J 1J~~ws,f, ~wsAlIDilUlJ1ir~) ~M' ~1iI~' ~~~WSA~~ l ~W3 ,f,5lfOf5J&f,f,~~~ws ~. @~ , jfmg r~19~ :g-&~~;g-~It~ftg.n~7i'iJ $&~7&~t!tWiHlJm~~ IT~cplJJljlli '.,fHli!i6~ ~
W~~IJ)t,I7t{'F~*Ei~IT $J $Ji~-*5SiwsmtJ~ ~. tEws ~ cp 7 milj' it!!. W31J~fj!~~. 3tCPtljJ!j.f m ~ft ~CD4roJ!I@~ ( i'iJ~~~. fJi*~fr'~~1J ~,~m-WJ!!;B~~~~W3 (9tB){f"J@\~~~W3~B1'fI-7 Ij'ZP:IW8'!J r~191W:$J 8i rxlliJ W~ftZra91J ~ ~ , .I!jH4!~~~!ltl,5l:ttt~ $1JW3A~.g-o,~? ~~$- ~1J&fM '*lm7t~.:g-~r~ ;;pt~tl:1fli :tJIt.i53l jJ!!lE : ~. ~ ws $ tt:it ~ {'F ~ :
Mra9ff 35 %9EL' fffff5J&f,f. *.!l!ttl:1 ' :U:f!niJl~-Jt&:1:f ff1lE,'/;!\ 11i~~19W3~iMcp r~19~$J .RiUHV,f,;g- lliJ IT ~ IJ i! J!{. ~ ~ ~ ff~~W3W~19IY:J5lM 'Ji f. &:~;g-1'fffi r~19~ {,'(CDc)8'!J7t~1J~5t5]lj* CD4Wj!l8'!JttrlJo ' iTIi~~ff rc9 ' ffl!i~~.1JD r~~J , ~.
~~t~ r ~15t J
tiI\~~ ;
i!m>
r xlliJ
mii~mlJ*H}jr
J!j.f/j''Pm r ~19ffj$
{flli-ft r ~fjJ 'lfE1l! iE ~ , en - t1 OJ ttt .1Jo ,f. :g- . an 1995~ , 1I*+ZP:~(ili l

~!Jl~~~Y::
'
:{~~~ t} ,
(...t)
\
r fl~tl$ J ~ft~tf~ m~ m~ltltl~~~U~ ~ ~ m i! ~
m~H{]~, ~ 89
WHia!ff-~M(1'~BJ3m~tl
CD4~ll jj1JD? ~,:l:' f4 ~jj1J[] ll~:g1'~IUI~

~~F!ffl r~~1ittJ ~~ .wtt W~89nxr)]Um . -@:
~.R~1i~ '1'1llUm~
'"
r~:!l4mJ!~?-1HJttJ 89&f Ji: ~ 1t. 1 j!.iij ~ (41C-42C' W rS ~ ffj

.Pfi~~U89tNlttifl5J)mffj
J!. mrm
r~~ffjttJ
1IW'l ttJ
t3ZmL~HmrgW~[tl: ~'mi*1t1J~?'!~' ~ 1&JfIZ~?nW'lAJtnf$W'l~ffl ft~ ~1&r:k~ . ~1tI '~I= ~/J4~~lIDUC~7~~ ft :g,ffl1l1'i1J~?nW'lii' ;+IHm:gffilUl&fJi:~3t~~ . ~~W'l'UDAge.l3t~II@W'l &fJi:~1l"i~~fiIJ1.~m~
filfJi:~$iWtjiHt!1'~m
rf! $.:j: ~ t\\.H1J, A 89 CD4 klII . J;) ~ ,@,~~tf~ Jffi!. 1IlHiUU CD4 mtm*zp: ~~flijA~l:1JD~ . ffift5* ~m7t~m~zfJ] . ~/J\ZP: entm~9~jtgEfJ~7~/J\ ZP: tHilJl.ff r$~mf$J mfW'l~ rfJ!~$J ~. ;1tcp~ J! : -~{lE~CD4kl11Jffi!89~
~mf$ J
rffiiJji~5 IA1U1il1!9~:
~ 'lJtn~CP~1JD89~$7t
mii~tEW'l$ftff)!J:flUili *899(~mtt89W'l$(ll~~ ~m$~-fi~ff(~~~1'

~:gttm$)'
WJltI5JIlif . ~
M;
-~IlIl.IT~~~CD4kl11 /}2fS89/Nfl.iliilH;UU,',~~
. .~~~~~ 7 Jffi!899EC~{f.!ijC ;l'l;1&89&f mcptf~l:.m::g,:g~89kl11Jffi! l: r ~ Ji: . *AEfJ~7 ft!!.89ti?J!rr ll T . @ '& *!.Jl r fJ! ~ 11 i~J 7C1l89iWlifltt~5U&f rettl:&fJi:~BJ3' flH1tm~ $J 1&. ~:g~89kl11Jffi!ll ~. iU~~ ~7t~~m - THIMWlJffi!ll~89Y-~m~ Tilitm~$ill~"F~' K:: l'Jl~.!i[-~~m$tt89 /J\ f{JaWlJffi!1f-*2. :j:~~~A ~f!~UttmmfiW~f!89* Ff< ~-m~~~m$~tt ~f7'3W1Jffi!ge.l3t&J' . :M!PJ~ 2fS. 20~m~ r~~ffj$J ~,',~~89/J\~ Ul:.1'M89 ~BWlJffi!' ffl7JU~CD4~B 89,',*89fifi~m~1'~m ~m~IT.w~~ . tt~~~ klIIJffi!iftijC~~;l'l;CP . aklll tBili~89*B* Wlw~~~m.',7C~~~W'l Jffi!~2PJJ;)O~BWlJffi! . CD4kl11Jffi!ti:Jitm~ . itit ~W'l.',7C89!lfB~fjti ~m ffl7JU~CD4~BklIIJffi!jjl:. . y ~m~ CD4~BklIIJffi!iftijc ~U . ~M4~89ft~1:l1J1~tB7 -~m*J{tl~~~~P3kl11Jffi!ii $~~~ - @lm~89$Jffi!r)] tEI&89t5*- -~~ ttT-~BWI~(C1L)-@1 fig~1M89~m ~CD4~B ~t',~~-m/J~',~ m~WlJffi!llT' ~/Pls891i1f WlJffi!iftijc$~"f* . ~CD4 f~/J~~~ Ji: IJ\ m ft ~ ~U: r ~ ~ 1i WlJffi!lf{:tf{J itit itt l:~ . 1 .1996~ . $mf4~~ili ttJ ilJ~~~IHiWlJffi!llTJ!il ~ rf! ~ ffj $J ~ ~tl!19 r)] ~~7~~:g~~W'lii89j}] *J:ff-' ~. ~-MJt r J;)$l;t$J l'JA~D{BJ;)g~89ft~ .ll* :t rf!~ffj$J .D{B~fj g,*!I9ffj$' .rttJ:~~,', .jf-A15 &f~A~89*~~lf cp . ~/J\ZjS89&fJi:/Nlljgft ~~IJ7 -?X~?!l89ge.m:~Jj S-{tt$~1&89j}]4m~tmM1J[] ~i1JfiRmffj~~iH~MCD4m ~ . ~ffiiaJ3&:jt;ftP3~mge. ~9EC89 ffii7CktBJf-ft!!.1l"i BWlJffi!iftijL:$l:ff-' ~~W'l m:ll.y!i1JD . 6:*!~mA~ ~*'l-89ft~*5*1:l1J~ : fiRfS ~ltA:!i1J[]' @1*!.Jl r~ @l~m:~m~fJ - ?x*89~ ~l;t(!~IY:Jj}]4m . ~~m~ ~ffj$J 1& . :jt;CD4~BWI ~ W'lBJ3!1IiffH~7 . ffif*fiR~~ Jffi!~C$ill~"FI\!l' I\!lf! ~~-@l3U'j!j~t;$m$89 ):;C(!~89j}]4m ~~W'lm:~ ~mffjiiU*ZjS ~~W'l~~ m1i1.i$ ~-@lf4!J!ffif~ ~ ~ ~ tB 1:. HD ~
0
.1997~
~~7'
A:iliill~~f!'ffiilil\!lm~!I9~m~~'ili~-M1'
l~ml ra"5~J ~fd5lm~ 1iiW89~*ZjS l!l~/J\zp: ~f1tAJ!M891i~'
o D..
a:
..J
a:
I~1Mti~~~WlEiffl ~/j ...zpi!! . Jlt1f$JF1' ;~PfT-N,~. ~tm~::
. rmR~fflm-- $5t~~~ii~~~ .
f&CD4it*E.k4BJleIt~1:.BJ3:Wi
m~~ /J\ ZfiW (f:]fJJ &!iJf~ ft ~ . R -N r1!itE~ ~~i!~~CP M%(CD4k4BJleIH ~

. tE~ . ~$7t A~~~ra'*~ 3-5~ . .1ilEJ;) r S~1f$ J ~*~Jl~ , rm~m-CD4>500f't:J~~;g . fU1'~ffl~-1l!'f $ C~qOO~~~ M~A.&rS~.$:JR~~Z~~-@mfUf't:J~~&~ CD4mJleI1'~LttU~i%*Zfi . 111'~gft~i~U;J liJlUJ\Zfi~u . liIJftl!.1E:(~'fifHf(f:]-~!iJfJE~~JJR:(~~~~~f;1J:cpM . ~~~ J, 1~15?ffi{J:J(f:]mmmA . 7tJJU&J;) r 1i!~1f$ J fO r *~~ J mffi J;)MmloJft~ r fi! j 1l!'f$ J m1f{&;!tCD4k4BJIeI*ZP::&~ff~:!ifO~$ . HPPfTffi1lf't:J~tI!7tmCi1i;*t100!iJf~ j
~M(f:]!J. ~CPOJJ;)W~U~BJ3:Wi(f:]k4EJIeI~T&~
0
200-500Zra'(f:]CDC II ~,'.:g) . tlf1ilE ,- ~~1f$:.J
1I*/J\Zfi~
c(
fiMm-.{&R~r1i!~.$J(f:].~~~~~*.~fflo@:(.~~-~ZliIJ~ /
~1'~~~~~m~:g~~r~~.$ J (f:]~mm.o
r 1i!~~5t;; J + r ~~~~5t;; J
~~. f.tf~- rJifl~.l@.$J
-fl -
r~~.$:J ili:ffjgmm~~~
~/J \!
~ftl!.ma~r.~.$Jmftl!.A(f:]r.~l@.$:J(f:]!iJf~cp~~7m*(f:]~fflo~~ ! !iJfJE8*~MBJ3
. CD4it*Ek4BJIeI(MrnCD4~JIeI);~~~frJ(f:] r.mm J k4EJIeI . :(~frJm t'{H . ~~~~~J}]figli1TttT~ . f&~I~~~m

0
1E~~~~~noom.+7tM.fOm~~~ffloWXftl!.PfTfiB~(f:]a~~:f~(f:]; ~
~~~:t~~f;1J:m~l:!!CD4k4BJIeI ~[
~~~+7t~~~f;1J:~fia~~fO%1:.~(ffjjtE~~J}]~g1E~JIj\~T~~a~~m%~ k ~1'~~~~~~~fi~m(f:]~.tt~~~~ili~.~m~~~~Rtt.8 o IT ~:(~fim15?T~APfT~(f:]~tt~~m15?T~~m&8~.~~.o
M* ~M j
-WAa*~~!Jl~~W'l~~f;1J:CD4Wl~fD;!tftl!mlffi!(f:]fiMmi!mk4B~if4~(f:]iJJjJ *;L
fi ~~f4*~ff"ili8*~ttiUY$~~J3.Jt~-iJJ1J*iJfi8':J1.J$~P rm~im~$J _ .
0
m~~~cp~Dk4B~~m~.cp(f:]~*$7t~~m~fi~~*.$7t(f:]C~k4B~ ofl
;.
r.~l@.$J ~~$~ff!!\[(,J5;ff;Ef.6 cp~~$*~~*1tm r~H~J

0
(f:]CD4JJ;J;E r
~)~tt:J~~wHl!~~g.jJ
~~~~M.~tm~.ttrm~ .W'l~~ ff!!\[(f:]1.J$~~:(rm~l@.$ Je
. I-~
....
W
...a..-;. :
~mT.~ek4EJleIft~~.$m.tt&MmXftl!.(f:]-~~~.$ @W~fi~ m ff ~
0
l~jlUJ \ZRR~ftl!f't:J!iJf~*B**il!~'
r .~$: J mOJ~~iJ-@l59i~!!(f:]$~M~~
~~~~~X~~~~~5t~'~ffi~~Xcp(f:]~~~*,
. 3fik4B~rzgT(EHiII~ft*2 . ek4Blffi!ft~6m~8!!9Erzg T-a) O r ~H~ J tt:J~c.ttttT-it*Ek4Blffi!('t5CD4mn~) ~+Zfi ~ (f:]!iJf~ft!J1. r 1i!~.$ J OJ:Wi.rrF.ii~~~3fik4B~rzgT(f:]f't:J*Zfi rzgffjjftl!.ftEil!~ i fii ~.$ J -N~~gi%(~~fi r ~H~ J (f:]CD.tWlJffl! . ~ffjj~~fi~~~tt:J r ~H~ J k4EJIeI~ r
iE~~~~~~~J;)~M(i:~~~)
0 0
~-mf4*~ft~HU
~~~(f:]r~~Jk4B~.~ffjj r m~ , ~~tEm~rzgm~f't:J~~W'l$ ilif.t~~
r fi!~.$ J oTfigfi r m~ J m$&ii'fI!i!(f:]{'Fffl rzgJlt . ~+zP:~;U! . ~ r ~~.it OJ~~ji(f:]~~~$m~te* . DOL i itHi@1l!'f$ J . gefi~figfT&)gmjl#;~~(f:]3 ifj( ~ . ilif.t-N~~gmffii~~~ . ~:giIJJ}j1):fI3~fO~M~lWmi1f(f:](f:] . ~~~~. r.~l@1f$J.~.m~.ffjj~ftMffl.~~~ffi~*-fiAftE ~~ffi~.$~i~m~(f:]~~.~.mffl.w~,rzgJlt~~r$~.$ "f r m~l@1f$ J *5~(f:]!iJfJi:fig~I1XJJJ . ~~tf~*J:tgi~~*f't:J~~W'l.~.:t
0
...
~ ! ~ti}:tifg $ 11/f'!:1- J, h-I~ Vr.~ .. j ~

'rft~j6{{ ttl1 &ft 1i
J
1J!l i'i 1'2 / II}I~ -It Ti
~111;:(,iriSJ ~rf~~'ft ~~ lr);1r-l%~;{~A~

~, ~S Y1.v:,"kil \~b t11's 12 \~ J , hl~ {+ 2-: :1;>
{
j
i.-
J \i] i- j~ ,jf~ fi~t ;:: 'fo%r ~ i:;t ~/," -:J;(~ , 1~
v(}I'Z-J!2'4
I 1- IX-
J:~ <Sj207jLJ,~vP~tJ1;-.Jtf~1:idZ/~ I::J , I l' ~;\ UCLA i <ij Ac,,<:# J. :It t IV3 ~-f11'1 1. I~;).j/ t 31[ / , -1\1 ~ 11; tK,JJ 1' 1'* h rll J ~ lM111,,, tf ;U{, ~/ (.Jg.
v-:;'f!.A
H~pJ;cl\ iJ,ff ~ is II' i 1{Ji \~j:-H'(' ~4( HA~: ~~ 'i

J
00
>J
/\1:x"z11l {1'; JI~tci t i~ .:,,-f~i

l'
~fi ~ ) 3 ,(
a- 11)~Hl S Hb/1\/.:dl f (':f'1~ 4dt 1\'~2 ~ I~]g

\~3 ci / 4' 2: "1' ~ I~ ;;;iJiL -iJ-;tU, ~ yj) f.)L ~d) {ric J" / if:J ~f ~ 1{7 3-);: J7 iiTY ~fJ3 2z- 11q:ill~t '
if t~ I~ ~~~j) 1* Ii {i;; ~~i ~fl~, i i /11t-tll

u-
1if;J! ~H til qq 04 CWn~ 1'1; I~ 7-flt, ~}k I~

I
\~ , \f.k~L J fi 4 tfj ~ $ ,ff~", l~(\ ,' I \<l c:e" ~ j I q!if IIp -1 %I~ r-frt ,0 krz ~ Wi {v q rl';," l1c. ht{J7r~rtJr ~ If f& (:~PJ :t~kE1tf- t{:i;, is~) ~~~ ~ J 1~lk Ifd; ,f1;ifit. j311 '1#1; ~yrZl- ~%f f /;;i/, ~p) 1~ y-lli;f) ro 'i 'Y')( .A . ) ~:; k 11 ;?r; ! 11' 7&1-b!fr fp l1; {tJ1 L~11Ii!- fu-~~ ,,7 ~ :> ~/ 7--/\'
1
3 ~M11 ~ SIC fi:r!; :if t ff~1>~~ ~t1G. Of I qq ~1 i~
r-
'7
:it~)1,: \~f / t 2-1(vtl iffoJ 14 i~1r-t~ 4, ; :fo;!f!f-~ r?

I
7ut 9t g :r I~J ~!~ ItJJ ~ ~1 {~)1'l11!, ~itii ~i ;t
rq' , j{]:}l ~ I~ ~-!t- t Iit: (,9 ~ 1;, 'i ? iTv ) j; t~ H;" ti'ff :;Vq 1tQ>z, jt?vHn 1?8) \{1]rl~l~df~ln1 H~l1Ucl,
~v41 ~, ~ ~ i~ 'f ff 2 ;p,r~1J 11; -;pfJt- ~ ~ I:f/i g:}'iZP!l,
#~ 1d t;~ ~f10--{it)
~11'l1,~ ~
I
iJiyJ-fl
fi;Hf vI,;ft ~ 1%~

I
i{ }/~~'lGlI\ ~Y(, 111 I-j 14": l<JH~ $>~1J
/1 }4 dJ fli~ If~ ~)! f7:rk~1

~
~ I~ { 7-1 Ii II' H~11lli

(jj,{qq> .
)It ) '':l. Sf r). / k 1-/71 ~J 1-ttt C 2JK 1.l--~ 00 11 U p~ j.;t~ ~"11-
J~~~~\,~i~. ~~ ) ~~~lBfoJ47z~ c.tI ' 1; >.<i hJ? .-f'.1 . -,.h '"'{ ,~ I- , ,~) '" l' l!, at' ~~ YZ-r- Zld\0 10: ~ v>' 1oL 1 1:: -:iff.:]I t:~
J
1L/~
)"'--0)
'$
-f:
rk/~vnL~d\ ~ ~J1 ~ H y .;t;(q:t 12 , ~11"d Iqq3~f6(4t-f:iy{t~~ I~jttk f1Ji ~ i~ ,1\ HIU ~I?{~ pi ~ {lA~ rI-tl",(,:c!\ ~ t ! J Att, 1
f 1lZ/1 is (tAl If
1}"
~1fvy", f11~ ll6l)l~:if if~ ~1iJ3 (f, ~tl3 H~tJ '"
t~41-W It tt~ ~31 qq?~ ar:;{1 'dJ!+~ if'
") fI-- g
~ 11,,--;(1). c...l;;i /' ~ ~~

11
':l
1 ,\ c;-!)
U/"I \
~ I qqif~ 1> H ~rl\L~I, ~ 1

.
'iar
j
vd /
~ wt-t 1~
yZ
~11 ~ ~ r)~ ~ '!::f/ t iM-~ [.b#JJ I'~i ;f\~; ~? 1'-.1 H~vn~h) ~"9- {w-jJ ft j lit- {1j 't -If%) t ff i) at ~ rqq 3~ ~ ntg,VjH i -t-i -r;1\ ~;~ )v~lL;t ~ 'tr~;: ~ :t1 fA9 t VO'~/I ti 4f!f 1, Hi ~~! / f f
J ')
;J-~J .\1 Iqq Z~ iJv'<tli-VI ~11 i:t
. Hev"'lA-[~ VIP 1; jf 1 I' 'r <l>t

I '
/>
v?
~: : --17~
.--,
. 1"t
I J ' I n-tM>1 lC h
L\ 1"2 ) --i 7" .;f, /~
1~~ 'I~ 1t J cit-:7t~ I qqq-+ ~~n1 f1j ~-1' .:vl~i.!::-/

(
iVY H\ll /)}II/<, \,~:i3k A,J-t'f~Tk ' ~rrt31-&7-tlj'iHb ~7;G ~ -il?-p-J ~~.i' ~'h-- .;q'11'dl J )t--~ , ~ ~ }\.t~n~tli t4-~~ 'f ;ft~ / w- ~ Iqq 11- $ tt~:tz-~?v c:en G~ ~14 11 t'D ~ ~I~ <fti;fi~ ~ \:f;) i tr;t15~1J; ~,i 3~)
I
p~5e I skid, ef f)11Ak~tlw-"fla- trr HIv 4-e"Y Yt I~M1Y i \,r1~~11 H~~h 1rn ;ffi m ~:01kri'J
I
l-tif~-h fil <1v1~;fit,;U. if-h~i1~t1t t~f+ ~ ~ }1-e,~rn~h~]'-o i! 1%jcPr1(i ~ ~~ ;j1;1/ih ~t~~ i#f
}
"
/ qq2-~;f f i .fi,fM: j11~ i ~~, t-)f fll,z ~,SRAJ-e-J I qq cf;') ~ t'i4, ;ft {i.~ i1; f, i jJ HI U$,-J;}. r f j I q10 ff;ffiI H.u.~l1{~(,~ ;ji1kd'J If; i i ~ JrI i 3~ / ;qq ?;J r}:i: iff iii "~f; I~ y1?! Hlu~4:;.. iJKi01)V;ziAf;l;fi4i lxl~ ~A:fi S L E ~ .,.j:1<t. tiS}J~4i9- IT" i ~4. <1 H~ m~(,h
1
/
-f'1
Jf
1~ {~ ')};-t:t / 3Jj~i\'\ ~!%l~ )p ~ ~t 11 I'ill ' ~11'l { 14 j] 11lJI\ HIV ~i , Jf.;t~~ t!1t- M ~~rv~ 1.:f lJ,f Hj) JJ~ tli~i0J~~ ~7~{~/
. ~ tMt.fi If/ jJ ~i ~ HI V ~ I ;,. JJ-1fN I),D?J:. J1 \~_ :i)'ff ~....ll :riveS 1- Jtt l}, ~:h @J-l' J,
~~
1'~~vt~/~i ~~~ 1~ 8 #} Xf~ ~ i-- 10- yti";:L ~ (.J 5J- ' ;J 1~ ~~ U+ r1 J,-~ #11 #1f
/.7 ~ Itt.:t- \
f--tlt13!~ ~~~~
'1~
)
pi, I t,
II.
.-
' t~mm~~~I~m,tffl~~~~~~OO
WM~~M~m_~~fi~~!t~~~
i~
~jj~~:~~~~fi~~~~W~~fi~~.~~*~~(~~~~jj~~
~)
: ~t 1i1i A if :{,i z :$
~~~.W~~li~*~.~jj~~~~*~m~MM ~ fi~~n~
%.tt~R~~m~~~mm~~fi.~, *w~~~~~~*o
~~~~~~)ffl~~~~*~~m~~~M*, ~ ~~ ~ ~ , ) ffl~ ~~~ ~ JJ ~ ~ ~
*.&
~ PIHz: %~ J'G FJT I'f.J ~:m .lL :R; FJT

II
~~
iJ< ~ i.$!. ~ ~ - 1J, ({ ~ :P:ij lz: %1i1f ~ FJT 00:

jlU:a
t:~~~'fJ~,,:;i:.",;;"~8;'~ '. ~- ")7H"
~ ~ 1J< ~ i;z ~
*=jj
1ft flL ?J'- i 1!;l. ({ ) ffl" ~ ~

0
th- 1;Z'' t~ tJ. T Ai- jj
1JW:" '-' ;.;..,.,. ::; .
....... : " ..
~ff~~~~~~~1J<~~~B~.Ao
~ff~MOO~~,~JJ~~~,fo~m~~~~.~~~~~~m~~a~
+;:;t;:.l
~~/'O ~ .
, ",
~~~~~AAM~~~~~~~~,~~~~m~~A~~~~ o
~~~~m~&~, %~*Hm~~~.,.~~~k,~*k~~.k~
~#o~~k,~.fi~~fi&.~~~Tl O~~.~~o~~*=~fi&~~
!;l. i1!tf~
.. 5.
m~oo*~(~m~~*)~.:mlz:%~~m,~~~m~~fi*~~.~
fi~*~~~fi~*~3~~~.&3~~~~~~m~**~o ~~D~*~~
.~~~~~~*~~*l'f.Jm~, ~w~~~ml'f.J~~~.m~~~, ~fi'&
..
c :
-\-
-{ i
:
j
i !
I
-. .
,
"-. ,
.. ..
.
.: ;
-~
J'
;.
~~X~~~m~M~~.~*m~~m*~oowoom/*~~R~o~fi~~~
6~~~~Mm~_~~~~~~f*~~fio~~~M~m~~~.~~o~
-:.,-
. if ~ qm A f 4 Et: 5 ~ ~ ~t:mJ! liT I~H!m ~
J!1J3 JI3 A*~~Z~tl
1lA ~~t,:ltrJ.rtF1j3-!l;fIQ%"
~~~~~ZnB~~~~fi~~~m, B~.~~%~~~*~~mif~~
'(~~3L%~~m"
:lJW:
~ff ~%~~~~*m~~~~~.Ao ~ff$*.~~~~~~~~~Ao tlt{#;~~1T*fi~

~lI}J:
&,~ f0 ~~L~ ,. ~*J:1'f:J ~.& if;t: (f.Jl1Us} 0
aw 1 0 i91J,Bj~~!jtllJJ20
0 0 ~jT;;m~~fi,
Wsfiffi
6 ~Jj~~ijL&
~i5ffltllC~~*1!ff0~fflo
~~~~~H~~f0H~/~*~~~~.~~~~~Z~~m~4000
~jT;/~~Bmffi~m~~~~~fi~fi~~~A, ~~~~m~~~~6~ Jj(f.J~~o~~*~~6~~S~*1!f(f.J~Bm.o
~ f ~ Ii
(f.J t#} i~ :
B ( 1 9 9 3 ~ 3 Jj.3 0 B) ~Jr4~ C1 0 ) ,~1~tiE;W
3I~1A1A~~~ Jj ~~
A~~fi~m./i!@m~~~Fm(f.Jm.~~W(f.J~~o
~~~fi~mm*~W~~.~T-~~~~I'f:J~~o
xJ.:lJFcJ ~: *~~~~~ f0 ~. *~~~{ffcJ lji:IJ ::ftt;f!J m ~::f~~:lJFcJ ~ffM

lit :IJ ::f ~ *fJ ffl
0
~J:if~~~(f.J~~~~*~~M#.W~~, &~M~/*~~~~fi~
~."~~.*(f.J - .~/f.1A1A~~~Jj~ffiB
(I
992~6JjI 5B ) ~
*$A~:Jt~1N)1tIrP$lj5Eo
-2-
. .i
: 1- :
-.
. . ,.. . . -.-: :
.,
.'
. ...;
. .. ...
..
.
'
..' : .:. .#-~:

",
"
-3-
', '
.. ::- -
Dear Dr. Heimlich, I have contacted the related officers of the municipal and provincial governments. They have promised, the issue of cooperation continuation will be discussed later on and they pleased you do not contact with the Embassy of The People's Republic of China in Washington, D.C. and do not directly contact with the heads of the governments, because this is a department (science and technology committee) issue of the local governments. They said that our cooperation agreement was not a scientific research agreement but a trade contract after they reviewed it, because there is no a scientific research funding comes after research data obtaining. I understand that, they said so because they have paid a lot of money for the project. . An urgent issue is that you should give us a written declaration to declare that you agree to publish our paper titled "Impact of acute vivax malaria on the immune system of HIV+ subjects" in a format I sent you in my email of Feb. 7. And also, I have not yet received your response on this manuscript which I sent you by email over two months ago. So we have not yet known your any ideas about this manuscript so far. This has delayed our paper publication and is unusual internationally. Based on this and the research payment issue, Dr. Xiao and my other colleagues as well as the officials of the governments recommended many times to cancel your authorship in this paper but instead in the section of acknowledgements. But I persist in putting your name in the position of the second author based on our both understanding. Best regards to you, your family and your colleagues. Chen Xiao Ping, M.D.
= ~a7e
~~ ~ge
co
~ac-e
~~e
related officers of the municipal and provincial governments. T
t i ss ue is that you s houl d give us a written declaration to declare that you
3es C' e
regards to you, your family and your colleagues. xi ao ping, M.D.
At 01 - 1-26 12:02:00 you wrote: >Dear Dr. Chen: > >Thank you for your e-mail of December 8, 2000. >viral load lab is fully operational.
>
We are glad to hear your
>Apparently your municipal and provincial governments have the incorrect >impression that "the Heimlich Institute broke the cooperation >agreement." Perhaps their translators did not make the terms of the >agreement clear. It is important that we correct this misunderstanding >so that we can continue to carry out our research together.
>
>You will recall, as we discussed and agreed upon during your 1997 visit >here, and in our correspondence, it was required that viral loads be >performed at the time of pre-treatment, post-treatment and follow-up >examinations. This was vital because: 1) it was necessary to ensure >patients were definitely HIV-infected, 2) determination of >malariotherapy's ability to control the infection needed to be made, and >3) medical reviewers require such data for our results to be accepted. >Our agreement (as discussed and agreed upon) also called for payment by >The Heimlich Institute upon receipt of complete patient reports. Since >viral loads and other data are part of these complete reports, and none >have been received, payment is not due. > >The provincial and municipal governments should be advised the delay in >getting the viral loads was through no fault of yours or Dr. Xiao. It >resulted, as you wrote, because the Chinese government had forbidden >blood to be sent out of China; therefore, you could not send blood >samples to Dr. Fahey's laboratory. Additionally, the university in >Guangzhou did not want to handle HIV-infected blood. > >The Heimlich Institute is known internationally for meeting its >obligations, and, as you know, Dr. Heimlich has maintained a good >relationship with the Chinese government for many years. Please feel >free to inform the officials that their impression was inaccurate. If >you prefer, we can send this information to the heads of the provincial >and municipal governments, through a contact at the Embassy of The >People's Republic of China in Washington, D.C. We would include the >agreement, the above information, and our bank records indicating the >dates and amounts transferred to the numbered accounts in China. This >should satisfy them and allow us to continue our work together. > >Dr. Heimlich and I look forward to the continuation of our studies with >you. Please extend our greetings and best wishes to your family and all >of our colleagues for the upcoming New Year. > >Sincerely, > >Eric Spletzer, PhD
2/12/01 8:12 AM
D ar Dr. Chen:
Thank you for your Holiday greetings.
My Chinese friends have sent me a copy of a newspaper for which you have provided information. They have translated this into English for me. It concerns the malariotherapy for AIDS. They are concerned that your name appeared six times in the article with no single mention of Dr. Heimlich, The Heimlich Institute or Dr. Cionci. You also state you proposed malariotherapy of AIDS in 1993.
In an e-mail of March 29, 2001 you claim, "Dr. Heimlich proposed the idea of malariotherapy for HIV infection early in 1992." You also claim that you independently proposed the same idea a year later in 1993.
I have in my hand a letter dated December 3, 1990, handwritten in English by you, to Dr. Cionci. Your letter responds to his having told you about my discovery of using malariotherapy to treat people with cancer and AIDS. You state, "Dear Dr. Cionci: Many thanks for your letter and information. I am also interested in the Malariotherapy on treating people with cancer and AIDS. I am glad you said Dr. Heimlich had asked you to accompany him to the opening of the clinic in Nanjing. But I have one question about it. Why don't you plan to open the clinic in Guangzhou instead of Nanjing?" You have proved in this letter that in 1990 you were told about my discovery and research for using malariotherapy to treat cancer and AIDS.
I have been informed there will be two more parts to the story in the Chinese newspaper. If you have corrected your omissions and given proper credit to my origination of malariotherapy for cancer and AIDS, we will be most pleased. As I stated once before, it is not unusual for one to learn of a new concept and, several years later, think it was conceived independently. If this is the case, you need only write to me and others to withdraw your claim.
If I do not hear from you to that effect within the next two weeks, it would be appropriate
we put this information before our colleagues and the public. I propose to do it in the following fashion :
1) I suggested once before that I will provide your letter, and all other information, to the People' s Republic of China embassy. In addition, similar information will be provided to be distributed to officials and medical colleagues in China to obtain an official opinion of the evidence. 2) My colleagues in China, and Chinese colleagues in the U.S. , will write to the newspaper and the authorities mentioned above with their opinion.
cc: Dr. Hua Dr. Fahey Dr. Cionci
Jear Dr. Heimlich:
After I majled the package of the material on Malaria Therapy of my last week, I tried to find more evidence. Because I used to keep my correspondences, finally I found several printed articles enclosed here as Appendix 6. These were articles on the Philadelphia Inquirer sent to me after Dr. Cionci's May, 1990 visit to China. Please look at the places circled with red pen. Apparently, by that time, you already told Dr. Cionci the idea of malaria therapy of mY, and Dr. Cioinci has introduced the this idea to Chen and others during his visit in Guangzhou. Chen's letter to Dr. Cionci, dated September 3, 1990 mentioned that he thanked for the information and he was interested in malaria therapy of cancer and AIDS. Also, there is another section in Chen's letter in his letter to me in Appendix 4,in which Chen wrote: "In 1994, Heimlich mentioned in his letter to me that he had already had the ides (of malaria therapy of AIDS patients) in 1992. By that time, I thought :' Had he have been the world's first thought of malaria therapy of AIDS in 1992, he would personbf that ides.' But he had not disclosed that ides, and I have never heard of such an idea. fact, two persons proposed the idea independently, one is Heimlich and the another one is Chen Xiao Ping." Chen betrayed himself
In
I have mailed a copy of all these material to Dr. Cionci. He certajnly will be able to provide you more evidence to support you.
Fraternally,
Hongshun
Area M.D., task force member takes AIDS mess e to China

By Tony SWllnlck Imagine it is 1981. There are only 300 or so reported cases of AIDS in a r('llIliv('ly small and restricted area . The federal governmenl nnd the medical communily mobilize to learn as much as they can about the dreaded disease and lake steps to prevent irs spread. Now imagine II person with a great deal of knowledge aboulthe subject coming in to educate the doctors and government leaders on just what course il should lake. If Ihls scenario sounds like II fanlasy il isn't. That is exactly the positil)n the People's ncpublic of China finds itself in today . Enle. Jack Cioncl, M.D . Cionci, a member of the board of directors of the Montgomery County AIDS Task Force, recently returned from China afler a five-city tour where he spoke to doctors and there are a great many misunder tandings about the disease in hina, as there were here when lhe utbreak first occurred. Fortunately, they can learn from u~ and our experience." It was Cioncl who was chosen to bring the most basic Information about the disease, what he calls "AIDS-IOI," to the Chinese doctors. Clonci's trip was sponsored by government leaders about the posi- such groups as the AIDS Task Force tive things which have occurred in of Philadelphia, the American Red the United Slates since AIDS was Cross of Southeastern Pennsylvania recognized in 1981, and about the and REBASHT (Rlack~ EdllC',..Ung mistakes made here. R1ll!:!t;!: ."bout SP.xu;rlllealth Issu'!S). "Hopefully, we can gel a jump on He was lhe first. wp-stern physida n to the spread of the disease in China in- tr'lvel to China to pr0vide AIDS stead of letting It get a jump on us education and training. the way It happened here," said Clond visiled the cities of NanJCioncl as he relaxed al his Dresher home. "The AIDS epidemic Is In its . lng, Shang Hai, Beijing, Canton and infancy in China. In February they Xlan and spoke to hundreds of docreported 300 cases which puts them tors abOut the illness, how to Ireat it, where we were in 1981. Already Please turn to Page 7
Because of Dr. Cloud's trip, Dr. Henry J. Heimlich, will be able to estahlish a clinic to u!'Ie "Malaria therapy" in the treatment of cancer, Lyme disease and perhaps even AIDS ... Story page 7.
With Dr. Cionci, second from left, in China, are Bin Quan Xiao, M .D., far left, Jin Zing Liv, M.D., and Xiao Ping Chen, M.D.
AIDS cropping upin:CnJna ~i.
Continued (rom Png(' r. 1
The trip was arranged t.hrough an exchange program between the American and Chinese Red Cross, and sponsored by the AIDS Task Force of Philadel phia, The American Red Cross of Southeast Pennsylvania and BEBASHL Clonci paid his own way. lIe traveled to Xian, Bel Jlng, Gunng Zho, Nan Jing, and Shanghai, training doctors and educating government officials about AIDS. It was his second trip to Chinn. In 1980 he went as part of a group of doctors on a cultural and medical exchange tour. He . saw many changes in the 10 yeatS. "On that first trip we did not go anywhere on our own," he said. "We couldn't communicate with the people for one thing, because almost no one spoke English. The hotels were very primitive, no European style services or food, and you couldn't get anything but chopsticks to eat with. "That was all changed this time. I was welcomed with open arms . People would come to greet me and hold up the Red Cross flag . They seemed much more opel1." In 1980 everyone wore the drab blue trouser and jacket uniform of the People's Republic, and he saw no television sets in ordinary homes. This spring, the streets were full of color, western style garb was everywhere, televisions were common and the children had many more toys. But Clonci said there was still a closed quality on some Issues. "I am well aware of what happened in Tiananmen Square but I was able to talk about that with only one person. The purpose of my visit was to teach the doctors, not to discuss phiiosophkal or political differences." Cionci said the differences made by China's open-door policy showed In other, nf.'gat!ve wnys. During his 1980 trip he wu::. told that v.enereal disease had " STDs weaken the Immune been virlually wiped out between . system and the more often a per1950 and 1957 because of a strict son. contacts an STD the more program of enforced medical vulnerable they become. treatment for anyone with R. ve "Right now for women or child
norenl C\lSCRSll, al1d InW8 mnkln~ .. bcnrihltagej AIDS' 18 one ot the prostllnllon n crlmo punishable top klfters,' Cloncl floinUld bUt. by deportallon to a Islnnd colony "These women, aged-15 to 44, are as well as harsh re-educatlon prothe most vulnerable segment of grams. . the population and the majority In April Cloncl was told that of new cnses of HIV infection are Chinn has at least 300 cases of women. AIDS and there has been a re- . "We do not have a cure, yet, surgence of other sexually trans- and education is the best weapon mllted diseases. Clonci trained we have." . .. doctors at clinics and hospitals, Including "the barefoot doctors" who work in poverty and primitive conditions in remote communes. And he met Important goverment officials, among them ' a minister of h'alth and a doctor who runs a 100-bed cancer research center . Those two meetings may mean a quick return to China for Cionci. He got a letter from the minis- . ter of health authorizing an ex- I change program which will allow Dr. Henry Heimlich of Cincin nati to work In China on an experimental cancer therapy pro gram at the cen~er_ Heimlich has asked Cionci to go with him, perhaps as early as next spring, to get the program going. For now, Cionci has a full schedule of lectures and training sessions around the count.ry, including the preparation Of a curriculum for Southeastern University of Health Sciences in Miami for training physicians In dealing wlt.h and treating AIDS patients, a task he was recruited for and Is excited about. "We have pathetically low training of physicians in treating AIDS," he said. About 10 doctors . in Philadelphia take care of an estimated 2,859 AIDS patients. "And people are not listening to the message ahout practicir:g safe sex. STDs are spreading like wildfire" he added. "Since 1984 , the number of cases of syphilis have tripled across the U.S., and . quadrupled In Philadelphia.
~.":
.;.
<l~ '~'.
:(~~~
. :... . ~ '. ~
.~. ,
8y Tony Swanlek
Il.D. 's trip pave HEALT way for use of . AIDS authority .says 'Malariatherapy' disease has .becom~
Thursday, Nov. 22, 1990 .
/
~, ~ J;>biladelphia Inquire~.
. ,.
/
--------.
Jack Cloncl may have traveled the People's Republic of China In April to teach doctors .there aboutAlDS, but he also made important s ides.in er thera . . Because of Cionci's trip, Henry J . Heimlich, M.D. will be able to tablish a clinic in China to practice "Malaria therapy" which may ave implications for the treatment of cancer, Lyme ,disease and. rhaps even AIDS. . .-~-onc Irst visited China In 1980 with 31 others as part of a medical and cultural group. The group was composed of doctors, novelists, proCessors and others of diverse backgrounds~ Cloncl! for hit! part, 'l!)rked to tC4! ~ h t.~ c I-Ici:nlh::h ivlaneuver. On his most reccut trip, Cionci's time was spent teaching AIDS education to doctors. However Cionci, a member of the board of directors of the Montgomery County AIDS Task Force, also went as a representative oC his friend, Dr. Heimlich, president of Cincinnati 's Heimlich Institute Foundation Inc. Heimlich ,,'ants to treat cancer patients there by giving them Malaria. According to Heimlich, It's not a far fetched as It may sound. Malariatherapy, he said In a recent phone interview, was used since 1917 as a treatment for syphilis of the brain until the disease was all but wiped ont. Heimlich's plan is to Introduce Malaria to those with With cancer. He said hyperthermia - Increasing the body temperature ~ can kill cancer cells . According to Heimlich, recent reports indicate that when a person has Malaria , the body produces tumor necrosis factors, TNF, which nre " known to destroy cancers, It In addition to TNF, Malaria patients also produce other regulators of cellular immunity ' Buchas Interleukins. In 1917, Dr. Wagner Jauregg reported treating neurosyphilis by introducing benign Malaria . The Malaria was halted after three weeks. Through the use of this procedure, tens of thousands of people were cured from 1917 to 1975, Heimlich said, and Wagner Jauregg won the Nobel prize in 1927 for his efforts. . It was generally believed at the time that fever was responsible for curing the neurosyphilis, but Heimlich said that was a simplistic conclusion. Heimlich said it was an immune reaction which was the curative factor due to the production of TNF. In an April article In The New England Journal of Medicine, Heimlich cited the possibility for using Malariatherapy for cu1'lng Lyme disease - an ' affliction which Is endemic to Montgomery and Bucks counties. According to Heimlich, ailhough penicillin, tetracycline and ceCtriaxone are used to successfully treat early Lyme dlsca nt neurolo Ie diseRlle oc urs In some cases. elmlich said he also Is studying the effects of a ar a lerapy on treating people with AIDS . _ , n wan 0 say we lave a cure-all for everything and I don't want to hold out any false hope," Heimlich said, "but we've been discovering the effect of Malariatherapy on treating AIDS. I personally believe it has great potential." Cionci may be retUrning to China sooner than he originally thought. He said Heimlich has asked him to accompany him to the opening of the clinic In Nanjing . "If this procedures works for cancer It wlll be II landmark," Cioncl said. "It will make a form of cancer therapy available to third world nations that they do not currently have. Most people in third world nations can't afford chemotherapy or radiation therapy which is often worse than the illness. This procedure is relalively inexpensive. If it works, they wll\ be erecting statues of Dr. Heimlich all over Ule third world. It would be nice to know I had some small part in making that happen."
.more .controllabl<:~:;~
. ' .but l' nsulin -and other medicatior. By Shaun Stanert ~cial 10 Th< '"quor" have made it manageable," he said It's unlikely that a cure for acquired The methods currently availab! immune deficiency syndrome will be are drugs that retard the virus' repl discovered in this century, but there's cation, treat opportunistic infectior good news: Its symptoms and methods and bolster the immune syster of transmission have been identified, Cionci said. . money is being spent to try to find a Researchers are trying to impe( cure, and ' there are ways to short- ' the replication process further . . circuit the virus' replication, increas"Then, maybe, victims can live 1 ing the length and quality of AIDS IS, 20 years," Cionci said. victims' lives: . . .' '. The severity of the insidious vin That was the message Dr. Jack has prompted the government to fu ' Cionci, an Internationally recognizednel .~'e.bout 30 times more money IX AIDS authority and chairman ofthe 'eapita to AIDS research" than io ' Montgomery County AIDS Task Force, .studyof other major diseases, Cion brought to abOut SO people at the '" sa1d~ . . weekly adult forum of the Yardley As of last month, more than lSO,O<' United Methodist Church on Sunday. AIDS cases had been reported in U He is to speak again at the church United States in 1981. More than 90,0<' next Sunday. . of the AIDS patients have died; aecor The AIDS virus, human hnmunode- ing to the Centersfor Disease Contr ficiency virus (HIV), weakens the in Atlanta . body's immune system,: leaving ;the . The illness is 'underreported, Cion victim vulnerable to many opportu- contends, because families sometim nlstic infections and rare cancers. The request doctors making out death a disease causes death within three tificates to name only the opportun years, on the average, from the time tic infections that killed loved on symptoms appear. with AIDS. And some people comnMoreover, the virus, which spreads suicide before their mv infection t mainly through exchange of bodily comes symptomatic. fluids, bas mutated into hundreds of strains. It can take up to a year after exr "It changes geographically," Cionci sure to the virus to test positive, wi said. "We don't know why." an average of 14 weeks, he said.. This evolution makes it <lifncult to According to Cionci, recent ngur find the ammunition needed to ldll inc11cate that the rise in the number the. virus' variouS strains. . confirmed cases hAs slowed.. When t The latest advances focus on mak- virus was first isolated, confirm 1ng the disease more controllable, cases "were doobllDg every 12 to . months because no one knew what Cionci said. "People used to die from diabetes, do about it or where it was from
~O:
0 . Chen Xiao Ping Dr. Henry J. Heimlich January 18,2002
- 0.>: D. IE:
I wish to advise you of the following facts:
1) I have in my hand a newspaper article from one of the leading newspapers in the United States, the Philadelphia Inquirer, dated Thursday, November 22, 1990. Dr. Jack Cianci and Dr. Hua Hong Shun also have this newspaper article. The story tells of Dr. Cionci's trip to China in 1990, and that he traveled through China speaking on his specialty, AIDS, to many Chinese doctors. It describes how Dr. Cionci told the Chinese doctors about Dr. Heimlich's method of malariatherapy for the treatment of cancer, Lyme disease and AIDS. On the first page of the article is a picture, measuring 61/2 x 4 inches, showing the doctors who were present when Dr. Cionci was arranging to establish a clinic in Guangzhou for the treatment of cancer and AIDS. Under the picture, it states, "With Dr. Cionci, second from left, in China, are Bin Quan Xiao, M.D., far left, Jin Zing Liv, M.D., and Xiao Ping Chen, M.D." Your picture is very clear. Next to you is a large sign saying, "Welcome to Dr. Cionci Our Guide". You were present in 1990 when Dr. Cionci described Dr. Heimlich's method of using malariotherapy to treat AIDS.
2) Drs. Cianci, Hua and Heimlich each possess a letter you sent to Dr. Cionci on the stationary of The Municipal Health & Anti-epidemic Station of Guangzhou. The letter is from you to Dr. Cianci, dated September 3, 1990. You say, "Dear Dr. Cionci: Many thanks for your letter and information. I am also interested in the Malariotherapy on treating people with cancer and AIDS. I am glad you said Dr. Heimlich had asked yo u to accompany him to the opening of the clinic in Nanjing. But I have one question about it. Why don't you plan to open the clinic in Guangzhou instead of Nanjing?"
::.:- _-ou describe the reasons why we should treat cancer and AIDS patients in . er than in Nanjing_ Your letter is not typed; it is hand-written and signed
-_ G-;:u Xiao PinK Thanks to Dr. Cionci 's lecture, you were fully aware of my
"'ry of using malariotherapy for cancer and AIDS when you wrote to him on ember 3, 1990_
3) In your e-mail of February 23, 2001, you state you would like to put the following quote in a scientific paper, "We acknowledge Dr. Henry J _Heimlich for his successful cooperation with us in the pilot study of malariotherapy for HIV infection during 1993-1996. He independently proposed the idea of malariotherapy for HIV infection in 1992 (note: in the contributors section: Dr. Chen independently proposed the idea of malariotherapy for HIV/AIDS in early 1993 will be mentioned)."
You add, "Dr. Heimlich and Dr. Chen independently proposed the idea of malariotherapy for HIV infection respectively in 1992 and in early 1993".
It is evident from points 1 and 2 above, that you did not independently propose the idea
of malariotherapy for HIV infection. You learned it in 1990 from Dr. Cionci's report to you and your colleagues, wherein, he described my work.
I am advised of the following from Dr. Hua: On December 12 and 26, 2001, an article appeared in the paper The Chinese Medical Research, published in New York in the Chinese language, and distributed in New York, Taiwan and China. The material was obviously provided by you. The name Chen Xiao Ping appears 21 times throughout this article. It states that Chen Xiao Ping proposed malariotherapy for the treatment of AIDS in 1993. There is not one mention about Dr. Cionci, Dr. Hua, Dr. Heimlich or The Heimlich Institute. Furthermore, there was no mention of the tens of thousands of dollars The Heimlich Institute granted to the account of Dr. Chen Xiao Ping for carrying out the research. As you know, we possess the receipts for the funds sent to and received by your
..-
in China.
also informed me of your letter to him dated October 11, 2001, in which you d in Chinese), "Dr. Cionci visited Guangzhou in 1990. That was for the first time mentioned to me about malaria therapy of cancer. I agree that is a very reasonable assumption. Not until Spring Festival of 1993, I proposed to the Director of the Municipal Health & Anti-Epidemic Station of Guangzhou, Dr. Shao Bin Quan that malaria therapy of HIV might be a more valuable treatment method and later I got Dr. Shao's full support. Two months later, I received Dr. Heimlich's letter suggesting that malaria therapy might be used in treatment of AIDS. This was a coincidence. Chen Xiao Ping independently proposed malaria therapy in treatment of HIV infection In fact, two persons proposed the idea independently, one is Dr. Heimlich and the other one is Chen Xiao Ping."
Dr. Chen, I strongly recommend that you inform the Medical Research newspaper that: Dr. Henry Heimlich, President of The Heimlich Institute in Cincinnati, Ohio, USA, was the first to discover malariotherapy for treating cancer and AIDS. Dr. Heimlich carried out his research in the 1980's. This fact was reported to Dr. Chen Xiou Ping and his colleagues in Guangzhou in May, 1990, by Dr. Jack Cionci, a prominent AIDS specialist from Philadelphia, PA, in the United States. These facts were described in the newspaper, The Philadelphia Inquirer, on November 22, 1990. Your newspaper statement that Dr. Chen Xiao Ping independently proposed malariatherapy for treating AIDS in 1993 is not correct. Dr. Chen learned of Dr. Heimlich 's discovery from Dr. Cionci, in 1990 in Guangzhou. Dr. Hua Hong Shun participated with Dr. Cionci and Dr. Heimlich in providing all of the medical references cited by Dr. Chen Xiao Ping in his papers and in your newspaper. The Heimlich Institute granted many thousands of dollars for the treatment of AIDS patients and studies done in Guangzhou.
I: is
- ry important that you provide this same information to your colleagues and
fit
-= : rom
'-
agencies who have been told that, in 1993, Chen Xiao Ping independently
vered malariotherapy for the treatment of AIDS . By carrying out this action, you
",ill relieve me of the necessity to inform our colleagues and my friends in the Chinese government of this matter, by sending them a copy of the Philadelphia Inquirer, your letter of September 3,1990, and my receipts for the money sent to you.
I expect you to inform me within the next two weeks that you have taken this action.
Sincerely,
Henry Heimlich, M.D.
CC: Drs. Cionci, Hua, Fahey
,5-":"r0-8~~C~~T~~~u ~rs~ - d~a~y!!!!!,! ! !N! ! !O~~,V~~ka!!!!2!!!!, ~l~ ,;W~,~Th~,~'! ! !'p!! ! "b~i!!!!!la~d!!!!!e~lp!!!!!h!!!!!ia~I~n~q~Ui~r~er~!!!!!!!!!!~ , .~ -~ ~l
HEALTH
..
AIDS authority says disease has " become more controllable:::

"
Sp.iol 10
but Insulin ' and other medications have made it manageable," he said. It's unlikely that a cure for acquired The methods currently available immune deficiency syndrome will be are drugs that retard the virus' repli discovered in this century, but there's cation, treat opportunistic infections good news: Its symptoms and methods and bolster the immune system. of transmission have been identified, Cionci said. " money is being spent to try to find a Researchers are trying to impede cure, and ' there are ways to short- 'the replication process further. " circuit the virus' replication, increas''Then, maybe, victims can live 10, ing the length and quality of AIDS IS, 20 years," Cionci said. victims' lives: " ' The severity of the insidious virus That was the message Dr. Jack ' has prompted the government to fun. Cionci, an Internationally recognized nel ,~'about 30 times more money per AIDS authority and chairman of the :eapita to AIDS research" than into Montgomery County AIDS Task Force, study of other major diseases, Cionci brought to abOut SO people at the ", said. ' ' , weekly adult forum of the Yardley As of last month, more than 150,000 United Methodist Church on Sunday. AIDS cases had been reported in the He Is to speak again at the church United States in 1981. More than 90,000 next Sunday. ' The AIDS virus, human immunode- of the AIDS patients have died; aCGOrd fic1ency virus (lllV , ), weakens the ' tng to the Centersfor Disease Control tnAtlanta. ' body's immune system,: leaving ,the : The illness Is'underreported, Cionci victim vulnerable to many opportu nistlc infections and rare cancers. The contends, because families sometimes disease causes death within three request doctors making out death cer years, on the average, from the time tificates to name only the opportunissymptoms appear. tic infections that killed loved ones Moreover, the virus, which spreads with AIDS. And some people commit mainly through exchange of bodily suicide before their mv infection befluids, has mutated into hundreds of comes symptomatic. strains. It can take up to a year after expo"It changes geographically," Cionci sure to the virus to test positive, with said. "We don't know why." an averege of 14 weeks, be said. This evolution makes It dlfftcult to ACGOrding to Cionci. recent find the ammunition needed to ldll inc11cate that the rise in the number of the, virus' variouS strains. confirmed cases has slowed. When the The latest advances focus on mak "virus was first isolated. confirmed tog the diseage more controllable, cases "were doubling every 12 to 15 Cioncl said. months because no one knew what to "People used to die from diabetes, do about it or where it was fro!ll."
By Shaun Stanert
Th~
'"quircr
n&ures
Pee p e
~~~ -?i~j~:~-~~.
~
.ot-.
8 -. -_ _ _
. -; _:: ,;.':_
~-'-.
.::....r_...;..._~c.-...___ ... ':.......:~ __.......... ~Ji'.._-;r.,;.'!.-.a'"; .. .. ~...;....:_~....,;..;):......._ ......._ ...
:~~.'
'; ~ ..' >.1
-::~'::-':~"'-' .. ~~.;,~, ..~.~. :~:::~'('. ~:{:~.~;:.-f~~::.:~t.~~~ .,;:(,~.:~/!: I. ;/~:;.;t::';~~J~:i:~): ::.~.j~~~i;'!~~~:'~~

lllll
Jo~OoooJ' .. _l"""L:-....... ~ "';~lr...~o>'J.,Y~".J.u..:~,",...-.f.~';
...
~.:t.~ ... ,
- 1
. Phil adelp hia DO edu cates Chinese about AIDS

.I at- - Ci
nei. DO. a se mirelired gen -
e ... 1pranilioner from Ph iladelphia,
$pen( th ree weeks lasl spt-ing ed ucHin' Chinese physicia ns aboul acqttired im lllun e d efIc ien cy syndrollte. T his was hi s second trip lo Ch in a. III 1~lH O . Dr Cionci hecallle (l lle of the firsl ph ysicians from lhe West to enler China since it was riosed to foreign visitors in 1949. I Ie W ;IS the only no among :~2 phy~ i( 'ia liS Oil a cull ural anti Ilted ical exchange . During that t rip, Dr Cionci was smprised to find that the Chinese h;\d 110 knowledge of the Heimlich In;\nClI\'cr. so he began demonstrat ing it. He becallle acquainted with ;\ surgeon in Nal~ing. Hong-Shun Hila . ~ID. who was eager to learn tIIore aboul the technique. The two pll\'siriam became friends and corroplln<icd lIIonthl\'. E\'enttl;tlly. Dr 1111;1 1I\()\'t'd the Uniled States and is 11011' working , for Henry J. Heimlich. MD, in EI Monle, Calif. Dr Cionci madt~ a promise that he \\'()t1ld relUrn to China in 10
yea rs.
Dr C ionci (ce n ter) parlicipalc ,~ in a panel discussion on AIDS while in China.
III t he mid-I !lHOs, 1h Cillnci heC\II\e fallliliar with AIDS while workillg at a health cenler for sexually lr;lI\smitled diseases (STDs) in Philadelphia. He was immedialely fasci natcd with the deadly virus and began studying the disease. Dr Cionci lIas ' certifIed by Philadelphia's Hahnelllalln University School of 1'.ledicine in .!anuary to lrain other physicians on AIDS.
Dr H ua was able to contact associates back in China, who arranged for DrCionci to visit thecountry officially as an AIDS spokesman through the Chinese Red Cross. He is believed to be the lirst Western physician to travel through China providing AIDS education and trainmg. Throtlgh an interpreter, Dr Cillnci icC! lII'ed in hospitals alld c1illics ill five cities: Nanjillg, Shallghai, Xi'an, Beijing and Guangzhou. He represented several US organizations, incltlding the American Red Cross, the AIDS Task Force of Philaddphia and BEBASHI (Blacks EduCHing Blacks Abollt Sexual Health hsues). The World Health Organi7~lti()n sellt Dr Cionci videotapes and brodlllres, and the US Centers for Disease Control provided six sets of slides. In each city, Dr Cionci says he received a warm reception and found a willingness to learn . One physician in Guangzholl who had spent tilll: in the United States in-
qllired aboul settiIlg up a COIIIITlU nity-based organization and a lask force for AIDS education. "It was slich a moving experi ence," he says. "Ther love words like friendship and cultuml exc/uwgl' . They're a very pro ud people. Th ey were fascinated in learning about AIDS. They thirsted for knowledge. And they would ralher Icaru hy verbal exchallge lhan hy reading." Chilla has approximalel y :\O(J reported cases of AIDS , most purportedly due to intravenous drug use. Although Chinese laws rigidly restricl the use and sale of illegal drug~ and prohibit prWltilUtioli. Dr Cionci .says drugs come into tile country from its neighbors Nepal and Bhutan. Although Dr Ciollci saw 110 AIDS patients, he did hear ahout a handful of people who had contractecl the human imlTlunodeficiency virus. The . m;~jority of AIDS cases, he says, have stayed in the provinces near China's southern border. Dr Ciollci obse rved little overt
'I'll F. DO Novemher 1990
People 43
e 'ery most you see is and lhe Chinese have asexuality," - - , ho 'ever, China has ;an increase in STDs, e '0 an in ux of foreign en. especiall uden, Dr Cianci ina has a least 300,000 rened cases of, el ereal disease, the majorit} of ,hidl are cases of gonorrhea or ;yphilis. ~ hould AIDS strike China as it has 111.1 II Yother cou ntries, Dr Cionci sa. s the disease would have a profound e(fect. "They're trying to prevent AI[)S from exploding expon enlially Ii ke it has in the United States," he says. "If ever it starts to spread like it has spread here, it will devastate them ." China is an exceptionally poor count ry with a population exceeding I billion. Already, a vast majority of its citizens cannot afford adequate healthcare, and many villages are situated far from hospitals. In the cities he visited, Dr Cionci observed Illany unclean facilities, deteriorating equipment and overworked physicians. 'They're going to have a problem in testing people [for AIDS] because it's going to be an extra expense. And when aHyone d~)es get sick, they're going to spread other diseases [such as opportunistic infections] because Chinese hospitals don't have complete sterilization," he explains. "They've already had this in Russia. and Russia is not nearly as poor as China. "Worse, the Chinese are not going to spend the kind of money [needed to get zidovudine]: they just don't have it. They don't even have enough money for chemotherapy for cancer patients." Dr Cionci says he probably will return to China next year with Dr Heimlich, who is trying to set up an iilstitute for malaria therapy for
baJod--h.;~::!g,
treating cancerous tumors. Dr Cionci has received several lellers from variotls physicians in Chilla asking that he return. Most recently, Dr Cionci received a federal grant to develop a module for training Florida physicians about AIDS. The module will be taught at the state's four medical schools, induding the Southeastern University of the Health Sciences ,College of Osteopathic Medicine in North Miami Beach. The module, called ''Train the Trainer," will he completed in January 1991. -Ruth A. Mack
.i
THE DO November 1990 .
5 Feb 2002 10:33:1 9 , page 1
p. g" <chenxping@netease. com> " <heimlich@juno.com> 2002 11 :56 :15 +0800
lich: ow what media you refer to. I checked the media which I know, e statements as follow: 1995 in Refe rence News: Dr. Chen and Dr. Heimlich tried malariotherapy or HIV/AIDSi-i-The reporters got the message from the International Immunology Conference in San Francisco where we attended the meeting. 1996 in Yangcheng Evening: Heimlich Institute of USA and Municipal Health and Anti-Epidemic Station of Guangzhou got a progress from the cooperation in the project of malariotherapy for HIV/AIDSi-i-. 2000 in Health News: Dr. Chen and Dr. Heimlich further cooperate in malariotherapy for HIV after completion of malariotherapy for cancefj-i- 2001 in the Health News: Dr. Chen and his team got a progress in findings of mechanisms of malariotherapy for HIV infection and based on these findings, Dr. Chen further proposed a new idea of highly active antiretroviral therapy (HAART) plus malariotherapy in attempting to eradicate HIV in vivOi-i-(by the way, according my memory, you opposed the idea of malariotherapy plus HAART in an email to me). I could not find any words like iOinventedi, iOinventioni in any original media reports. In fact, any contributions of you to malariotherapy for HIV/AIDS have well documented in a couple of meeting abstracts and two published papers. If malariotherapy alone for HIV/AIDS will win the Nobel Prize in the future , you must be one of the winners even though you have discontinued the study since 1997. It really was a pity that your wrong memory leaded the discontinuation of our cooperation . We have a document with your Signature to confirm that the earliest time you independently proposed the idea of malariotherapy for HIV/AIDS is 1992. We will preserve this document for final use. The fact is in the follow, which I mentioned before: Regarding to the letter from Dr. Cionci to Dr. Heimlich, it is not true for saying that Dr. Heimlich spoke to my group on the use of malariotherapy for HIV. The fact is that in 1990, Dr. Cionci as a representative of Philadelphia Red Cross Society visited to Guangzhou . I met him in the White Swan Hotel where he stayed. We talked very friendly, when I told him about my hypothesis on that HIV might originated from the molecular hybridization of SIV and human sperm gene (I published this idea in early 1990), then he told me the idea of malariotherapy for cancer proposed by Dr. Heimlich, when my response was "this idea is very reasonable" since I had been a physician for infectious disease for many years and had treated over one hundred malaria patients. Then Dr. Cionci returned to USA and told Dr. Heimlich about my interest in malariotherapy for cancer even though I had been worked at AIDS laboratory since 1988. Dr. Heimlich came to Guangzhou in 1991 to talk with us on the cooperation of malariotherapy for cancer. Dr. Heimlich did give lectures in Zengcheng County People's Hospital and Dongshan District Hospital, and I did be there as an interpreter for Dr. Heimlich , but Dr. Heimlich never mentioned malariotherapy for HIV in his lectures and thereafter until the
Fe 2 02 10:33:1 9 , page 2 . e spoke to Dr. Xiao, the Director of -e ' ea 0 alarioth erapy for HIV in early 1993 on the ; - - . -=---0 a I g vacation of Chinese New Year holidays. I received a letter from Dr. Heimlich by which I first had e same idea and I told Dr. Xiao about this. e er again after completion of malariotherapy for a Ho g Shun came a couple of times on behalf of Dr. .. eel us a couple of times for our cancer research / e docum ent telling us that Dr. Heimlich proposed the a . en letter from Dr. Heimlich to me in 1994. Any - - - sa ' g Dr. Helm lich proposed the idea prior to 1992 are e. S' ultaneously, any statements denying Dr. Chen e proposed the same idea in early 1993 are also unacceptable. ese s!ate ents will lead to no way to go for our cooperation, because ese s!ate ents are not true. We also had different ideas on ala ' erapy for different diseases: Heimlich's Lyme disease idea and C IS S E idea which I mentioned before. lease excuse me to CC this message to Dr. Fahey, because I think we o Id talk very openly, and Dr. Fahey helped us a lot in IV-malariotherapy projects. Sincerely, Xiao Ping Chen, M.D., Ph.D. Original Message ----From : Henry J Heimlich <heimlich@juno.com> To: <chenxping@netease.com> Sent: Saturday, January 26, 2002 2:41 AM Subject: malariotherapy for hiv/AIDS
> TO: > > FROM: > Date: >
Dr. Chen Xiao Ping Dr. Henry J. Heimlich January 25, 2002
>
> > > > >
I wish to advise you of the following: 1. It has come to my attention that there is a report in current media on malaria therapy of hiv/AIDS. It states that Dr. Chen Xiao Ping independently invented that treatment in 1993.
> > 2. There is firm documentation that proves: > a) Chen Xiao Ping was informed of malaria therapy for the treatment of > hiv/AIDS prior to 1992. > b) Chen Xiao Ping received comprehensive literature on malaria therapy > from the > Heimlich Institute . > c) It is through the Heimlich Institute that Chen Xiao Ping learned of > malaria therapy to treat both AIDS and cancer. > d) Chen Xiao Ping's research on malaria therapy was funded by the > Heimlich Institute.
> > > Dr. Chen, I strongly recommend that you inform the media that Dr. Henry > J. Heimlich, President of The Heimlich Institute in Cincinnati, Ohio, > USA, was the first to discover malaria therapy for treating cancer and
Fri, 15 Feb 2002 10:33:19, page 3 carried out his research in the 1980's. This fact Dr. Chen Xiou Ping and his colleagues in Guangzhou in :J . Jack Cianci, a prom inent AIDS specialist from USA Your newspaper statement that Dr. Chen Xiou
> ' ~-
= --~:~
proposed malariatherapy for treating AIDS in 1993 is not . C en learned of Dr. Heim lich's discovery from Dr. Cianci, G a gzhou. Dr. Hua Hong Shun participated with Dr. Cionci
lich in providing all of the medical references cited by Dr.

> Xia
P' g. Funds for the treatment of AIDS patients and studies done
> G a gzhou were granted by the Heimlich Institute .. > > . also very important that you provide this same information to your > colleagues and government agencies who have been told that, in 1993, Chen > Xiao Ping independently discovered malariotherapy for the treatment of > AIDS. By carrying out this action, you will relieve me of the necessity > to inform and present documentation to our colleagues and my friends in > the Chine'S~ government of this matter. > > I expect you to inform me within the next two weeks that you have taken > this action.
Affiliated with Deaconess Associations Inc.
lf~
1- J4
'r'- -r r
~ ~ MWw
i>:I
J).
A-I])$
~ -t, ~/?W...
tlA..{.. H
~~
~Mil-1~~~'
J~7
:J,;r 1~~ (~W ~e-~ 1~

1 ~ .;. ;[7) 1$
~
I.
ar J w- <t-6~ r-k
1;
.A-U- ")r
Aio ~ -~
/.}L:jt rJ>.<..
..w "-.
R.ML 1';"~~' S't. ~

9.A.L
a),..,d~.
~ +Mu ~ ~'.
,(JL-hJt
~ ~k.w7~
11-
1-
t~..K~J -b; ~ ~ ~~
tJ..t? f).,4.,
7kd ~~~
).,.
Jt~~t;
MU-
~ ~ ~ ~d;-It?
(;j tW..--If~ V~~~,
i..-p f;, jfL ~ hllifwifQAo.

~it~
1),~~~~"-"<l,~
.'
-a
~;,t
.~~~?Ut{-PuN...
:; C l - .
. Cj f-;
~ i; ~ ~ ~
r1be
~ ~
~d, ~M ~ ~ 1;, i;..t..r ~fJwA- ~,'Aw.

~
1- ~ VJ;.v
{)-Jf,.
~~
~ ~ u-..}JJL
~~~.
])~ ;pro &~ "-' ~ ~ ~ -ffi. ~..~
~HtN~i M~. Jf&kAU~~~'rfp U1-L 1;
tv+;-- tMt r O.
.
;P1A.v ~~. j . ~ ~ ~~~~.;.
0Rw- ~ It q,r ..~

~ .;. ~:
it ~ ~ ~4.t
t;,
if ~ y..t. .
/}.fJ..
J.J; ~
8'1t>\
MJ
'fk-~.
1-
Hvv
~ hC..11~av. J ~.tf."..
7~
~~~.
~ J;~a.. ~
. JM-.~
1<k
!r'-. .
,
Bd ~adv tf, Dr. JIw..~ a.J., Jw ~ L ~ -te. ~ .
~M~
~h~
..1.e _d:unicipal Institute For Preventive Medicine of Guangzhou

=A-r'::_~23~
""-a: ... F; ,
~
IE,
5 =8 1714103 (
.am)
No. 23. The 3rd Zhongsban Road, Ouangzhou The People's Republic of China Tel. 777'103 (ext)
eury J, Heimlich, M.D., Sc.D. ' HeWich Institute Foundation. Inc. 2368 Victory Parkway C inci~ati~ Ohio'45206 Dear Dr. Heimlich:
April 8, 1993
We have considered , thoroughly the use of ' llalariatherapy for treating HlV infected patients. Halariatherapy has proven to be a s~fe and effective method for treating cancer. Th~re is every reason to be, convinced that it can be effective and safe for treati~ AIDS. We are ready to provide malariatherapy to HIV positive patients at this tiae., My background experience with AIDS includes:- I have worked in the field of infectious diseases for thirteen years and special in the field of ,AIDS ' for five years. I have extensive, and deep knowledse on AIDS in the l'espests of eteology, epidemiology and clinics., Four years ago, ,I first proposed the hypothesis of HlV origenatiIl9. froll human spirlll genes in an international coilference. In lIlY , laboratory. I can do.any things on AIDS including HIV culture.
"
The_ scientific evidence we possess of the ' possibility of increasing production of iuune substances is ,very ,souna. 'The ' study showill9the survival of . children who' have AIDSand-lRalarla,whHe -. 35';' of those with AIDS alone died is very convincill9.
")
. . - '
It . is obviously not pQs'sible- to . predict what our findings will be frolll our
research stu4ies. -To not .a.ti, eIl1Pt aalariatherapy. however. i~aves AIDS patients with' " no pOS$ibility of effective treataent. ...,
,
'r
Sincerelc::k
. .
. .
Dr. Chen Xiaoping The Municipal Health and Anti-epidelllic St.-ation of Guangzhou, No.23, 3rd ZhoIl9shan Road, Guangzhou 510080, P.R. China
. . ~.
(no
b . ect : (no subject) Date: ed, ~O Feb 2002 10:27:56 -0500 From: "Henry 1. Heimlich, MD, ScD" <heimlich@iglou.com> Jl1!:anization: Heimlich Institute To : chenxping@netease.com
Joc tor s Fah ey, Hua, and Cionci e - ail to me of 6 Feb 2002, contains several errors. You say, once I t h a t Dr. Cionci, during his visit to Guangzhou in 1990, spoke to abo t Dr. Heimlich's plan to use malariotherapy to treat cancer. ~gnor e the fact that Dr. Cionci told you about Dr. Heimlich's idea o se malariotherapy to treat AIDS. You also say, "Any statements say ing Dr. Heimlich proposed the idea (using malariotherapy for HIV) pr i o r to 1992 are unacceptable. Simultaneously, any statement denying Jr . Chen independently proposed the same idea in early 1993 are also acceptable." In y our e-mail of 23 Feb 2001, you state you would like to put the following quote in a scientific paper: "Dr. Heimlich and Dr. Chen independently proposed the idea of malariotherapy for HIV infection respectively in 1992 and in early 1993." The documents cited below prove that Chen xiao ping learned about Dr. Heimlich ' s idea for using malariotherapy to treat AIDS from Dr. Cionci in 1990. The documents also confirm that Chen did not independently propose malariotherapy for AIDS. They further prove that Dr. Xiao Bin Quan, Head of the Municipal Health & Anti-Epidemic Station of Guangzhou, was misinformed, in 1993, when Chen advised him that the proposal to use malariotherapy for AIDS was Chen's independent idea. 1) I have in my possession a newspaper article from a well respected newspaper, the Philadelphia Inquirer, dated Thursday, November 22, 1990. The article was sent to me by Dr. John Cionci and Dr. Hua Hong Shun. The story tells of Dr. Cionci's travels through China in May 1990, and that he spoke there on his specialty, AIDS, to many Chinese doctors. The headline states "Area M.D., task force member takes AIDS message to China." It describes how Dr. Cionci told the Chinese doctors about Dr. Heimlich's method of malariatherapy for the treatment of cancer, Lyme disease and AIDS. The article also tells of Dr. Cionci's plan to establish a clinic in China to treat patients with cancer and AIDS, using malariatherapy. On the first page of the article is a photo, measuring 6 1/2 x 4 inches, showing doctors who were present when Dr. Cionci presented that information on AIDS. The caption under the photo states, "with Dr. Cionci, second from left, in China, are Bin Quan Xiao, M.D., far left, Jin Zing Liv, M.D., and Xiao Ping Chen, M.D." Your picture is unmistakable. Next to you is a large sign saying, "WELCOME DR. CIONCI TO OUR STATION AS OUR GUIDE". The picture is taken at the Municipal Health & Anti-Epidemic Station of Guangzhou. However, your e-mail to me of February 6, 2002, says you only "met him (Dr. Cionci) in the White Swan Hotel". You fail to mention that you were present when Dr. Cionci spoke at your Station. In that e-mail you only say Dr. Cionci was a representative of the Red Cross. You fail to mention, as stated in the newspaper, Dr. Cionci's lecture was on AIDS and was "sponsored by the AIDS Task Force of Philadelphia". The facts are clear: You did not independently propose malariotherapy to treat AIDS in 1993 because you were present in 1990, when Dr. Cionci described Dr. Heimlich ' s method of using malariotherapy to treat AIDS. 2)You wrote a letter to Dr. Cionci on the stationary of The Municipal Health & Anti- epidemic Station of Guangzhou, dated September 3, 1990. Dr. Cionci sent Drs. Hua and Heimlich copies of this letter of September 3, 1990, which are in our possession. In this letter, you say, "Dear Dr. Cionci: Many thanks for your letter and information. I am also interested in the Malariatherapy on treating people with cancer and AIDS. I am glad you said Dr. Heimlich had asked you to accompany him to the opening of
lof2
2/20/02 10:57 AM
(no
___
:::_~
~_~_c
o pe
~-== ~e~~e~
a njing . But I have one question about it. the clinic in Guangzhou instead of Nanjing?" is h and-written and signed Chen xiao Ping.
Why don't you
= ~E =ac-s are clear: ~e ~~arioth erapy Se~~e=ber 3, 1990.
You were fully aware of Dr. Heimlich's proposal to for cancer and AIDS when you wrote to Dr. Cionci on You did not independently propose malariatherapy for
"!.-;S
993 .
3J : you r e-mail of 6 Feb 2002, once again, you claim that you i2 e?e dently proposed the idea of malariotherapy for AIDS in 1993. You ~de the same claim in a letter to Dr. Hua Hong Shun, dated October 11, 200: .
:t is e vi dent from documents cited in points 1 and 2 above, that you did not independently propose the idea of malariotherapy for HIV infection in 1993. You learned about the concept in 1990 from Dr. Cionci's report to you and your colleagues, when he described Dr. Heimlich's idea to tr eat AIDS with malariotherapy. In keeping with your desire that we "should talk very openly", I am sending copies of this e-mail, the Philadelphia Inquirer, and your letter of September 3, 1990, to Dr. Fahey, whose knowledge and integrity are well known to us. Perhaps we are each interpreting the meaning of "independently proposed " differently. To us, a person who "independently proposed" an idea means he conceived of it and had never heard of it being thought of before by anyone else. That could not be the case with your 1993 proposal for malariotherapy to treat HIV since you heard about my concept and background research in 1990. On the other hand, perhaps you feel "independently proposed" means that you independently proposed to Dr . Xiao that my method be used to treat HIV and you should be credited with recommending it be used in his Station. If so, that is acceptable. We should also talk very openl y with Dr. Xiao Bin Quan. I suggest you tell Dr. Xiao your memory was incorrect when you informed him in 1993 that you independently proposed using malariotherapy for AIDS. It is always better to correc t an error when you learn of it, rather than have people hear it from other sources. I will be pleased to send Dr. Xiao copies of the 1990 Philadelphia Inquirer and your letter of September 3, 1990, if he wishes me to do so. I look forward to your response within the next two weeks. address the matter of the media. We can then
_ of 2
2/20/02 10:57 AM
1296 SOUTH OCEAN BLVD.
PALM BEACH,
FL
33480
lOllt"". Uemry HdmHdht :);ll1 Itlt""'dl~ght tlF"<eet CU.JrlldJrlllfll<dld, Ohu.o 45'21l9 lD)(e,dllF" lH[;auotlk., Tlhl;amlk. Y0llJ[ ffOlt"" YOU[]t"" ~ett(elt"" off M;aunch :);oth, whu.clhl l[ necdved today. l[ ;aIm OJrlry th;allt YollJ[r phoJrlle caU to lme welne
l11[]fllllJ[CCeJfllJ[~, a lmy JrllllJ[mbelt"" exoeplt ffOlt"" tlhte ;aut""ea cod(e lhl;alve
dllbnfllolt llO y(e,dllt""Y Jrllot chaJrllged un ,
l[Jrll;am eveJrllt, JfOlt"" ffu[1tu[]t""e
1t""effe1t""eJrllCe the 1fllllJ[mbelt"" u. 561l~:);'2-645 aJrlld the ff.:atx u. 561l=:);'2=
6 559'
How lfllu.oe th,allt Y0llJ[ wuU be pealldJrllg at the lPa~m lBleiilldhl ROllJ[Jrlld Tablle mexlt )l;aLJOl1ll[;allry. The lmomlelfllt Y0llJ[ klfllOW Ith(e (eX,dlct d,al1te, pll(eiill(e ~et 1m(e klfllOW o we CiillJrll lmiilllkte ;al dat(e JfOlt"" ~l11[][lldht Olt"" di.JrllJrllelt"" ;al wdU ][ Wiill h;alpPY to 1neiilld that tlhlte m;al~ad.a thelt""apy to tlneiillt Al[lOl h,dl beeJrll ]pllF"Olmu.H.lfllg, that YollJ['v(e h,dld llJ[Icoe H.lfll Clhlu.lfll<dl, aJrlld that the ollJ[th Affdciilllfll tlt""eatmeJrllt wiU lpllF"Ovu.de the lfll(eCea1ry evu.deJrllce to lmalkte u.t accepted throllJ[ghollJ[t the woJdld. lBllt"";alvo,. H;amk! lOlavilldl W0111[~d u.mdl(e(ed be p~ea(ed to e(e whiillt Y0llJ[ h,alV(e dOJrlle, i.Jf he halfll'lt allJt""(e;aldy!!!! Love to Y0llJ[ iillJrlld )laJrlle aJrlld l[ ~ook ffoll"Wan:ll to eeRng Y0llJ[ mext )laJrllllJ[;allry, iff Jrllot beffore, A (ev(elt"",.
mailbox: C '"l XDO'V
Application%20Data/MozillaIProfiles/def...
" ",r""'"_,,,. -:::-w:
Re: onta t "ith Beijing ~. J Heimlich <heimli hgjuno.com>

_ 1ar _00 10:_9:-l8
-O ~ OO
hgiglou.com
--------- = o~~ ar ded message -- --- ---- .:-:::-: ::;:;:: ~ :.:' - Heimlich <heimlich@juno . com> ::: ~~::~~E:~~eerencores . o rg ==.-:.=: .:::::::, ~ .. ar 2002 1 0 : 25 : 33 - 0500 ~-===:-:. : ~e : conL aCL with Beijing .. ;:;~~=-;e - : J : <20020304 . 102735 . - 239985 . 0 . h e imlich@juno . com>
===-~
~C~
::c::gshun ,
~a7e
~e=ar~able .
-:. c
C~ e n ,
accompli shed out goal! The information you have obtained is I s uppo se we should wait for a response to our last message then act accordingly. Do you agree to this?
3est: wi s he s, ::en ry Heimlich
GST I NTERNET ACCESS FROM JUNO ! J no o ffers FREE or PREMIUM Internet access for less! Jo i n Juno today ! For your FREE software , visit :
.~t P : //d l . www . juno . com/get/web/ .
1 of 1
3/4/02 12:30 P 1
--------------
--~
FACSIMILE
Date: Oct. 17, 2002 To: John L. Fahey, MD From: Henry J. Heimlich, MD
Number of pages to follow: 3
Attached is a second letter from the anonymous "Dr. Bob Smith." Oddly, both letters show "Bob Smith" receives his e-mail from a server in Czechoslovakia. Similar letters have been sent out over the last ten years.
cc:
Steven Peckman
c<opy _,PJ:esse note

Ootoba
Dr.
00: list for
addressee
e. ZOO2
'Leonard Madu, Director panAfrica AIDS Conferenoe 2002

1016 18:thAve. Sooth
NutN'.,
TN. 37212
Dear Dr. MadlJ: y,ou may recalJ I'd copied you on my letter of October 2 to Mr. steven Peckman, Aasooia1e !Oirector of UCLA'. Offtoe for the Protection of Reaearcn SUbjects, Since :tending that letter, fve received some unexpected information which 1felt should be brought to the attention of the PanAfrica 2002 Conference.
In my letter to Mr. Peokman, as youtll recan, I raised concerns about UCLA's pa~ in ab-u&lve AIDS experiments which have been conducted in China by Or. Henry J. Heimlich. Chinese patients with HJV and fuU-bIown AIDS have been given mUM by being injected with malarial blood and subjected to weeks of feVM exceeding 105 degrees. I provided substantial documentation showing that woric has been widely denounced 8$ a medical research atrocity and eritlcized for H$ questionable scientific merit.
th.
t also provided substantial documentation from Dr. Heimlich's fundraising newsle1tel'$ and interviews in which he dalmed that the Univer$ity of California at Loa An.;eles and two UCLA profesaora were in partnel1lhip W'ith him in this research. My ~tter, along with full documentation and a contact list may be found at: the following web add ..... :
http://researchwatch.web1000.comlUCLA.html
The day after t sent my letter to UCLA. I ~ an e-mail from Or. John Fahey. one of the UCLA profe880r8 in question, which took me by surprise. Dr. Fahey advised me. along with long Ii8t of othef& he copied. that he wee not involved with the Heimlich AIDS malaria experiments. that no UCLA funds W8I1I used, that Dr. Heimlich's claims of his participation were misrepresentations, and that he was contacting Dr. HeimHch to cease using his name and that of UCLA. A ffNI days later, I received an ... mail from Mr. Peckman, who advised that he
had taken my concems seriously and that his office was conducting an Inveetigation into these matters.
of the Heimlich mataria experimen1$, uncertain why Dr. HeimliCh' we. Invtted to be II featured speaker at PeMfrica 2002 and to promote "malariotherapy" at the conference. That i& wtTy ~ brought my letter to Mr. Peckman to your attention.
Due to the ove:rwhetrmng international efitjc~
'was
Now, added to 'these scientlfic and ethical concerns, Dr. Heimlich's claims of his atmtat}on 'fIi!ith UCLA and Dr. Fahey have been refuted by Or. Fahey and are ~ invectigated by UCLA. J have not received a responae from Or. Heinlic:h.
\
Before my' letter to Mr. Peckman, you may n~ have been aware of the regarding Dr. Heimlich's "m.. ariotherapyz projects in China and MexiCo. Considering the information in my preVIous letter and this new Infonnation about UCLA, I felt you should be made aware of the situation.
con1roYef'sjes
I would ~
your reply regarding the position of PanAfrica 2002 on these
matters, in particular, why Dr. Heimlich was invited as a spaker, I would also invite' you to contact Mr, Packman and Or. Heimlich to clarify the. issues,
lin order to protect my privacy and that my colleagues. I am submitting this
letter t..n:ier a pseudonym.
Thank
you for your time and consideration. I look forward to your reply.
Sincerely,
"Dr. Bob Smith" E..mail: bob-amith@VoIny.cz voicemail & FAX: (978)4 77 -8349
00:
Chane, Peterson, Director General

PanAtriea 2002 Henry J ..Heim. lich, MD, President The Heimlich Institute
tII/L__ .........
Steven Packman, Aisoctate Olrvctor UCLA, Office for the Protection of Research Subjects Or. James Hefner, PreSident Tennessee State University
\ \
\
\
\ Ra,mcnd
v. aUmann.
Chairman, P.... ident.
ceo
Men:k. Co. Petet 'Dolan, CnaalTTlan CEO BristoJ..Myers Squibb Co.

l
MEvin Foot., President eon.tituency for Africa

James L. Pahla, Chainnan.
Deaconess Associations
&
Inc.
Board Member, The Heimlich Institute

HOsPital Ethics Committee
Or. Charles Bemstei", Chainnan

o.acon ...

UCLA-Masterfile 03-08-13 Opt Direct Download At: HTTP://DB - tt/wl2hdhlk

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

UCLA-Masterfile 03-08-13 Opt Direct Download At: HTTP://DB - tt/wl2hdhlk

Uploaded by

Copyright:

Available Formats

~Yw!

H-eiml-ich, M-.D. Professor ofAdvanced Clinical Sciences

JuLy 14, 1986

3800 Victory Parkway Cincinnati, Ohio 45207-1096 513/531-1053

Apr il 12, 1988

Benefiting Humanity Through

Health and Peace

333 MAIN STREET MADISON, NEW JERSEY 07940-2394

Very truly yours, FANNIE E. RIPPEL FOUNDATION

$ 75,000.00 of this grant

You have notified us of your acceptance prior to April 30, 1988.

Re: Dear Eric:

Report for six months ending December 31, 1988

XAVIER UNIVERSITY 3800 VICTORY PARKWAY CINCINNATI OHIO 45207 513745-1099

Benefiting Humanity Through Health and Peace

May 15, 1989

Eric R. Rippel President ERR:nlc

XAVIER UNIVERSITY 3800 VICTORY PARKWAY CINCINNATI

Benefiting Humanity Through Health and Peace

~ -t" <p-J?,;.."... ~ Min

:J.;1JM<-1~ ~(~ w ~~ ~~ '/ ~l

1- t...ue .;. J7) 1.0 ~ :.pr .NO' ~ -.J.,..., ~ w .....

~ a,..;.~ M.- 'Ad? ~

Jr/liRwT~ (;; (,UL-Ifi V~~~,

~~, ~M ~ ~t;, t;.L.r ~~ ~,'h.w..-

])bv 'Jr. ~-R-e-

~ HAN ~1 Mitt. J ~ 1& ~

c,Rw.- k, /f q,r ..~

~.;.~: J~~ t;, ~~~. /fR

r...L ttfA.<l ~' .

. fjv.t ~w.v -If, Dr. JIw..~ ~4J ~ ; ~ ~ fur.., .

M.D . ~-S ' I Av e nu e, 12 a dwi 9 1 731 CA t e,

fl~~,~L~~~e imli ch,

Enclosure Eric Rippel

Benefiting HumanITy Through Health and Peace

SHS (t1il<: :;O

J -. k -;..tJJ ~ 74- !1~~'f ~

w'~ ~er tvu/ AIDS, J

J,t.if5 GUft~~ ~~~ttY,

:.- ' :aII"~

~.~,_ ~. ....... t .... ~'.

~?<~Jk :tLt ~ N~'7 ,S'~ 7~ ~

tPU'1 ~ -tii-trr ~t;U.

H~ ~~, .uU ;..

"7 fi-{""p-- fftik-.

7/z.~/, a~k( n- ?v.ftnJrL,n p~.:. ~ ~

~, :;"td4 c.. L....,.,.

trf ~~ r ~~~A-I-. CM~;:' r /r {<:<r( muJl m.~ Cff111/~f-r'- CUA41"J<?1f( ~ .

The Municipal Health & Anti-epidemic Station of Guangzhou

People's Republic of China.

C/L-"r t'r ~ . al,J ~, (JH<

;" -t~ w;J;4

tfut rfJ~~1ikm.#r ey~rt ;" c~ ~d 17 C'-r~ ~, 7 1~ ;, v/:.th ,0t- rr '

tV""'" ""(/ -tu.-t/fu.s

uJ~ Iv-4 w..'J/-J

0~. J oh ~... ~. C! O~l_~!_.. ... tv) ~._H~tL>J J. Heih! I ;J,

Dr~51t~~ P/~~.~~!.f._.-'-_ U_~tl . _

_ .. __ .. __. .. ____ ._._... _. _ . TO COME TO _ ____ . ___ .. _. _ _ _ __

DAYS. PLS APPLY FORTHWITH lo O R

_ ._.ENTRY VISA(S)AT THE CHINESE EMD ASSY (OR CO NSULATE-GE NERAL,

OR VISA OFFICE OF THE MINISTRY OF FORE IGN IN

AFFAIRS IN lIONG KONG) ( tELEGRAM)

:J.;1JM<-1~ ~(~ w '/ ~l

~.;.~: J t;, ~. /fR

J,t.if5 GUft ~ttY,

trf r ~A-I-. CM~;:' r /r {<:<r( muJl m.~ Cff111/~f-r'- CUA41"J<?1f( ~ .

Dr~51t P/.~~!.f._.-'-_ U_~tl . _

_ .. .. . .. ____ ._._... _. _ . TO COME TO _ __ . _ .. _. _ _ _ __